WO2013173720A1 - Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors - Google Patents
Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors Download PDFInfo
- Publication number
- WO2013173720A1 WO2013173720A1 PCT/US2013/041601 US2013041601W WO2013173720A1 WO 2013173720 A1 WO2013173720 A1 WO 2013173720A1 US 2013041601 W US2013041601 W US 2013041601W WO 2013173720 A1 WO2013173720 A1 WO 2013173720A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkyl
- trans
- pyrimidin
- pyrazol
- cyclobutyl
- Prior art date
Links
- -1 Piperidinylcyclobutyl Chemical group 0.000 title claims abstract description 92
- 150000004944 pyrrolopyrimidines Chemical class 0.000 title abstract description 4
- 150000005255 pyrrolopyridines Chemical class 0.000 title abstract description 3
- 229940122245 Janus kinase inhibitor Drugs 0.000 title description 25
- 239000000203 mixture Substances 0.000 claims abstract description 181
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 91
- 238000000034 method Methods 0.000 claims abstract description 84
- 201000010099 disease Diseases 0.000 claims abstract description 69
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 39
- 201000011510 cancer Diseases 0.000 claims abstract description 26
- 208000023275 Autoimmune disease Diseases 0.000 claims abstract description 16
- 208000027866 inflammatory disease Diseases 0.000 claims abstract description 15
- WEVYAHXRMPXWCK-UHFFFAOYSA-N methyl cyanide Natural products CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 298
- 150000001875 compounds Chemical class 0.000 claims description 225
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 137
- 125000000217 alkyl group Chemical group 0.000 claims description 132
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 105
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical group C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 91
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 85
- 150000003839 salts Chemical class 0.000 claims description 73
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 63
- 125000004432 carbon atom Chemical group C* 0.000 claims description 57
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 47
- 125000001072 heteroaryl group Chemical group 0.000 claims description 45
- 125000003566 oxetanyl group Chemical group 0.000 claims description 41
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 claims description 35
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 35
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 29
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 27
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 23
- 229910052757 nitrogen Inorganic materials 0.000 claims description 21
- 125000002393 azetidinyl group Chemical group 0.000 claims description 20
- 125000001188 haloalkyl group Chemical group 0.000 claims description 20
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical group C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 claims description 18
- 125000000304 alkynyl group Chemical group 0.000 claims description 18
- 229910052799 carbon Inorganic materials 0.000 claims description 18
- 125000003118 aryl group Chemical group 0.000 claims description 17
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 17
- 125000003342 alkenyl group Chemical group 0.000 claims description 16
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 13
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 13
- 201000004681 Psoriasis Diseases 0.000 claims description 12
- 125000003545 alkoxy group Chemical group 0.000 claims description 11
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 11
- 229910052739 hydrogen Inorganic materials 0.000 claims description 11
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 10
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 10
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 9
- 208000014767 Myeloproliferative disease Diseases 0.000 claims description 9
- 206010028537 myelofibrosis Diseases 0.000 claims description 9
- 208000006386 Bone Resorption Diseases 0.000 claims description 7
- 230000024279 bone resorption Effects 0.000 claims description 7
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 7
- 210000000056 organ Anatomy 0.000 claims description 7
- 208000003476 primary myelofibrosis Diseases 0.000 claims description 7
- 208000017520 skin disease Diseases 0.000 claims description 7
- 230000009885 systemic effect Effects 0.000 claims description 7
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims description 6
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 6
- 206010012442 Dermatitis contact Diseases 0.000 claims description 6
- 206010070834 Sensitisation Diseases 0.000 claims description 6
- 125000006598 aminocarbonylamino group Chemical group 0.000 claims description 6
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims description 6
- 206010003246 arthritis Diseases 0.000 claims description 6
- 208000019664 bone resorption disease Diseases 0.000 claims description 6
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 6
- 230000008313 sensitization Effects 0.000 claims description 6
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 5
- 208000009525 Myocarditis Diseases 0.000 claims description 5
- 208000010247 contact dermatitis Diseases 0.000 claims description 5
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 claims description 5
- 208000010201 Exanthema Diseases 0.000 claims description 4
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 claims description 4
- 206010070835 Skin sensitisation Diseases 0.000 claims description 4
- 125000003282 alkyl amino group Chemical group 0.000 claims description 4
- 230000001363 autoimmune Effects 0.000 claims description 4
- 201000005884 exanthem Diseases 0.000 claims description 4
- 201000008482 osteoarthritis Diseases 0.000 claims description 4
- 206010037844 rash Diseases 0.000 claims description 4
- 231100000370 skin sensitisation Toxicity 0.000 claims description 4
- 208000011231 Crohn disease Diseases 0.000 claims description 3
- 206010048643 Hypereosinophilic syndrome Diseases 0.000 claims description 3
- 108060003951 Immunoglobulin Proteins 0.000 claims description 3
- 125000004949 alkyl amino carbonyl amino group Chemical group 0.000 claims description 3
- 125000004471 alkyl aminosulfonyl group Chemical group 0.000 claims description 3
- 102000018358 immunoglobulin Human genes 0.000 claims description 3
- 208000017169 kidney disease Diseases 0.000 claims description 3
- 208000032839 leukemia Diseases 0.000 claims description 3
- 206010025135 lupus erythematosus Diseases 0.000 claims description 3
- 201000006417 multiple sclerosis Diseases 0.000 claims description 3
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 3
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 3
- 231100000046 skin rash Toxicity 0.000 claims description 3
- 206010003645 Atopy Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010073069 Hepatic cancer Diseases 0.000 claims description 2
- 208000003456 Juvenile Arthritis Diseases 0.000 claims description 2
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims description 2
- 208000007766 Kaposi sarcoma Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 2
- 206010040880 Skin irritation Diseases 0.000 claims description 2
- 208000024799 Thyroid disease Diseases 0.000 claims description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 2
- ZVQOOHYFBIDMTQ-UHFFFAOYSA-N [methyl(oxido){1-[6-(trifluoromethyl)pyridin-3-yl]ethyl}-lambda(6)-sulfanylidene]cyanamide Chemical compound N#CN=S(C)(=O)C(C)C1=CC=C(C(F)(F)F)N=C1 ZVQOOHYFBIDMTQ-UHFFFAOYSA-N 0.000 claims description 2
- 201000010902 chronic myelomonocytic leukemia Diseases 0.000 claims description 2
- 230000003054 hormonal effect Effects 0.000 claims description 2
- 238000001794 hormone therapy Methods 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 229910052702 rhenium Inorganic materials 0.000 claims description 2
- 230000036556 skin irritation Effects 0.000 claims description 2
- 231100000475 skin irritation Toxicity 0.000 claims description 2
- 201000002510 thyroid cancer Diseases 0.000 claims description 2
- 125000001475 halogen functional group Chemical group 0.000 claims 6
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- 125000006432 1-methyl cyclopropyl group Chemical group [H]C([H])([H])C1(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 235000009581 Balanites aegyptiaca Nutrition 0.000 claims 1
- 206010028372 Muscular weakness Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 claims 1
- 230000036473 myasthenia Effects 0.000 claims 1
- 230000002071 myeloproliferative effect Effects 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 102000015617 Janus Kinases Human genes 0.000 abstract description 26
- 108010024121 Janus Kinases Proteins 0.000 abstract description 26
- 230000000694 effects Effects 0.000 abstract description 26
- 238000011282 treatment Methods 0.000 abstract description 26
- 229910052740 iodine Inorganic materials 0.000 abstract description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 191
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 121
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 120
- 238000005481 NMR spectroscopy Methods 0.000 description 112
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 111
- 239000000047 product Substances 0.000 description 100
- 229910001868 water Inorganic materials 0.000 description 78
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 72
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 67
- 239000000243 solution Substances 0.000 description 66
- 238000006243 chemical reaction Methods 0.000 description 65
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 60
- 235000002639 sodium chloride Nutrition 0.000 description 58
- 238000003756 stirring Methods 0.000 description 57
- 235000019439 ethyl acetate Nutrition 0.000 description 52
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 48
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 47
- 239000003814 drug Substances 0.000 description 46
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 42
- 102000042838 JAK family Human genes 0.000 description 42
- 108091082332 JAK family Proteins 0.000 description 42
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 42
- 229910052938 sodium sulfate Inorganic materials 0.000 description 42
- 235000011152 sodium sulphate Nutrition 0.000 description 42
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 40
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 39
- 239000002904 solvent Substances 0.000 description 38
- 239000000284 extract Substances 0.000 description 34
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 34
- 238000006073 displacement reaction Methods 0.000 description 29
- 238000003818 flash chromatography Methods 0.000 description 29
- 238000000746 purification Methods 0.000 description 29
- 238000004293 19F NMR spectroscopy Methods 0.000 description 27
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 27
- 239000012267 brine Substances 0.000 description 27
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 27
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 27
- 239000000543 intermediate Substances 0.000 description 26
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 24
- 239000012458 free base Substances 0.000 description 24
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 23
- 238000010511 deprotection reaction Methods 0.000 description 23
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 23
- 229940124597 therapeutic agent Drugs 0.000 description 23
- 208000035475 disorder Diseases 0.000 description 22
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 21
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 21
- 102000004127 Cytokines Human genes 0.000 description 21
- 108090000695 Cytokines Proteins 0.000 description 21
- 210000004027 cell Anatomy 0.000 description 21
- 239000000741 silica gel Substances 0.000 description 21
- 229910002027 silica gel Inorganic materials 0.000 description 21
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 18
- 101000997832 Homo sapiens Tyrosine-protein kinase JAK2 Proteins 0.000 description 18
- 238000012360 testing method Methods 0.000 description 18
- 102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 description 17
- 239000003795 chemical substances by application Substances 0.000 description 17
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 17
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 16
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 16
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 16
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 16
- 239000002253 acid Substances 0.000 description 16
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 16
- 239000004480 active ingredient Substances 0.000 description 15
- 239000012043 crude product Substances 0.000 description 15
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 15
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 15
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 15
- 206010013774 Dry eye Diseases 0.000 description 14
- 229920000642 polymer Polymers 0.000 description 14
- 239000011541 reaction mixture Substances 0.000 description 14
- 239000007787 solid Substances 0.000 description 14
- 239000011592 zinc chloride Substances 0.000 description 14
- 235000005074 zinc chloride Nutrition 0.000 description 14
- DYLIWHYUXAJDOJ-OWOJBTEDSA-N (e)-4-(6-aminopurin-9-yl)but-2-en-1-ol Chemical compound NC1=NC=NC2=C1N=CN2C\C=C\CO DYLIWHYUXAJDOJ-OWOJBTEDSA-N 0.000 description 13
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 13
- 125000005843 halogen group Chemical group 0.000 description 13
- 125000002950 monocyclic group Chemical group 0.000 description 13
- 230000002829 reductive effect Effects 0.000 description 13
- 235000011121 sodium hydroxide Nutrition 0.000 description 13
- 108010000837 Janus Kinase 1 Proteins 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 102100033438 Tyrosine-protein kinase JAK1 Human genes 0.000 description 12
- 230000015572 biosynthetic process Effects 0.000 description 12
- 125000005842 heteroatom Chemical group 0.000 description 12
- 239000000546 pharmaceutical excipient Substances 0.000 description 12
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 12
- 230000002401 inhibitory effect Effects 0.000 description 11
- 239000011159 matrix material Substances 0.000 description 11
- IZDROVVXIHRYMH-UHFFFAOYSA-N methanesulfonic anhydride Chemical compound CS(=O)(=O)OS(C)(=O)=O IZDROVVXIHRYMH-UHFFFAOYSA-N 0.000 description 11
- 230000000699 topical effect Effects 0.000 description 11
- 125000003821 2-(trimethylsilyl)ethoxymethyl group Chemical group [H]C([H])([H])[Si](C([H])([H])[H])(C([H])([H])[H])C([H])([H])C(OC([H])([H])[*])([H])[H] 0.000 description 10
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 10
- 239000002552 dosage form Substances 0.000 description 10
- 239000003921 oil Substances 0.000 description 10
- 235000019198 oils Nutrition 0.000 description 10
- 229910052760 oxygen Inorganic materials 0.000 description 10
- 239000008194 pharmaceutical composition Substances 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 229910052717 sulfur Inorganic materials 0.000 description 10
- 239000000725 suspension Substances 0.000 description 10
- 241000282414 Homo sapiens Species 0.000 description 9
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 9
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 9
- 239000002585 base Substances 0.000 description 9
- 125000002619 bicyclic group Chemical group 0.000 description 9
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 9
- 229960003957 dexamethasone Drugs 0.000 description 9
- 238000009472 formulation Methods 0.000 description 9
- 230000005764 inhibitory process Effects 0.000 description 9
- 239000002674 ointment Substances 0.000 description 9
- 239000008177 pharmaceutical agent Substances 0.000 description 9
- 239000000843 powder Substances 0.000 description 9
- 239000011734 sodium Substances 0.000 description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- 206010061218 Inflammation Diseases 0.000 description 8
- 108091000080 Phosphotransferase Proteins 0.000 description 8
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 8
- 125000002947 alkylene group Chemical group 0.000 description 8
- 238000003556 assay Methods 0.000 description 8
- 125000004429 atom Chemical group 0.000 description 8
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 8
- 230000008901 benefit Effects 0.000 description 8
- 239000010410 layer Substances 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 239000001301 oxygen Substances 0.000 description 8
- 239000002245 particle Substances 0.000 description 8
- 102000020233 phosphotransferase Human genes 0.000 description 8
- 230000004044 response Effects 0.000 description 8
- 239000011593 sulfur Substances 0.000 description 8
- 0 *Cc1cc(OC(CC2)CCN2C(C2)CC2(CC#N)[n]2ncc(-c3c(cc[n]4)c4ncn3)c2)nc(C(F)(F)F)c1 Chemical compound *Cc1cc(OC(CC2)CCN2C(C2)CC2(CC#N)[n]2ncc(-c3c(cc[n]4)c4ncn3)c2)nc(C(F)(F)F)c1 0.000 description 7
- 208000032027 Essential Thrombocythemia Diseases 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 206010035226 Plasma cell myeloma Diseases 0.000 description 7
- 208000017733 acquired polycythemia vera Diseases 0.000 description 7
- 150000001721 carbon Chemical group 0.000 description 7
- 239000010408 film Substances 0.000 description 7
- 230000014509 gene expression Effects 0.000 description 7
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 7
- 230000004054 inflammatory process Effects 0.000 description 7
- 229940043355 kinase inhibitor Drugs 0.000 description 7
- 230000014759 maintenance of location Effects 0.000 description 7
- 230000007170 pathology Effects 0.000 description 7
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 7
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 7
- 208000037244 polycythemia vera Diseases 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 238000006722 reduction reaction Methods 0.000 description 7
- 238000000926 separation method Methods 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 230000005951 type IV hypersensitivity Effects 0.000 description 7
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 6
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical group CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 6
- 201000004624 Dermatitis Diseases 0.000 description 6
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 6
- 101000617830 Homo sapiens Sterol O-acyltransferase 1 Proteins 0.000 description 6
- 101000934996 Homo sapiens Tyrosine-protein kinase JAK3 Proteins 0.000 description 6
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 6
- 208000034578 Multiple myelomas Diseases 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 229940124639 Selective inhibitor Drugs 0.000 description 6
- 102100021993 Sterol O-acyltransferase 1 Human genes 0.000 description 6
- 101000697584 Streptomyces lavendulae Streptothricin acetyltransferase Proteins 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 6
- 102100025387 Tyrosine-protein kinase JAK3 Human genes 0.000 description 6
- 206010046851 Uveitis Diseases 0.000 description 6
- 150000007513 acids Chemical class 0.000 description 6
- 150000001412 amines Chemical class 0.000 description 6
- 238000001704 evaporation Methods 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 238000010438 heat treatment Methods 0.000 description 6
- 239000003112 inhibitor Substances 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 230000011664 signaling Effects 0.000 description 6
- 239000012279 sodium borohydride Substances 0.000 description 6
- 229910000033 sodium borohydride Inorganic materials 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 6
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 description 5
- 108090001005 Interleukin-6 Proteins 0.000 description 5
- 241000283984 Rodentia Species 0.000 description 5
- 210000001744 T-lymphocyte Anatomy 0.000 description 5
- 206010052779 Transplant rejections Diseases 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 5
- 239000003246 corticosteroid Substances 0.000 description 5
- SHQSVMDWKBRBGB-UHFFFAOYSA-N cyclobutanone Chemical compound O=C1CCC1 SHQSVMDWKBRBGB-UHFFFAOYSA-N 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 239000006196 drop Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 210000005069 ears Anatomy 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 239000003102 growth factor Substances 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 230000002757 inflammatory effect Effects 0.000 description 5
- 239000004005 microsphere Substances 0.000 description 5
- 239000002480 mineral oil Substances 0.000 description 5
- 235000010446 mineral oil Nutrition 0.000 description 5
- 239000012044 organic layer Substances 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 210000002345 respiratory system Anatomy 0.000 description 5
- 210000003491 skin Anatomy 0.000 description 5
- 239000008247 solid mixture Substances 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- LZRDHSFPLUWYAX-UHFFFAOYSA-N tert-butyl 4-aminopiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(N)CC1 LZRDHSFPLUWYAX-UHFFFAOYSA-N 0.000 description 5
- 239000012049 topical pharmaceutical composition Substances 0.000 description 5
- LBUJPTNKIBCYBY-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinoline Chemical compound C1=CC=C2CCCNC2=C1 LBUJPTNKIBCYBY-UHFFFAOYSA-N 0.000 description 4
- MYEAZMKFNMHNGR-UHFFFAOYSA-N 2-[3-oxo-1-[4-[7-(2-trimethylsilylethoxymethyl)pyrrolo[2,3-d]pyrimidin-4-yl]pyrazol-1-yl]cyclobutyl]acetonitrile Chemical compound N1=CN=C2N(COCC[Si](C)(C)C)C=CC2=C1C(=C1)C=NN1C1(CC#N)CC(=O)C1 MYEAZMKFNMHNGR-UHFFFAOYSA-N 0.000 description 4
- XUMSHCRPQCZRGX-UHFFFAOYSA-N 3-aminocyclobutan-1-ol;hydrochloride Chemical compound Cl.NC1CC(O)C1 XUMSHCRPQCZRGX-UHFFFAOYSA-N 0.000 description 4
- 206010010741 Conjunctivitis Diseases 0.000 description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
- 206010020751 Hypersensitivity Diseases 0.000 description 4
- 230000004163 JAK-STAT signaling pathway Effects 0.000 description 4
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 4
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 4
- 241001529936 Murinae Species 0.000 description 4
- 101100335081 Mus musculus Flt3 gene Proteins 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 206010039705 Scleritis Diseases 0.000 description 4
- 229920002125 Sokalan® Polymers 0.000 description 4
- 235000011114 ammonium hydroxide Nutrition 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 125000003710 aryl alkyl group Chemical group 0.000 description 4
- 208000006673 asthma Diseases 0.000 description 4
- 229920002988 biodegradable polymer Polymers 0.000 description 4
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 4
- 229920001577 copolymer Polymers 0.000 description 4
- KJOZJSGOIJQCGA-UHFFFAOYSA-N dichloromethane;2,2,2-trifluoroacetic acid Chemical compound ClCCl.OC(=O)C(F)(F)F KJOZJSGOIJQCGA-UHFFFAOYSA-N 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 230000008020 evaporation Effects 0.000 description 4
- 230000007062 hydrolysis Effects 0.000 description 4
- 238000006460 hydrolysis reaction Methods 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000028709 inflammatory response Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- TWBYWOBDOCUKOW-UHFFFAOYSA-N isonicotinic acid Chemical compound OC(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-N 0.000 description 4
- 229960004592 isopropanol Drugs 0.000 description 4
- 201000005962 mycosis fungoides Diseases 0.000 description 4
- 239000002105 nanoparticle Substances 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- 239000004584 polyacrylic acid Substances 0.000 description 4
- 125000003367 polycyclic group Chemical group 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 125000006239 protecting group Chemical group 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 125000006413 ring segment Chemical group 0.000 description 4
- 238000011808 rodent model Methods 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 125000000037 tert-butyldiphenylsilyl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1[Si]([H])([*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 4
- 238000011200 topical administration Methods 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 3
- LOTKRQAVGJMPNV-UHFFFAOYSA-N 1-fluoro-2,4-dinitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(F)C([N+]([O-])=O)=C1 LOTKRQAVGJMPNV-UHFFFAOYSA-N 0.000 description 3
- DVPXDZWZLKNLJX-UHFFFAOYSA-N 3,3-dimethylazetidine;hydrochloride Chemical compound Cl.CC1(C)CNC1 DVPXDZWZLKNLJX-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 108010036949 Cyclosporine Proteins 0.000 description 3
- 102100037813 Focal adhesion kinase 1 Human genes 0.000 description 3
- 101000632319 Homo sapiens Septin-7 Proteins 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 239000004372 Polyvinyl alcohol Substances 0.000 description 3
- 102000001253 Protein Kinase Human genes 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 102100027981 Septin-7 Human genes 0.000 description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 102100025093 Zinc fingers and homeoboxes protein 2 Human genes 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- 235000019270 ammonium chloride Nutrition 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 208000007502 anemia Diseases 0.000 description 3
- 239000007900 aqueous suspension Substances 0.000 description 3
- 230000037182 bone density Effects 0.000 description 3
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 3
- PBAYDYUZOSNJGU-UHFFFAOYSA-N chelidonic acid Natural products OC(=O)C1=CC(=O)C=C(C(O)=O)O1 PBAYDYUZOSNJGU-UHFFFAOYSA-N 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000000973 chemotherapeutic effect Effects 0.000 description 3
- 238000004296 chiral HPLC Methods 0.000 description 3
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 210000000744 eyelid Anatomy 0.000 description 3
- FEBLZLNTKCEFIT-VSXGLTOVSA-N fluocinolone acetonide Chemical group C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O FEBLZLNTKCEFIT-VSXGLTOVSA-N 0.000 description 3
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 3
- 125000005885 heterocycloalkylalkyl group Chemical group 0.000 description 3
- 238000002868 homogeneous time resolved fluorescence Methods 0.000 description 3
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 3
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 3
- 239000003018 immunosuppressive agent Substances 0.000 description 3
- 239000003456 ion exchange resin Substances 0.000 description 3
- 229920003303 ion-exchange polymer Polymers 0.000 description 3
- 201000004614 iritis Diseases 0.000 description 3
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 3
- 229960001924 melphalan Drugs 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 3
- 230000026731 phosphorylation Effects 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 3
- 229920001610 polycaprolactone Polymers 0.000 description 3
- 239000004632 polycaprolactone Substances 0.000 description 3
- 229920002451 polyvinyl alcohol Polymers 0.000 description 3
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 3
- 108060006633 protein kinase Proteins 0.000 description 3
- 206010039083 rhinitis Diseases 0.000 description 3
- QTTRZHGPGKRAFB-OOKHYKNYSA-N rimexolone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CC)(C)[C@@]1(C)C[C@@H]2O QTTRZHGPGKRAFB-OOKHYKNYSA-N 0.000 description 3
- 239000012312 sodium hydride Substances 0.000 description 3
- 229910000104 sodium hydride Inorganic materials 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- DGPDOSYSAGNAEW-UHFFFAOYSA-N tert-butyl 2-chloro-6-(trifluoromethyl)pyridine-4-carboxylate Chemical compound CC(C)(C)OC(=O)C1=CC(Cl)=NC(C(F)(F)F)=C1 DGPDOSYSAGNAEW-UHFFFAOYSA-N 0.000 description 3
- PWQLFIKTGRINFF-UHFFFAOYSA-N tert-butyl 4-hydroxypiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(O)CC1 PWQLFIKTGRINFF-UHFFFAOYSA-N 0.000 description 3
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 3
- 230000002103 transcriptional effect Effects 0.000 description 3
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- 239000003643 water by type Substances 0.000 description 3
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- FFTVPQUHLQBXQZ-KVUCHLLUSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 description 2
- ZPFAVCIQZKRBGF-UHFFFAOYSA-N 1,3,2-dioxathiolane 2,2-dioxide Chemical compound O=S1(=O)OCCO1 ZPFAVCIQZKRBGF-UHFFFAOYSA-N 0.000 description 2
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 2
- MVXVYAKCVDQRLW-UHFFFAOYSA-N 1h-pyrrolo[2,3-b]pyridine Chemical compound C1=CN=C2NC=CC2=C1 MVXVYAKCVDQRLW-UHFFFAOYSA-N 0.000 description 2
- CNIIGCLFLJGOGP-UHFFFAOYSA-N 2-(1-naphthalenylmethyl)-4,5-dihydro-1H-imidazole Chemical compound C=1C=CC2=CC=CC=C2C=1CC1=NCCN1 CNIIGCLFLJGOGP-UHFFFAOYSA-N 0.000 description 2
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 2
- OWAVBHXGGCELLQ-UHFFFAOYSA-N 2-[2-chloro-6-(trifluoromethyl)pyridin-4-yl]ethanol Chemical compound OCCC1=CC(Cl)=NC(C(F)(F)F)=C1 OWAVBHXGGCELLQ-UHFFFAOYSA-N 0.000 description 2
- OKDGRDCXVWSXDC-UHFFFAOYSA-N 2-chloropyridine Chemical compound ClC1=CC=CC=N1 OKDGRDCXVWSXDC-UHFFFAOYSA-N 0.000 description 2
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 2
- HPJALMWOZYIZGE-UHFFFAOYSA-N 2-oxa-6-azaspiro[3.3]heptane Chemical compound C1NCC11COC1 HPJALMWOZYIZGE-UHFFFAOYSA-N 0.000 description 2
- YQEMORVAKMFKLG-UHFFFAOYSA-N 2-stearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 2
- 206010006895 Cachexia Diseases 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 2
- 206010009900 Colitis ulcerative Diseases 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 206010010099 Combined immunodeficiency Diseases 0.000 description 2
- 208000013586 Complex regional pain syndrome type 1 Diseases 0.000 description 2
- 108010062580 Concanavalin A Proteins 0.000 description 2
- 206010011715 Cyclitis Diseases 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 206010015084 Episcleritis Diseases 0.000 description 2
- 108010075944 Erythropoietin Receptors Proteins 0.000 description 2
- 102100036509 Erythropoietin receptor Human genes 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 208000009386 Experimental Arthritis Diseases 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 201000005569 Gout Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 2
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 2
- 241000701806 Human papillomavirus Species 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 208000004575 Infectious Arthritis Diseases 0.000 description 2
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 208000029725 Metabolic bone disease Diseases 0.000 description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- OPKOKAMJFNKNAS-UHFFFAOYSA-N N-methylethanolamine Chemical compound CNCCO OPKOKAMJFNKNAS-UHFFFAOYSA-N 0.000 description 2
- 229910017974 NH40H Inorganic materials 0.000 description 2
- 206010049088 Osteopenia Diseases 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- NMLMACJWHPHKGR-NCOIDOBVSA-N P(1),P(4)-bis(uridin-5'-yl) tetraphosphate Chemical compound N1([C@@H]2O[C@@H]([C@H]([C@H]2O)O)COP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@H]([C@@H](O2)N2C(NC(=O)C=C2)=O)O)O)C=CC(=O)NC1=O NMLMACJWHPHKGR-NCOIDOBVSA-N 0.000 description 2
- 206010034277 Pemphigoid Diseases 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 108010047620 Phytohemagglutinins Proteins 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 2
- 108091008611 Protein Kinase B Proteins 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 201000001947 Reflex Sympathetic Dystrophy Diseases 0.000 description 2
- 208000021386 Sjogren Syndrome Diseases 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 description 2
- 201000008736 Systemic mastocytosis Diseases 0.000 description 2
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- 102000000887 Transcription factor STAT Human genes 0.000 description 2
- 108050007918 Transcription factor STAT Proteins 0.000 description 2
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 150000001336 alkenes Chemical class 0.000 description 2
- 125000004450 alkenylene group Chemical group 0.000 description 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 2
- 125000005115 alkyl carbamoyl group Chemical group 0.000 description 2
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 2
- 125000004644 alkyl sulfinyl group Chemical group 0.000 description 2
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 2
- 125000004414 alkyl thio group Chemical group 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 150000008064 anhydrides Chemical class 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 2
- 239000000607 artificial tear Substances 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 239000004621 biodegradable polymer Substances 0.000 description 2
- 229920013641 bioerodible polymer Polymers 0.000 description 2
- 239000004305 biphenyl Substances 0.000 description 2
- 235000010290 biphenyl Nutrition 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000010072 bone remodeling Effects 0.000 description 2
- 229960001467 bortezomib Drugs 0.000 description 2
- 206010006451 bronchitis Diseases 0.000 description 2
- 208000000594 bullous pemphigoid Diseases 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 210000000845 cartilage Anatomy 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 125000003636 chemical group Chemical group 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 229960001265 ciclosporin Drugs 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000012230 colorless oil Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- LPIQUOYDBNQMRZ-UHFFFAOYSA-N cyclopentene Chemical compound C1CC=CC1 LPIQUOYDBNQMRZ-UHFFFAOYSA-N 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 229930182912 cyclosporin Natural products 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 2
- 229910052805 deuterium Inorganic materials 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 229950003529 diquafosol Drugs 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 229960004679 doxorubicin Drugs 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000012055 enteric layer Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 238000010575 fractional recrystallization Methods 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 229940014259 gelatin Drugs 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000002489 hematologic effect Effects 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 2
- 229960002411 imatinib Drugs 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000008629 immune suppression Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 208000026278 immune system disease Diseases 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 229960003444 immunosuppressant agent Drugs 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 210000004561 lacrimal apparatus Anatomy 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- IUYHWZFSGMZEOG-UHFFFAOYSA-M magnesium;propane;chloride Chemical compound [Mg+2].[Cl-].C[CH-]C IUYHWZFSGMZEOG-UHFFFAOYSA-M 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 210000003593 megakaryocyte Anatomy 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 238000003801 milling Methods 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 229960004023 minocycline Drugs 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 206010028417 myasthenia gravis Diseases 0.000 description 2
- 125000006574 non-aromatic ring group Chemical group 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 2
- TWSTVYFPWIGASI-UHFFFAOYSA-N oxetan-3-ol Chemical compound OC1COC1.OC1COC1 TWSTVYFPWIGASI-UHFFFAOYSA-N 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 230000001885 phytohemagglutinin Effects 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 229960004618 prednisone Drugs 0.000 description 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 238000002390 rotary evaporation Methods 0.000 description 2
- 201000000306 sarcoidosis Diseases 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 238000007423 screening assay Methods 0.000 description 2
- 201000001223 septic arthritis Diseases 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 201000009890 sinusitis Diseases 0.000 description 2
- 229960001922 sodium perborate Drugs 0.000 description 2
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 2
- YKLJGMBLPUQQOI-UHFFFAOYSA-M sodium;oxidooxy(oxo)borane Chemical compound [Na+].[O-]OB=O YKLJGMBLPUQQOI-UHFFFAOYSA-M 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- BNWFLFQIJRPMHC-UHFFFAOYSA-N tert-butyl 4-[[4-(hydroxymethyl)-6-(trifluoromethyl)pyridin-2-yl]-methylamino]piperidine-1-carboxylate Chemical compound C=1C(CO)=CC(C(F)(F)F)=NC=1N(C)C1CCN(C(=O)OC(C)(C)C)CC1 BNWFLFQIJRPMHC-UHFFFAOYSA-N 0.000 description 2
- SGADHBKDBASSPN-UHFFFAOYSA-N tert-butyl-(1,3-dibromopropan-2-yloxy)-diphenylsilane Chemical compound C=1C=CC=CC=1[Si](OC(CBr)CBr)(C(C)(C)C)C1=CC=CC=C1 SGADHBKDBASSPN-UHFFFAOYSA-N 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 150000003522 tetracyclines Chemical class 0.000 description 2
- 229960003433 thalidomide Drugs 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 206010043554 thrombocytopenia Diseases 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- YWWDBCBWQNCYNR-UHFFFAOYSA-N trimethylphosphine Chemical compound CP(C)C YWWDBCBWQNCYNR-UHFFFAOYSA-N 0.000 description 2
- ONDSBJMLAHVLMI-UHFFFAOYSA-N trimethylsilyldiazomethane Chemical compound C[Si](C)(C)[CH-][N+]#N ONDSBJMLAHVLMI-UHFFFAOYSA-N 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- 229910052722 tritium Inorganic materials 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 description 1
- FMCGSUUBYTWNDP-ONGXEEELSA-N (1R,2S)-2-(dimethylamino)-1-phenyl-1-propanol Chemical compound CN(C)[C@@H](C)[C@H](O)C1=CC=CC=C1 FMCGSUUBYTWNDP-ONGXEEELSA-N 0.000 description 1
- SFWLDKQAUHFCBS-AOEYGKNYSA-N (1S,4S,13S,16S,19S,22S,25S,28R,31S,37S,40S,41S,44R,47S,50S,53S,56R,65S,70S)-44-amino-47-(4-aminobutyl)-4,16,22-tribenzyl-31-[(R)-carboxy(hydroxy)methyl]-2,5,14,17,20,23,26,29,32,35,38,45,48,51,54,57,67-heptadecahydroxy-37-(2-hydroxy-2-iminoethyl)-50-(3-hydroxy-3-iminopropyl)-41,70-dimethyl-8-oxo-25-propan-2-yl-42,69,72-trithia-3,6,9,15,18,21,24,27,30,33,36,39,46,49,52,55,58,60,66-nonadecazapentacyclo[38.18.9.319,56.328,53.09,13]triheptaconta-2,5,14,17,20,23,26,29,32,35,38,45,48,51,54,57,66-heptadecaene-65-carboxylic acid Chemical compound CC(C)[C@@H]1\N=C(O)/[C@H](Cc2ccccc2)\N=C(O)/[C@@H]2\N=C(O)/[C@H](Cc3ccccc3)\N=C(O)/[C@@H]3CCCN3C(=O)C\N=C(O)/[C@H](Cc3ccccc3)\N=C(O)/[C@@H]3CNCCCC[C@H](\N=C(O)\[C@@H]4\N=C(O)\[C@H](CC(O)=N)\N=C(O)\C\N=C(O)/[C@@H](\N=C(O)\[C@H](CSC[C@@H](N=C(O)[C@H](CCC(O)=N)N=C(O)[C@H](CCCCN)N=C(O)[C@@H](N)CS[C@H]4C)C(O)=N[C@@H](CS[C@H]2C)C(O)=N3)\N=C1\O)[C@@H](O)C(O)=O)C(O)=O SFWLDKQAUHFCBS-AOEYGKNYSA-N 0.000 description 1
- HXKKHQJGJAFBHI-GSVOUGTGSA-N (2R)-1-aminopropan-2-ol Chemical compound C[C@@H](O)CN HXKKHQJGJAFBHI-GSVOUGTGSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- BKMMTJMQCTUHRP-GSVOUGTGSA-N (2r)-2-aminopropan-1-ol Chemical compound C[C@@H](N)CO BKMMTJMQCTUHRP-GSVOUGTGSA-N 0.000 description 1
- DNISEZBAYYIQFB-PHDIDXHHSA-N (2r,3r)-2,3-diacetyloxybutanedioic acid Chemical compound CC(=O)O[C@@H](C(O)=O)[C@H](C(O)=O)OC(C)=O DNISEZBAYYIQFB-PHDIDXHHSA-N 0.000 description 1
- HXKKHQJGJAFBHI-VKHMYHEASA-N (2s)-1-aminopropan-2-ol Chemical compound C[C@H](O)CN HXKKHQJGJAFBHI-VKHMYHEASA-N 0.000 description 1
- MDKGKXOCJGEUJW-VIFPVBQESA-N (2s)-2-[4-(thiophene-2-carbonyl)phenyl]propanoic acid Chemical compound C1=CC([C@@H](C(O)=O)C)=CC=C1C(=O)C1=CC=CS1 MDKGKXOCJGEUJW-VIFPVBQESA-N 0.000 description 1
- PHOZOHFUXHPOCK-QMMMGPOBSA-N (2s)-2-ethyl-8-methyl-1-thia-4,8-diazaspiro[4.5]decan-3-one Chemical compound N1C(=O)[C@H](CC)SC11CCN(C)CC1 PHOZOHFUXHPOCK-QMMMGPOBSA-N 0.000 description 1
- MHOVLDXJDIEEMJ-PGMHMLKASA-N (3r)-oxolan-3-amine;hydrochloride Chemical compound Cl.N[C@@H]1CCOC1 MHOVLDXJDIEEMJ-PGMHMLKASA-N 0.000 description 1
- JHHZLHWJQPUNKB-SCSAIBSYSA-N (3r)-pyrrolidin-3-ol Chemical compound O[C@@H]1CCNC1 JHHZLHWJQPUNKB-SCSAIBSYSA-N 0.000 description 1
- MHOVLDXJDIEEMJ-WCCKRBBISA-N (3s)-oxolan-3-amine;hydrochloride Chemical compound Cl.N[C@H]1CCOC1 MHOVLDXJDIEEMJ-WCCKRBBISA-N 0.000 description 1
- JHHZLHWJQPUNKB-BYPYZUCNSA-N (3s)-pyrrolidin-3-ol Chemical compound O[C@H]1CCNC1 JHHZLHWJQPUNKB-BYPYZUCNSA-N 0.000 description 1
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 1
- HMLGSIZOMSVISS-ONJSNURVSA-N (7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2,2-dimethylpropanoyloxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@@H]1C(N2C(=C(C=C)CSC21)C(O)=O)=O)C(=O)\C(=N/OCOC(=O)C(C)(C)C)C1=CSC(N)=N1 HMLGSIZOMSVISS-ONJSNURVSA-N 0.000 description 1
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 description 1
- BKMMTJMQCTUHRP-VKHMYHEASA-N (S)-2-aminopropan-1-ol Chemical compound C[C@H](N)CO BKMMTJMQCTUHRP-VKHMYHEASA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- 125000004502 1,2,3-oxadiazolyl group Chemical group 0.000 description 1
- 125000004511 1,2,3-thiadiazolyl group Chemical group 0.000 description 1
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 description 1
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 description 1
- 125000004514 1,2,4-thiadiazolyl group Chemical group 0.000 description 1
- 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 description 1
- KTZQTRPPVKQPFO-UHFFFAOYSA-N 1,2-benzoxazole Chemical compound C1=CC=C2C=NOC2=C1 KTZQTRPPVKQPFO-UHFFFAOYSA-N 0.000 description 1
- QGVDSWMSHDZOMW-UHFFFAOYSA-N 1,3,2-dioxathiolane Chemical compound C1COSO1 QGVDSWMSHDZOMW-UHFFFAOYSA-N 0.000 description 1
- 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 description 1
- 125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 description 1
- FLBAYUMRQUHISI-UHFFFAOYSA-N 1,8-naphthyridine Chemical compound N1=CC=CC2=CC=CN=C21 FLBAYUMRQUHISI-UHFFFAOYSA-N 0.000 description 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
- RQEUFEKYXDPUSK-UHFFFAOYSA-N 1-phenylethylamine Chemical compound CC(N)C1=CC=CC=C1 RQEUFEKYXDPUSK-UHFFFAOYSA-N 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- JSFATNQSLKRBCI-VAEKSGALSA-N 15(S)-HETE Chemical compound CCCCC[C@H](O)\C=C\C=C/C\C=C/C\C=C/CCCC(O)=O JSFATNQSLKRBCI-VAEKSGALSA-N 0.000 description 1
- XWIYUCRMWCHYJR-UHFFFAOYSA-N 1h-pyrrolo[3,2-b]pyridine Chemical compound C1=CC=C2NC=CC2=N1 XWIYUCRMWCHYJR-UHFFFAOYSA-N 0.000 description 1
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 1
- LSIXBBPOJBJQHN-UHFFFAOYSA-N 2,3-Dimethylbicyclo[2.2.1]hept-2-ene Chemical compound C1CC2C(C)=C(C)C1C2 LSIXBBPOJBJQHN-UHFFFAOYSA-N 0.000 description 1
- SNTWKPAKVQFCCF-UHFFFAOYSA-N 2,3-dihydro-1h-triazole Chemical compound N1NC=CN1 SNTWKPAKVQFCCF-UHFFFAOYSA-N 0.000 description 1
- GRXQKQOTJVCSLM-UHFFFAOYSA-N 2-(1h-pyrazol-4-yl)-7h-pyrrolo[2,3-d]pyrimidine Chemical compound N1=C2NC=CC2=CN=C1C=1C=NNC=1 GRXQKQOTJVCSLM-UHFFFAOYSA-N 0.000 description 1
- MJKCEAQJGAVKPX-UHFFFAOYSA-N 2-(methylamino)piperidine-1-carboxylic acid Chemical compound CNC1CCCCN1C(O)=O MJKCEAQJGAVKPX-UHFFFAOYSA-N 0.000 description 1
- UZYQSNQJLWTICD-UHFFFAOYSA-N 2-(n-benzoylanilino)-2,2-dinitroacetic acid Chemical compound C=1C=CC=CC=1N(C(C(=O)O)([N+]([O-])=O)[N+]([O-])=O)C(=O)C1=CC=CC=C1 UZYQSNQJLWTICD-UHFFFAOYSA-N 0.000 description 1
- WFWUVWTUXHHFSI-UHFFFAOYSA-N 2-[2-piperidin-4-yloxy-6-(trifluoromethyl)pyridin-4-yl]ethanol Chemical compound FC(F)(F)C1=CC(CCO)=CC(OC2CCNCC2)=N1 WFWUVWTUXHHFSI-UHFFFAOYSA-N 0.000 description 1
- NYNXJUXMNDCLPM-UHFFFAOYSA-N 2-[3-[tert-butyl(diphenyl)silyl]oxycyclobutylidene]acetonitrile Chemical compound C=1C=CC=CC=1[Si](C=1C=CC=CC=1)(C(C)(C)C)OC1CC(=CC#N)C1 NYNXJUXMNDCLPM-UHFFFAOYSA-N 0.000 description 1
- LITLYURNEZUUDO-UHFFFAOYSA-N 2-[3-oxo-1-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]cyclobutyl]acetonitrile Chemical compound C1C(=O)CC1(CC#N)N1N=CC(C=2C=3C=CNC=3N=CN=2)=C1 LITLYURNEZUUDO-UHFFFAOYSA-N 0.000 description 1
- LOKHZMGNOVQHAI-UHFFFAOYSA-N 2-[3-oxo-1-[4-[1-(2-trimethylsilylethoxymethyl)pyrrolo[2,3-b]pyridin-4-yl]pyrazol-1-yl]cyclobutyl]acetonitrile Chemical compound C1=CN=C2N(COCC[Si](C)(C)C)C=CC2=C1C(=C1)C=NN1C1(CC#N)CC(=O)C1 LOKHZMGNOVQHAI-UHFFFAOYSA-N 0.000 description 1
- IJXJGQCXFSSHNL-UHFFFAOYSA-N 2-amino-2-phenylethanol Chemical compound OCC(N)C1=CC=CC=C1 IJXJGQCXFSSHNL-UHFFFAOYSA-N 0.000 description 1
- JHKQSKCFLAXPKK-UHFFFAOYSA-N 2-chloro-4-iodo-6-(trifluoromethyl)pyridine Chemical compound FC(F)(F)C1=CC(I)=CC(Cl)=N1 JHKQSKCFLAXPKK-UHFFFAOYSA-N 0.000 description 1
- ADVQMCQMDHBTHJ-UHFFFAOYSA-N 2-chloro-6-(trifluoromethyl)pyridine Chemical compound FC(F)(F)C1=CC=CC(Cl)=N1 ADVQMCQMDHBTHJ-UHFFFAOYSA-N 0.000 description 1
- KWMBADTWRIGGGG-UHFFFAOYSA-N 2-diethoxyphosphorylacetonitrile Chemical compound CCOP(=O)(CC#N)OCC KWMBADTWRIGGGG-UHFFFAOYSA-N 0.000 description 1
- AUVALWUPUHHNQV-UHFFFAOYSA-N 2-hydroxy-3-propylbenzoic acid Chemical class CCCC1=CC=CC(C(O)=O)=C1O AUVALWUPUHHNQV-UHFFFAOYSA-N 0.000 description 1
- ASUDFOJKTJLAIK-UHFFFAOYSA-N 2-methoxyethanamine Chemical compound COCCN ASUDFOJKTJLAIK-UHFFFAOYSA-N 0.000 description 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
- VHMICKWLTGFITH-UHFFFAOYSA-N 2H-isoindole Chemical compound C1=CC=CC2=CNC=C21 VHMICKWLTGFITH-UHFFFAOYSA-N 0.000 description 1
- MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 1
- YYVPZQADFREIFR-UHFFFAOYSA-N 3,3-difluoropyrrolidine;hydrochloride Chemical compound [Cl-].FC1(F)CC[NH2+]C1 YYVPZQADFREIFR-UHFFFAOYSA-N 0.000 description 1
- UVCFMVJBVVLPAC-UHFFFAOYSA-N 3-[2-chloro-6-(trifluoromethyl)pyridin-4-yl]oxetan-3-ol Chemical compound C=1C(Cl)=NC(C(F)(F)F)=CC=1C1(O)COC1 UVCFMVJBVVLPAC-UHFFFAOYSA-N 0.000 description 1
- NUKGKQXCAFBCJI-UHFFFAOYSA-N 3-[2-piperidin-4-yloxy-6-(trifluoromethyl)pyridin-4-yl]oxetan-3-ol Chemical compound C=1C(OC2CCNCC2)=NC(C(F)(F)F)=CC=1C1(O)COC1 NUKGKQXCAFBCJI-UHFFFAOYSA-N 0.000 description 1
- 125000006305 3-iodophenyl group Chemical group [H]C1=C([H])C(I)=C([H])C(*)=C1[H] 0.000 description 1
- NQVWMPOQWBDSAI-UHFFFAOYSA-N 3-methyloxetan-3-amine Chemical compound CC1(N)COC1 NQVWMPOQWBDSAI-UHFFFAOYSA-N 0.000 description 1
- ROADCYAOHVSOLQ-UHFFFAOYSA-N 3-oxetanone Chemical compound O=C1COC1 ROADCYAOHVSOLQ-UHFFFAOYSA-N 0.000 description 1
- QFWVAJQVYBRTCL-UHFFFAOYSA-N 4,6-dichloro-2-(trifluoromethyl)pyrimidine Chemical compound FC(F)(F)C1=NC(Cl)=CC(Cl)=N1 QFWVAJQVYBRTCL-UHFFFAOYSA-N 0.000 description 1
- XJPZKYIHCLDXST-UHFFFAOYSA-N 4,6-dichloropyrimidine Chemical class ClC1=CC(Cl)=NC=N1 XJPZKYIHCLDXST-UHFFFAOYSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- CYKQBISFMXUEBJ-UHFFFAOYSA-N 4-(methylamino)piperidine-1-carboxylic acid Chemical compound CNC1CCN(C(O)=O)CC1 CYKQBISFMXUEBJ-UHFFFAOYSA-N 0.000 description 1
- NQNQKLBWDARKDG-UHFFFAOYSA-N 4-amino-1-piperidinecarboxylic acid Chemical compound NC1CCN(C(O)=O)CC1 NQNQKLBWDARKDG-UHFFFAOYSA-N 0.000 description 1
- VUTBELPREDJDDH-UHFFFAOYSA-N 4-amino-5-hydroxymethyl-2-methylpyrimidine Chemical compound CC1=NC=C(CO)C(N)=N1 VUTBELPREDJDDH-UHFFFAOYSA-N 0.000 description 1
- DBCAQXHNJOFNGC-UHFFFAOYSA-N 4-bromo-1,1,1-trifluorobutane Chemical compound FC(F)(F)CCCBr DBCAQXHNJOFNGC-UHFFFAOYSA-N 0.000 description 1
- DBPKMSBWOKAKLA-UHFFFAOYSA-N 4-chloropyrimidine Chemical compound ClC1=CC=NC=N1 DBPKMSBWOKAKLA-UHFFFAOYSA-N 0.000 description 1
- RTLUPHDWSUGAOS-UHFFFAOYSA-N 4-iodopyridine Chemical compound IC1=CC=NC=C1 RTLUPHDWSUGAOS-UHFFFAOYSA-N 0.000 description 1
- NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 description 1
- 102100030310 5,6-dihydroxyindole-2-carboxylic acid oxidase Human genes 0.000 description 1
- 101710163881 5,6-dihydroxyindole-2-carboxylic acid oxidase Proteins 0.000 description 1
- 125000006163 5-membered heteroaryl group Chemical group 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 description 1
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- 241001442567 Acoela Species 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 206010027654 Allergic conditions Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 244000036975 Ambrosia artemisiifolia Species 0.000 description 1
- 235000003129 Ambrosia artemisiifolia var elatior Nutrition 0.000 description 1
- 229930183010 Amphotericin Natural products 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 206010053555 Arthritis bacterial Diseases 0.000 description 1
- 206010003267 Arthritis reactive Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 108010001478 Bacitracin Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- KHKBSYSPXXGLAM-JWAQTBJPSA-N C/C=C\C(\C(/N)=N\C=N)=C(\C)/c1c[nH]nc1 Chemical compound C/C=C\C(\C(/N)=N\C=N)=C(\C)/c1c[nH]nc1 KHKBSYSPXXGLAM-JWAQTBJPSA-N 0.000 description 1
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 description 1
- XFWOEYPSLKRIHM-UHFFFAOYSA-N C=C1CC(CC#N)CCCC1 Chemical compound C=C1CC(CC#N)CCCC1 XFWOEYPSLKRIHM-UHFFFAOYSA-N 0.000 description 1
- HYRBHOKMJKBACC-UHFFFAOYSA-N CC(C)(C)[Si+](c1ccccc1)c1c(C(C(C2)O)C2=O)cccc1 Chemical compound CC(C)(C)[Si+](c1ccccc1)c1c(C(C(C2)O)C2=O)cccc1 HYRBHOKMJKBACC-UHFFFAOYSA-N 0.000 description 1
- XVNFQOZZIWOKQJ-FJZQHTSQSA-N CCC(C1)=CN=C2NC=CC2=C1/C(/C=C\C)=C/NC Chemical compound CCC(C1)=CN=C2NC=CC2=C1/C(/C=C\C)=C/NC XVNFQOZZIWOKQJ-FJZQHTSQSA-N 0.000 description 1
- FHTGZDVYPCEHFQ-UHFFFAOYSA-N CNC1CCNCC1 Chemical compound CNC1CCNCC1 FHTGZDVYPCEHFQ-UHFFFAOYSA-N 0.000 description 1
- 229940122739 Calcineurin inhibitor Drugs 0.000 description 1
- 101710192106 Calcineurin-binding protein cabin-1 Proteins 0.000 description 1
- 102100024123 Calcineurin-binding protein cabin-1 Human genes 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010007279 Carcinoid tumour of the gastrointestinal tract Diseases 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- 208000005024 Castleman disease Diseases 0.000 description 1
- 238000003734 CellTiter-Glo Luminescent Cell Viability Assay Methods 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 208000018458 Colitis-Associated Neoplasms Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 208000023890 Complex Regional Pain Syndromes Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- 206010011219 Costochondritis Diseases 0.000 description 1
- 229920001651 Cyanoacrylate Polymers 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- 102100038497 Cytokine receptor-like factor 2 Human genes 0.000 description 1
- DYDCUQKUCUHJBH-UWTATZPHSA-N D-Cycloserine Chemical compound N[C@@H]1CONC1=O DYDCUQKUCUHJBH-UWTATZPHSA-N 0.000 description 1
- DYDCUQKUCUHJBH-UHFFFAOYSA-N D-Cycloserine Natural products NC1CONC1=O DYDCUQKUCUHJBH-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 239000012623 DNA damaging agent Substances 0.000 description 1
- FMGSKLZLMKYGDP-UHFFFAOYSA-N Dehydroepiandrosterone Natural products C1C(O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CC=C21 FMGSKLZLMKYGDP-UHFFFAOYSA-N 0.000 description 1
- 208000006313 Delayed Hypersensitivity Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 1
- 101100256637 Drosophila melanogaster senju gene Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 206010014025 Ear swelling Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 108010008165 Etanercept Proteins 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 229920003134 Eudragit® polymer Polymers 0.000 description 1
- 229910052693 Europium Inorganic materials 0.000 description 1
- 102100034719 Extracellular glycoprotein lacritin Human genes 0.000 description 1
- 229940124783 FAK inhibitor Drugs 0.000 description 1
- KGDWJKAOKRTYTG-UHFFFAOYSA-N FC(F)(F)C1=NC(CO)=CC(NC2CCN(CC2)C(O)=O)=N1 Chemical compound FC(F)(F)C1=NC(CO)=CC(NC2CCN(CC2)C(O)=O)=N1 KGDWJKAOKRTYTG-UHFFFAOYSA-N 0.000 description 1
- LLIGUEULYWZINZ-UHFFFAOYSA-N FC(c1nc(OC2CCNCC2)cc(CNC2COC2)c1)(F)F Chemical compound FC(c1nc(OC2CCNCC2)cc(CNC2COC2)c1)(F)F LLIGUEULYWZINZ-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000001640 Fibromyalgia Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 208000004262 Food Hypersensitivity Diseases 0.000 description 1
- ZPACYDRSPFRDHO-ROBAGEODSA-N Gefarnate Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CCC(=O)OC\C=C(/C)CCC=C(C)C ZPACYDRSPFRDHO-ROBAGEODSA-N 0.000 description 1
- 229920001386 Gefarnate Polymers 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 206010018341 Gliosis Diseases 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 206010018634 Gouty Arthritis Diseases 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 208000010496 Heart Arrest Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000956427 Homo sapiens Cytokine receptor-like factor 2 Proteins 0.000 description 1
- 101001090521 Homo sapiens Extracellular glycoprotein lacritin Proteins 0.000 description 1
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 1
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 description 1
- 238000006130 Horner-Wadsworth-Emmons olefination reaction Methods 0.000 description 1
- 241000598436 Human T-cell lymphotropic virus Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 description 1
- 108700021006 Interleukin-1 receptor antagonist Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 229940116839 Janus kinase 1 inhibitor Drugs 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- ZCGOMHNNNFPNMX-YHYDXASRSA-N Levocabastinum Chemical compound C1([C@@]2(C(O)=O)CCN(C[C@H]2C)C2CCC(CC2)(C#N)C=2C=CC(F)=CC=2)=CC=CC=C1 ZCGOMHNNNFPNMX-YHYDXASRSA-N 0.000 description 1
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- MWCLLHOVUTZFKS-UHFFFAOYSA-N Methyl cyanoacrylate Chemical compound COC(=O)C(=C)C#N MWCLLHOVUTZFKS-UHFFFAOYSA-N 0.000 description 1
- 238000006845 Michael addition reaction Methods 0.000 description 1
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241001237732 Microtia Species 0.000 description 1
- 102100034256 Mucin-1 Human genes 0.000 description 1
- 108010063954 Mucins Proteins 0.000 description 1
- 108010093825 Mucoproteins Proteins 0.000 description 1
- 102000001621 Mucoproteins Human genes 0.000 description 1
- 101100346764 Mus musculus Mtln gene Proteins 0.000 description 1
- 229940121743 Muscarinic receptor agonist Drugs 0.000 description 1
- 206010028561 Myeloid metaplasia Diseases 0.000 description 1
- 201000002481 Myositis Diseases 0.000 description 1
- IJHNSHDBIRRJRN-UHFFFAOYSA-N N,N-dimethyl-3-phenyl-3-(2-pyridinyl)-1-propanamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=CC=C1 IJHNSHDBIRRJRN-UHFFFAOYSA-N 0.000 description 1
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
- FMCGSUUBYTWNDP-UHFFFAOYSA-N N-Methylephedrine Natural products CN(C)C(C)C(O)C1=CC=CC=C1 FMCGSUUBYTWNDP-UHFFFAOYSA-N 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- 239000004100 Oxytetracycline Substances 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- UOZODPSAJZTQNH-UHFFFAOYSA-N Paromomycin II Natural products NC1C(O)C(O)C(CN)OC1OC1C(O)C(OC2C(C(N)CC(N)C2O)OC2C(C(O)C(O)C(CO)O2)N)OC1CO UOZODPSAJZTQNH-UHFFFAOYSA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 201000011152 Pemphigus Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- 244000113945 Pinus torreyana Species 0.000 description 1
- 235000006235 Pinus torreyana Nutrition 0.000 description 1
- 208000007452 Plasmacytoma Diseases 0.000 description 1
- 102000004179 Plasminogen Activator Inhibitor 2 Human genes 0.000 description 1
- 108090000614 Plasminogen Activator Inhibitor 2 Proteins 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 108010040201 Polymyxins Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 description 1
- 102000001744 Purinergic P2Y2 Receptors Human genes 0.000 description 1
- 108010029812 Purinergic P2Y2 Receptors Proteins 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 229940123690 Raf kinase inhibitor Drugs 0.000 description 1
- ALLWOAVDORUJLA-UHFFFAOYSA-N Rebamipida Chemical compound C=1C(=O)NC2=CC=CC=C2C=1CC(C(=O)O)NC(=O)C1=CC=C(Cl)C=C1 ALLWOAVDORUJLA-UHFFFAOYSA-N 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 206010038910 Retinitis Diseases 0.000 description 1
- 238000011579 SCID mouse model Methods 0.000 description 1
- QCHFTSOMWOSFHM-UHFFFAOYSA-N SJ000285536 Natural products C1OC(=O)C(CC)C1CC1=CN=CN1C QCHFTSOMWOSFHM-UHFFFAOYSA-N 0.000 description 1
- 108010017324 STAT3 Transcription Factor Proteins 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 208000009359 Sezary Syndrome Diseases 0.000 description 1
- 208000021388 Sezary disease Diseases 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 101710173693 Short transient receptor potential channel 1 Proteins 0.000 description 1
- 102100024040 Signal transducer and activator of transcription 3 Human genes 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 238000006619 Stille reaction Methods 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 201000009594 Systemic Scleroderma Diseases 0.000 description 1
- 206010042953 Systemic sclerosis Diseases 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 102000036693 Thrombopoietin Human genes 0.000 description 1
- 108010041111 Thrombopoietin Proteins 0.000 description 1
- 208000026317 Tietze syndrome Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- LVTKHGUGBGNBPL-UHFFFAOYSA-N Trp-P-1 Chemical compound N1C2=CC=CC=C2C2=C1C(C)=C(N)N=C2C LVTKHGUGBGNBPL-UHFFFAOYSA-N 0.000 description 1
- 101710116241 Tyrosine-protein phosphatase non-receptor type 11 Proteins 0.000 description 1
- 102100033019 Tyrosine-protein phosphatase non-receptor type 11 Human genes 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 206010047571 Visual impairment Diseases 0.000 description 1
- 229910021536 Zeolite Inorganic materials 0.000 description 1
- ALTFVFYUEMQYKB-UHFFFAOYSA-N [2-(piperidin-4-ylamino)-6-(trifluoromethyl)pyridin-4-yl]methanol Chemical compound FC(F)(F)C1=CC(CO)=CC(NC2CCNCC2)=N1 ALTFVFYUEMQYKB-UHFFFAOYSA-N 0.000 description 1
- RRDRHWJDBOGQHN-JWCTVYNTSA-N [2-[(2s,5r,8s,11s,14r,17s,22s)-17-[(1r)-1-hydroxyethyl]-22-[[(2s)-2-[[(2s,3r)-3-hydroxy-2-[[(2s)-2-[6-methyloctanoyl(sulfomethyl)amino]-4-(sulfomethylamino)butanoyl]amino]butyl]amino]-4-(sulfomethylamino)butanoyl]amino]-5,8-bis(2-methylpropyl)-3,6,9,12,15 Chemical compound CCC(C)CCCCC(=O)N(CS(O)(=O)=O)[C@@H](CCNCS(O)(=O)=O)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCNCS(O)(=O)=O)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](CCNCS(O)(=O)=O)NC(=O)[C@H](CCNCS(O)(=O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCNCS(O)(=O)=O)NC1=O RRDRHWJDBOGQHN-JWCTVYNTSA-N 0.000 description 1
- ZVXSQXQSJHKYCJ-UHFFFAOYSA-N [2-piperidin-4-yloxy-6-(trifluoromethyl)pyridin-4-yl]methanol Chemical compound FC(F)(F)C1=CC(CO)=CC(OC2CCNCC2)=N1 ZVXSQXQSJHKYCJ-UHFFFAOYSA-N 0.000 description 1
- OBRAXOIASGCSQV-UHFFFAOYSA-N [6-(piperidin-4-ylamino)-2-(trifluoromethyl)pyrimidin-4-yl]methanol Chemical compound FC(F)(F)C1=NC(CO)=CC(NC2CCNCC2)=N1 OBRAXOIASGCSQV-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 229940081735 acetylcellulose Drugs 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- 125000004656 alkyl sulfonylamino group Chemical group 0.000 description 1
- 125000004419 alkynylene group Chemical group 0.000 description 1
- 208000002029 allergic contact dermatitis Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 229960004821 amikacin Drugs 0.000 description 1
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 229960004238 anakinra Drugs 0.000 description 1
- 230000019552 anatomical structure morphogenesis Effects 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 235000003484 annual ragweed Nutrition 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 229960002469 antazoline Drugs 0.000 description 1
- REYFJDPCWQRWAA-UHFFFAOYSA-N antazoline Chemical compound N=1CCNC=1CN(C=1C=CC=CC=1)CC1=CC=CC=C1 REYFJDPCWQRWAA-UHFFFAOYSA-N 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 208000037875 astrocytosis Diseases 0.000 description 1
- 230000007341 astrogliosis Effects 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 201000004982 autoimmune uveitis Diseases 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- ZSIQJIWKELUFRJ-UHFFFAOYSA-N azepane Chemical compound C1CCCNCC1 ZSIQJIWKELUFRJ-UHFFFAOYSA-N 0.000 description 1
- UQUPQEUNHVVNKW-UHFFFAOYSA-N azetidin-1-ium-3-ol;chloride Chemical compound Cl.OC1CNC1 UQUPQEUNHVVNKW-UHFFFAOYSA-N 0.000 description 1
- MJZQSPDYIKSJCN-UHFFFAOYSA-N azetidine-3-carbonitrile;hydrochloride Chemical compound Cl.N#CC1CNC1 MJZQSPDYIKSJCN-UHFFFAOYSA-N 0.000 description 1
- 125000003943 azolyl group Chemical group 0.000 description 1
- 229960003071 bacitracin Drugs 0.000 description 1
- 229930184125 bacitracin Natural products 0.000 description 1
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 125000006267 biphenyl group Chemical group 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 235000006263 bur ragweed Nutrition 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 229960003340 calcium silicate Drugs 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical class C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 229960001777 castor oil Drugs 0.000 description 1
- 108020001778 catalytic domains Proteins 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000012054 celltiter-glo Methods 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 150000005753 chloropyridines Chemical class 0.000 description 1
- 239000000064 cholinergic agonist Substances 0.000 description 1
- 208000017568 chondrodysplasia Diseases 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- 230000010405 clearance mechanism Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 229940108538 colistimethate Drugs 0.000 description 1
- 108700028201 colistinmethanesulfonic acid Proteins 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 235000003488 common ragweed Nutrition 0.000 description 1
- 230000002508 compound effect Effects 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 239000000039 congener Substances 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 239000012059 conventional drug carrier Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- QTCANKDTWWSCMR-UHFFFAOYSA-N costic aldehyde Natural products C1CCC(=C)C2CC(C(=C)C=O)CCC21C QTCANKDTWWSCMR-UHFFFAOYSA-N 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 229960000265 cromoglicic acid Drugs 0.000 description 1
- 125000002188 cycloheptatrienyl group Chemical group C1(=CC=CC=CC1)* 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 description 1
- SSJXIUAHEKJCMH-UHFFFAOYSA-N cyclohexane-1,2-diamine Chemical compound NC1CCCCC1N SSJXIUAHEKJCMH-UHFFFAOYSA-N 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 229960003077 cycloserine Drugs 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000002074 deregulated effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 150000001975 deuterium Chemical group 0.000 description 1
- 125000004431 deuterium atom Chemical group 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 description 1
- VLARUOGDXDTHEH-UHFFFAOYSA-L disodium cromoglycate Chemical compound [Na+].[Na+].O1C(C([O-])=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C([O-])=O)O2 VLARUOGDXDTHEH-UHFFFAOYSA-L 0.000 description 1
- DLNKOYKMWOXYQA-UHFFFAOYSA-N dl-pseudophenylpropanolamine Natural products CC(N)C(O)C1=CC=CC=C1 DLNKOYKMWOXYQA-UHFFFAOYSA-N 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 210000003717 douglas' pouch Anatomy 0.000 description 1
- 230000007783 downstream signaling Effects 0.000 description 1
- 229960003722 doxycycline Drugs 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 108010067071 duramycin Proteins 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- IWCWQNVIUXZOMJ-MISYRCLQSA-N ecabet Chemical compound OC(=O)[C@@](C)([C@@H]1CC2)CCC[C@]1(C)C1=C2C=C(C(C)C)C(S(O)(=O)=O)=C1 IWCWQNVIUXZOMJ-MISYRCLQSA-N 0.000 description 1
- 229950003246 ecabet Drugs 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 229960000284 efalizumab Drugs 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000012156 elution solvent Substances 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 150000002081 enamines Chemical class 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 150000002084 enol ethers Chemical class 0.000 description 1
- 229960002549 enoxacin Drugs 0.000 description 1
- IDYZIJYBMGIQMJ-UHFFFAOYSA-N enoxacin Chemical compound N1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 IDYZIJYBMGIQMJ-UHFFFAOYSA-N 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 229960002179 ephedrine Drugs 0.000 description 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
- 229960001433 erlotinib Drugs 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000010437 erythropoiesis Effects 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229960000403 etanercept Drugs 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 125000001033 ether group Chemical group 0.000 description 1
- VFRSADQPWYCXDG-LEUCUCNGSA-N ethyl (2s,5s)-5-methylpyrrolidine-2-carboxylate;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CCOC(=O)[C@@H]1CC[C@H](C)N1 VFRSADQPWYCXDG-LEUCUCNGSA-N 0.000 description 1
- 239000002024 ethyl acetate extract Substances 0.000 description 1
- FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 1
- STVZJERGLQHEKB-UHFFFAOYSA-N ethylene glycol dimethacrylate Substances CC(=C)C(=O)OCCOC(=O)C(C)=C STVZJERGLQHEKB-UHFFFAOYSA-N 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012054 flavored emulsion Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000020375 flavoured syrup Nutrition 0.000 description 1
- 229960004884 fluconazole Drugs 0.000 description 1
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 1
- XRECTZIEBJDKEO-UHFFFAOYSA-N flucytosine Chemical compound NC1=NC(=O)NC=C1F XRECTZIEBJDKEO-UHFFFAOYSA-N 0.000 description 1
- 229960004413 flucytosine Drugs 0.000 description 1
- 229940043075 fluocinolone Drugs 0.000 description 1
- 229960001347 fluocinolone acetonide Drugs 0.000 description 1
- 229960001048 fluorometholone Drugs 0.000 description 1
- FAOZLTXFLGPHNG-KNAQIMQKSA-N fluorometholone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@]2(F)[C@@H](O)C[C@]2(C)[C@@](O)(C(C)=O)CC[C@H]21 FAOZLTXFLGPHNG-KNAQIMQKSA-N 0.000 description 1
- 229940124307 fluoroquinolone Drugs 0.000 description 1
- 229960002390 flurbiprofen Drugs 0.000 description 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
- 235000020932 food allergy Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 description 1
- 229960003779 gefarnate Drugs 0.000 description 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
- 229960002584 gefitinib Drugs 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 238000001879 gelation Methods 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 230000006589 gland dysfunction Effects 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000011554 guinea pig model Methods 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 238000013415 human tumor xenograft model Methods 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 239000012051 hydrophobic carrier Substances 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 description 1
- 229960004171 hydroxychloroquine Drugs 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 208000014796 hyper-IgE recurrent infection syndrome 1 Diseases 0.000 description 1
- 206010051040 hyper-IgE syndrome Diseases 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000005934 immune activation Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000002991 immunohistochemical analysis Methods 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 230000005917 in vivo anti-tumor Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- ISTFUJWTQAMRGA-UHFFFAOYSA-N iso-beta-costal Natural products C1C(C(=C)C=O)CCC2(C)CCCC(C)=C21 ISTFUJWTQAMRGA-UHFFFAOYSA-N 0.000 description 1
- TWBYWOBDOCUKOW-UHFFFAOYSA-M isonicotinate Chemical compound [O-]C(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-M 0.000 description 1
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 1
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- 229960004752 ketorolac Drugs 0.000 description 1
- OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 238000000021 kinase assay Methods 0.000 description 1
- 150000003951 lactams Chemical class 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- SFWLDKQAUHFCBS-WWXQEMPQSA-N lancovutide Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H]2C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@@H](CCCCNC[C@H]4C(=O)N[C@@H](CC=5C=CC=CC=5)C(=O)NCC(=O)N5CCC[C@H]5C(=O)N[C@@H](CC=5C=CC=CC=5)C(=O)N[C@H]([C@@H](SC[C@H](NC(=O)[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CSC3C)CSC2)C(=O)N4)C)C(=O)N1)C(O)=O)[C@@H](O)C(O)=O)=O)C(C)C)C1=CC=CC=C1 SFWLDKQAUHFCBS-WWXQEMPQSA-N 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 229960003376 levofloxacin Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000011344 liquid material Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- RVGLGHVJXCETIO-UHFFFAOYSA-N lodoxamide Chemical compound OC(=O)C(=O)NC1=CC(C#N)=CC(NC(=O)C(O)=O)=C1Cl RVGLGHVJXCETIO-UHFFFAOYSA-N 0.000 description 1
- 229960004305 lodoxamide Drugs 0.000 description 1
- 229960002422 lomefloxacin Drugs 0.000 description 1
- ZEKZLJVOYLTDKK-UHFFFAOYSA-N lomefloxacin Chemical compound FC1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNC(C)C1 ZEKZLJVOYLTDKK-UHFFFAOYSA-N 0.000 description 1
- 229960003744 loteprednol etabonate Drugs 0.000 description 1
- DMKSVUSAATWOCU-HROMYWEYSA-N loteprednol etabonate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)OCCl)(OC(=O)OCC)[C@@]1(C)C[C@@H]2O DMKSVUSAATWOCU-HROMYWEYSA-N 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- MIKKOBKEXMRYFQ-WZTVWXICSA-N meglumine amidotrizoate Chemical compound C[NH2+]C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I MIKKOBKEXMRYFQ-WZTVWXICSA-N 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 238000006263 metalation reaction Methods 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 229960002509 miconazole Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000007479 molecular analysis Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 229940066491 mucolytics Drugs 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 239000000472 muscarinic agonist Substances 0.000 description 1
- DOZYTHNHLLSNIK-JOKMOOFLSA-M mycophenolate sodium Chemical compound [Na+].OC1=C(C\C=C(/C)CCC([O-])=O)C(OC)=C(C)C2=C1C(=O)OC2 DOZYTHNHLLSNIK-JOKMOOFLSA-M 0.000 description 1
- 229960000951 mycophenolic acid Drugs 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- AGVKXDPPPSLISR-UHFFFAOYSA-N n-ethylcyclohexanamine Chemical compound CCNC1CCCCC1 AGVKXDPPPSLISR-UHFFFAOYSA-N 0.000 description 1
- YCWKZLXTHMGYAO-UHFFFAOYSA-N n-methylcyclopropanamine;hydrochloride Chemical compound Cl.CNC1CC1 YCWKZLXTHMGYAO-UHFFFAOYSA-N 0.000 description 1
- 229940073569 n-methylephedrine Drugs 0.000 description 1
- 229960005016 naphazoline Drugs 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 229960003255 natamycin Drugs 0.000 description 1
- 239000004311 natamycin Substances 0.000 description 1
- 235000010298 natamycin Nutrition 0.000 description 1
- NCXMLFZGDNKEPB-FFPOYIOWSA-N natamycin Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C[C@@H](C)OC(=O)/C=C/[C@H]2O[C@@H]2C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 NCXMLFZGDNKEPB-FFPOYIOWSA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000031990 negative regulation of inflammatory response Effects 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- ZBGPYVZLYBDXKO-HILBYHGXSA-N netilmycin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@]([C@H](NC)[C@@H](O)CO1)(C)O)NCC)[C@H]1OC(CN)=CC[C@H]1N ZBGPYVZLYBDXKO-HILBYHGXSA-N 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 1
- 229960001180 norfloxacin Drugs 0.000 description 1
- OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 description 1
- 125000005482 norpinyl group Chemical group 0.000 description 1
- 238000007339 nucleophilic aromatic substitution reaction Methods 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 230000009437 off-target effect Effects 0.000 description 1
- 229960001699 ofloxacin Drugs 0.000 description 1
- 239000012053 oil suspension Substances 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 229910000489 osmium tetroxide Inorganic materials 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- AHVQYHFYQWKUKB-UHFFFAOYSA-N oxan-4-amine Chemical compound NC1CCOCC1 AHVQYHFYQWKUKB-UHFFFAOYSA-N 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- OJEOJUQOECNDND-UHFFFAOYSA-N oxetan-3-amine Chemical compound NC1COC1 OJEOJUQOECNDND-UHFFFAOYSA-N 0.000 description 1
- 238000007248 oxidative elimination reaction Methods 0.000 description 1
- 229960000625 oxytetracycline Drugs 0.000 description 1
- IWVCMVBTMGNXQD-PXOLEDIWSA-N oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 description 1
- 235000019366 oxytetracycline Nutrition 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229960001914 paromomycin Drugs 0.000 description 1
- UOZODPSAJZTQNH-LSWIJEOBSA-N paromomycin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO UOZODPSAJZTQNH-LSWIJEOBSA-N 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 201000001976 pemphigus vulgaris Diseases 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 1
- RGSFGYAAUTVSQA-UHFFFAOYSA-N pentamethylene Natural products C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000009038 pharmacological inhibition Effects 0.000 description 1
- 125000001792 phenanthrenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C=CC12)* 0.000 description 1
- 229960001190 pheniramine Drugs 0.000 description 1
- DLNKOYKMWOXYQA-APPZFPTMSA-N phenylpropanolamine Chemical compound C[C@@H](N)[C@H](O)C1=CC=CC=C1 DLNKOYKMWOXYQA-APPZFPTMSA-N 0.000 description 1
- 229960000395 phenylpropanolamine Drugs 0.000 description 1
- 102000051624 phosphatidylethanolamine binding protein Human genes 0.000 description 1
- 108700021017 phosphatidylethanolamine binding protein Proteins 0.000 description 1
- 229960001416 pilocarpine Drugs 0.000 description 1
- KASDHRXLYQOAKZ-ZPSXYTITSA-N pimecrolimus Chemical compound C/C([C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@@H](OC)C[C@@H](C)C/C(C)=C/[C@H](C(C[C@H](O)[C@H]1C)=O)CC)=C\[C@@H]1CC[C@@H](Cl)[C@H](OC)C1 KASDHRXLYQOAKZ-ZPSXYTITSA-N 0.000 description 1
- 229960005330 pimecrolimus Drugs 0.000 description 1
- XUWHAWMETYGRKB-UHFFFAOYSA-N piperidin-2-one Chemical compound O=C1CCCCN1 XUWHAWMETYGRKB-UHFFFAOYSA-N 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 229960005235 piperonyl butoxide Drugs 0.000 description 1
- 229920000771 poly (alkylcyanoacrylate) Polymers 0.000 description 1
- 229920000962 poly(amidoamine) Polymers 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001299 polypropylene fumarate Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 230000003334 potential effect Effects 0.000 description 1
- 229960002847 prasterone Drugs 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- 230000007112 pro inflammatory response Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 229940121649 protein inhibitor Drugs 0.000 description 1
- 239000012268 protein inhibitor Substances 0.000 description 1
- 230000005588 protonation Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 235000009736 ragweed Nutrition 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 208000002574 reactive arthritis Diseases 0.000 description 1
- 229950004535 rebamipide Drugs 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940075993 receptor modulator Drugs 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 231100001019 reduced numbers of red blood cells Toxicity 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 229940053174 restasis Drugs 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 229940061341 retisert Drugs 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229940120975 revlimid Drugs 0.000 description 1
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 1
- 229960001225 rifampicin Drugs 0.000 description 1
- 229960001487 rimexolone Drugs 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- XMSXOLDPMGMWTH-UHFFFAOYSA-N rivoglitazone Chemical compound CN1C2=CC(OC)=CC=C2N=C1COC(C=C1)=CC=C1CC1SC(=O)NC1=O XMSXOLDPMGMWTH-UHFFFAOYSA-N 0.000 description 1
- 229950010764 rivoglitazone Drugs 0.000 description 1
- 102200087780 rs77375493 Human genes 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 210000003786 sclera Anatomy 0.000 description 1
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
- 229960002646 scopolamine Drugs 0.000 description 1
- 230000000580 secretagogue effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000012056 semi-solid material Substances 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 208000002491 severe combined immunodeficiency Diseases 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 201000002314 small intestine cancer Diseases 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 229960002668 sodium chloride Drugs 0.000 description 1
- UKLNMMHNWFDKNT-UHFFFAOYSA-M sodium chlorite Chemical compound [Na+].[O-]Cl=O UKLNMMHNWFDKNT-UHFFFAOYSA-M 0.000 description 1
- 229960002218 sodium chlorite Drugs 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 125000003003 spiro group Chemical group 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- 239000012058 sterile packaged powder Substances 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 229960004492 suprofen Drugs 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 229960001967 tacrolimus Drugs 0.000 description 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 230000004489 tear production Effects 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
- IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 description 1
- CZYUGTLMFHDODF-UHFFFAOYSA-N tert-butyl 4-(methylamino)piperidine-1-carboxylate Chemical compound CNC1CCN(C(=O)OC(C)(C)C)CC1 CZYUGTLMFHDODF-UHFFFAOYSA-N 0.000 description 1
- RZDIGLQBCOPUMG-UHFFFAOYSA-N tert-butyl 4-[4-(3-azidooxetan-3-yl)-6-(trifluoromethyl)pyridin-2-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1OC1=CC(C2(COC2)N=[N+]=[N-])=CC(C(F)(F)F)=N1 RZDIGLQBCOPUMG-UHFFFAOYSA-N 0.000 description 1
- ZGXBKDXNLAFWIP-UHFFFAOYSA-N tert-butyl 4-[4-(3-hydroxyoxetan-3-yl)-6-(2,2,2-trifluoroethyl)pyridin-2-yl]oxypiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(CC1)Oc1cc(cc(CC(F)(F)F)n1)C1(O)COC1 ZGXBKDXNLAFWIP-UHFFFAOYSA-N 0.000 description 1
- FWGXHLHQWHBPCL-UHFFFAOYSA-N tert-butyl 4-[4-(3-hydroxyoxetan-3-yl)-6-(trifluoromethyl)pyridin-2-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1OC1=CC(C2(O)COC2)=CC(C(F)(F)F)=N1 FWGXHLHQWHBPCL-UHFFFAOYSA-N 0.000 description 1
- ALKNFLZDUULHGH-UHFFFAOYSA-N tert-butyl 4-[4-(hydroxymethyl)-6-(trifluoromethyl)pyridin-2-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1OC1=CC(CO)=CC(C(F)(F)F)=N1 ALKNFLZDUULHGH-UHFFFAOYSA-N 0.000 description 1
- LHQPZJRBNJQGCB-UHFFFAOYSA-N tert-butyl 4-[6-(trifluoromethyl)pyridin-2-yl]oxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1OC1=CC=CC(C(F)(F)F)=N1 LHQPZJRBNJQGCB-UHFFFAOYSA-N 0.000 description 1
- GHBPEZDCGPWOMI-UHFFFAOYSA-N tert-butyl 4-[[4-(hydroxymethyl)-6-(trifluoromethyl)pyridin-2-yl]amino]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1NC1=CC(CO)=CC(C(F)(F)F)=N1 GHBPEZDCGPWOMI-UHFFFAOYSA-N 0.000 description 1
- GTBZUSYJFBIGGK-UHFFFAOYSA-N tert-butyl 4-[[6-chloro-2-(trifluoromethyl)pyrimidin-4-yl]amino]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1NC1=CC(Cl)=NC(C(F)(F)F)=N1 GTBZUSYJFBIGGK-UHFFFAOYSA-N 0.000 description 1
- CUXVFSKLZXEERE-UHFFFAOYSA-N tert-butyl 4-[[6-formyl-2-(trifluoromethyl)pyrimidin-4-yl]amino]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1NC1=CC(C=O)=NC(C(F)(F)F)=N1 CUXVFSKLZXEERE-UHFFFAOYSA-N 0.000 description 1
- ROUYFJUVMYHXFJ-UHFFFAOYSA-N tert-butyl 4-oxopiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(=O)CC1 ROUYFJUVMYHXFJ-UHFFFAOYSA-N 0.000 description 1
- MHTKMXCUZXWIGS-UHFFFAOYSA-N tert-butyl-(3-methylsulfanyl-3-methylsulfinylcyclobutyl)oxy-diphenylsilane Chemical compound C1C(SC)(S(C)=O)CC1O[Si](C(C)(C)C)(C=1C=CC=CC=1)C1=CC=CC=C1 MHTKMXCUZXWIGS-UHFFFAOYSA-N 0.000 description 1
- JJDHEJYRBKJJOM-UHFFFAOYSA-N tert-butyl-[[2-chloro-6-(trifluoromethyl)pyridin-4-yl]methoxy]-diphenylsilane Chemical compound C=1C=CC=CC=1[Si](C=1C=CC=CC=1)(C(C)(C)C)OCC1=CC(Cl)=NC(C(F)(F)F)=C1 JJDHEJYRBKJJOM-UHFFFAOYSA-N 0.000 description 1
- MHYGQXWCZAYSLJ-UHFFFAOYSA-N tert-butyl-chloro-diphenylsilane Chemical compound C=1C=CC=CC=1[Si](Cl)(C(C)(C)C)C1=CC=CC=C1 MHYGQXWCZAYSLJ-UHFFFAOYSA-N 0.000 description 1
- APDBDUMVHPEPOE-UHFFFAOYSA-N tert-butyl-diphenyl-[[2-piperidin-4-yloxy-6-(trifluoromethyl)pyridin-4-yl]methoxy]silane Chemical compound C=1C=CC=CC=1[Si](C=1C=CC=CC=1)(C(C)(C)C)OCC(C=C(N=1)C(F)(F)F)=CC=1OC1CCNCC1 APDBDUMVHPEPOE-UHFFFAOYSA-N 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 229940040944 tetracyclines Drugs 0.000 description 1
- 125000005329 tetralinyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 206010043778 thyroiditis Diseases 0.000 description 1
- 229960000707 tobramycin Drugs 0.000 description 1
- NLVFBUXFDBBNBW-PBSUHMDJSA-S tobramycin(5+) Chemical compound [NH3+][C@@H]1C[C@H](O)[C@@H](C[NH3+])O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H]([NH3+])[C@H](O)[C@@H](CO)O2)O)[C@H]([NH3+])C[C@@H]1[NH3+] NLVFBUXFDBBNBW-PBSUHMDJSA-S 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
- 229960005294 triamcinolone Drugs 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- WARKYKQCOXTIAO-UHFFFAOYSA-N tributyl(2-ethoxyethenyl)stannane Chemical compound CCCC[Sn](CCCC)(CCCC)\C=C/OCC WARKYKQCOXTIAO-UHFFFAOYSA-N 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 229960000497 trovafloxacin Drugs 0.000 description 1
- WVPSKSLAZQPAKQ-CDMJZVDBSA-N trovafloxacin Chemical compound C([C@H]1[C@@H]([C@H]1C1)N)N1C(C(=CC=1C(=O)C(C(O)=O)=C2)F)=NC=1N2C1=CC=C(F)C=C1F WVPSKSLAZQPAKQ-CDMJZVDBSA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 231100000588 tumorigenic Toxicity 0.000 description 1
- 230000000381 tumorigenic effect Effects 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- JABYJIQOLGWMQW-UHFFFAOYSA-N undec-4-ene Chemical compound CCCCCCC=CCCC JABYJIQOLGWMQW-UHFFFAOYSA-N 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-O vancomycin(1+) Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C([O-])=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)[NH2+]C)[C@H]1C[C@](C)([NH3+])[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-O 0.000 description 1
- 229940099039 velcade Drugs 0.000 description 1
- 229940055059 vexol Drugs 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000004034 viscosity adjusting agent Substances 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
- BICRTLVBTLFLRD-PTWUADNWSA-N voclosporin Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C=C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O BICRTLVBTLFLRD-PTWUADNWSA-N 0.000 description 1
- 229960005289 voclosporin Drugs 0.000 description 1
- 108010057559 voclosporin Proteins 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 238000001238 wet grinding Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- 239000010457 zeolite Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- YKPUWZUDDOIDPM-VURMDHGXSA-N zucapsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C/C(C)C)=CC=C1O YKPUWZUDDOIDPM-VURMDHGXSA-N 0.000 description 1
- 229960002860 zucapsaicin Drugs 0.000 description 1
- 150000003952 β-lactams Chemical class 0.000 description 1
- PAPBSGBWRJIAAV-UHFFFAOYSA-N ε-Caprolactone Chemical compound O=C1CCCCCO1 PAPBSGBWRJIAAV-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
Definitions
- the present invention provides piperidinylcyclobutyl substituted pyrrolopyrimidines and pyrrolopyridines, as well as their compositions and methods of use, that modulate the activity of Janus kinases (JAKs) and are useful in the treatment of diseases related to the activity of JAKs including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.
- JAKs Janus kinases
- Protein kinases regulate diverse biological processes including cell growth, survival, differentiation, organ formation, morphogenesis, neovascularization, tissue repair, and regeneration, among others. Protein kinases also play specialized roles in a host of human diseases including cancer. Cytokines, low-molecular weight polypeptides or glycoproteins, regulate many pathways involved in the host inflammatory response to sepsis. Cytokines influence cell differentiation, proliferation and activation, and can modulate both pro-inflammatory and antiinflammatory responses to allow the host to react appropriately to pathogens.
- JAKs Janus kinase family
- JAK2 Janus kinase-1
- JAK2 JAK2
- JAK3 also known as Janus kinase, leukocyte
- JAKL protein-tyrosme kinase 2
- TYK2 protein-tyrosme kinase 2
- Cytokine-stimulated immune and inflammatory responses contribute to pathogenesis of diseases: pathologies such as severe combined immunodeficiency (SCID) arise from suppression of the immune system, while a hyperactive or inappropriate immune/inflammatory response contributes to the pathology of autoimmune diseases (e.g., asthma, systemic lupus erythematosus, thyroiditis, myocarditis), and illnesses such as scleroderma and osteoarthritis (Ortmann, R. A., T. Cheng, et al. (2000) Arthritis Res 2(1): 16-32).
- SCID severe combined immunodeficiency
- JAKs Deficiencies in expression of JAKs are associated with many disease states. For example, Jakl-/- mice are runted at birth, fail to nurse, and die perinatally (Rodig, S. J., M. A. Meraz, et al. (1998) Cell 93(3): 373-83). Jak2-/- mouse embryos are anemic and die around day 12.5 postcoitum due to the absence of definitive erythropoiesis.
- the JAK/STAT pathway and in particular all four JAKs, are believed to play a role in the pathogenesis of asthmatic response, chronic obstructive pulmonary disease, bronchitis, and other related inflammatory diseases of the lower respiratory tract.
- Multiple cytokines that signal through JAKs have been linked to inflammatory diseases/conditions of the upper respiratory tract, such as those affecting the nose and sinuses (e.g., rhinitis and sinusitis) whether classically allergic reactions or not.
- the JAK/STAT pathway has also been implicated in inflammatory diseases/conditions of the eye and chronic allergic responses.
- Activation of JAK/STAT in cancers may occur by cytokine stimulation (e.g. IL-6 or GM-CSF) or by a reduction in the endogenous suppressors of JAK signaling such as SOCS (suppressor or cytokine signaling) or PIAS (protein inhibitor of activated STAT) (Boudny, V., and Kovarik, J., Neoplasm. 49:349-355, 2002).
- Activation of STAT signaling, as well as other pathways downstream of JAKs e.g., Akt
- Elevated levels of circulating cytokines that signal through JAK STAT play a causal role in cachexia and/or chronic fatigue. As such, JAK inhibition may be beneficial to cancer patients for reasons that extend beyond potential anti-tumor activity.
- JAK2 tyrosine kinase can be beneficial for patients with myeloproliferative disorders, e.g., polycythemia vera (PV), essential thrombocythemia (ET), myeloid metaplasia with myelofibrosis (MMM) (Levin, et al, Cancer Cell, vol. 7, 2005: 387- 397).
- PV polycythemia vera
- ET essential thrombocythemia
- MMM myeloid metaplasia with myelofibrosis
- JAKs may benefit patients suffering from skin immune disorders such as psoriasis, and skin sensitization.
- skin immune disorders such as psoriasis, and skin sensitization.
- the maintenance of psoriasis is believed to depend on a number of inflammatory cytokines in addition to various chemokines and growth factors (JCI, 113 : 1664-1675), many of which signal through JAKs (Adv Pharmacol. 2000;47: 1 13-74).
- JAK inhibitors including pyrrolopyridine and
- new or improved agents which inhibit kinases such as JAKs are continually needed for developing new and more effective pharmaceuticals that are aimed at augmentation or suppression of the immune and inflammatory pathways (such as immunosuppressive agents for organ transplants), as well as agents for the prevention and treatment of autoimmune diseases, diseases involving a hyperactive inflammatory response (e.g. , eczema), allergies, cancer (e.g. , prostate, leukemia, multiple myeloma), and some immune reactions (e.g., skin rash or contact dermatitis or diarrhea) caused by other therapeutics.
- the compounds of the invention, as well as its compositions and methods described herein are directed toward these needs and other ends.
- the present invention provides, inter alia, compounds of Formula I:
- the present invention further provides pharmaceutical compositions comprising a compound of Formula I as described herein, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.
- the present invention further provides methods of modulating an activity of JAK1 comprising contacting JAK1 with a compound of Formula I as described herein, or a pharmaceutically acceptable salt thereof.
- the present invention further provides methods of treating a disease or a disorder associated with abnormal kinase expression or activity in a patient by administering to a patient a therapeutically effective amount of a compound of Formula I as described herein, or a pharmaceutically acceptable salt thereof.
- the present invention further provides methods of treating an autoimmune disease, a cancer, a myeloproliferative disorder, an inflammatory disease, a bone resorption disease, or organ transplant rejection in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of a compound of Formula I as described herein, or a pharmaceutically acceptable salt thereof.
- the present invention also provides compounds of Formula I as described herein, or pharmaceutically acceptable salts thereof, as described herein for use in methods of treating autoimmune diseases, cancer, myeloproliferative disorders, inflammatory diseases, a bone resorption disease, or organ transplant rejection.
- the present invention further provides compounds of Formula I as described herein, or pharmaceutically acceptable salts thereof, for use in methods of modulating a JAKl .
- the present invention also provides uses of compounds of Formula I as described herein, or pharmaceutically acceptable salts thereof, for the preparation of medicaments for use in treating autoimmune diseases, cancer, myeloproliferative disorders, inflammatory diseases, a bone resorption disease, or organ transplant rejection.
- the present invention further provides uses of compounds of Formula I as described herein, or pharmaceutically acceptable salts thereof, for the preparation of medicaments for use in methods of modulating a JA 1.
- the present invention provides, inter alia, a compound of Formula I:
- X is N or CH
- L is O or NR 2a ;
- Y is CH
- R 2 is CF 3 ;
- R 3 is -[CH(R 6a )] n -OR 6b , cyclopropyl, cyclobutyl, tetrahydro-2H-pyran ring, tetrahydrofuran ring, or oxetane ring, wherein said cyclopropyl, cyclobutyl, tetrahydro-2H-pyran ring, tetrahydrofuran ring, and oxetane ring are each optionally substituted with 1 or 2 groups independently selected from CN, OH, methyl, ethyl, n- propyl, isopropyl, methoxy, ethoxy, and propoxy;
- R 4 is H, CH 3 , or -[CH(R & )] dividend-OR 6b ; or alternatively, R 3 and R 4 , taken together with the nitrogen atom to which they are attached, form an azetidinyl, lH-pyrazolyl, a lH-imidazolyl, or a 1H- triazolyl group, wherein said azetidinyl group is optionally substituted with 1 or 2 independently selected R 3a groups;
- each R 3a is independently CN, OH, methyl, ethyl, n-propyl, isopropyl, methoxy, ethoxy, propoxy, or -CH 2 -OH;
- R 5 is OH or NH 2 ;
- R 6a and R 6b are each independently H or CH 3 ;
- each n is independently 2 or 3;
- NR 3 R 4 is not NHCH 2 CH 2 -OH
- Y is CH or N
- R 1 is halo, cyano, nitro, Ci_ 6 alkyl, C
- R 2 is H, halo, cyano, nitro, .4 alley], or C
- R 2a is H or CH 3 ;
- each R", R c , R , R e , and R f is independently selected from H, Ci. 6 alkyl, haloalkyl, C alkenyl, C 2 -6 alkynyl, C3.io cycloalkyl, cycloalkyl-C lJ( -alkyl, C 2 -io heterocycloalkyl, C 2 -io heterocycloalkyl-Ci.4-alkyl, C6-io aryl, C6 aryl-Ci-4-alkyl, Ci_ heteroaryl, and Ci.io heteroaryl-Ci-4-alkyl; wherein said C
- 0 heteroaryl-Ci4-alkyl are each optionally substituted by 1, 2, 3, or 4 independently selected R B groups;
- each R b is independently selected from C alkyl, haloalkyl, C alkenyl, alkynyl, cycloalkyi, cycloalkyl-Ci -alkyl, C 2 .io heterocycloalkyl, heterocycloalkyl-Ci -alkyl, C6-io aryl, C 6 .] 0 aryl-Ci.
- each R 8 is independently selected from halo, cyano, nitro, Ci alkyl, haloalkyl, C alkenyl, C alkynyl, C3 cycloalkyi, C3 cycloalkyl-Ci_ 3 -alkyl, heterocycloalkyl, - heterocycloalliyl-C -alkyl, phenyl, phenyl-d -alkyl, heteroaryl, C
- heteroaryl-Ci -alkyl are each optionally substituted with 1, 2, 3, or 4 independently selected R h groups;
- each R al , R cl , R dl , R el , and R fl is independently selected from H, d. 6 alkyl, C]. haloalkyl, alkenyl, alkynyl, C3 cycloalkyi, C3 cycloalkyl-Cu-alkyl, heterocycloalkyl, C 2 -7 heterocycloalkyl-Ci -alkyl, phenyl, phenyl-Cu-alkyl, heteroaryl, and C
- heteroaryl-Ci -alkyl wherein said Cj alkyl, C2 alkenyl, C alkynyl, C3 cycloalkyi, C3 cycloalkyl-Cu-alkyl, -7 heterocycloalkyl, heterocycloalkyl-Ci -alkyl, phenyl, phenyl-Cu-alkyl, heteroaryl, and Ci. 7 heteroaryl-Ci -alkyl are each optionally substituted by 1, 2, 3, or 4 independently selected R b groups;
- each R b1 is independently selected from alkyl, Ci haloalkyl, C 2 - 6 alkenyl, lkynyl, C3 cycloalkyi, C3 cycloalkyl-Ci -alkyl, -7 heterocycloalkyl, heterocycloalkyl-Cu-alkyl, phenyl, phenyl-C 1.3 -alky 1, C]. 7 heteroaryl, and C1- heteroaryl-C
- 3 -alkyl are each optionally substituted by 1, 2, 3, or 4 independently selected R h groups; and each R h is independently selected from cyano, halo, hydroxy, Ch alky!, Ci_ 4 haloalkyl, Cu alkoxy, Ci-4 haloalkoxy, amino, C1.4 alkylamino, di-Ci_4-alkylamino, hydroxy -C 1,4 alky 1, Ci4 alkoxy-Ci_4 lkyl, cyano-Ci ⁇ alk l, thio, C1.6 alkylthio, C]_6 alkylsulfinyl, C,.
- alkylsulfonyl carbamyl, Ci-s alkylcarbamyl, di(C
- alkyl)aminosulfonyl aminosulfonylamino, C i.6 alkylaminosulfonylamino, difCi-6 alkyl)aminosulfonylarnino, aminocarbonylamino, Ci ⁇ alkylaminocarbonylamino, and di(C!-6 alkyl)aminocarbonylamino.
- X is N.
- X is CH.
- Y is N.
- Y is CH.
- the compound is a compound of Formula II:
- R 3 is -CH(R 6a )CH 2 -OR 6b , -CH 2 CH(R 6a )-OR 6b , cyclopropyl, cyclobutyl, tetrahydro-2H-pyran ring, tetrahydrofiiran ring, or oxetane ring, wherein said cyclopropyl, cyclobutyl, tetrahydro-2H-pyran ring, tetrahydrofiiran ring, and oxetane ring are each optionally substituted with 1 or 2 groups independently selected from C3 ⁇ 4, CN, OH, and OC3 ⁇ 4; and
- R 4 is H, CH 3 , -CH(R 6ll )CH 2 -OR 6b > or -CH 2 CH(R 6a )-OR 6b ;
- R 3 and R 4 taken together with the nitrogen atom to which they are attached, form an azetidinyl, I H-pyrazolyl, a lH-imidazolyl, a 1H-1,3,4- triazolyl, or a lH-l,2,4-triazolyl group, wherein said azetidinyl group is optionally substituted with I or 2 independently selected R 3a groups.
- R 3 is -CH 2 CH 2 -OR 6b , -CH(CH 3 )CH 2 -OR 6b , -CH 2 CH(CH 3 )-OR 6b , cyclopropyl, cyclobutyl, tetrahydro-2H-pyran ring, tetrahydrofuran ring, or oxetane ring, wherein said cyclopropyl, cyclobutyl, tetrahydro-2H-pyran ring, tetrahydrofuran ring, and oxetane ring are each optionally substituted with 1 or 2 groups independently selected from CH 3 , CN, OH, and OCH 3 ;
- R 4 is H, C3 ⁇ 4, -C3 ⁇ 4CH 2 -OR 6b , -CH(CH 3 )CH 2 -OR 6b , or -CH 2 CH(CH 3 )-OR 6b ; or alternatively, R 3 and R 4 , taken together with the nitrogen atom to which they are attached, form an azetidinyl, IH-pyrazolyl, a lH-imidazolyl, a IH-1,3,4- ti'iazolyl, or a lH- l,2,4-triazolyl group, wherein said azetidinyl group is optionally substituted with 1 or 2 independently selected R 3 " groups;
- each R 3a is independently CN, OH, methyl, ethyl, n-propyl, isopropyl, methoxy, ethoxy, propoxy, or -CH 2 -OH;
- R 5 is OH or NH 2 ;
- R 6 is independently H or C3 ⁇ 4.
- each R * is independently C3 ⁇ 4, CN, OH, OCH 3 , or -CH2-OH; or alternatively, two R 3a groups, taken together with the carbon atom to which they are both attached, form an oxetane ring.
- X is N or CH
- R 2 is CF 3 ;
- R 3 is -CH(R 6a )CH 2 -OR 6b , -CH 2 CH(R 6a )-OR 6b , cyclopropyl, cyclobutyl, tetrahydro-2H-pyran ring, tetrahydrofiiran ring, or oxetane ring, wherein said cyclopropyl, cyclobutyl, tetrahydro-2H-pyran ring, tetrahydrofiiran ring, and oxetane ring are each optionally substituted with 1 or 2 groups independently selected from CH 3 , CN, OH, and OC3 ⁇ 4;
- R 4 is H, CH 3 , -CH(R 6a )CH 2 -OR 6 , or -CH 2 CH(R 6a )-OR 6b ;
- R 3 and R 4 taken together with the nitrogen atom to which they are attached, form an azetidinyl, lH-pyrazolyl, a lH-imidazolyl, a 1H-1,3,4- triazolyl, or a lH-l,2,4-triazolyl group, wherein said azetidinyl group is optionally substituted with 1 or 2 independently selected R a groups;
- each R 3a is independently CH 3 , CN, OH, OCH 3 , or -CH 2 -OH;
- R 5 is OH or NH 2 ;
- X is N or CH
- R 1 is an oxetane ring, wherein the oxetane ring is optionally substituted with
- R 2 is CF 3 ;
- R s is OH or NH 2 .
- the compound is a compound of Formula Ila:
- the compound is a compound of Formula Ila,
- R 3 is -CH(R 6a )CH 2 -OR 6b , -CH 2 CH(R 6a )-OR 6b , cyclopropyl, cyclobutyl, tetrahydro-2H-pyran ring, tetrahydrofuran ring, or oxetane ring, wherein said cyclopropyl, cyclobutyl, tetrahydro-2H-pyran ring, tetrahydrofuran ring, and oxetane ring are each optionally substituted with 1 or 2 groups independently selected from CH 3 , CN, OH, and OCH 3 ;
- R 4 is H, C3 ⁇ 4, -CH(R 6a )CH 2 -OR 6b , or -CH 2 CH(R 6a )-OR 6b ;
- R 3 and R 4 taken together with the nitrogen atom to which they are attached, form an azetidinyl, 1 H-pyrazolyl, a IH-imidazolyl, a 1H-1,3,4- triazolyl, or a lH-l,2,4-triazolyl group, wherein said azetidinyl group is optionally substituted with 1 or 2 independently selected R 3a groups;
- each R 3a is independently C3 ⁇ 4, CN, OH, OCH 3 , or -CH 2 -OH;
- R 5 is OH or NH 2 ;
- R 6a and R 6b are each independently H or C3 ⁇ 4;
- NR R is not NHCH 2 CH 2 -OH, 5 V , or 5 V .
- the compound is a compound of Formula Ila,
- R 3 is -CH 2 CH 2 -OR 6b , -CH(CH 3 )CH 2 -OR 6b , -CH 2 CH(CH 3 )-OR 6 , cyclopropyl, cyclobutyl, tetrahydro-2H-pyran ring, tetrahydrofuran ring, or oxetane ring, wherein said cyclopropyl, cyclobutyl, tetrahydro-2H-pyran ring, tetrahydrofuran ring, and
- oxetane ring are each optionally substituted with 1 or 2 groups independently selected from CH 3 , CN, OH, and OCH 3 ;
- R 4 is H, CH 3 , -CH 2 CH 2 -OR 6b , -CH(CH 3 )CH 2 -OR 6b , or -CH 2 CH(CH 3 )-OR 6b ; or alternatively, R 3 and R 4 , taken together with the nitrogen atom to which they are attached, form an azetidinyl, IH-pyrazolyl, a IH-imidazolyl, a 1H- 1,3,4- triazolyl, or a lH-l,2,4-triazolyl group, wherein said azetidinyl group is optionally substituted with 1 or 2 independently selected R 3a groups;
- each R 3a is independently CH 3 , CN, OH, OCH 3 , or -C3 ⁇ 4-OH;
- R 5 is OH or NH 2 ;
- R 6b is independently H or CH 3 ;
- NR 3 R 4 is not NHCH 2 CH 2 -OH
- the compound is a compound of Formula Ila,
- R 3 is -CH(R 6a )CH 2 -OR 6b or -CH 2 CH(R 6a )-OR 6b ;
- R 4 is H, CH 3 , -CH(R 6a )CH 2 -OR 6b , or -CH 2 CH(R 6n )-OR 6b ;
- R 6a and R 6b are each independently H or CH 3 ;
- NR 3 R 4 is not HCH 2 C3 ⁇ 4-OH.
- the compound is a compound of Formula Ha:
- R 3 is -CH 2 CH 2 -OR 6b , -CH(CH 3 )CH 2 -OR 6b , or -CH 2 CH(CH 3 )-OR 6b ;
- R 4 is H, CH 3 , -CH 2 CH 2 -OR 6b , -CH(CH 3 )CH 2 -OR 6b , or -CH 2 CH(CH 3 )-OR 6b ;
- R 6b is independently H or CH 3 ;
- R3 ⁇ 4 4 is not NHCH 2 CH 2 -OH.
- the compound is a compound of Formula lla,
- R 3 is cyclopropyl, cyclobutyl, tetrahydro-2H-pyran ring, tetrahydrofuran ring, or oxetane ring, wherein said oyclopropyl, cyclobutyl, tetrahydro-2H-pyran ring, tetrahydrofuran ring, and oxetane ring are each optionally substituted with 1 or 2 groups independently selected from CH 3 , CN, OH, and OCI3 ⁇ 4 and
- R 4 is H.
- the compound is a compound of Formula lla,
- R 3 and R 4 taken together with the nitrogen atom to which they are attached, form an azetidinyl group, which is optionally substituted with 1 or 2 independently selected R 3a groups;
- each R 3a is independently C3 ⁇ 4 CN, OH, OCH 3 , or -CH 2 -OH;
- the compound is a compound of Formula lla,
- R 3 and R 4 taken together with the nitrogen atom to which they are attached, form a lH-pyrazolyl, a lH-imidazolyl, a lH-l,3,4-triazolyl, or a lH-l ,2,4-triazolyl group.
- the compound is a compound of Formula III:
- R 1 is cyano, halo, Ci_ 6 alkyl, or haloalkyl, wherein said C] ⁇ , alkyl is optionally substituted by 1 , 2, 3, or 4 independently selected R s groups.
- R E is heterocycloalkyl, heteroaryl, -OR" 1 , or -NR cl R fl .
- each R al , R cl , R dl , R el , and R fl is independently selected from H, Ci. 6 alkyl, C
- . -alkyl, phenyl, phenyl-C) . -alkyl, C . heteroaryl, and Ci_ 7 heteroaryl-Ci -alkyl are each optionally substituted by 1 or 2 R h groups independently selected from cyano, halo, hydroxyl, alkoxy, C
- each R bl is independently selected from C
- heterocycloalkyl C heterocycloalkyl-C u-alkyl, phenyl, phenyl-C ⁇ -alkyl, heteroaryl, and heteroaryl-Cu-alkyl are each optionally substituted by 1 or 2 R h groups independently selected from cyano, halo, hydroxyl, C 1. alkoxy, C
- R 1 is alkyl substituted by heterocycloalkyl, heteroaryl, -OR"', or -NR el R n ,
- R 1 is C alkyl substituted by C 2 - 7 heterocycloalkyl, -OR"', or -NR el R n .
- L is NR 2a :
- R 1 is d alkyl substituted by -0R AL , -NR el R fl , or C 2 . 7 heterocycloalkyl;
- R al is H or C
- R e l is H or C 1 .4 alkyl; wherein CM alkyl is substituted by 1 or 2 independently selected R h groups;
- R f ' is H, Ci- 4 alkyl, cyclopropyl, cyclobutyl, or cyclohexyl; wherein CM alkyl, cyclopropyl, cyclobutyl, or cyclohexyl are each substituted by 1 or 2 independently selected R h groups; and
- R 2 is CF 3 .
- Y is N.
- L is NR 2a
- Y is CH
- X is CH.
- the compound is a compound of Formula I, or a pharmaceutically acceptable salt thereof; wherein:
- X is N or CH
- L is NR 2a ;
- Y is CH or N
- R 1 is Ci- 3 alkyl substituted by -OR" 1 , -NR el R n , or C 2 - 7 heterocycloalkyl;
- R 2 is CF 3 ;
- R 2a is H or CH 3 ;
- R al is H or C M alkyl
- R el is H or C 1 . 4 alkyl; wherein C alkyl is substituted by 1 or 2 independently selected R h groups;
- R fl is H, CM alkyl, cyclopropyl, cyclobutyl, or cyclohexyl; wherein C alkyl, cyclopropyl, cyclobutyl, or cyclohexyl are each substituted by 1 or 2 independently selected R h groups; and
- each R h is independently selected from hydroxy, halo, cyano, C alkyl, and C alkoxy.
- the cyclobutyl ring in Formula I, II, Ila, or III is the cis form. In some embodiments, the cyelobutyl ring in Formula I, II, lla, or III is the trans form.
- the phrase "optionally substituted” means unsubstituted or substituted.
- substituted means that a hydrogen atom is removed and replaced by a substituent. It is to be understood that substitution at a given atom is limited by valency.
- C Intel_ m indicates a range which includes the endpoints, wherein n and m are integers and indicate the number of carbons. Examples include and the like.
- n-membered where n is an integer typically describes the number of ring-forming atoms in a moiety where the number of ring-forming atoms is n.
- piperidinyl is an example of a 6-membered heterocycloalkyl ring
- pyrazolyl is an example of a 5-membered heteroaryl ring
- pyridyl is an example of a 6- membered heteroaryl ring
- 1,2,3,4-tetrahydro-naphthalene is an example of a 10- membered cycloalkyl group.
- C n . m alkyl refers to a saturated hydrocarbon group that may be straight-chain or branched, having n to m carbons.
- the alkyl group contains from 1 to 3 carbon atoms.
- alkyl moieties include, but are not limited to, chemical groups such as methyl, ethyl, »-propyl, and isopropyl.
- alkoxy refers to a group of formula -O-alkyl, wherein the alkyl group has n to m carbons.
- Example alkoxy groups include methoxy, ethoxy, and propoxy (e.g., n- propoxy and isopropoxy).
- the alkyl group has 1 to 3 carbon atoms.
- alkylene employed alone or in combination with other terms, refers to a divalent alkyl linking group. Examples of alkylene groups
- Example alkenyl groups include, but are not limited to, ethenyl, n-propenyl, isopropenyl, n-biitenyl, sec- butenyl, and the like.
- m alkynyl refers to an alkyl group having one or more triple carbon-carbon bonds and having n to m carbons.
- Example alkynyl groups include, but are not limited to, ethynyl, propyn-l-yl, propyn-2-yl, and the like.
- the alkynyl moiety contains 2 to 6 or 2 to 4 carbon atoms.
- C, Mt1 alkylamino refers to a group of formula -NH(alkyl), wherein the alkyl group has n to m carbon atoms. In some embodiments, the alkyl group has 1 to 6 or 1 to 4 carbon atoms.
- di-C n _ m -alkylamino refers to a group of formula -
- each alkyl group independently has 1 to 6 or 1 to 4 carbon atoms.
- C Copper. m alkoxycarbonyl
- the term "C Intel. m alkoxycarbonyl” refers to a group of formula -C(0)0-alkyl, wherein the alkyl group has n to m carbon atoms. In some embodiments, the alkyl group has 1 to 6 or 1 to 4 carbon atoms.
- C n m alkylcarbonyl refers to a group of formula -C(0)-alkyl, wherein the alkyl group has n to ra carbon atoms. In some embodiments, the alkyl group has 1 to 6 or 1 to 4 carbon atoms.
- m alk lcarbonylamino refers to a group of formula -NHC(0)-alkyl, wherein the alkyl group has n to m carbon atoms. In some embodiments, the alkyl group has 1 to 6 or 1 to 4 carbon atoms.
- C n . m alkylsulfonylamino refers to a group of formula -NHS(0)2-alkyl, wherein the alkyl group has n to m carbon atoms. In some embodiments, the alkyl group has 1 to 6 or 1 to 4 carbon atoms.
- the term “C Intel. m alkylaminosulfonyl” refers to a group of formula -S(0)2NH(alkyl), wherein the alkyl group has n to m carbon atoms. In some embodiments, the alkyl group has 1 to 6 or 1 to 4 carbon atoms.
- di(C n familiar m alkyl)aminosulfonyl refers to a group of formula -S(0) 2 N(alkyl) 2 , wherein each alkyl group independently has n to m carbon atoms. In some embodiments, each alkyl group has, independently, I to 6 or 1 to 4 carbon atoms.
- aminosulfonylamino refers to a group of formula - NHS(0) 2 NH 2 .
- C Intel. m alkylaminosulfonylamino refers to a group of formula -NHS(0) 2 NH(alkyl), wherein the alkyl group has n to m carbon atoms. In some embodiments, the alkyl group has 1 to 6 or 1 to 4 carbon atoms.
- di(C Intel. m alkyl)aminosulfonylamino refers to a group of formula -NHS(0) 2 N(alkyl) 2 , wherein each alkyl group independently has n to m carbon atoms. In some embodiments, each alkyl group has, independently, 1 to 6 or 1 to 4 carbon atoms.
- aminocarbonylamino refers to a group of formula -NHC(0)N3 ⁇ 4.
- C n , m alkylaminocarbonylamino refers to a group of formula -NHC(0)NH(alkyl), wherein the alkyl group has n to m carbon atoms. In some embodiments, the alkyl group has 1 to 6 or 1 to 4 carbon atoms.
- di(C Intel. m alkyl)aminocarbonylamino refers to a group of formula -NHC(0)N(alkyl) 2 , wherein each alkyl group independently has n to m carbon atoms. In some embodiments, each alkyl group has, independently, 1 to 6 or 1 to 4 carbon atoms.
- C Intel. m alkylcarbamyl refers to a group of formula -C(0)-NH(alkyl), wherein the alkyl group has n to m carbon atoms. In some embodiments, the alkyl group has 1 to 6 or 1 to 4 carbon atoms.
- di(C, >ra -all ⁇ yl)carbamyl refers to a group of formula -C(0)N(alkyl) 2 , wherein the two alkyl groups each has, independently, n to m carbon atoms. In some embodiments, each alkyl group independently has 1 to 6 or 1 to 4 carbon atoms.
- thio refers to a group of formula -SH.
- C n _ m alkylthio refers to a group of formula -S-alkyl, wherein the alkyl group has n to m carbon atoms. In some embodiments, the alkyl group has 1 to 6 or 1 to 4 carbon atoms.
- m alkylsulfinyl refers to a group of formula
- the alkyl group has n to m carbon atoms. In some embodiments, the alkyl group has 1 to 6 or 1 to 4 carbon atoms.
- C n . m alkylsulfonyl refers to a group of formula -S(0) 2 -alkyl, wherein the alkyl group has n to m carbon atoms. In some embodiments, the alkyl group has 1 to 6 or 1 to 4 carbon atoms.
- amino refers to a group of formula -NH2.
- hydroxy-C -alkyl refers to a group of formula - alkylene-OH, wherein said alkylene group has n to m carbon atoms. In some embodiments, the alkylene group has 1 to 4 carbon atoms.
- C 0 . p alkoxy-C -alkyl refers to a group of formula
- alkylene group has n to m carbon atoms and said alkyl group has o to p carbon atoms,
- the alkyl and alkylene groups each independently have 1 to 4 carbon atoms.
- cyano-C Intel As used herein, the term "cyano-C Intel. m -alkyl” refers to a group of formula - alkylene-CN, wherein said alkylene group has n to m carbon atoms. In some embodiments, the alkylene group has 1 to 4 carbon atoms.
- aryl refers to a monocyclic or polycyclic (e.g., having 2, 3 or 4 fused rings) aromatic hydrocarbon, such as, but not limited to, phenyl, 1-naphthyl, 2-naphthyl, anthracenyl, phenanthrenyl, and the like.
- aryl is aryl.
- the aryl group is a naphthalene ring or phenyl ring.
- the aryl group is phenyl.
- arylalkyl refers to a group of formula -alkylene- aryl.
- arylalkyl is Ce-io aryl-C alkyl.
- arylalkyl is aryl-Cj alkyl.
- arylalkyl is benzyl.
- carboxylate refers to a group of formula -C(0)NH 2 .
- the terra "carbonyi”, employed alone or in combination with other terms, refers to a -C(0)- group.
- carboxy refers to a group of formula -C(0)OH.
- cycloalkyl refers to a non-aromatic cyclic hydrocarbon moiety, which may optionally contain one or more alkenylene groups as part of the ring structure
- Cycloalkyl groups can include mono- or polycyclic (e.g., having 2, 3 or 4 fused rings) ring systems.
- moieties that have one or more aromatic rings fused (i.e., having a bond in common with) to the cycloalkyl ring, for example, benzo derivatives of cyciopentane, cyclopentene, cyclohexane, and the like.
- cycloalkyl is C3.12 cycloalkyl, which is monocyclic or bicyclic.
- Examplary cycloalkyl groups include 1,2,3,4-tetrahydro-naphthalene, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclopentenyl, cyclohexenyl, cyclohexadienyl, cycloheptatrienyl, norbornyl, norpinyl, norcarnyl, adamantyl, and the like.
- the cycloalkyl group is cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl.
- cycloalkylalkyl refers to a group of formula -alkylene-cycloalkyl.
- cycloalkylalkyl is C3.
- cycloalkylalkyl is C3-i2 cycloalkyl-Ci.4 alkyl, wherein the cycloalkyl portion is monocyclic or bicyclic.
- C n . m haloalkoxy refers to a group of formula -O-haloalkyl having n to m carbon atoms.
- An example haloalkoxy group is OCF3.
- the haloalkoxy group is fliiorinated only.
- the alkyl group has 1 to 6 or 1 to 4 carbon atoms.
- halo refers to a halogen atom selected from F, CI, I or Br.
- m haloalkyl refers to an alkyl group having from one halogen atom to 2s+l halogen atoms which may be the same or different, where "s" is the number of carbon atoms in the alkyl group, wherein the alkyl group has n to m carbon atoms.
- the haloalkyl group is fluorinated only.
- the haloalkyl group is fluoromethyl, difluoromethyl, or trifluoromethyl.
- the haloalkyl group is trifluoromethyl.
- the alkyl group has 1 to 6 or 1 to 4 carbon atoms.
- heteroaryl refers to a monocyclic or polycyclic (e.g., having 2, 3 or 4 fused rings) aromatic hydrocarbon moiety, having one or more heteroatom ring members selected from nitrogen, sulfur and oxygen,
- heteroaryl is 5- to 10- membered heteroaryl, which is monocyclic or bicyclic and which has 1, 2, 3, or 4 heteroatom ring members independently selected from nitrogen, sulfur and oxygen.
- the heteroaryl group contains more than one heteroatom ring member, the heteroatoms may be the same or different.
- Example heteroaryl groups include, but are not limited to, pyridine, pyrimidine, pyrazine, pyridazine, pyrrole, pyrazole, azolyl, oxazole, thiazole, imidazole, fiiran, thiophene, quinoline, isoquinoline, indole, benzothiophene, benzofuran, benzisoxazole, imidazo[l,2-b]thiazole, purine, or the like.
- a five-membered ring heteroaryl is a heteroaryl with a ring having five ring atoms wherein one or more (e.g., 1 , 2, or 3) ring atoms are independently selected from N, O, and S.
- Exemplary five-membered ring heteroaryls are thienyl, furyl, pyrrolyl, imidazolyl, thiazolyl, oxazolyl, pyrazolyl, isothiazolyl, isoxazolyl, 1,2,3- triazolyl, tetrazolyl, 1,2,3-thiadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-triazolyl, 1,2,4- thiadiazolyl, 1,2,4-oxadiazolyl, 1,3,4-triazolyl, 1,3,4-thiadiazolyl, and 1,3,4- oxadiazolyl.
- a six-membered ring heteroaryl is a heteroaryl with a ring having six ring atoms wherein one or more (e.g., 1, 2, or 3) ring atoms are independently selected from N, O, and S.
- Exemplary six-membered ring heteroaryls are pyridyl, pyrazinyl, pyrimidinyl, triazinyl and pyridazinyl.
- heteroarylalkyl refers to a group of formula - alkylene-heteroaryl.
- heteroarylalkyl is Ci- i heteroaryl-Cu alkyl, wherein the heteroaryl portion is monocyclic or bicyclic and has 1, 2, 3, or 4 heteroatom ring members independently selected from nitrogen, sulfur and oxygen.
- heteroarylalkyl is Ci.g heteroaryl-Cn alkyl, wherein the heteroaryl portion is monocyclic or bicyclic and has 1, 2, 3, or 4 heteroatom ring members independently selected from nitrogen, sulfur and oxygen.
- heterocycloalkyl refers to non-aromatic ring system, which may optionally contain one or more alkenylene or alkynylene groups as part of the ring structure, and which has at least one heteroatom ring member independently selected from nitrogen, sulfur and oxygen.
- heterocycloalkyl groups contains more than one heteroatom, the heteroatoms may be the same or different.
- Heterocycloalkyl groups can include mono- or polycyclic (e.g., having 2, 3 or 4 fused rings) ring systems, including spiro systems.
- heterocycloalkyl moieties that have one or more aromatic rings fused (i.e., having a bond in common with) to the non-aromatic ring, for example, 1,2,3, 4-tetrahydro-quinoline and the like.
- the carbon atoms or heteroaioms in the ring(s) of the heterocycloalkyl group can be oxidized to form a carbonyl, or sulfonyl group (or other oxidized linkage) or a nitrogen atom can be quaternized.
- heterocycloalkyl is 5- to 10-membered C2 heterocycloalkyl, which is monocyclic or bicyclic and which has 1, 2, 3, or 4 heteroatom ring members independently selected from nitrogen, sulfur and oxygen.
- heterocycloalkyl groups include 1 ,2,3,4-tetrahydro-quinoline, azetidine, azepane, pyrrolidine, piperidine, piperazine, morpholine, thiomorpholine, pyran, and a 2-oxo-l,3-oxazolidine ring.
- heterocycloalkylalkyl refers to a group of formula -alkylene-heterocycloalkyl.
- heterocycloalkylalkyl is C2 heterocycloalkyl-C alkyl, wherein the heterocycloalkyl portion is monocyclic or bicyclic and has 1, 2, 3, or 4 heteroatom ring members independently selected from nitrogen, sulfur and oxygen.
- heterocycloalkylalkyl is C2 heterocycloalkyl-C alkyl, wherein the heterocycloalkyl portion is monocyclic or bicyclic and has 1, 2, 3, or 4 heteroatom ring members independently selected from nitrogen, sulfur and oxygen.
- the compounds described herein can be asymmetric (e.g., having one or more stereocenters). All stereoisomers, such as enantiomers and diastereomers, are intended unless otherwise indicated.
- An example method includes fractional recrystallization using a chiral resolving acid which is an optically active, salt-forming organic acid.
- Suitable resolving agents for fractional recrystallization methods are, for example, optically active acids, such as the D and L forms of tartaric acid, diacetyltartaric acid, dibenzoyitartaric acid, mandelic acid, malic acid, lactic acid or the various optically active camphorsulfonic acids such as p-camphorsulfonic acid.
- resolving agents suitable for fractional crystallization methods include stereoisomerically pure forms of a-methylbenzylamine (e.g., S and R forms, or diastereomerically pure forms), 2-phenylglycinol, norephedrine, ephedrine, N- methylephedrine, cyclohexylethylamine, 1 ,2-diaminocyclohexane, and the like.
- Resolution of racemic mixtures can also be carried out by elution on a column packed with an optically active resolving agent (e.g., dinitrobenzoylphenylglycine).
- an optically active resolving agent e.g., dinitrobenzoylphenylglycine
- Suitable elution solvent composition can be determined by one skilled in the art.
- Tautomeric forms result from the swapping of a single bond with an adjacent double bond together with the concomitant migration of a proton.
- Tautomeric forms include prototropic tautomers which are isomeric protonation states having the same empirical formula and total charge.
- Example prototropic tautomers include ketone - enol pairs, amide - imidic acid pairs, lactam - lactim pairs, amide - imidic acid pairs, enamine - imine pairs, and annular forms where a proton can occupy two or more positions of a heterocyclic system, for example, IH- and 3H-imidazole, 1H-, 2H- and 4H- 1,2,4- triazole, IH- and 2H- isoindole, and IH- and 2H-pyrazole.
- Tautomeric forms can be in equilibrium or sterically locked into one form by appropriate substitution.
- Compounds of the invention can also include all isotopes of atoms occurring in the intermediates or final compounds.
- Isotopes include those atoms having the same atomic number but different mass numbers.
- isotopes of hydrogen include tritium and deuterium. In some embodiments, 1 , 2, or 3 C3 ⁇ 4 or CH groups in or CD 2 group. In some
- some embodiments of the compounds of Formula I may have a deuterium atom attached to one atom of the cyclobutyl ring:
- compound as used herein is meant to include all stereoisomers, geometric iosomers, tautomers, and isotopes of the structures depicted.
- Compounds herein identified by name or structure as one particular tautomeric form are intended to include other tautomeric forms unless otherwise specified (e.g., in the case of purine rings, unless otherwise indicated, when the compound name or structure has the 9H tautomer, it is understood that the 7H tautomer is also encompassed).
- All compounds, and pharmaceutically acceptable salts thereof, can be found together with other substances such as water and solvents (e.g. hydrates and solvates) or can be isolated.
- the compounds of the invention, or salts thereof are substantially isolated.
- substantially isolated is meant that the compound is at least partially or substantially separated from the environment in which it was formed or detected.
- Partial separation can include, for example, a composition enriched in the compounds of the invention.
- Substantial separation can include compositions containing at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 97%, or at least about 99% by weight of the compounds of the invention, or salt thereof. Methods for isolating compounds and their salts are routine in the art.
- phrases "pharmaceutically acceptable” is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
- ambient temperature and “room temperature,” as used herein, are understood in the art, and refer generally to a temperature, e.g. a reaction temperature, that is about the temperature of the room in which the reaction is carried out, for example, a temperature from about 20 °C to about 30 °C.
- the present invention also includes pharmaceutically acceptable salts of the compounds described herein.
- pharmaceutically acceptable salts refers to derivatives of the disclosed compounds wherein the parent compound is modified by converting an existing acid or base moiety to its salt form.
- examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like.
- the pharmaceutically acceptable salts of the present invention include the conventional non-toxic salts of the parent compound formed, for example, from non-toxic inorganic or organic acids.
- the pharmaceutically acceptable salts of the present invention can be synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical methods.
- such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; generally, non-aqueous media like ether, ethyl acetate, alcohols (e.g., methanol, ethanol, iso-propanol, or butanol) or acetonitrile (ACN) are preferred.
- non-aqueous media like ether, ethyl acetate, alcohols (e.g., methanol, ethanol, iso-propanol, or butanol) or acetonitrile (ACN) are preferred.
- non-aqueous media like ether, ethyl acetate, alcohols (e.g., methanol, ethanol, iso-propanol, or butanol) or acetonitrile (ACN) are preferred.
- ACN acetonitrile
- Suitable solvents can be substantially non-reactive with the starting
- suitable solvents for a particular reaction step can be selected
- Reactions can be monitored according to any suitable method known in the
- product formation can be monitored by spectroscopic means, such as
- nuclear magnetic resonance spectroscopy e.g., ⁇ or , C
- infrared spectroscopy e.g., ⁇ or , C
- HPLC high performance liquid chromatography
- Useful intermediates 3-4 can be made according to the methods outlined in
- Compound of Formula I can be made by the methods shown in Scheme II. Accordingly formula 4-2 can be formed by reaction of the cyclobutanone of formula 4- 1 with a Horner- Wadsworth-Emmons reagent. A protected pyrazol-4-yl- pyrrolo[2,3-d]pyrimidine or pyrrolo[2,3-b]pyridine of formula 4-3 is reacted with a protected alkene of formula 4-2 in a Michael addition in the presence of a coupling agent to give the compound of formula 4-4. Removal of ether protecting group of formula 4-4 gives an alcohol derivative of formula 4-5, which can be oxidized to give the compound of formula 4-6. The compound of formula 4-6 can be converted to compound of formula 4-7 and 4-8 via reductive animation, which can be deprotected to remove P
- Specific compounds of Formula 111 can by made by the processes in Schemes III-X.
- a 4,6-dichloropyrimidine derivative can be treated with tert-butyl 4-aminopiperidine-l-carboxylate in a nucleophilic aromatic substitution reaction to provide the adduct.
- the resulting 6-chloropyrimidine is then used in a Stille coupling to afford the enol ether intermediate which can undergo oxidative cleavage to afford the aldehyde.
- the aldehyde can be reduced to the alcohol using sodium borohydride, and the resulting compound is then Boc-deprotected to provide piperidine for the reductive animation.
- 4-iodopyridine can be reacted via a lithium-halogen exchange, followed by reaction with 1,3,2-dioxathiolane. The sulfate is then hydrolyzed to the alcohol. The chlorine of the resulting 2-chloropyridine can be displaced again by heating with tert-butyl 4- aminopiperidine-l-carboxylate. The resulting adduct is Boc-deprotected using HCl/dioxane and subjected to the same reductive animation conditions with the cyclobutanone as found in the preceding Schemes. The resulting cis and trans isomers can be separated by HPLC. The isomers were deprotected separately under the usual condions of TFA/DCM followed by ethylenediamine in methanol.
- (methylamino)piperidine-l-carboxylate is formed by reductive animation between the piperidinone and methylamine. Displacement of the chloro group is followed by hydrolysis and reduction as previously described. Boc deprotection can be carried out with HCl/dioxane, and reductive animation can then be performed between the deprotected piperidine and cyclobutanone to afford cis and trans isomers, which were separable by HPLC. As in the previous examples, the hydroxymethyl compound can be directly deprotected, or converted to its mesylate at the SEM-protected stage and reacted with amines before deprotection as shown in Scheme X.
- JAK inhibitors are JAK inhibitors, and the majority of the compounds of the invention are JAKl selective inhibitors.
- a JAKl selective inhibitor is a compound that inhibits JAKl activity preferentially over other Janus kinases.
- the compounds of the invention preferentially inhibit JAKl over one or more of JAK2, JAK3, and TYK2. Jn some embodiments, the compounds inhibit JAKl preferentially over JAK2 (e.g., have a JAK1/JAK2 IC 5 o ratio >1).
- JAKl plays a central role in a number of cytokine and growth factor signaling pathways that, when dysregulated, can result in or contribute to disease states. For example, IL-6 levels are elevated in rheumatoid arthritis, a disease in which it has been suggested to have detrimental effects (Fonesca, J.E. et al., Autoimmunity Reviews, 8:538-42, 2009). Because IL-6 signals, at least in part, through JAK l, antagonizing IL-6 directly or indirectly through JAKl inhibition is expected to provide clinical benefit (Guschin, D., N., et al Embo J 14: 1421, 1995; Smolen, J. S., et al. Lancet 371 :987, 2008).
- JAKl is mutated resulting in constitutive undesirable tumor cell growth and survival (Mullighan CG, Proc Natl Acad Sci U S A.106:9414-8, 2009; Flex E., et al.J Exp Med. 205:751-8, 2008).
- JAKl inhibition In other autoimmune diseases and cancers elevated systemic levels of inflammatory cytokines that activate JAKl may also contribute to the disease and/or associated symptoms. Therefore, patients with such diseases may benefit from JAKl inhibition.
- Selective inhibitors of JAK1 may be efficacious while avoiding unnecessary and potentially undesirable effects of inhibiting other JAK kinases.
- JAK1 erythropoietin
- Tpo thrombopoietin
- Epo is a key growth factor for red blood cells production; hence a paucity of Epo-dependent signaling can result in reduced numbers of red blood cells and anemia (Kaushansky K, NEJM 354:2034-45, 2006).
- Tpo another example of a JAK2-dependent growth factor, plays a central role in controlling the proliferation and maturation of megakaryocytes - the cells from which platelets are produced (Kaushansky K, NEJM 354:2034-45, 2006). As such, reduced Tpo signaling would decrease megakaryocyte numbers (megakaryocytopenia) and lower circulating platelet counts (thrombocytopenia). This can result in undesirable and/or uncontrollable bleeding.
- JAK3 and Tyk2 may also be desirable as humans lacking functional version of these kinases have been shown to suffer from numerous maladies such as severe-combined immunodeficiency or hyperimmunoglobulin E syndrome (Minegishi, Y, et al. Immunity 25 :745-55, 2006; Macchi P, et al. Nature. 377:65-8, 1995). Therefore a JAK1 inhibitor with reduced affinity for other JAKs would have significant advantages over a less-selective inhibitor with respect to reduced side effects involving immune suppression, anemia and thrombocytopenia.
- a JAK-associated disease can include any disease, disorder or condition that is directly or indirectly linked to expression or activity of the JAK, including overexpression and/or abnormal activity levels.
- a JAK-associated disease can also include any disease, disorder or condition that can be prevented, ameliorated, or cured by modulating JAK activity.
- the JAK-associated disease is a JAK 1 -associated disease.
- JA -associated diseases include diseases involving the immune system including, for example, organ transplant rejection (e.g., allograft rejection and graft versus host disease).
- JAK-associated diseases include autoimmune diseases such as multiple sclerosis, rheumatoid arthritis, juvenile arthritis, psoriatic arthritis, type I diabetes, lupus, psoriasis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, myasthenia gravis, immunoglobulin nephropathies, myocarditis, autoimmune thyroid disorders, and the like.
- the autoimmune disease is an autoimmune bullous skin disorder such as pemphigus vulgaris (PV) or bullous pemphigoid (BP).
- JAK-associated diseases include allergic conditions such as asthma, food allergies, atopie dermatitis and rhinitis.
- Further examples of JAK- associated diseases include viral diseases such as Epstein Barr Virus (EBV), Hepatitis B, Hepatitis C, HIV, HTLV 1, Varicella-Zoster Virus (VZV) and Human Papilloma Virus (HPV).
- EBV Epstein Barr Virus
- HBV Human Papilloma Virus
- HPV Human Papilloma Virus
- JAK-associated disease examples include diseases associated with cartilage turnover, for example, gouty arthritis, septic or infectious arthritis, reactive arthritis, reflex sympathetic dystrophy, algodystrophy, Tietze syndrome, costal athropathy, osteoarthritis deformans endemica, Mseleni disease, Handigodu disease, degeneration resulting from fibromyalgia, systemic lupus erythematosus, scleroderma, or ankylosing spondylitis.
- diseases associated with cartilage turnover for example, gouty arthritis, septic or infectious arthritis, reactive arthritis, reflex sympathetic dystrophy, algodystrophy, Tietze syndrome, costal athropathy, osteoarthritis deformans endemica, Mseleni disease, Handigodu disease, degeneration resulting from fibromyalgia, systemic lupus erythematosus, scleroderma, or ankylosing spondylitis.
- JAK-associated disease examples include congenital cartilage malformations, including hereditary chrondrolysis, chrondrodysplasias, and pseudochrondrodysplasias (e.g., microtia, enotia, and metaphyseal
- JAK-associated diseases or conditions include skin disorders such as psoriasis (for example, psoriasis vulgaris), atopic dermatitis, skin rash, skin irritation, skin sensitization (e.g., contact dermatitis or allergic contact dermatitis).
- skin disorders such as psoriasis (for example, psoriasis vulgaris), atopic dermatitis, skin rash, skin irritation, skin sensitization (e.g., contact dermatitis or allergic contact dermatitis).
- certain substances including some pharmaceuticals when topically applied can cause skin sensitization.
- coadministration or sequential administration of at least one JAK inhibitor of the invention together with the agent causing unwanted sensitization can be helpful in treating such unwanted sensitization or dermatitis.
- the skin disorder is treated by topical administration of at least one JAK inhibitor of the invention.
- the JAK-associated disease is cancer including those characterized by solid tumors (e.g., prostate cancer, renal cancer, hepatic cancer, pancreatic cancer, gastric cancer, breast cancer, lung cancer, cancers of the head and neck, thyroid cancer, glioblastoma, Kaposi's sarcoma, Castleman's disease, melanoma etc.), hematological cancers (e.g., lymphoma, leukemia such as acute lymphoblastic leukemia, acute myelogenous leukemia (AML) or multiple myeloma), and skin cancer such as cutaneous T-cell lymphoma (CTCL) and cutaneous B-cell lymphoma.
- CTCLs include Sezary syndrome and mycosis fungoides.
- the JAK inhibitors described herein, or in combination with other JAK inhibitors, such as those reported in U.S. Ser. No. 1 1/637,545, which is incorporated herein by reference in its entirety, can be used to treat inflammation- associated cancers.
- the cancer is associated with inflammatory bowel disease.
- the inflammatory bowel disease is ulcerative colitis.
- the inflammatory bowel disease is Crohn's disease.
- the inflammation-associated cancer is colitis-associated cancer.
- the inflammation-associated cancer is colon cancer or colorectal cancer.
- the cancer is gastric cancer, gastrointestinal carcinoid tumor, gastrointestinal stromal tumor (GIST), adenocarcinoma, small intestine cancer, or rectal cancer.
- JAK-associated diseases can further include those characterized by expression of: JAK2 mutants such as those having at least one mutation in the pseudo-kinase domain (e.g. , JAK2 V617F); JAK2 mutants having at least one mutation outside of the pseudo-kinase domain; JAK1 mutants; JAK3 mutants; erythropoietin receptor (EPOR) mutants; or deregulated expression of CRLF2.
- JAK2 mutants such as those having at least one mutation in the pseudo-kinase domain (e.g. , JAK2 V617F); JAK2 mutants having at least one mutation outside of the pseudo-kinase domain; JAK1 mutants; JAK3 mutants; erythropoietin receptor (EPOR) mutants; or deregulated expression of CRLF2.
- JAK2 mutants such as those having at least one mutation in the pseudo-kinase domain (e.g. , JAK2 V617F); JAK2 mutants having
- JAK-associated diseases can further include myeloproliferative disorders (MPDs) such as polycythemia vera (PV), essential thrombocythemia (ET), myelofibrosis with myeloid metaplasia (MMM), primary myelofibrosis (PMF), chronic myelogenous leukemia (CML), chronic myelomonocytic leukemia (CMML), hypereosinophilic syndrome (HES), systemic mast cell disease (SMCD), and the like.
- MPDs myeloproliferative disorders
- PV polycythemia vera
- ET essential thrombocythemia
- MMM myelofibrosis with myeloid metaplasia
- PMF primary myelofibrosis
- CML chronic myelogenous leukemia
- CMML chronic myelomonocytic leukemia
- HES hypereosinophilic syndrome
- SMCD systemic mast cell disease
- the myeloproliferative disorder is myelofibrosis (e.g., primary myelofibrosis (PMF) or post polycythemia vera/essential thrombocythemia myelofibrosis (Post-PV/ET F)).
- myelofibrosis e.g., primary myelofibrosis (PMF) or post polycythemia vera/essential thrombocythemia myelofibrosis (Post-PV/ET F)
- PMF primary myelofibrosis
- Post-PV/ET F post polycythemia vera/essential thrombocythemia myelofibrosis
- the present invention further provides methods of treating psoriasis or other skin disorders by administration of a topical formulation containing a compound of the invention.
- JAK inhibitors described herein can be used to treat pulmonary arterial hypertension.
- the present invention further provides a method of treating dermatological side effects of other pharmaceuticals by administration of the compound of the invention.
- numerous pharmaceutical agents result in unwanted allergic reactions which can manifest as acneiform rash or related dermatitis.
- Example pharmaceutical agents that have such undesirable side effects include anti-cancer drugs such as gefitinib, cetuximab, erlotinib, and the like.
- the compounds of the invention can be administered systemically or topically (e.g., localized to the vicinity of the dermatitis) in combination with (e.g., simultaneously or sequentially) the pharmaceutical agent having the undesirable dermatological side effect.
- compositions of the invention include topical formulations containing the compound of the invention and a further pharmaceutical agent which can cause dermatitis, skin disorders, or related side effects.
- JAK-associated diseases include inflammation and inflammatory diseases.
- Example mflammatory diseases include sarcoidosis, inflammatory diseases of the eye (e.g., ulceris, uveitis, scleritis, conjunctivitis, or related disease), inflammatory diseases of the respiratory tract (e.g., the upper respiratory tract including the nose and sinuses such as rhinitis or sinusitis or the lower respiratory tract including bronchitis, chronic obstructive pulmonary disease, and the like), inflammatory myopathy such as myocarditis, and other inflammatory diseases.
- sarcoidosis include sarcoidosis, inflammatory diseases of the eye (e.g., ulceritis, uveitis, scleritis, conjunctivitis, or related disease), inflammatory diseases of the respiratory tract (e.g., the upper respiratory tract including the nose and sinuses such as rhinitis or sinusitis or the lower respiratory tract including bronchitis, chronic obstructive
- the JAK inhibitors described herein can further be used to treat ischemia reperfusion injuries or a disease or condition related to an inflammatory ischemic event such as stroke or cardiac arrest.
- the JAK inhibitors described herein can further be used to treat anorexia, cachexia, or fatigue such as that resulting from or 5 associated with cancer.
- the JAK inhibitors described herein can further be used to treat restenosis, sclerodermitis, or fibrosis.
- the JAK inhibitors described herein can further be used to treat conditions associated with hypoxia or astrogliosis such as, for example, diabetic retinopathy, cancer, or neurodegeneration. See, e.g., Dudley, A.C. et al. Biochem. J.
- JAK inhibitors described herein can be used to treat Alzheimer's disease.
- the JAK inhibitors described herein can further be used to treat other inflammatory diseases such as systemic inflammatory response syndrome (SIRS) and 15 septic shock.
- SIRS systemic inflammatory response syndrome
- 15 septic shock 15 septic shock.
- JAK inhibitors described herein can further be used to treat gout and increased prostate size due to, e.g., benign prostatic hypertrophy or benign prostatic hyperplasia.
- JAK-associated diseases include bone resorption diseases such as0 osteoporosis, osteoarthritis. Bone resorption can also be associated with other conditions such as hormonal imbalance and/or hormonal therapy, autoimmune disease (e.g. osseous sarcoidosis), or cancer (e.g. myeloma).
- the reduction of the bone resorption due to the JAK inhibitors can be about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, or about 90%.
- JAK inhibitors described herein can further be used to treat a dry eye disorder.
- dry eye disorder is intended to encompass the disease states summarized in a recent official report of the Dry Eye Workshop (DEWS), which defined dry eye as "a multifactorial disease of the tears and ocular surface that results in symptoms of discomfort, visual disturbance, and tear film0 instability with potential damage to the ocular surface. It is accompanied by increased osmolarity of the tear film and inflammation of the ocular surface.”
- DEWS Dry Eye Workshop
- the dry eye disorder is selected from aqueous tear- deficient dry eye (ADDE) or evaporative dry eye disorder, or appropriate combinations thereof.
- the dry eye disorder is Sjogren syndrome dry eye (SSDE), In some embodiments, the dry eye disorder is non- Sjogren syndrome dry eye (NSSDE).
- the present invention provides a method of treating conjunctivitis, uveitis (including chronic uveitis), chorioditis, retinitis, cyclitis, sclieritis, episcleritis, or ulceris; treating inflammation or pain related to corneal transplant, LASIK (laser assisted in situ keratomileusis), photorefractive keratectomy, or LASEK (laser assisted sub-epithelial keratomileusis); inhibiting loss of visual acuity related to corneal transplant, LASIK, photorefractive keratectomy, or LASEK; or inhibiting transplant rejection in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of the compound of the invention, or a pharmaceutically acceptable salt thereof.
- the compounds of the invention can be used to treat respiratory dysfunction or failure associated with viral infection, such as influenza and SARS.
- the present invention provides a compound of Formula I, pharmaceutically acceptable salt thereof, as described in any of the embodiments herein, for use in a method of treating any of the diseases or disorders described herein.
- the present invention provides the use of a compound of Formula I as described in any of the embodiments herein, for the preparation of a medicament for use in a method of treating any of the diseases or disorders described herein.
- the present invention provides a compound of Formula I as described herein, or a pharmaceutically acceptable salt thereof, for use in a method of modulating a JAK 1. In some embodiments, the present invention also provides use of a compound of Formula I as described herein, or a pharmaceutically
- contacting refers to the bringing together of indicated moieties in an in vitro system or an in vivo system.
- "contacting" a JAK with a compound of the invention includes the administration of a compound of the present invention to an individual or patient, such as a human, having a JAK, as well as, for example, introducing a compound of the invention into a sample containing a cellular or purified preparation containing the JAK.
- the term "individual” or “patient,” used interchangeably, refers to any animal, including mammals, preferably mice, rats, other rodents, rabbits, dogs, cats, swine, cattle, sheep, horses, or primates, and most preferably humans.
- the phrase "therapeutically effective amount” refers to the amount of active compound or pharmaceutical agent that elicits the biological or medicinal response that is being sought in a tissue, system, animal, individual or human by a researcher, veterinarian, medical doctor or other clinician.
- the term "treating" or “treatment” refers to one or more of (1) preventing the disease; for example, preventing a disease, condition or disorder in an individual who may be predisposed to the disease, condition or disorder but does not yet experience or display the pathology or symptomatology of the disease; (2) inhibiting the disease; for example, inhibiting a disease, condition or disorder in an individual who is experiencing or displaying the pathology or symptomatology of the disease, condition or disorder (i.e., arresting further development of the pathology and/or symptomatology); and (3) ameliorating the disease; for example, ameliorating a disease, condition or disorder in an individual who is experiencing or displaying the pathology or symptomatology of the disease, condition or disorder (i.e., reversing the pathology and/or symptomatology) such as decreasing the severity of disease.
- preventing the disease for example, preventing a disease, condition or disorder in an individual who may be predisposed to the disease, condition or disorder but does not yet experience or display the pathology or symptomatology of
- One or more additional pharmaceutical agents such as, for example, chemotherapeutics, anti-inflammatory agents, steroids, immunosuppressants, as well as Bcr-Abl, Flt-3, RAF and FAK kinase inhibitors such as, for example, those described in WO 2006/056399, which is incorporated herein by reference in its entirety, or other agents can be used in combination with the compounds described herein for treatment of JAK-associated diseases, disorders or conditions.
- the one or more additional pharmaceutical agents can be administered to a patient simultaneously or sequentially.
- Example chemotherapeutic include proteosome inhibitors (e.g., bortezomib), thalidomide, revlimid, and DNA-damaging agents such as melphalan, doxorubicin, cyclophosphamide, vincristine, etoposide, carmustine, and the like,
- Example steroids include coriticosteroids such as dexamethasone or prednisone.
- Example Bcr-Abl inhibitors include the compounds, and pharmaceutically acceptable salts thereof, of the genera and species disclosed in U.S. Pat. No.
- Example suitable Flt-3 inhibitors include compounds, and their pharmaceutically acceptable salts, as disclosed in WO 03/037347, WO 03/099771, and WO 04/046120, all of which are incorporated herein by reference in their entirety.
- Example suitable RAF inhibitors include compounds, and their pharmaceutically acceptable salts, as disclosed in WO 00/09495 and WO 05/028444, both of which are incorporated herein by reference in their entirety.
- Example suitable FAK inhibitors include compounds, and their pharmaceutically acceptable salts, as disclosed in WO 04/080980, WO 04/056786, WO 03/024967, WO 01/064655, WO 00/053595, and WO 01/014402, all of which are incorporated herein by reference in their entirety.
- one or more of the compounds of the invention can be used in combination with one or more other kinase inhibitors including imatinib, particularly for treating patients resistant to imatinib or other kinase inhibitors.
- one or more JAK inhibitors of the invention can be used in combination with a chemotherapeutic in the treatment of cancer, such as multiple myeloma, and may improve the treatment response as compared to the response to the chemotherapeutic agent alone, without exacerbation of its toxic effects.
- additional pharmaceutical agents used in the treatment of multiple myeloma can include, without limitation, melphalan, melphalan plus prednisone [MP], doxorubicin, dexamethasone, and Velcade (bortezomib).
- Further additional agents used in the treatment of multiple myeloma include Bcr-Abl, Flt-3, RAF and FAK kinase inhibitors.
- Additive or synergistic effects are desirable outcomes of combining a JAK inhibitor of the present invention with an additional agent.
- resistance of multiple myeloma cells to agents such as dexamethasone may be reversible upon treatment with a JAK inhibitor of the present invention.
- the agents can be combined with the present compounds in a single or continuous dosage form, or the agents can be administered simultaneously or sequentially as separate dosage forms.
- a corticosteroid such as dexamethasone is administered to a patient in combination with at least one JAK bihibitor where the dexamethasone is administered intermittently as opposed to continuously.
- combinations of one or more JAK inhibitors of the invention with other therapeutic agents can be administered to a patient prior to, during, and/or after a bone marrow transplant or stem cell transplant.
- the additional therapeutic agent is fluocinolone acetonide (Retisert®), or rimexolone (AL-2178, Vexol, Alcoii).
- the additional therapeutic agent is cyclosporine (Restasis®).
- the additional therapeutic agent is a corticosteroid.
- the corticosteroid is triamcinolone, dexamethasone, fluocinolone, cortisone, prednisolone, or flumetholone.
- the additional therapeutic agent is selected from DehydrexTM (Holies Labs), Civamide (Opko), sodium hyaluronate (Vismed, Lantibio/TRB Chemedia), cyclosporine (ST-603, Sirion Therapeutics), ARG101(T) (testosterone, Argentis), AGR1012(P) (Argentis), ecabet sodium (Senju-Ista), gefarnate (Santen), 15-(s)-hydroxyeicosatetraenoic acid (15(S)-H£TE), cevilemine, doxycycline (ALTY-0501, Alacrity), minocycline, iDestrinTM (NP50301, Nascent Pharmaceuticals), cyclosporine A (Nova22007, Novagali), oxytetracycline (Duramycin, MOLI1901 , Lantibio), CF101 (2S,3S,4R,5R)-3,4-dihydroxy-5-[6-[(3
- the additional therapeutic agent is an anti-angiogenic agent, cholinergic agonist, TRP-1 receptor modulator, a calcium channel blocker, a mucin secretagogue, MUC1 stimulant, a calcineurin inhibitor, a corticosteroid, a P2Y2 receptor agonist, a muscarinic receptor agonist, another JAK inhibitor, Bcr-Abl kinase inhibitor, Flt-3 kinase inhibitor, RAF kinase inhibitor, and FAK kinase inhibitor such as, for example, those described in WO 2006/056399, which is incorporated herein by reference in its entirety.
- the additional therapeutic agent is a tetracycline derivative (e.g., minocycline or doxycline).
- the additional therapeutic agent(s) are demulcent eye drops (also known as "artificial tears"), which include, but are not limited to, compositions containing polyvinylalcohol, hydroxypropyl methylcellulose, glycerin, polyethylene glycol (e.g. PEG400), or carboxymethyl cellulose. Artificial tears can help in the treatment of dry eye by compensating for reduced moistening and lubricating capacity of the tear film.
- the additional therapeutic agent is a mucolytic drug, such as N-acetyl-cysteine, which can interact with the mucoproteins and, therefore, to decrease the viscosity of the tear film.
- the additional therapeutic agent includes an antibiotic, antiviral, antifungal, anesthetic, anti-inflammatory agents including steroidal and nonsteroidal anti-inflammatories, and anti-allergic agents.
- suitable medicaments include aminoglycosides such as amikacin, gentamycin, tobramycin, streptomycin, netilmycin, and kanamycin; fluoroquinolones such as ciprofloxacin, norfloxacin, ofloxacin, trovafloxacin, lomefloxacin, levofloxacin, and enoxacin; naphthyridine; sulfonamides; polymyxin; chloramphenicol; neomycin; paromomycin; colistimethate; bacitracin; vancomycin; tetracyclines; rifampin and its derivatives ("rifampins"); cycloserine; beta-lactams; cephalosporins; amphoter
- the compounds of the invention can be administered in the form of pharmaceutical compositions.
- These compositions can be prepared in a manner well known in the pharmaceutical art, and can be administered by a variety of routes, depending upon whether local or systemic treatment is desired and upon the area to be treated. Administration may be topical (including transdermal, epidermal, ophthalmic and to mucous membranes including intranasal, vaginal and rectal delivery), pulmonary (e.g., by inhalation or insufflation of powders or aerosols, including by nebulizer; intratracheal or intranasal), oral or parenteral.
- topical including transdermal, epidermal, ophthalmic and to mucous membranes including intranasal, vaginal and rectal delivery
- pulmonary e.g., by inhalation or insufflation of powders or aerosols, including by nebulizer; intratracheal or intranasal
- oral or parenteral e.g., by inhal
- Parenteral administration includes intravenous, intraarterial, subcutaneous, intraperitoneal intramuscular or injection or infusion; or intracranial, e.g., intrathecal or intraventricular, administration.
- Parenteral administration can be in the form of a single bolus dose, or may be, for example, by a continuous perfusion pump.
- compositions and formulations for topical administration may include transdermal patches, ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and powders.
- Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the like may be necessary or desirable.
- compositions which contain, as the active ingredient, the compound of the invention or a pharmaceutically acceptable salt thereof, in combination with one or more pharmaceutically acceptable carriers (excipients).
- the composition is suitable for topical administration.
- the active ingredient is typically mixed with an excipient, diluted by an excipient or enclosed within such a carrier in the form of, for example, a capsule, sachet, paper, or other container.
- the excipient serves as a diluent, it can be a solid, semi-solid, or liquid material, which acts as a vehicle, carrier or medium for the active ingredient.
- compositions can be in the form of tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols (as a solid or in a liquid medium), ointments containing, for example, up to 10% by weight of the active compound, soft and hard gelatin capsules, suppositories, sterile injectable solutions, and sterile packaged powders.
- the active compound can be milled to provide the appropriate particle size prior to combining with the other ingredients. If the active compound is substantially msoluble, it can be milled to a particle size of less than 200 mesh. If the active compound is substantially water soluble, the particle size can be adjusted by milling to provide a substantially uniform distribution in the formulation, e.g. about 40 mesh.
- the compounds of the invention may be milled using known milling procedures such as wet milling to obtain a particle size appropriate for tablet formation and for other formulation types.
- Finely divided (nanoparticulate) preparations of the compounds of the invention can be prepared by processes known in the art, e.g., see International App. No. WO 2002/000196.
- excipients include lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, and methyl cellulose.
- the formulations can additionally include: lubricating agents such as talc, magnesium stearate, and mineral oil; wetting agents; emulsifying and suspending agents; preserving agents such as methyl- and propylhydroxy-benzoates; sweetening agents; and flavoring agents.
- the compositions of the invention can be formulated so as to provide quick, sustained or delayed release of the active ingredient after administration to the patient by employing procedures known in the art.
- compositions can be formulated in a unit dosage form, each dosage containing from about 5 to about 1 ,000 mg (1 g), more usually about 100 mg to about 500 mg, of the active ingredient.
- unit dosage forms refers to physically discrete units suitable as unitary dosages for human subjects and other mammals, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, in association with a suitable pharmaceutical excipient.
- the compositions of the invention contain from about 5 mg to about 50 mg of the active ingredient.
- compositions of the invention contain from about 50 mg to about 500 mg of the active ingredient.
- compositions of the invention contain from about
- the active compound may be effective over a wide dosage range and is generally administered in a pharmaceutically effective amount. It will be understood, however, that the amount of the compound actually administered will usually be determined by a physician, according to the relevant circumstances, including the
- the principal active ingredient is mixed with a pharmaceutical exeipient to form a solid preformulation
- composition containing a homogeneous mixture of a compound of the present invention.
- the active ingredient is typically dispersed evenly throughout the composition so that the composition can be readily subdivided into equally effective unit dosage forms such as tablets, pills and capsules.
- This solid preformulation is then subdivided into unit dosage forms of the type described above containing from, for example, about 0.1 to about 1000 mg of the active ingredient of the present invention.
- the tablets or pills of the present invention can be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action.
- the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former.
- the two components can be separated by an enteric layer which serves to resist disintegration in the stomach and permit the inner component to pass intact into the duodenum or to be delayed in release.
- enteric layers or coatings such materials including a number of polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol, and cellulose acetate.
- liquid forms in which the compounds and compositions of the present invention can be incorporated for administration orally or by injection include aqueous solutions, suitably flavored syrups, aqueous or oil suspensions, and flavored emulsions with edible oils such as cottonseed oil, sesame oil, coconut oil, or peanut oil, as well as elixirs and similar pharmaceutical vehicles.
- compositions for inhalation or insufflation include solutions and suspensions in pharmaceutically acceptable, aqueous or organic solvents, or mixtures thereof, and powders.
- the liquid or solid compositions may contain suitable pharmaceutically acceptable excipients as described supra.
- the compositions are administered by the oral or nasal respiratory route for local or systemic effect.
- Compositions in can be nebulized by use of inert gases. Nebulized solutions may be breathed directly from the nebulizing device or the nebulizing device can be attached to a face masks tent, or intermittent positive pressure breathing machine. Solution, suspension, or powder compositions can be administered orally or nasally from devices which deliver the formulation in an appropriate manner.
- Topical formulations can contain one or more conventional carriers.
- ointments can contain water and one or more hydrophobic carriers selected from, for example, liquid paraffin, polyoxyethylene alkyl ether, propylene glycol, white vaseline, and the like.
- Carrier compositions of creams can be based on water in combination with glycerol and one or more other components, e.g.
- topical formulations contain at least about 0.1, at least about 0.25, at least about 0.5, at least about 1, at least about 2, or at least about 5 wt % of the compound of the invention.
- the topical formulations can be suitably packaged in tubes of, for example, 100 g which are optionally associated with instructions for the treatment of the select indication, e.g., psoriasis or other skin condition.
- compositions can be administered to a patient already suffering from a disease in an amount sufficient to cure or at least partially arrest the symptoms of the disease and its complications. Effective doses will depend on the disease condition being treated as well as by the judgment of the attending clinician depending upon factors such as the severity of the disease, the age, weight and general condition of the patient, and the like.
- compositions administered to a patient can be in the form of pharmaceutical compositions described above. These compositions can be sterilized by conventional sterilization techniques, or may be sterile filtered. Aqueous solutions can be packaged for use as is, or lyophilized, the lyophilized preparation being combined with a sterile aqueous carrier prior to administration.
- the pH of the compound preparations typically will be between 3 and 1 1, more preferably from 5 to 9 and most preferably from 7 to 8. It will be understood that use of certain of the foregoing excipients, carriers, or stabilizers will result in the formation of pharmaceutical salts.
- the therapeutic dosage of a compound of the present invention can vary according to, for example, the particular use for which the treatment is made, the manner of administration of the compound, the health and condition of the patient, and the judgment of the prescribing physician.
- the proportion or concentration of a compound of the invention in a pharmaceutical composition can vary depending upon a number of factors including dosage, chemical characteristics (e.g., hydrophobicity), and the route of administration.
- the compounds of the invention can be provided in an aqueous physiological buffer solution containing about 0.1 to about 10% w/v of the compound for parenteral administration. Some typical dose ranges are from about 1 ⁇ kg to about 1 g/kg of body weight per day.
- the dose range is from about 0.01 mg/kg to about 100 mg/kg of body weight per day.
- the dosage is likely to depend on such variables as the type and extent of progression of the disease or disorder, the overall health status of the particular patient, the relative biological efficacy of the compound selected, formulation of the excipient, and its route of administration. Effective doses can be extrapolated from dose-response curves derived from in vitro or animal model test systems.
- compositions of the invention can further include one or more additional pharmaceutical agents such as a chemotherapeutic, steroid, anti-inflammatory compound, or immunosuppressant, examples of which are listed hereinabove.
- additional pharmaceutical agents such as a chemotherapeutic, steroid, anti-inflammatory compound, or immunosuppressant, examples of which are listed hereinabove.
- the compound, or pharmaceutically acceptable salt thereof is administered as an ophthalmic composition.
- the methods comprise administration of the compound, or pharmaceutically acceptable salt thereof, and an ophthalmically acceptable carrier.
- the ophthalmic composition is a liquid composition, semi-solid composition, insert, film, microparticles or nanoparticles.
- the ophthalmic composition is a liquid composition. In some embodiments, the ophthalmic composition is a semi-solid composition. In some embodiments, the ophthalmic composition is an topical composition.
- the topical compositions include, but are not limited to liquid and semi-solid compositions.
- the ophthalmic composition is a topical composition, In some embodiments, the topical composition comprises aqueous solution, an aqueous suspension, an ointment or a gel. In some embodiments, the ophthalmic composition is topically applied to the front of the eye, under the upper eyelid, on the lower eyelid and in the cul-de-sac. In some embodiments, the ophthalmic composition is sterilized.
- the sterilization can be accomplished by known techniques like sterilizing filtration of the solution or by heating of the solution in the ampoule ready for use.
- the ophthalmic compositions of the invention can further contain pharmaceutical excipients suitable for the preparation of ophthalmic formulations. Examples of such excipients are preserving agents, buffering agents, chelating agents, antioxidant agents and salts for regulating the osmotic pressure.
- the term "ophthalmically acceptable carrier” refers to any 5 material that can contain and release the compound, or pharmaceutically acceptable salt thereof, and that is compatible with the eye.
- the ophthalmically acceptable carrier is water or an aqueous solution or suspension, but also includes oils such as those used to make ointments and polymer matrices such as used in ocular inserts.
- the composition may be an aqueous
- Liquid ophthalmic compositions may have a viscosity that is suited for the selected route of administration.
- the ophthalmic composition has a viscosity in the range of from about 1,000 to about 30,000 centipoise.
- the ophthalmic compositions may further comprise one or more of surfactants, adjuvants, buffers, antioxidants, tonicity adjusters, preservatives (e.g., EDTA, BAK (benzalkonium chloride), sodium chlorite, sodium perborate, polyquaterium-1), thickeners or viscosity modifiers (e.g., carboxymethyl cellulose, hydroxymethyl cellulose, polyvinyl alcohol, polyethylene glycol, glycol
- Additives in the formulation may include, but are not limited to, sodium chloride, sodium bicarbonate, sorbic acid, methyl paraben, propyl paraben, chlorhexidine, castor oil, and sodium perborate.
- Aqueous ophthalmic compositions (solutions or suspensions) generally do not
- purified or deionized water is used in the composition.
- the pH may be adjusted by adding any physiologically and ophthalmically acceptable pH adjusting acids, bases or buffers to within the range of about 5.0 to 8.5.
- Ophthalmically acceptable examples of acids include acetic, boric, citric, lactic, phosphoric,
- hydrochloric, and the like, and examples of bases include sodium hydroxide, sodium phosphate, sodium borate, sodium citrate, sodium acetate, sodium lactate, tromethamine, trishydroxymethylamino-methane, and the like.
- Salts and buffers include citrate/dextrose, sodium bicarbonate, ammonium chloride and mixtures of the aforementioned acids and bases.
- the methods involve forming or supplying a depot of the therapeutic agent in contact with the external surface of the eye.
- a depot refers to a source of therapeutic agent that is not rapidly removed by tears or other eye clearance mechanisms. This allows for continued, sustained high concentrations of therapeutic agent to be present in the fluid on the external surface of the eye by a single application.
- absorption and penetration may be dependent on both the dissolved drug concentration and the contact duration of the external tissue with the drug containing fluid. As the drug is removed by clearance of the ocular fluid and/or absorption into the eye tissue, more drug is provided, e.g. dissolved, into the replenished ocular fluid from the depot.
- the use of a depot may more easily facilitate loading of the ocular tissue for more insoluble therapeutic agents.
- the depot can remain for up to eight hours or more.
- the ophthalmic depot forms includes, but is not limited to, aqueous polymeric suspensions, ointments, and solid inserts.
- the ophthalmic composition is an ointment or gel.
- the ophthalmic composition is an oil-based delivery vehicle.
- the composition comprises a petroleum or lanolin base to which is added the active ingredient, usually as 0.1 to 2%, and excipients, Common bases may include, but are not limited to, mineral oil, petrolatum and combinations thereof.
- the ointment is applied as a ribbon onto the lower eyelid.
- the ophthalmic composition is an ophthalmic insert.
- the ophthalmic insert is biologically inert, soft, bio-erodible, viscoelastie, stable to sterilization after exposure to therapeutic agents, resistant to infections from air borne bacteria, bio- erodible, biocompatible, and/or viscoelastie.
- the insert comprises an ophthalmically acceptable matrix, e.g., a polymer matrix.
- the matrix is typically a polymer and the therapeutic agent is generally dispersed therein or bonded to the polymer matrix.
- the therapeutic agent may be slowly released from the matrix through dissolution or hydrolysis of the covalent bond.
- the polymer is bioerodible (soluble) and the dissolution rate thereof can control the release rate of the therapeutic agent dispersed therein.
- the polymer matrix is a biodegradable polymer that breaks down such as by hydrolysis to thereby release the therapeutic agent bonded thereto or dispersed therein.
- the matrix and therapeutic agent can be surrounded with an additional polymeric coating to further control release.
- the insert comprises a biodegradable polymer such as polycaprolactone (PCL), an ethylene/vinyl acetate copolymer (EVA), polyalkyl cyanoacrylate, polyurethane, a nylon, or poly (dl-lactide-co-glycolide) (PLGA), or a copolymer of any of these.
- the therapeutic agent is dispersed into the matrix material or dispersed amongst the monomer composition used to make the matrix material prior to polymerization.
- the amount of therapeutic agent is from about 0.1 to about 50%, or from about 2 to about 20%.
- the biodegradable or bioerodible polymer matrix is used so that the spent insert does not have to be removed. As the biodegradable or bioerodible polymer is degraded or dissolved, the therapeutic agent is released.
- the ophthalmic insert comprises a polymer, including, but are not limited to, those described in Wagh, et al., "Polymers used in ocular dosage form and drug delivery systems", Asian J. Pharm., pages 12-17 (Jan. 2008), which is incorporated herein by reference in its entirety.
- the insert comprises a polymer selected from polyvinylpyrrolidone (PVP), an acrylate or methacrylate polymer or copolymer (e.g., Eudragit® family of polymers from Rohm or Degussa), hydroxymethyl cellulose, polyacrylic acid, poly(amidoamine) dendrimers, poly(dimethyl siloxane), polyethylene oxide, poly(lactide-co-glycolide), poly(2-hydroxyethylmethacrylate), polyvinyl alcohol), or poly(propylene fumarate).
- the insert comprises Gelfoam® R.
- the insert is a polyacrylic acid of 450 kDa-cysteine conjugate.
- the ophthalmic composition is a ophthalmic film.
- Polymers suitable for such films include, but are not limited to, those described in Wagh, et al. (ibid),
- the film is a soft-contact lens, such as ones made from copolymers of ⁇ , ⁇ -diethylacrylamide and methacrylic acid crosslinked with ethyleneglycol dimethacrylate.
- the ophthalmic compositon comprises microspheres or nanoparticles.
- the microspheres comprise gelatin.
- the microspheres are injected to the posterior segment of the eye, in the chroroidal space, in the sclera, intravitreally or sub-retinally.
- the microspheres or nanoparticles comprises a polymer including, but not limited to, those described in Wagh, et al. (ibid), which is incorporated herein by reference in its entirety.
- the polymer is chitosan, a polycarboxylic acid such as polyacrylic acid, albumin particles, hyaluronic acid esters, polyitaconic acid, poly(butyl)cyanoacrylate, polycaprolactone, poly(isobutyl)caprolactone, poly(lactic acid-co-glycolic acid), or poly(lactic acid).
- the microspheres or nanoparticles comprise solid lipid particles.
- the ophthalmic composition comprises an ion- exchange resin.
- the ion-exchange resin is an inorganic zeolite or synthetic organic resin.
- the ion-exchange resin includes, but is not limited to, those described in Wagh, et al. (ibid), which is incorporated herein by reference in its entirety.
- the ion-exhange resin is a partially neutralized polyacrylic acid.
- the ophthalmic composition is an aqueous polymeric suspension.
- the therapeutic agent or a polymeric suspending agent is suspended in an aqueous medium.
- the aqueous polymeric suspensions may be formulated so that they retain the same or substantially the same viscosity in the eye that they had prior to administration to the eye. In some embodiments, they may be formulated so that there is increased gelation upon contact with tear fluid.
- Another aspect of the present invention relates to labeled compounds of the invention (radio-labeled, fluorescent-labeled, etc.) that would be useful not only in imaging techniques but also in assays, both in vitro and in vivo, for localizing and quantitating JAK in tissue samples, including human, and for identifying JAK ligands by inhibition binding of a labeled compound.
- the present invention includes JAK assays that contain such labeled compounds.
- the present invention further includes isotopically-labeled compounds of the invention.
- an “isotopically” or “radio-labeled” compound is a compound of the invention where one or more atoms are replaced or substituted by an atom having an atomic mass or mass number different from the atomic mass or mass number typically found in nature (i.e., naturally occurring).
- Suitable radionuclides that may be incorporated in compounds of the present invention include but are not limited to 3 H (also written as T for tritium), ' 'C, l 3 C, l 4 C, ,3 N, 15 N, 13 0, l 7 0, l s O, , B F, 3S S, 36 C1, S2 Br, 75 Br, 76 Br, 77 Br, 123 I, l24 1, 125 I and 131 I.
- radionuclide that is incorporated in the instant radio-labeled compounds will depend on the specific application of that radio- labeled compound. For example, for in vitro JAK labeling and competition assays, compounds that incorporate 3 H, 14 C, 82 Br, l25 I , l 3 , l, 35 S or will generally be most useful. For radio-imaging applications "C, 1S F, , 25 I, l23 I, l 24 I, l31 1, 75 Br, 76 Br or 77 Br will generally be most useful.
- a “radio-labeled " or “labeled compound” is a compound that has incorporated at least one radionuclide.
- the radionuclide is selected from the group consisting of 3 H, l 4 C, , 25 1 , 35 S and 82 Br.
- the compound incorporates 1, 2, or 3 deuterium atoms.
- the present invention can further include synthetic methods for incorporating radio-isotopes into compounds of the invention. Synthetic methods for incorporating radio-isotopes into organic compounds are well known in the art, and an ordinary skill in the art will readily recognize the methods applicable for the compounds of invention.
- a labeled compound of the invention can be used in a screening assay to identify/evaluate compounds.
- a newly synthesized or identified compound (i.e., test compound) which is labeled can be evaluated for its ability to bind a JAK by monitoring its concentration variation when contacting with the JAK, through tracking of the labeling.
- a test compound (labeled) can be evaluated for its ability to reduce binding of another compound which is known to bind to a JAK (i.e., standard compound). Accordingly, the ability of a test compound to compete with the standard compound for binding to the JAK directly correlates to its binding affinity.
- the standard compound is labeled and test compounds are unlabeled. Accordingly, the concentration of the labeled standard compound is monitored in order to evaluate the competition between the standard compound and the test compound, and the relative binding affinity of the test compound is thus ascertained.
- kits useful for example, in the treatment or prevention of JAK-associated diseases or disorders, such as cancer, which include one or more containers containing a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention.
- Such o kits can further include, if desired, one or more of various conventional
- kits such as, for example, containers with one or more pharmaceutically acceptable carriers, additional containers, etc., as will be readily apparent to those skilled in the art. Instructions, either as inserts or as labels, indicating quantities of the components to be administered, guidelines for
- Step 2 tert-bittyl ⁇ [3-(methyh lfinyl)-3-(methylthio)cychbutyl]oxy ⁇ diphenylsilarie
- Step 5 cis and trans ⁇ 3- ⁇ [tert-butyl(diphenyl)silyl]oxy ⁇ -l-[4-(7- ⁇ [2- (trimethylsUyl)ethoxy]methyl ⁇ -7H-pyrrolo[2,3 l]pyrimidin-4-yl)-lH-pyrazol-l- yl]cyclobiityl ⁇ acetonitrile
- Step 6 cis and trans ⁇ 3-hydroxy-l-[4-(7 ⁇ [2-(trimethylsilyl)ethoxy]methyl ⁇ -7H- pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]cyclobutyl ⁇ acetonitrile
- Step B 4-( ⁇ [ tert-Butyl(diphenyl)silyl]oxy ⁇ methyl)-2-chloro-6- (trifluoromethyl)pyridine
- Step C tert-Butyl 4- ⁇ [4-( ⁇ [tert-bittyl(diphenyl)silyl]oxy ⁇ methyl)-6- (trifluoromethyl)pyridin-2-yl]oxyjpiperidine-l-carboxylate
- Step E ⁇ 3-(4- ⁇ [4-( ⁇ [tert-Butyl(diphenyl)silyl]oxy ⁇ methyl)-6-(trifluoromethyl)pyridi>i- 2-yl]oxy ⁇ piperidin-l-yl)-l-[4-(7- ⁇ [2-(trimethylsilyl)ethoxy]methyl ⁇ -7H-pyrrolo[2,3- d]pyrimidin-4-yl)-lH-pyrazol-l-yl]cyclobiityl ⁇ acetonitrile (a mixture of cis- and trans- isomers)
- Step F ⁇ cis-3-(4- ⁇ [4-(hydroxymethyl)-6-(trifliioromethyl)pyridin-2-yi]oxy ⁇ piperidiri- i-yl)-l-[4-(7- ⁇ [2-(trimethylsilyl)ethoxy]methyl ⁇ -7H-pyrrolo[2, 3-d]pyrimidin-4-yl)- lH-pyrazol-l-yl]cyclobutyl ⁇ acetonitrile and ⁇ trans-3-(4- ⁇ [4-(hydroxymethyl)-6- (trifluoromethyl)pyridin-2-yl]oxy ⁇ piperidin-l-y!-l-[4-(7- ⁇ [2- (trimethylsilyl)ethoxy]methyl ⁇ -7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l- yljcyclobittyljaceto trile (each diastereomer isolated)
- Step A ⁇ 3- ⁇ [tert-Butyl(diphenyl)silyl]oxy ⁇ -l-[4-(l- ⁇ [2- (trimethylsilyl)ethoxy]methyl ⁇ -JH-pyrrolo[2,3-b]pyridin-4-yl)-lH-pyrazo!-l- yljcyclobittyljacetonitrile (a mixture of diastereomers)
- Step B ⁇ 3-hydroxy-l-[4-(l- ⁇ [2-(trimethylsilyl)ethoxy]methyl ⁇ -lH-pyrrolo[2,3- b]pyridin-4-yl)-lH-pyrazol-l-yl]cyclobutyl ⁇ acetonitrile(a mixture of diastereomers)
- Step C ⁇ 3-oxo-l-[4-(l- ⁇ [2-(trimethylsilyl)ethoxy]methyl ⁇ -lH-pyrrolo[2, i-b]pyridin- 4-yl)-lH-pyrazol-l-yl]cyclobutyI ⁇ acetonitrile
- N,N-Diisopropylethylamine (9.4 uL, 0.054 mmol) and methanesulphonic anhydride (7.9 mg, 0.045 mmol) were added to a solution of ⁇ trans-3-(4- ⁇ [4- (hydroxymethyl)-6-(trifluoromethyl)pyi'idin-2-yl]oxy ⁇ piperidin-l-yl)-l-[4-(7- ⁇ [2- (trimethylsilyl)ethoxy]methyl ⁇ -7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l- yl]cyclobutyl ⁇ acetonitrile (10.0 mg, 0.018 mmol, Peak 1 from Intermediate Example A2, Step F) in methylene chloride (0.30 mL) , and the mesylate formation was stirred for 30 minutes.
- the product was purified using preparative HPLC- MS (C18 eluting with a gradient of MeCN/H 2 0 containing 0.15% NH 4 OH). The eluent was frozen and lyophilized to afford the product as the free base (6.0 mg, 54%).
- Example 1 The procedure of Example 1 was followed, using tetrahydro-2H-pyran-4-amine (1 1 mg, 0.1 1 mmol, Combi-Blocks) in the displacement step at 40 °C overnight (7.9 mg, 56%).
- Example 1 The procedure of Example 1 was followed, using ⁇ trans-3-(4- ⁇ [4- (hydroxymethyl)-6-(ti'ifluoromethyl)pyridin-2-yl]oxy ⁇ piperidin-l-yl)-l-[4-(7- ⁇ [2- (trimethylsilyl)ethoxy]methyl ⁇ -7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l- yl]cyclobutyl ⁇ acetonitrile (21 mg, 0,031 mmol, Peak 1 from Intermediate Example A2, Step F), N,N-dusopropylethylamine (1 1 iL, 0.062 mmol) and methanesulphonic anhydride (7.5 mg, 0.043 mmol, Aldrich) in methylene chloride (0.42 niL).
- substitution step was carried out using 3-methyloxetan-3-amine (40. ⁇ , 0.46 mmol, Synthonix) in tetrahydrofuran (0.42 mL) and methanol (0.20 mL) at 55 °C for 4 hours followed by 50 °C overnight. Deprotection and purification carried out similarly to afford product as the free base (1 1 mg, 58%).
- Example 9 The procedure of Example 9 was followed, using 1-methylcyclopropariamine hydrochloride (33 mg, 0.31 mmol, ChemBridge Corp.) and N,N- diisopropylethylamine (64 ⁇ L, 0.37 mmol) in the substitution step, which was carried out at 55°C for 2.5 hours. The product was obtained as the free base (6.2 mg, 33%).
- Example 9 The procedure of Example 9 was followed, using oxetan-3-amine (34 mg, 0.4 6 mmol, Synthonix) in the substitution step, carried out at 55 °C for 1.5 hours.
- the desired product was obtained as the free base (9.7 mg, 52%).
- Example 9 The procedure of Example 9 was followed, using trans-3-aminocyclobutanol hydrochloride (38 mg, 0.31 mmol, Advanced Chem Blocks) and N,N- diisopropylethylamine (64 ⁇ , 0.37 mmol) in the displacement step, carried out at 55 °C for 1.5 hours (yield 9.8 mg).
- Example 9 The procedure of Example 9 was followed, using 3,3-dimethylazetidine hydrochloride (22 mg, 0.18 mmol, Princeton Bio) and N,N-diisopropylethylamine (54 ⁇ ⁇ , 0.31 mmol) in the displacement step, which was carried out at room temperature overnight. (10 mg, 52%).
- Example 14 ⁇ trans-3-(4- ⁇ [4-( ⁇ [(2R)-2-hydroxypropyI]amino ⁇ metliyI)-6- (trifluoromethyl)pyridin-2-yl]oxy ⁇ piperidin-l-yl)-l-[4-(7H-pyrrolo[2,3- d]pyrimidin-4-yl)-lH-pyrazol-l-yI]cyclobutyl ⁇ acetonitrile
- Example 9 The procedure of Example 9 was followed, using (2R)- l-aminopropan-2-ol (12 iL, 0.15 mmol, Aldrich) in the displacement step, which was carried out at 50 °C for 2 hours. The product was obtained as the free base (8.7 mg, 46%).
- Example 9 The procedure of Example 9 was followed, using diethanolamine (15 ⁇ , 0.15 mmol, Aldrich) in the displacement step, which was carried out at 40 °C overnight (7.4 mg, 38%).
- Example 9 The procedure of Example 9 was followed, using 2-(methylamino)ethanol (12 ⁇ , 0.15 mmol, Aldrich) in the displacement step, which was carried out at 40 °C overnight (8.5 mg, 45%).
- Step 1 tert-biilyl 4- ⁇ [6-(trifluoromethyl)pyridin-2-yl]oxy ⁇ piperidme-l-carboxyl te
- sodium hydride (0.88 g, 60% in mineral oil, 22 mmol
- tetrahydrofuran 50. mL
- tert-butyl 4-hydroxypiperidine-l - carboxylate 4.4 g, 22 mmol, Aldrich
- Example 20 ⁇ trans-3-(4- ⁇ [4-(2-hydroxyethyl)-6-(trifluoromethyI)pyridin-2- yl]oxy ⁇ piperidin-l-yl)-l-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l- yl]cyclobutyl ⁇ acetonitrile
- the reaction was stirred at -78 °C for 1 hour and then allowed to warm to room temperature overnight.
- the reaction was quenched with water, then ammonium chloride was added.
- the layers were separated and the aqueous was extracted with two portions of ethyl acetate, The combined organic extracts were washed with water, then sat'd NaCl solution, dried over NajS0 4 , filtered and concentrated.
- the crude product which was a mixture of two regioisomers, was purified by flash chromatography, eluting with 2% EtOAc in hexanes, in 3 batches, each on a 330 g silica gel cartridge.
- the first product to elute was the desired regioisomer, which also contained some unreacted starting material, The product rystallized on standing and the oil, which contained some unreacted starting material, was decanted away, leaving a more pure crystalline product (9.58 g, 30%).
- Step 6 ⁇ trans-3-(4- ⁇ [4- ⁇ [(2-hydroxyethyl)amino]methyl ⁇ -6-(trifluoromethyl)pyridin- 2-yl]oxy ⁇ piperidin-l-yl)-l-[4-(lH-pyrrolo[2 -b]pyridin-4-yl)-lH-pyrazol-l- yl]cyclobuty! ⁇ acetonitrile
- Methanesulphonic anhydride 43 mg, 0.25 mmol, Aldrich was added to a solution of ⁇ trans-3-(4- ⁇ [4-(hydroxymethyl)-6-(trifluoromethyl)pyridin-2- yl]oxy ⁇ piperidin-l -yl)-l -[4-(l- ⁇ [2-(trimethylsilyl)ethoxy]methyl ⁇ -lH-pyrrolo[2,3- b]pyridin-4-yl)-l H-pyrazol-l-yl]cyclobutyl ⁇ acetonitrile (85 mg, 0.10 mmol, Peak 2 from Step 5) and N,N-diisopropylethylamine (52 uL, 0.30 mmol) in Methylene chloride (2.0 mL) .
- N,N-Diisopropylethylamine (1 1 pL, 0.062 mmol) and methanesulphonic anhydride (7.5 mg, 0.043 mmol) were added to a solution of ⁇ trans-3-(4- ⁇ [4- (hydroxymethyl)-6-(trifiiioi methyl)pyridin-2-yl]oxy ⁇ piperidin-l -yl)-l -[4-(7- ⁇ [2- (trimethylsilyl)ethoxy]methyl ⁇ -7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-
- reaction mixture was heated to 40 °C for 2 hours.
- Example 22 The procedure of Example 22 was followed, using lH-l,2,4-triazole (1 1 mg,
- Step 1 tert-bitty! 4- ⁇ [4-[(3,3-dimelhylazetidin-l-yl)carbonyl]-6- (trifluoromethyl)pyridin-2-yl]oxy ⁇ piperidine-l-carboxylate
- Step 3 ⁇ trans-3-(4- ⁇ [4-[(3,3-dimethylazetidin-l-yl)carbonyl]-6- (trifluoromethyl)pyridm-2-ylJoxy ⁇ p ⁇ eridm-l-y!-]-[4-(7H ⁇ yrrolo[2,3-d]pyiimidiri- 4-yl)-lH-pyrazol - 1 -yljcyclob tyljacetonitrile
- Example 27 ⁇ trans-3-(4- ⁇ [6-(hydroxymethyl)-2-(trifluoromethyl)pyrimidin-4- yl]aniino ⁇ piperidin-l-yl)-l-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l- yI]cyclobutyl ⁇ acetonitrile
- Step 6 ⁇ cis-3-(4- ⁇ [6-(hydroxymethyl)-2-(trifluoro ethyl)pyri idin-4- yl]annno ⁇ piperidm-l-yl)-l-[4-(7- ⁇ [2-(trimet ylsilyl)ethoxy]methylj-7H-pyrrolo[2,3- d]pyrimidin-4-yl)-lH-pyrazol-l-yJ]cyclobiityl ⁇ acetomtrile and ⁇ trans-3-(4- ⁇ [6- (hydroxymethyl)-2-(lriflwromethyl)pyrimidm-4-yl]amino ⁇ piperidiri-l-yl)
- Example 28 ⁇ trans-3-(4- ⁇ [6-[(ethylamino)methyl]-2-(trifluoromethyl)pyrimidin- 4-yl]araino ⁇ piperidin-l-yl)-l-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l- yl]cyclobutyl ⁇ acetonitrile
- Example 30 ⁇ trans-3-(4- ⁇ [6- ⁇ [(trans-3-hydroxycyclobutyl)amino]methyl ⁇ -2- (trifluoromethyI)pyrimidin-4-yl]amino ⁇ piperidiii-l-yI)-l-[4-(7H-pyrrolo[2,3- d]pyrimidin-4-yl)-lH-pyrazol-l-yI]cyclobutyl ⁇ acetonitrile
- Example 31 ⁇ trans-3-(4- ⁇ [4-(hydroxymethyI)-6-(trifluoromethyl)pyridin-2- yl]amino ⁇ piperidin-l-yl)-l-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l- yl]cyclobutyl ⁇ acetonitrile
- a reducing mixture was generated by combining sodium cyanoborohydride (0.27 g, 4.4 mmol) and zinc dichloride (0.30 g, 2.2 mmol) in methanol (25 mL) and stirring for 2 hours).
- the isomers could be separated using preparative HPLC-MS (CI 8 eluting with a gradient of MeCN and 3 ⁇ 40 containing 0.15% NH 4 OH) to afford Peakl, cis- isomer and Peak 2, trans- isomer. Step 6.
- Methanesulphonic anhydride (12 mg, 0.070 mmol, Aldrich) and N,N- diisopropylethylamine (14 ⁇ )L, 0.082 mmol) were added to a solution of ⁇ trans-3-(4- ⁇ [4-(hydroxymethyl)-6-(trifluoromethyl)pyridin-2-yl]amino ⁇ piperidin-l-yl)- l -[4-(7- ⁇ [2-(trimethylsilyl)ethoxy]methyl ⁇ -7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l - yl]cyclobutyl ⁇ acetonitrile (16 mg, 0.023 mmol, Peak 2 from Example 31, Step 5) in methylene chloride (0.32 mL) .
- Example 33 ⁇ trans-3-(4- ⁇ [4- ⁇ [(2-hydrox ethyl)amino]methyl ⁇ -6- (trifluoromethyl)pyridiii-2-yl]amino ⁇ piperidin-l-yl)-l-[4-(7H- d]pyrimidin-4-yl)-lH-pyrazol-l-yl]cycIobutyl ⁇ acetonitrile
- Example 34 ⁇ trans-3-(4- ⁇ [4- ⁇ [(trans-3-hydroxycyclobutyI)amino]methyl ⁇ -6- (trifluoromethyl)pyridin-2-yl]amino ⁇ piperidin-l-yl)-l-[4-(7H-pyrrolo[2,3- d]pyrimidin-4-yl)-lH-pyrazol-l-yl]cyclobutyl ⁇ acetonitrile
- Example 35 ⁇ trans-3-(4- ⁇ [4-[(3,3-dimethylazetidin-l-yI)methyl]-6- (tr!fluoromethyl)pyridin-2-yl]amino ⁇ piperidiii-l-yl)-l-[4-(7H-pyrrolo[2,3- d]pyrimidin-4-yl)-lH-pyrazol-l-yl]cyclobutyl ⁇ acetonitrile
- ⁇ , ⁇ -diisopropyIethylamine (15 ⁇ L ⁇ , 0.088 mmol) and methanesulphonic anhydride (13 mg, 0.073 mmol, Aldrich) were added to a solution of ⁇ trans-3-(4- ⁇ [4- (hydroxymethyl)-6-(trifluoromethyl)pyridin-2-yl]amino ⁇ piperidin-l-yl)-l -[4-(7- ⁇ [2- (trimethylsilyl)ethoxy]methyl ⁇ -7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l- yl]eyclobutyl ⁇ acetonitrile (20.
- Example 36 ⁇ trans-3-(4- ⁇ [4-[(3,3-difluoropyrrolidin-l-yl)methyl]-6- (trifluoromethyl)pyridiii-2-yl]amino ⁇ piperidin-l-yI)-l-[4-(7H-pyrrolo[2,3- d]pyrimidin-4-yl)-lH-pyrazol-l-yI]cyclobutyl ⁇ acetoiiitrile
- Example 37 ⁇ trans-3-(4- ⁇ [4- ⁇ [cyclopropyl(methyl)amino]methyl ⁇ -6- (trifluoromethyl)pyridin-2-yl]amino ⁇ piperidin-l-yl)-l-[4-(7H-pyrrolo[2,3- d]pyrimidin-4-yl)-lH-pyrazol-l-yl]cyclobutyl ⁇ acetonitrile
- Example 38 ⁇ cis-3-(4- ⁇ [4-(2-hydroxyethyl)-6-(trifluoromethyl)pyridin-2- yl]amino ⁇ piperidin-l-yl)-l-[4-(7H-pyrroIo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l- yl]cyclobutyl ⁇ acetonitrile and ⁇ trans-3-(4- ⁇ [4-(2-hydroxyethyl)-6- 15 (trifluoromethyl)pyridin-2-yllamino ⁇ piperidin-l-yl)-l-[4-(7H-pyrrolo[2,3- d]pyrimidiii-4-yl)-lH-pyrazol-l-yl]cyclobutyl ⁇ acetonitrile
- Step 3 ⁇ cis-3-(4- ⁇ [4-(2-hydroxyethyI)-6-(trifluoromethyl)pyridin-2- yl]amino ⁇ piperidin-l-yl)-l-[4-(7H-pyrrolo[2,3-d]pyrimidm-4-yl)-lH-pyrazol-l- yljcyclobutylj cetonitrile
- Example 39 ⁇ trans-3-(4- ⁇ [4-(azetidin-l-ylmethyl)-6-(trifluoromethyI)pyridin-2- yl]amino ⁇ piperidin-l-yl)-l-[4-(7H-pyrroIo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l- yl]cyclobutyl ⁇ acetonitrile
- Methanesulphonic anhydride (9.6 mg, 0.055 mmol, Aldrich) was added to a solution of ⁇ trans-3-(4- ⁇ [4-(hydroxymethyl)-6-(trifluoromethyl)pyridin-2- yl]amino ⁇ piperidin-l-yl) -[4-(7- ⁇ [2-(trimethylsilyl)ethoxy]methyl ⁇ -7H-pyrrolo[2,3- d]pyrimidin-4-yl)-lH-pyrazol-l-yl]cyolobutyl ⁇ acetonitrile (15 mg, 0.022 mmol, Peak 2 of Example 31, Step 5) and ⁇ , ⁇ -diisopropylethylamine (1 1 ⁇ , 0.066 mmol) in methylene chloride (0.30 mL) .
- Example 40 ⁇ trans-3-(4- ⁇ [4-(morpholin-4-ylmethyl)-6-(trifluoromethyl)pyridin- 2-yl]aniino ⁇ piperidin-l-yl)-l-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l- yljcyclobutyljacetonitrile
- Example 39 Prepared according to the method of Example 39, using azetidin-3-ol hydrochloride (12 mg, 0.1 1 mmol, Oakwood) and N,N-diisopropylethylamine (0.019 mL, 0.1 1 mmol) in the displacement step. Yield: (4.7 mg, 35%).
- Example 45 ⁇ trans-3-(4- ⁇ [4-(methoxymethyl)-6-(trifluoromethyl)pyridin-2- yl]amino ⁇ piperidin-l-yl)-l-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l- yl]cyclobutyl ⁇ acetonitrile
- Methanesulphonic anhydride (13 mg, 0.073 mmol, Aldrioh) was added to a solution of ⁇ trans-3-(4- ⁇ [4-(hydiOxymethyl)-6-(trifluoromethyl)pyi'idin-2- yl]amino ⁇ piperidin-l-yl)-l-[4-(7- ⁇ [2-(trimethylsilyl)ethoxy]methyl ⁇ -7H-pyrrolo[2,3- d]pyrimidin-4-yl)-lH-pyrazol-l-yl]cyclobutyl ⁇ acetoniti'ile (20.
- the carboxylic acid was dissolved in tetrahydrofuran (3.0 mL) and cooled in an ice bath. Triefhylamine (0.18 mL, 1.3 mmol) followed by Isobutyl chloroformate (0.10 mL, 0.78 mmol) were introduced. After stirring for 30 minutes, the reaction was filtered through a short pad of celite into a flask containing ice-cold Sodium tetrahydroborate (86 mg, 2.3 mmol) in Water (1.4 mL). THF (10 mL) was used to rinse through the celite pad, into the reaction flask. The reaction was allowed to warm to room temperature and stir for 1 hour.
- Step 4 ⁇ cis-3- ⁇ 4-[[4-(hydroxymethyl)-6-(trifliioro ethyl)pyridin-2- yl](melhyl)amino]piperidin-l-yl ⁇ -l-[4-(7- ⁇ [2-(trimethylsilyl)ethoxy]methyl ⁇ -7H- pyrrolo[2 -d]pyrimidm-4-yl)-lH-pyrazol-l-yl]cyclob tyl ⁇ acetoivtrile and ⁇ trans-3- ⁇ 4-[[4-ftydroxymethyl)-6-(triflimromethyl)pyridiri-2-yl](methyl)ammo]piperidm-l- yl ⁇ -l-[4-(7- ⁇ [2-(trimethylsilyl)ethoxy]methyl ⁇ -7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH- pyrazol-l-yl]
- a reducing mixture was prepared by combining sodium cyanoborohydride (16 mg, 0.25 mmol) and zinc dichloride (17 mg, 0.13 mmol) in methanol (0.95 mL) and stirring for 2 hours. After the Boc-deprotection and extraction, the piperidine was mixed with ⁇ 3-oxo-l-[4-(7- ⁇ [2- (trimethylsilyl)ethoxy]methyl ⁇ -7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l- yl]cyclobutyl ⁇ acetonitrile (78 mg, 0.18 mmol, Intermediate Example Al, Step 7) in methanol (2.0 mL) and the reducing mixture generated by combining NaCNB3 ⁇ 4 and Zn ⁇ 3 ⁇ 4 was added.
- Step 5 ⁇ trans-3- ⁇ 4-[[4-(hydroxymethyS)-6-(trifliioromethyI)pyridin-2- ylJ(methyl)ammoJpiperidin-l-yl ⁇ -l-[4-(7H-pyrrolo[2,3-dJpyrimidw-4-yl)-lH- pyrazol-l-yl]cyc biity ⁇ acetonitrile
- Example 48 ⁇ trans-3- ⁇ 4-[[4-[(ethylamino)methyl]-6-(trifluoromethyl)pyridin-2- yl](methyl)amino]piperidin-l-yl ⁇ -l-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH- pyrazol-l-yl]cyclobiityl ⁇ acetonitrile
- Methanesulphonic anhydride (3.8 mg, 0.022 mmol, Aldrich) was added to a solution of ⁇ trans-3- ⁇ 4-[[4-(hydroxymethyl)-6-(trifluoromethyl)pyndin-2- yl](methyl)araino]piperidin-l-yl ⁇ -l-[4-(7- ⁇ [2-(trimethyIsilyl)ethoxy]methyI ⁇ -7H- pyrrolo[2,3 -d]pyrim idin-4-y 1)- 1 H-pyrazol- 1 -y ljcyclobutyl ⁇ acetonitri le (5.0 mg, 0.0072 mmol, Peak 2 from Example 47, Step 4) and N,N-diisopropylethylamine (6.2xL, 0.036 mmol) in methylene chloride (0.20 mL) and the reaction was stirred for 30 minutes.
- the reaction was cooled to room temperature and water was added, followed by saturated ammonium chloride to adjust the pH to between 7 and 8.
- the product was extracted with two portions of DCM. The combined organic extracts were dried over sodium sulfate, decanted and concentrated.
- the product was purified by flash chromatography, eluting with a gradient from 0-20% EtOAc in hexanes, on a 40 g silica gel column to afford 0.17 g of desired product (yield 30%).
- Step 4 ⁇ cis-3-(4- ⁇ [4-(3-hydroxyoxetan-3-yl)-6-(trifluoromethyl)pyridin-2- yl]oxy ⁇ piperidm-l-yl)-l-[4-(7H-pyi olo[2,3-d]pyrimidm-4-yl)-lH-pyrazol-l- yl]cyclobutyl ⁇ acetonitrile and ⁇ trans-3-(4- ⁇ [4-(3-hydroxyoxetan-3-yl)-6- (trifluoro ethyl)pyridin-2-yl]oxy ⁇ piperidin-l-yl)-l-[4-(7H-pyrrolo[2,3-d]pyrimidin- 4-yl)-lH-pyrazol-l-yI]cyclobutyl ⁇ acetomtrile
- a reducing mixture was prepared by combining sodium cyanoborohydride (1 1 mg, 0.17 mmol) and zinc dichloride (12 mg, 0.087 mmol) in methanol (0.65 mL) and stirring for 2 hours. Then, 3-[2-(piperidin-4-yloxy)-6-(trifluoromethyl)pyridin-4- yl]oxetan-3-ol (44 mg, 0.12 mmol, from Step 3) and ⁇ 3-oxo-l-[4-(7H-pyrrolo[2,3- d]pyrimidin-4-yl)-lH-pyrazol-l-yl]cyclobutyl ⁇ acetonitriIe (44 mg, 0.15 mmol) (prepared by stirring the product of Intermediate Example Al , Step 7 in 1 : 1 TFA/DCM for an hour, then evaporating solvent and stirring with ammonium hydroxide/Methanol until deprotection complete, followed by purification via preparative HPLC-MS (C 18,
- Example 50 ⁇ trans-3-(4- ⁇ [4-(3-aminooxetan-3-yl)-6-(trifluoromethyl)pyridiii-2- yl]oxy ⁇ piperidin-l-yl)-l-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l- yl]cyclobutyl ⁇ acetoiiitrile
- Step I tert-butyl 4- ⁇ [4- ⁇ 3-[(methylsulfortyl)oxy]oxetan-3-yl ⁇ -6- (trifliioromethyl)pyridin-2-yl]oxy ⁇ piperidine-l -carboxylate
- Methanesulfonyl chloride 50 . .iL, 0.64 mmol was added to a solution of tert- butyl 4- ⁇ [4-(3-hydroxyoxetan-3-yl)-6-(trifluoromethyl)pyridin-2-yl]oxy ⁇ piperidine- l - carboxylate (0.20 g, 0.43 mmol, from Example 49, Step 2) and triethylamine (120 ⁇ , 0.86 mmol) in methylene chloride ( 5 .0 mL) at 0 °C. The mixture was allowed to warm to room temperature and stir for 1 hour, then the reaction was further diluted with DCM and water, and the mixture was neutralized by the addition of saturated sodium bicarbonate.
- Step 3 ⁇ cis-3-(4- ⁇ [4-(3-aminooxetan-3-yl)-6-(trifliioromethyl)pyridin-2- ylJoxy ⁇ piperidm-l-yl)-l-[4-(7H-pyrro [2,3-d]pyrimidin-4-yl)-lH-pyi-azol-l- yljcyclobiityljacetonitrile and ⁇ trans-3-(4- ⁇ [4-(3-aminooxetan-3-yl)-6- (trifluowmethyl)pyridin-2 ⁇ yl]oxy ⁇ piperidin-l-yl) ⁇ -[4-(7H ⁇ yrrolo[2,3-d]pyrm d ⁇ 4-yl)-lH-pyrazol-l-yl]cyclobutyl ⁇ acetonitrile
- ICsos of compounds were measured for each kinase in the 40 microL reactions that contain the enzyme, ATP and 500 nM peptide in 50 mM Tris (pH 7.8) buffer with 100 mM NaCl, 5 mM DTT, and 0.1 mg/mL (0.01%) BSA.
- ATP concentration in the reactions was 1 mM.
- Reactions were carried out at room temperature for 1 hour and then stopped with 20 ⁇ , 45 mM EDTA, 300 nM SA-APC, 6 nM Eu-Py20 in assay buffer (Perkin Elmer, Boston, MA). Binding to the Europium labeled antibody took place for 40 minutes and HTRF signal was measured on a Fusion plate reader (Perkin Elmer, Boston, MA). See Table A for data related to compounds of the
- Cancer cell lines dependent on cytokines and hence JA /STAT signal transduction, for growth, can be plated at 6000 cells per well (96 well plate format) in
- RPMI 1640, 10% FBS, and 1 nG/mL of appropriate cytokine Compounds can be added to the cells in DMSO/media (final concentration 0.2% DMSO) and mcubated for 72 hours at 37 °C, 5% CO2. The effect of compound on cell viability is assessed using the CellTiter-Glo Luminescent Cell Viability Assay (Promega) followed by TopCount (Perkin Elmer, Boston, MA) quantitation. Potential off-target effects of compounds are measured in parallel using a non-JAK driven cell line with the same assay readout. All experiments are typically performed in duplicate.
- the above cell lines can also be used to examine the effects of compounds on phosphorylation of JAK kinases or potential downstream substrates such as STAT proteins, Akt, Shp2, or Erk. These experiments can be performed following an overnight cytokine starvation, followed by a brief preincubation with compound (2 hours or less) and cytokine stimulation of approximately 1 hour or less. Proteins are then extracted from cells and analyzed by techniques familiar to those schooled in the art including Western blotting or ELISAs using antibodies that can differentiate between phosphorylated and total protein. These experiments can utilize normal or cancer cells to investigate the activity of compounds on tumor cell survival biology or on mediators of inflammatory disease.
- cytokines such as IL-6, IL-12, IL-23, or IFN can be used to stimulate JAK activation resulting in phosphorylation of STAT protein(s) and potentially in transcriptional profiles (assessed by array or qPCR technology) or production and/or secretion of proteins, such as IL-17.
- the ability of compounds to inhibit these cytokine mediated effects can be measured using techniques common to those schooled in the art.
- JAKs can also be tested in cellular models designed to evaluate their potency and activity against mutant JAKs, for example, the JA 2V617F mutation found in myeloid proliferative disorders. These experiments often utilize cytokine dependent cells of hematological lineage (e.g. BaF/3) into which the wild- type or mutant JAK kinases are ectopically expressed (James, C, et al. Nature 434: 1 144-1 148; Staerk, J., et al. JBC 280:41893-41899). Endpoints include the effects of compounds on cell survival, proliferation, and phosphorylated JAK, STAT, Akt, or Erk proteins.
- cytokine dependent cells of hematological lineage e.g. BaF/3
- Endpoints include the effects of compounds on cell survival, proliferation, and phosphorylated JAK, STAT, Akt, or Erk proteins.
- PBMCs Peripheral blood mononuclear cells
- Freshly isolated human T-cells can be maintained in culture medium (RPMI 1640 supplemented with 10% fetal bovine serum, 100 U/ml penicillin, 100 ⁇ g/ml streptomycin) at a density of 2 x 10 6 cells/ml at 37 °C for up to 2 days.
- T-cells are first treated with Phytohemagglutinin (PHA) at a final concentration of 10 ⁇ g/mL for 72h. After washing once with PBS, 6000 cells/well are plated in 96-well plates and treated with compounds at different concentrations in the culture medium in the presence of 100 U/mL human IL-2 (ProSpec-Tany TechnoGene; ehovot, Israel). The plates are incubated at 37 °C for 72h and the proliferation index is assessed using CellTiter-Glo Luminescent reagents following the manufactory suggested protocol (Promega; Madison, WI).
- Example C In vivo anti-tumor efficacy
- Compounds herein can be evaluated in human tumor xenograft models in immune compromised mice.
- a tumorigenic variant of the ⁇ -6 plasmacytoma cell line can be used to inoculate SCID mice subcutaneously (Burger, R., el al. Hematol J. 2:42-53, 2001).
- Tumor bearing animals can then be randomized into drug or vehicle treatment groups and different doses of compounds can be administered by any number of the usual routes including oral, i.p., or continuous infusion using implantable pumps. Tumor growth is followed over time using calipers.
- tumor samples can be harvested at any time after the initiation of treatment for analysis as described above (Example B) to evaluate compound effects on JAK activity and downstream signaling pathways.
- selectivity of the compound(s) can be assessed using xenograft tumor models that are driven by other know kinases (e.g. Bcr-Abl) such as the 562 tumor model.
- Bcr-Abl know kinases
- the murine skin contact delayed-type hypersensitivity (DTH) response is considered to be a valid model of clinical contact dermatitis, and other T-lymphocyte mediated immune disorders of the skin, such as psoriasis (Immunol Today. 1998 Jan;19(l):37-44).
- Murine DTH shares multiple characteristics with psoriasis, including the immune infiltrate, the accompanying increase in inflammatory cytokines, and keratinocyte hyperproliferation. Furthermore, many classes of agents that are efficacious in
- mice On Day 0 and 1, Balb/c mice are sensitized with a topical application, to their shaved abdomen with the antigen 2,4,dinitro-fluorobenzene (DNFB). On day 5, ears are measured for thickness using an engineer's micrometer. This measurement is recorded and used as a baseline. Both of the animals' ears are then challenged by a topical application of DNFB in a total of 20 ⁇ , (10 on the internal pinna and 10 ]i on the external pinna) at a concentration of 0.2%. Twenty-four to seventy-two hours after the challenge, ears are measured again. Treatment with the test compounds is given throughout the sensitization and challenge phases (day -1 to day 7) or prior to and throughout the challenge phase (usually afternoon of day 4 to day 7).
- DNFB 2,4,dinitro-fluorobenzene
- test compounds in different concentration
- topical application of the treatment to the ears Efficacies of the test compounds are indicated by a reduction in ear swelling comparing to the situation without the treatment. Compounds causing a reduction of 20% or more were considered efficacious.
- the mice are challenged but not sensitized (negative control).
- the inhibitive effect (inhibiting activation of the JAK-STAT pathways) of the test compounds can be confirmed by immiinohistochemical analysis. Activation of the JAK-STAT pathway(s) results in the formation and translocation of functional transcription factors. Further, the influx of immune cells and the increased proliferation of keratinocytes should also provide unique expression profile changes in the ear that can be investigated and quantified. Formalin fixed and paraffin embedded ear sections (harvested after the challenge phase in the DTH model) are subjected to immunohistochemical analysis using an antibody that specifically interacts with phosphorylated STAT3 (clone 58E12, Cell Signaling Technologies).
- test compounds a clinically efficacious treatment for psoriasis
- dexamethasone a clinically efficacious treatment for psoriasis
- Test compounds and the dexamethasone can produce similar transcriptional changes both qualitatively and quantitatively, and both the test compounds and dexamethasone can reduce the number of infiltrating cells.
- Both systemically and topical administration of the test compounds can produce inhibitive effects, i.e., reduction in the number of infiltrating cells and inhibition of the transcriptional changes.
- Example E In vivo anti-inflammatory activity
- rodent models of arthritis can be used to evaluate the therapeutic potential of compounds dosed preventatively or therapeutically.
- These models include but are not limited to mouse or rat collagen-induced arthritis, rat adjuvant-induced arthritis, and collagen antibody- induced arthritis.
- Autoimmune diseases including, but not limited to, multiple sclerosis, type I-diabetes mellitus, uveoretinitis, thyroditis, myasthenia gravis, immunoglobulin nephropathies, myocarditis, airway sensitization (asthma), lupus, or colitis may also be used to evaluate the therapeutic potential of compounds herein.
- These models are well established in the research community and are familiar to those schooled in the art (Current Protocols in Immunology, Vol 3., Coligan, J.E. et al, Wiley Press.; Methods in Molecular Biology: Vol. 225, Inflammation Protocols., Winyard, P.G. and Willoughby, D.A., Humana Press, 2003.).
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
The present invention provides piperidinylcyclobutyl substituted pyrrolopyrimidines and pyrrolopyridines of Formula I, as defined herein, as well as their compositions and methods of use, that modulate the activity of Janus kinases (JAKs) and are useful in the treatment of diseases related to the activity of JAKs including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.
Description
PIPERIDINYLCYCLOBUTYL SUBSTITUTED PYRROLOPYRIDEME AND PYRROLOPYRIMTOINE DERIVATIVES AS JAK INHIBITORS
This application claims the benefit of priority of U.S. Provisional Application No. 61/648,869, fried May 18, 2012, which is incorporated herein by reference in its entirety.
TECHNICAL FIELD
The present invention provides piperidinylcyclobutyl substituted pyrrolopyrimidines and pyrrolopyridines, as well as their compositions and methods of use, that modulate the activity of Janus kinases (JAKs) and are useful in the treatment of diseases related to the activity of JAKs including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.
BACKGROUND OF THE INVENTION
Protein kinases (PKs) regulate diverse biological processes including cell growth, survival, differentiation, organ formation, morphogenesis, neovascularization, tissue repair, and regeneration, among others. Protein kinases also play specialized roles in a host of human diseases including cancer. Cytokines, low-molecular weight polypeptides or glycoproteins, regulate many pathways involved in the host inflammatory response to sepsis. Cytokines influence cell differentiation, proliferation and activation, and can modulate both pro-inflammatory and antiinflammatory responses to allow the host to react appropriately to pathogens.
Signaling of a wide range of cytokines involves the Janus kinase family (JAKs) of protein tyrosine kinases and Signal Transducers and Activators of Transcription (STATs). There are four known mammalian JAKs: JAK1 (Janus kinase-1), JAK2, JAK3 (also known as Janus kinase, leukocyte; JAKL; and L-JAK), and TYK2 (protein-tyrosme kinase 2).
Cytokine-stimulated immune and inflammatory responses contribute to pathogenesis of diseases: pathologies such as severe combined immunodeficiency (SCID) arise from suppression of the immune system, while a hyperactive or inappropriate immune/inflammatory response contributes to the pathology of autoimmune diseases (e.g., asthma, systemic lupus erythematosus, thyroiditis,
myocarditis), and illnesses such as scleroderma and osteoarthritis (Ortmann, R. A., T. Cheng, et al. (2000) Arthritis Res 2(1): 16-32).
Deficiencies in expression of JAKs are associated with many disease states. For example, Jakl-/- mice are runted at birth, fail to nurse, and die perinatally (Rodig, S. J., M. A. Meraz, et al. (1998) Cell 93(3): 373-83). Jak2-/- mouse embryos are anemic and die around day 12.5 postcoitum due to the absence of definitive erythropoiesis.
The JAK/STAT pathway, and in particular all four JAKs, are believed to play a role in the pathogenesis of asthmatic response, chronic obstructive pulmonary disease, bronchitis, and other related inflammatory diseases of the lower respiratory tract. Multiple cytokines that signal through JAKs have been linked to inflammatory diseases/conditions of the upper respiratory tract, such as those affecting the nose and sinuses (e.g., rhinitis and sinusitis) whether classically allergic reactions or not. The JAK/STAT pathway has also been implicated in inflammatory diseases/conditions of the eye and chronic allergic responses.
Activation of JAK/STAT in cancers may occur by cytokine stimulation (e.g. IL-6 or GM-CSF) or by a reduction in the endogenous suppressors of JAK signaling such as SOCS (suppressor or cytokine signaling) or PIAS (protein inhibitor of activated STAT) (Boudny, V., and Kovarik, J., Neoplasm. 49:349-355, 2002). Activation of STAT signaling, as well as other pathways downstream of JAKs (e.g., Akt), has been correlated with poor prognosis in many cancer types (Bowman, T., et al. Oncogene 19:2474-2488, 2000). Elevated levels of circulating cytokines that signal through JAK STAT play a causal role in cachexia and/or chronic fatigue. As such, JAK inhibition may be beneficial to cancer patients for reasons that extend beyond potential anti-tumor activity.
JAK2 tyrosine kinase can be beneficial for patients with myeloproliferative disorders, e.g., polycythemia vera (PV), essential thrombocythemia (ET), myeloid metaplasia with myelofibrosis (MMM) (Levin, et al, Cancer Cell, vol. 7, 2005: 387- 397). Inhibition of the JAK2V617F kinase decreases proliferation of hematopoietic cells, suggesting JAK2 as a potential target for pharmacologic inhibition in patients with PV, ET, and MMM.
Inhibition of the JAKs may benefit patients suffering from skin immune disorders such as psoriasis, and skin sensitization. The maintenance of psoriasis is believed to depend on a number of inflammatory cytokines in addition to various chemokines and growth factors (JCI, 113 : 1664-1675), many of which signal through JAKs (Adv Pharmacol. 2000;47: 1 13-74).
Accordingly, inhibitors of Janus kinases or related kinases are widely sought. For example, certain JAK inhibitors, including pyrrolopyridine and
pyrrolopyrimidines, are reported in U.S. Ser. No. 11/637,545, filed December 12, 2006.
Thus, new or improved agents which inhibit kinases such as JAKs are continually needed for developing new and more effective pharmaceuticals that are aimed at augmentation or suppression of the immune and inflammatory pathways (such as immunosuppressive agents for organ transplants), as well as agents for the prevention and treatment of autoimmune diseases, diseases involving a hyperactive inflammatory response (e.g. , eczema), allergies, cancer (e.g. , prostate, leukemia, multiple myeloma), and some immune reactions (e.g., skin rash or contact dermatitis or diarrhea) caused by other therapeutics. The compounds of the invention, as well as its compositions and methods described herein are directed toward these needs and other ends.
SUMMARY OF THE INVENTION
The present invention provides, inter alia, compounds of Formula I:
and pharmaceutically acceptable salts thereof; wherein X, Y, L, R1 and R2 are defined herein.
The present invention further provides pharmaceutical compositions comprising a compound of Formula I as described herein, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.
The present invention further provides methods of modulating an activity of JAK1 comprising contacting JAK1 with a compound of Formula I as described herein, or a pharmaceutically acceptable salt thereof.
The present invention further provides methods of treating a disease or a disorder associated with abnormal kinase expression or activity in a patient by administering to a patient a therapeutically effective amount of a compound of Formula I as described herein, or a pharmaceutically acceptable salt thereof.
The present invention further provides methods of treating an autoimmune disease, a cancer, a myeloproliferative disorder, an inflammatory disease, a bone resorption disease, or organ transplant rejection in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of a compound of Formula I as described herein, or a pharmaceutically acceptable salt thereof.
The present invention also provides compounds of Formula I as described herein, or pharmaceutically acceptable salts thereof, as described herein for use in methods of treating autoimmune diseases, cancer, myeloproliferative disorders, inflammatory diseases, a bone resorption disease, or organ transplant rejection.
The present invention further provides compounds of Formula I as described herein, or pharmaceutically acceptable salts thereof, for use in methods of modulating a JAKl .
The present invention also provides uses of compounds of Formula I as described herein, or pharmaceutically acceptable salts thereof, for the preparation of medicaments for use in treating autoimmune diseases, cancer, myeloproliferative disorders, inflammatory diseases, a bone resorption disease, or organ transplant rejection.
The present invention further provides uses of compounds of Formula I as described herein, or pharmaceutically acceptable salts thereof, for the preparation of medicaments for use in methods of modulating a JA 1.
DETAILED DESCRIPTION
The present invention provides, inter alia, a compound of Formula I:
I
or a pharmaceutically acceptable salt thereof; wherein:
X is N or CH;
L is O or NR2a;
(a) wherein when L is 0, then:
Y is CH;
R' is -C(=0)NR3R4, -CH2CH2OH, -CH2NR3R4, or an oxetane ring, wherein the oxetane ring is optionally substituted with R5;
R2 is CF3;
R3 is -[CH(R6a)]n-OR6b, cyclopropyl, cyclobutyl, tetrahydro-2H-pyran ring, tetrahydrofuran ring, or oxetane ring, wherein said cyclopropyl, cyclobutyl, tetrahydro-2H-pyran ring, tetrahydrofuran ring, and oxetane ring are each optionally substituted with 1 or 2 groups independently selected from CN, OH, methyl, ethyl, n- propyl, isopropyl, methoxy, ethoxy, and propoxy;
R4 is H, CH3, or -[CH(R&)]„-OR6b;
or alternatively, R3 and R4, taken together with the nitrogen atom to which they are attached, form an azetidinyl, lH-pyrazolyl, a lH-imidazolyl, or a 1H- triazolyl group, wherein said azetidinyl group is optionally substituted with 1 or 2 independently selected R3a groups;
each R3a is independently CN, OH, methyl, ethyl, n-propyl, isopropyl, methoxy, ethoxy, propoxy, or -CH2-OH;
or alternatively, two R3a groups, taken together with the carbon atom to which they are both attached, form an oxetane ring;
R5 is OH or NH2;
R6a and R6b are each independently H or CH3; and
each n is independently 2 or 3;
provided that when X is N, then NR3R4 is not NHCH2CH2-OH,
NHCH2CH2CH2-OH, 5 \/ , or 5 V ;
or alternatively,
(b) wherein when L is NR2a, then:
Y is CH or N;
R1 is halo, cyano, nitro, Ci_6 alkyl, C|.6 haloalkyl, C2_6 alkenyl, C2.6 alkynyl, C3. lo cycloalkyl, C3.10 cycloalkyl-Ci.4-alkyl, C2_io heterocycloalkyl, C2.io heterocycloalkyl-Ci-4-alkyl, C6-io aryl, C6-io aryl-Ci-4-alkyl, Ci.i o heteroaryl, C|.] 0 heteroaryl-Ci-4-alkyI, -OR", -SR", -S(=0)Rb, -S(=0)2Rb, -S(=0)2NRcRf, -C(=0)Rb, -C(=0)ORa, -C(=0)NRcRf, -OC(=0)R , -OC(=0)NReRf, -NR¾f, -NRcC(=0)Rd, - RcC(=0)ORd, -NRcC(=0)NRd, -NRcS(0)2Rd, or -NRcS(=0)2NReRf; wherein said Ci-6 alkyl, C2_6 alkenyl, C2.6 alkynyl, C3.io cycloalkyl, C3 cycloalkyl-Ci-4-alkyl, heterocycloalkyl, C2.io heterocycloalkyI-C|.4-alkyl, -io aryl, aryl-C n-alkyl, C|. lo heteroaryl, and Ci-io heteroaryl-C|.4-alkyl are each optionally substituted by 1, 2, 3, or 4 independently selected R groups;
R2 is H, halo, cyano, nitro, .4 alley], or C| 4 haloalkyl;
R2a is H or CH3;
each R", Rc, R , Re, and Rf is independently selected from H, Ci.6 alkyl, haloalkyl, C alkenyl, C2-6 alkynyl, C3.io cycloalkyl, cycloalkyl-ClJ(-alkyl, C2-io heterocycloalkyl, C2-io heterocycloalkyl-Ci.4-alkyl, C6-io aryl, C6 aryl-Ci-4-alkyl, Ci_ heteroaryl, and Ci.io heteroaryl-Ci-4-alkyl; wherein said C|.6 lkyl, C2 alkenyl, C2.6
alkynyl, C3.10 cycloalkyi, C3.10 cycloalkyl-Cj.4-alkyl, -io heterocycloalkyl, heterocycloalkyl-C -alkyl, C6-io aryl, _io aryl-C|_4-alkyl, Ct. heteroaryl, and Ci_|0 heteroaryl-Ci4-alkyl are each optionally substituted by 1, 2, 3, or 4 independently selected RB groups;
each Rb is independently selected from C alkyl, haloalkyl, C alkenyl, alkynyl, cycloalkyi, cycloalkyl-Ci -alkyl, C2.io heterocycloalkyl, heterocycloalkyl-Ci -alkyl, C6-io aryl, C6.]0 aryl-Ci.4-alkyl, Cuo heteroaryl, and heteroaryl-Ci -alkyl; wherein said C alkyl, alkenyl, alkynyl, C3 cycloalkyi, cycloalkyl-Ci -alkyl, -io heterocycloalkyl, -io heterocycloalkyl- C -alkyl, C6.io aryl, C aryl-Ci.4-alkyl, Ci_ioheteroaryl, and Ci.|o heteroaryl-C|.«t- alkyl are each optionally substituted by 1, 2, 3, or 4 independently selected Rg groups; each R8 is independently selected from halo, cyano, nitro, Ci alkyl, haloalkyl, C alkenyl, C alkynyl, C3 cycloalkyi, C3 cycloalkyl-Ci_3-alkyl, heterocycloalkyl, - heterocycloalliyl-C -alkyl, phenyl, phenyl-d -alkyl, heteroaryl, C|.7 heteroaryl-C^-alkyl, -ORal, -SRal, -S(=0)R l, -S(=0)2Rbl, -S(=0)2NRc,Rrl, -C(=0)RbI, -C(=0)ORa l, -C(=0)NRelRfl, -OC(=0)RbI, -OC(=0)NRe lRfl, -NRelRfl, -NRclC(=0)Rlil, -NRclC(=0)ORdl, -NRc,C(=0)NRd', - RclS(=0)2Rdl, and -NRclS(=0)2NRelRfl; wherein said C,.6 alkyl, C2.6 alkenyl, C2.6 alkynyl, C3 cycloalkyi, C3 cycloalkyl-C^-alkyl, heterocycloalkyl, heterocycloalkyl-Ci -alkyl, phenyl, phenyl-Cu-alkyl, heteroaryl, and C\.7 heteroaryl-Ci -alkyl are each optionally substituted with 1, 2, 3, or 4 independently selected Rh groups;
each Ral, Rcl, Rdl, Rel, and Rfl is independently selected from H, d.6 alkyl, C]. haloalkyl, alkenyl, alkynyl, C3 cycloalkyi, C3 cycloalkyl-Cu-alkyl, heterocycloalkyl, C2-7 heterocycloalkyl-Ci -alkyl, phenyl, phenyl-Cu-alkyl, heteroaryl, and C|.7 heteroaryl-Ci -alkyl; wherein said Cj alkyl, C2 alkenyl, C alkynyl, C3 cycloalkyi, C3 cycloalkyl-Cu-alkyl, -7 heterocycloalkyl, heterocycloalkyl-Ci -alkyl, phenyl, phenyl-Cu-alkyl, heteroaryl, and Ci.7 heteroaryl-Ci -alkyl are each optionally substituted by 1, 2, 3, or 4 independently selected Rb groups;
each Rb1 is independently selected from alkyl, Ci haloalkyl, C2-6 alkenyl, lkynyl, C3 cycloalkyi, C3 cycloalkyl-Ci -alkyl, -7 heterocycloalkyl,
heterocycloalkyl-Cu-alkyl, phenyl, phenyl-C 1.3 -alky 1, C].7 heteroaryl, and C1- heteroaryl-C|.3-alkyl; wherein said Ci^ alkyl, C2-6 lkenyl, C2.6 alkynyl, C3.7 cycloalkyl, C3.7 cycloalkyl-C|.3-alkyl, C2-7 heterocycloalkyl, C2_7 heteiOcycloalkyl-Ci_ 3-alkyl, phenyl, phenyl-Cij-alkyl, Ci-7 heteroaryl, and Ci.7 heteroaryl-C|.3-alkyl are each optionally substituted by 1, 2, 3, or 4 independently selected Rh groups; and each Rh is independently selected from cyano, halo, hydroxy, Ch alky!, Ci_4 haloalkyl, Cu alkoxy, Ci-4 haloalkoxy, amino, C1.4 alkylamino, di-Ci_4-alkylamino, hydroxy -C 1,4 alky 1, Ci4 alkoxy-Ci_4 lkyl, cyano-Ci^ alk l, thio, C1.6 alkylthio, C]_6 alkylsulfinyl, C,.6 alkylsulfonyl, carbamyl, Ci-s alkylcarbamyl, di(C|.6 alkyl)carbamyl, carboxy, Ci-6 alkylcarbonyl, Q.6 alkoxycarbonyl, C\. alkylcarbonylamino, Ci- alkylsulfonylamino, aminosulfonyl, Ci^ alkylaminosulfonyl, di(Ci-6
alkyl)aminosulfonyl, aminosulfonylamino, C i.6 alkylaminosulfonylamino, difCi-6 alkyl)aminosulfonylarnino, aminocarbonylamino, Ci^ alkylaminocarbonylamino, and di(C!-6 alkyl)aminocarbonylamino.
In some embodiments, X is N.
In some embodiments, X is CH.
In some embodiments, Y is N.
In some embodiments, Y is CH.
In some embodiments, the compound is a compound of Formula II:
II
or a pharmaceutically acceptable salt thereof.
g
In some embodiments, when L is O:
R3 is -CH(R6a)CH2-OR6b, -CH2CH(R6a)-OR6b, cyclopropyl, cyclobutyl, tetrahydro-2H-pyran ring, tetrahydrofiiran ring, or oxetane ring, wherein said cyclopropyl, cyclobutyl, tetrahydro-2H-pyran ring, tetrahydrofiiran ring, and oxetane ring are each optionally substituted with 1 or 2 groups independently selected from C¾, CN, OH, and OC¾; and
R4 is H, CH3, -CH(R6ll)CH2-OR6b > or -CH2CH(R6a)-OR6b;
or alternatively, R3 and R4, taken together with the nitrogen atom to which they are attached, form an azetidinyl, I H-pyrazolyl, a lH-imidazolyl, a 1H-1,3,4- triazolyl, or a lH-l,2,4-triazolyl group, wherein said azetidinyl group is optionally substituted with I or 2 independently selected R3a groups.
In some embodiments, when L is O:
R1 is -C(=0)NR3R4, -CH2CH2OH, -CH2NR3R4, or an oxetane ring, wherein the oxetane ring is optionally substituted with R5;
R3 is -CH2CH2-OR6b, -CH(CH3)CH2-OR6b, -CH2CH(CH3)-OR6b, cyclopropyl, cyclobutyl, tetrahydro-2H-pyran ring, tetrahydrofuran ring, or oxetane ring, wherein said cyclopropyl, cyclobutyl, tetrahydro-2H-pyran ring, tetrahydrofuran ring, and oxetane ring are each optionally substituted with 1 or 2 groups independently selected from CH3, CN, OH, and OCH3;
R4 is H, C¾, -C¾CH2-OR6b, -CH(CH3)CH2-OR6b, or -CH2CH(CH3)-OR6b; or alternatively, R3 and R4, taken together with the nitrogen atom to which they are attached, form an azetidinyl, IH-pyrazolyl, a lH-imidazolyl, a IH-1,3,4- ti'iazolyl, or a lH- l,2,4-triazolyl group, wherein said azetidinyl group is optionally substituted with 1 or 2 independently selected R3" groups;
each R3a is independently CN, OH, methyl, ethyl, n-propyl, isopropyl, methoxy, ethoxy, propoxy, or -CH2-OH;
or alternatively, two R3a groups, taken together with the carbon atom to which they are both attached, form an oxetane ring;
R5 is OH or NH2; and
R6 is independently H or C¾.
In some embodiments, when L is 0, each R * is independently C¾, CN, OH, OCH3, or -CH2-OH; or alternatively, two R3a groups, taken together with the carbon atom to which they are both attached, form an oxetane ring.
In some embodiments:
L is O;
X is N or CH;
R1 is -C(=0)NR3R4, -CH2CH2OH, -CH2NR3R4, or an oxetane ring, wherein the oxetane ring is optionally substituted with R5;
R2 is CF3;
R3 is -CH(R6a)CH2-OR6b, -CH2CH(R6a)-OR6b, cyclopropyl, cyclobutyl, tetrahydro-2H-pyran ring, tetrahydrofiiran ring, or oxetane ring, wherein said cyclopropyl, cyclobutyl, tetrahydro-2H-pyran ring, tetrahydrofiiran ring, and oxetane ring are each optionally substituted with 1 or 2 groups independently selected from CH3, CN, OH, and OC¾;
R4 is H, CH3, -CH(R6a)CH2-OR6 , or -CH2CH(R6a)-OR6b;
or alternatively, R3 and R4, taken together with the nitrogen atom to which they are attached, form an azetidinyl, lH-pyrazolyl, a lH-imidazolyl, a 1H-1,3,4- triazolyl, or a lH-l,2,4-triazolyl group, wherein said azetidinyl group is optionally substituted with 1 or 2 independently selected R a groups;
each R3a is independently CH3, CN, OH, OCH3, or -CH2-OH;
or alternatively, two R a groups, taken together with the carbon atom to which they are both attached, form a oxetane ring;
In some embodiments:
L is O;
X is N or CH;
R1 is an oxetane ring, wherein the oxetane ring is optionally substituted with
R2 is CF3; and
Rs is OH or NH2.
In some embodiments, the compound is a compound of Formula Ila:
Ila
or a pharmaceutically acceptable salt thereof.
In some embodiments, the compound is a compound of Formula Ila,
Ila
or a pharmaceutically acceptable salt thereof, wherein:
R3 is -CH(R6a)CH2-OR6b, -CH2CH(R6a)-OR6b, cyclopropyl, cyclobutyl, tetrahydro-2H-pyran ring, tetrahydrofuran ring, or oxetane ring, wherein said cyclopropyl, cyclobutyl, tetrahydro-2H-pyran ring, tetrahydrofuran ring, and oxetane
ring are each optionally substituted with 1 or 2 groups independently selected from CH3, CN, OH, and OCH3;
R4 is H, C¾, -CH(R6a)CH2-OR6b, or -CH2CH(R6a)-OR6b;
or alternatively, R3 and R4, taken together with the nitrogen atom to which they are attached, form an azetidinyl, 1 H-pyrazolyl, a IH-imidazolyl, a 1H-1,3,4- triazolyl, or a lH-l,2,4-triazolyl group, wherein said azetidinyl group is optionally substituted with 1 or 2 independently selected R3a groups;
each R3a is independently C¾, CN, OH, OCH3, or -CH2-OH;
or alternatively, two R¾ groups, taken together with the carbon atom to which they are both attached, form a oxetane ring;
R5 is OH or NH2; and
R6a and R6b are each independently H or C¾;
provided that NR R is not NHCH2CH2-OH, 5 V , or 5 V . In some embodiments, the compound is a compound of Formula Ila,
Ila
or a pharmaceutically acceptable salt thereof, wherein:
R3 is -CH2CH2-OR6b, -CH(CH3)CH2-OR6b, -CH2CH(CH3)-OR6 , cyclopropyl, cyclobutyl, tetrahydro-2H-pyran ring, tetrahydrofuran ring, or oxetane ring, wherein said cyclopropyl, cyclobutyl, tetrahydro-2H-pyran ring, tetrahydrofuran ring, and
oxetane ring are each optionally substituted with 1 or 2 groups independently selected from CH3, CN, OH, and OCH3;
R4 is H, CH3, -CH2CH2-OR6b, -CH(CH3)CH2-OR6b, or -CH2CH(CH3)-OR6b; or alternatively, R3 and R4, taken together with the nitrogen atom to which they are attached, form an azetidinyl, IH-pyrazolyl, a IH-imidazolyl, a 1H- 1,3,4- triazolyl, or a lH-l,2,4-triazolyl group, wherein said azetidinyl group is optionally substituted with 1 or 2 independently selected R3a groups;
each R3a is independently CH3, CN, OH, OCH3, or -C¾-OH;
or alternatively, two R3a groups, taken together with the carbon atom to which they are both attached, form a oxetane ring;
R5 is OH or NH2; and
R6b is independently H or CH3;
In some embodiments, the compound is a compound of Formula Ila,
Ila
or a pharmaceutically acceptable salt thereof, wherein:
R3 is -CH(R6a)CH2-OR6b or -CH2CH(R6a)-OR6b;
R4 is H, CH3, -CH(R6a)CH2-OR6b, or -CH2CH(R6n)-OR6b; and
R6a and R6b are each independently H or CH3;
provided that NR3R4 is not HCH2C¾-OH.
In some embodiments, the compound is a compound of Formula Ha:
or a pharmaceutically acceptable salt thereof, wherein:
R3 is -CH2CH2-OR6b, -CH(CH3)CH2-OR6b, or -CH2CH(CH3)-OR6b;
R4 is H, CH3, -CH2CH2-OR6b, -CH(CH3)CH2-OR6b, or -CH2CH(CH3)-OR6b; and
R6b is independently H or CH3;
provided that R¾4 is not NHCH2CH2-OH.
In some embodiments, the compound is a compound of Formula lla,
R3 is cyclopropyl, cyclobutyl, tetrahydro-2H-pyran ring, tetrahydrofuran ring, or oxetane ring, wherein said oyclopropyl, cyclobutyl, tetrahydro-2H-pyran ring, tetrahydrofuran ring, and oxetane ring are each optionally substituted with 1 or 2 groups independently selected from CH3, CN, OH, and OCI¾ and
R4 is H.
In some embodiments, the compound is a compound of Formula lla,
lla
or a pharmaceutically acceptable salt thereof, wherein:
R3 and R4, taken together with the nitrogen atom to which they are attached, form an azetidinyl group, which is optionally substituted with 1 or 2 independently selected R3a groups;
each R3a is independently C¾ CN, OH, OCH3, or -CH2-OH;
or alternatively, two R3a groups, taken together with the carbon atom to which they ar ring; and
In some embodiments, the compound is a compound of Formula lla,
Ila
or a pharmaceutically acceptable salt thereof, wherein:
R3 and R4, taken together with the nitrogen atom to which they are attached, form a lH-pyrazolyl, a lH-imidazolyl, a lH-l,3,4-triazolyl, or a lH-l ,2,4-triazolyl group.
In some embodiments, the compound is a compound of Formula III:
III
or a pharmaceutically acceptable salt thereof.
In some embodiments, wherein L is NR2a, R1 is cyano, halo, Ci_6 alkyl, or haloalkyl, wherein said C]^, alkyl is optionally substituted by 1 , 2, 3, or 4 independently selected Rs groups.
In some embodiments, Rg is heterocycloalkyl, Ci_7 heteroaryl, -ORal, -SRal , -S(=0)Rbl, -S(=0)2Rbl, -S(=0)2NRelRn, -C(=0)Rbl, -C(=0)ORa' ,
(=0)NRe,Rri , -OC(=0)Rbl, -OC(=0)NRelRfl, -NRelRfl, -NR (=0)Rdl, -NRc lC(=0)ORdl, -NRclC(=0)NRdl , -NRc, S(=0)2Rd l, or -NRcl S(=0)2NRdRf' .
In some embodiments, RE is heterocycloalkyl, heteroaryl, -OR"1 , or -NRcl Rfl.
In some embodiments:
each Ral , Rcl, Rdl, Rel, and Rfl is independently selected from H, Ci.6 alkyl, C|.6 haloalkyl, C3 cycloalkyl, C3 cycIoaIkyI-Ci -alkyl, C2_7 heterocycloalkyl, C2.7 heterocycloalkyl-Ci -alkyl, phenyl, phenyl-Cu-alkyl, C heteroaryl, and Cj.7 heteroaryl-C -alkyl; wherein said Ci_6 alkyl, C2-6 alkenyl, C2.6 alkynyl, C3_7 cycloalkyl, C3 cycloalkyI-C -alkyl, heterocycloalkyl, C2.7 heterocycloalkyl-C|. -alkyl, phenyl, phenyl-C) . -alkyl, C . heteroaryl, and Ci_7 heteroaryl-Ci -alkyl are each optionally substituted by 1 or 2 Rh groups independently selected from cyano, halo, hydroxyl, alkoxy, C|. haloalkoxy, amino, Ci- alkylamino, and di-Ci-4- alkylamino;
each Rbl is independently selected from C|.6 alkyl, Ci^ aloalkyl, C3 cycloalkyl, C3 cycloalkyl-Cu-alkyl, C heterocycloalkyl, C2.7 heterocycloalkyl-C |. -alkyl, phenyl, phenyl-^ _3-alkyl, Q heteroaryl, and Ci^ heteroaryl-Cu-alkyl; wherein said C|_s alkyl, C3 cycloalkyl, C3 cycloalkyl-Cu-alkyl, C
heterocycloalkyl, C heterocycloalkyl-C u-alkyl, phenyl, phenyl-C^-alkyl, heteroaryl, and heteroaryl-Cu-alkyl are each optionally substituted by 1 or 2 Rh groups independently selected from cyano, halo, hydroxyl, C 1. alkoxy, C|_4 haloalkoxy, amino, -4 alkylamino, and di-Ci-4-alkylamino.
In some embodiments, wherein L is NR2a, R1 is alkyl substituted by heterocycloalkyl, heteroaryl, -OR"', or -NRelRn ,
In some embodiments, wherein L is NR2a, R1 is C alkyl substituted by C2-7 heterocycloalkyl, -OR"', or -NRelRn .
In some embodiments, wherein L is NR2a:
R1 is d alkyl substituted by -0RAL, -NRelRfl, or C2.7 heterocycloalkyl; Ral is H or C|.4 lkyl;
Re l is H or C1.4 alkyl; wherein CM alkyl is substituted by 1 or 2 independently selected Rh groups;
Rf' is H, Ci-4 alkyl, cyclopropyl, cyclobutyl, or cyclohexyl; wherein CM alkyl, cyclopropyl, cyclobutyl, or cyclohexyl are each substituted by 1 or 2 independently selected Rh groups; and
each Rh is independently selected from hydroxy, halo, cyano, C alkyl, and Ci„4 alkoxy.
In some embodiments, wherein L is R2a, R2 is CF3.
In some embodiments, wherein L is NR2a, Y is N.
In some embodiments, wherein L is NR2a, Y is CH,
In some embodiments, wherein L is NR2", X is N.
In some embodiments, wherein L is NR2a, X is CH.
In some embodiments, the compound is a compound of Formula I, or a pharmaceutically acceptable salt thereof; wherein:
X is N or CH;
L is NR2a;
Y is CH or N;
R1 is Ci-3 alkyl substituted by -OR"1, -NRelRn, or C2-7 heterocycloalkyl;
R2 is CF3;
R2a is H or CH3;
Ral is H or CM alkyl;
Rel is H or C1.4 alkyl; wherein C alkyl is substituted by 1 or 2 independently selected Rh groups;
Rfl is H, CM alkyl, cyclopropyl, cyclobutyl, or cyclohexyl; wherein C alkyl, cyclopropyl, cyclobutyl, or cyclohexyl are each substituted by 1 or 2 independently selected Rh groups; and
each Rh is independently selected from hydroxy, halo, cyano, C alkyl, and C alkoxy.
In some embodiments, the cyclobutyl ring in Formula I, II, Ila, or III is the cis form.
In some embodiments, the cyelobutyl ring in Formula I, II, lla, or III is the trans form.
It is appreciated that certain features of the invention, which are, for clarity, described in the context of separate embodiments, can also be provided in combination in a single embodiment. Conversely, various features of the invention which are, for brevity, described in the context of a single embodiment, can also be provided separately or in any suitable subcombination.
As used herein, the phrase "optionally substituted" means unsubstituted or substituted. As used herein, the term "substituted" means that a hydrogen atom is removed and replaced by a substituent. It is to be understood that substitution at a given atom is limited by valency. Throughout the definitions, the term "C„_m" indicates a range which includes the endpoints, wherein n and m are integers and indicate the number of carbons. Examples include and the like.
The term "n-membered" where n is an integer typically describes the number of ring-forming atoms in a moiety where the number of ring-forming atoms is n. For example, piperidinyl is an example of a 6-membered heterocycloalkyl ring, pyrazolyl is an example of a 5-membered heteroaryl ring, pyridyl is an example of a 6- membered heteroaryl ring, and 1,2,3,4-tetrahydro-naphthalene is an example of a 10- membered cycloalkyl group.
As used herein, the term "Cn.m alkyl", employed alone or in combination with other terms, refers to a saturated hydrocarbon group that may be straight-chain or branched, having n to m carbons. In some embodiments, the alkyl group contains from 1 to 3 carbon atoms. Examples of alkyl moieties include, but are not limited to, chemical groups such as methyl, ethyl, »-propyl, and isopropyl.
As used herein, the term alkoxy", employed alone or in combination with other terms, refers to a group of formula -O-alkyl, wherein the alkyl group has n to m carbons. Example alkoxy groups include methoxy, ethoxy, and propoxy (e.g., n- propoxy and isopropoxy). In some embodiments, the alkyl group has 1 to 3 carbon atoms.
As used herein, the term "alkylene", employed alone or in combination with other terms, refers to a divalent alkyl linking group. Examples of alkylene groups
include, but are not limited to, ethan-l,2-diyl, propan-l,3-diyl, propan-l ,2-diyl, butan- 1 ,4-diyl, butan-l,3-diyl, butan- 1,2-diyl, 2-methyl-propan-l,3-diyl, and the like.
As used herein, "C„-,„ alkenyl" refers to an alkyl group having one or more double carbon-carbon bonds and having n to m carbons. In some embodiments, the alkenyl moiety contains 2 to 6 or to 2 to 4 carbon atoms. Example alkenyl groups include, but are not limited to, ethenyl, n-propenyl, isopropenyl, n-biitenyl, sec- butenyl, and the like.
As used herein, "C„.m alkynyl" refers to an alkyl group having one or more triple carbon-carbon bonds and having n to m carbons. Example alkynyl groups include, but are not limited to, ethynyl, propyn-l-yl, propyn-2-yl, and the like. In some embodiments, the alkynyl moiety contains 2 to 6 or 2 to 4 carbon atoms.
As used herein, the term "C,Mt1 alkylamino" refers to a group of formula -NH(alkyl), wherein the alkyl group has n to m carbon atoms. In some embodiments, the alkyl group has 1 to 6 or 1 to 4 carbon atoms.
As used herein, the term "di-Cn_m-alkylamino" refers to a group of formula -
N(alkyl)2, wherein the two alkyl groups each has, independently, n to m carbon atoms. In some embodiments, each alkyl group independently has 1 to 6 or 1 to 4 carbon atoms.
As used herein, the term "C„.m alkoxycarbonyl" refers to a group of formula -C(0)0-alkyl, wherein the alkyl group has n to m carbon atoms. In some embodiments, the alkyl group has 1 to 6 or 1 to 4 carbon atoms.
As used herein, the term "Cn m alkylcarbonyl" refers to a group of formula -C(0)-alkyl, wherein the alkyl group has n to ra carbon atoms. In some embodiments, the alkyl group has 1 to 6 or 1 to 4 carbon atoms.
As used herein, the term "C„.m alk lcarbonylamino" refers to a group of formula -NHC(0)-alkyl, wherein the alkyl group has n to m carbon atoms. In some embodiments, the alkyl group has 1 to 6 or 1 to 4 carbon atoms.
As used herein, the term "Cn.m alkylsulfonylamino" refers to a group of formula -NHS(0)2-alkyl, wherein the alkyl group has n to m carbon atoms. In some embodiments, the alkyl group has 1 to 6 or 1 to 4 carbon atoms.
As used herein, the term "aminosulfonyl", employed alone or in combination with other terms, refers to a group of formula -S(0)2N1¾.
As used herein, the term "C„.m alkylaminosulfonyl" refers to a group of formula -S(0)2NH(alkyl), wherein the alkyl group has n to m carbon atoms. In some embodiments, the alkyl group has 1 to 6 or 1 to 4 carbon atoms.
As used herein, the term "di(Cn„m alkyl)aminosulfonyl" refers to a group of formula -S(0)2N(alkyl)2, wherein each alkyl group independently has n to m carbon atoms. In some embodiments, each alkyl group has, independently, I to 6 or 1 to 4 carbon atoms.
As used herein, the term "aminosulfonylamino" refers to a group of formula - NHS(0)2NH2.
As used herein, the term "C„.m alkylaminosulfonylamino" refers to a group of formula -NHS(0)2NH(alkyl), wherein the alkyl group has n to m carbon atoms. In some embodiments, the alkyl group has 1 to 6 or 1 to 4 carbon atoms.
As used herein, the term "di(C„.m alkyl)aminosulfonylamino" refers to a group of formula -NHS(0)2N(alkyl)2, wherein each alkyl group independently has n to m carbon atoms. In some embodiments, each alkyl group has, independently, 1 to 6 or 1 to 4 carbon atoms.
As used herein, the term "aminocarbonylamino" refers to a group of formula -NHC(0)N¾.
As used herein, the term "Cn,m alkylaminocarbonylamino" refers to a group of formula -NHC(0)NH(alkyl), wherein the alkyl group has n to m carbon atoms. In some embodiments, the alkyl group has 1 to 6 or 1 to 4 carbon atoms.
As used herein, the term "di(C„.m alkyl)aminocarbonylamino" refers to a group of formula -NHC(0)N(alkyl)2, wherein each alkyl group independently has n to m carbon atoms. In some embodiments, each alkyl group has, independently, 1 to 6 or 1 to 4 carbon atoms.
As used herein, the term "C„.m alkylcarbamyl" refers to a group of formula -C(0)-NH(alkyl), wherein the alkyl group has n to m carbon atoms. In some embodiments, the alkyl group has 1 to 6 or 1 to 4 carbon atoms.
As used herein, the term "di(C,>ra-all<yl)carbamyl" refers to a group of formula -C(0)N(alkyl)2, wherein the two alkyl groups each has, independently, n to m carbon atoms. In some embodiments, each alkyl group independently has 1 to 6 or 1 to 4 carbon atoms.
As used herein, the term "thio" refers to a group of formula -SH.
As used herein, the term "Cn_m alkylthio" refers to a group of formula -S-alkyl, wherein the alkyl group has n to m carbon atoms. In some embodiments, the alkyl group has 1 to 6 or 1 to 4 carbon atoms.
As used herein, the term "C„.m alkylsulfinyl" refers to a group of formula
-S(0)-alkyl, wherein the alkyl group has n to m carbon atoms. In some embodiments, the alkyl group has 1 to 6 or 1 to 4 carbon atoms.
As used herein, the term "Cn.m alkylsulfonyl" refers to a group of formula -S(0)2-alkyl, wherein the alkyl group has n to m carbon atoms. In some embodiments, the alkyl group has 1 to 6 or 1 to 4 carbon atoms.
As used herein, the term "amino" refers to a group of formula -NH2.
As used herein, the term "hydroxy-C -alkyl" refers to a group of formula - alkylene-OH, wherein said alkylene group has n to m carbon atoms. In some embodiments, the alkylene group has 1 to 4 carbon atoms.
As used herein, the term "C0.p alkoxy-C -alkyl" refers to a group of formula
-alkylene-O-alkyl, wherein said alkylene group has n to m carbon atoms and said alkyl group has o to p carbon atoms, In some embodiments, the alkyl and alkylene groups each independently have 1 to 4 carbon atoms.
As used herein, the term "cyano-C„.m-alkyl" refers to a group of formula - alkylene-CN, wherein said alkylene group has n to m carbon atoms. In some embodiments, the alkylene group has 1 to 4 carbon atoms.
As used herein, the term "aryl", employed alone or in combination with other terms, refers to a monocyclic or polycyclic (e.g., having 2, 3 or 4 fused rings) aromatic hydrocarbon, such as, but not limited to, phenyl, 1-naphthyl, 2-naphthyl, anthracenyl, phenanthrenyl, and the like. In some embodiments, aryl is aryl. In some embodiments, the aryl group is a naphthalene ring or phenyl ring. In some embodiments, the aryl group is phenyl.
As used herein, the term "arylalkyl" refers to a group of formula -alkylene- aryl. In some embodiments, arylalkyl is Ce-io aryl-C alkyl. In some embodiments, arylalkyl is aryl-Cj alkyl. In some embodiments, arylalkyl is benzyl.
As used herein, the term "carbamyl" refers to a group of formula -C(0)NH2.
As used herein, the terra "carbonyi", employed alone or in combination with other terms, refers to a -C(0)- group.
As used herein, the term "carboxy" refers to a group of formula -C(0)OH.
As used herein, the term "cycloalkyl", employed alone or in combination with other terms, refers to a non-aromatic cyclic hydrocarbon moiety, which may optionally contain one or more alkenylene groups as part of the ring structure, Cycloalkyl groups can include mono- or polycyclic (e.g., having 2, 3 or 4 fused rings) ring systems. Also included in the definition of cycloalkyl are moieties that have one or more aromatic rings fused (i.e., having a bond in common with) to the cycloalkyl ring, for example, benzo derivatives of cyciopentane, cyclopentene, cyclohexane, and the like. One or more ring-forming carbon atoms of a cycloalkyl group can be oxidized to form carbonyi linkages. In some embodiments, cycloalkyl is C3.12 cycloalkyl, which is monocyclic or bicyclic. Examplary cycloalkyl groups include 1,2,3,4-tetrahydro-naphthalene, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclopentenyl, cyclohexenyl, cyclohexadienyl, cycloheptatrienyl, norbornyl, norpinyl, norcarnyl, adamantyl, and the like. In some embodiments, the cycloalkyl group is cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl.
As used herein, the term "cycloalkylalkyl" refers to a group of formula -alkylene-cycloalkyl. In some embodiments, cycloalkylalkyl is C3.|2 cycloalkyl-Ci„3 alkyl, wherein the cycloalkyl portion is monocyclic or bicyclic. In some embodiments, cycloalkylalkyl is C3-i2 cycloalkyl-Ci.4 alkyl, wherein the cycloalkyl portion is monocyclic or bicyclic.
As used herein, "Cn.m haloalkoxy" refers to a group of formula -O-haloalkyl having n to m carbon atoms. An example haloalkoxy group is OCF3. In some embodiments, the haloalkoxy group is fliiorinated only. In some embodiments, the alkyl group has 1 to 6 or 1 to 4 carbon atoms.
As used herein, the term "halo" refers to a halogen atom selected from F, CI, I or Br.
As used herein, the term "C„.m haloalkyl", employed alone or in combination with other terms, refers to an alkyl group having from one halogen atom to 2s+l halogen atoms which may be the same or different, where "s" is the number of carbon atoms in the alkyl group, wherein the alkyl group has n to m carbon atoms. In some
embodiments, the haloalkyl group is fluorinated only. In some embodiments, the haloalkyl group is fluoromethyl, difluoromethyl, or trifluoromethyl. In some embodiments, the haloalkyl group is trifluoromethyl. In some embodiments, the alkyl group has 1 to 6 or 1 to 4 carbon atoms.
As used herein, the term "heteroaryl", employed alone or in combination with other terms, refers to a monocyclic or polycyclic (e.g., having 2, 3 or 4 fused rings) aromatic hydrocarbon moiety, having one or more heteroatom ring members selected from nitrogen, sulfur and oxygen, In some embodiments, heteroaryl is 5- to 10- membered heteroaryl, which is monocyclic or bicyclic and which has 1, 2, 3, or 4 heteroatom ring members independently selected from nitrogen, sulfur and oxygen. When the heteroaryl group contains more than one heteroatom ring member, the heteroatoms may be the same or different. Example heteroaryl groups include, but are not limited to, pyridine, pyrimidine, pyrazine, pyridazine, pyrrole, pyrazole, azolyl, oxazole, thiazole, imidazole, fiiran, thiophene, quinoline, isoquinoline, indole, benzothiophene, benzofuran, benzisoxazole, imidazo[l,2-b]thiazole, purine, or the like.
A five-membered ring heteroaryl is a heteroaryl with a ring having five ring atoms wherein one or more (e.g., 1 , 2, or 3) ring atoms are independently selected from N, O, and S. Exemplary five-membered ring heteroaryls are thienyl, furyl, pyrrolyl, imidazolyl, thiazolyl, oxazolyl, pyrazolyl, isothiazolyl, isoxazolyl, 1,2,3- triazolyl, tetrazolyl, 1,2,3-thiadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-triazolyl, 1,2,4- thiadiazolyl, 1,2,4-oxadiazolyl, 1,3,4-triazolyl, 1,3,4-thiadiazolyl, and 1,3,4- oxadiazolyl.
A six-membered ring heteroaryl is a heteroaryl with a ring having six ring atoms wherein one or more (e.g., 1, 2, or 3) ring atoms are independently selected from N, O, and S. Exemplary six-membered ring heteroaryls are pyridyl, pyrazinyl, pyrimidinyl, triazinyl and pyridazinyl.
As used herein, the term "heteroarylalkyl" refers to a group of formula - alkylene-heteroaryl. In some embodiments, heteroarylalkyl is Ci- i heteroaryl-Cu alkyl, wherein the heteroaryl portion is monocyclic or bicyclic and has 1, 2, 3, or 4 heteroatom ring members independently selected from nitrogen, sulfur and oxygen. In some embodiments, heteroarylalkyl is Ci.g heteroaryl-Cn alkyl, wherein the
heteroaryl portion is monocyclic or bicyclic and has 1, 2, 3, or 4 heteroatom ring members independently selected from nitrogen, sulfur and oxygen.
As used herein, the term "heterocycloalkyl", employed alone or in combination with other terms, refers to non-aromatic ring system, which may optionally contain one or more alkenylene or alkynylene groups as part of the ring structure, and which has at least one heteroatom ring member independently selected from nitrogen, sulfur and oxygen. When the heterocycloalkyl groups contains more than one heteroatom, the heteroatoms may be the same or different. Heterocycloalkyl groups can include mono- or polycyclic (e.g., having 2, 3 or 4 fused rings) ring systems, including spiro systems. Also included in the definition of heterocycloalkyl are moieties that have one or more aromatic rings fused (i.e., having a bond in common with) to the non-aromatic ring, for example, 1,2,3, 4-tetrahydro-quinoline and the like. The carbon atoms or heteroaioms in the ring(s) of the heterocycloalkyl group can be oxidized to form a carbonyl, or sulfonyl group (or other oxidized linkage) or a nitrogen atom can be quaternized. In some embodiments, heterocycloalkyl is 5- to 10-membered C2 heterocycloalkyl, which is monocyclic or bicyclic and which has 1, 2, 3, or 4 heteroatom ring members independently selected from nitrogen, sulfur and oxygen. Examples of heterocycloalkyl groups include 1 ,2,3,4-tetrahydro-quinoline, azetidine, azepane, pyrrolidine, piperidine, piperazine, morpholine, thiomorpholine, pyran, and a 2-oxo-l,3-oxazolidine ring.
As used herein, the term "heterocycloalkylalkyl" refers to a group of formula -alkylene-heterocycloalkyl. In some embodiments, heterocycloalkylalkyl is C2 heterocycloalkyl-C alkyl, wherein the heterocycloalkyl portion is monocyclic or bicyclic and has 1, 2, 3, or 4 heteroatom ring members independently selected from nitrogen, sulfur and oxygen. In some embodiments, heterocycloalkylalkyl is C2 heterocycloalkyl-C alkyl, wherein the heterocycloalkyl portion is monocyclic or bicyclic and has 1, 2, 3, or 4 heteroatom ring members independently selected from nitrogen, sulfur and oxygen.
The compounds described herein can be asymmetric (e.g., having one or more stereocenters). All stereoisomers, such as enantiomers and diastereomers, are intended unless otherwise indicated. Compounds of the present invention that contain asymmetrically substituted carbon atoms can be isolated in optically active or racemic
forms. Methods on how to prepare optically active forms from optically inactive starting materials are known in the art, such as by resolution of racemic mixtures or by stereoselective synthesis. Many geometric isomers of olefins, C=N double bonds, and the like can also be present in the compounds described herein, and all such stable isomers are contemplated in the present invention. Cis and trans geometric isomers of the compounds of the present invention are described and may be isolated as a mixture of isomers or as separated isomeric forms,
Resolution of racemic mixtures of compounds can be carried out by any of numerous methods known in the art. An example method includes fractional recrystallization using a chiral resolving acid which is an optically active, salt-forming organic acid. Suitable resolving agents for fractional recrystallization methods are, for example, optically active acids, such as the D and L forms of tartaric acid, diacetyltartaric acid, dibenzoyitartaric acid, mandelic acid, malic acid, lactic acid or the various optically active camphorsulfonic acids such as p-camphorsulfonic acid. Other resolving agents suitable for fractional crystallization methods include stereoisomerically pure forms of a-methylbenzylamine (e.g., S and R forms, or diastereomerically pure forms), 2-phenylglycinol, norephedrine, ephedrine, N- methylephedrine, cyclohexylethylamine, 1 ,2-diaminocyclohexane, and the like.
Resolution of racemic mixtures can also be carried out by elution on a column packed with an optically active resolving agent (e.g., dinitrobenzoylphenylglycine). Suitable elution solvent composition can be determined by one skilled in the art.
Compounds of the invention also include tautomeric forms. Tautomeric forms result from the swapping of a single bond with an adjacent double bond together with the concomitant migration of a proton. Tautomeric forms include prototropic tautomers which are isomeric protonation states having the same empirical formula and total charge. Example prototropic tautomers include ketone - enol pairs, amide - imidic acid pairs, lactam - lactim pairs, amide - imidic acid pairs, enamine - imine pairs, and annular forms where a proton can occupy two or more positions of a heterocyclic system, for example, IH- and 3H-imidazole, 1H-, 2H- and 4H- 1,2,4- triazole, IH- and 2H- isoindole, and IH- and 2H-pyrazole. Tautomeric forms can be in equilibrium or sterically locked into one form by appropriate substitution.
Compounds of the invention can also include all isotopes of atoms occurring in the intermediates or final compounds. Isotopes include those atoms having the same atomic number but different mass numbers. For example, isotopes of hydrogen include tritium and deuterium. In some embodiments, 1 , 2, or 3 C¾ or CH groups in or CD2 group. In some
are replaced by a CHD, CD2 or CD group, respectively.
For example, some embodiments of the compounds of Formula I may have a deuterium atom attached to one atom of the cyclobutyl ring:
The term, "compound," as used herein is meant to include all stereoisomers, geometric iosomers, tautomers, and isotopes of the structures depicted. Compounds herein identified by name or structure as one particular tautomeric form are intended to include other tautomeric forms unless otherwise specified (e.g., in the case of purine rings, unless otherwise indicated, when the compound name or structure has the 9H tautomer, it is understood that the 7H tautomer is also encompassed).
All compounds, and pharmaceutically acceptable salts thereof, can be found together with other substances such as water and solvents (e.g. hydrates and solvates) or can be isolated.
In some embodiments, the compounds of the invention, or salts thereof, are substantially isolated. By "substantially isolated" is meant that the compound is at least partially or substantially separated from the environment in which it was formed or detected. Partial separation can include, for example, a composition enriched in the compounds of the invention. Substantial separation can include compositions containing at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 97%, or at least about 99% by weight of the compounds of the invention, or salt thereof. Methods for isolating compounds and their salts are routine in the art.
The phrase "pharmaceutically acceptable" is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
The expressions, "ambient temperature" and "room temperature," as used herein, are understood in the art, and refer generally to a temperature, e.g. a reaction temperature, that is about the temperature of the room in which the reaction is carried out, for example, a temperature from about 20 °C to about 30 °C.
The present invention also includes pharmaceutically acceptable salts of the compounds described herein. As used herein, "pharmaceutically acceptable salts" refers to derivatives of the disclosed compounds wherein the parent compound is modified by converting an existing acid or base moiety to its salt form. Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like. The pharmaceutically acceptable salts of the present invention include the conventional non-toxic salts of the parent compound formed, for example, from non-toxic inorganic or organic acids. The pharmaceutically acceptable salts of the present invention can be synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical methods.
Generally, such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; generally, non-aqueous media like ether, ethyl acetate, alcohols (e.g., methanol, ethanol, iso-propanol, or butanol) or acetonitrile (ACN) are preferred. Lists of suitable salts are found in Remington's Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, Pa., 1985, p. 1418 and Journal of Pharmaceutical Science, 66, 2 (1977), each of which is incorporated herein by reference in its entirety.
1
Synthesis
Compounds of the invention, including salts and N-oxides thereof, can be
prepared using known organic synthesis techniques and can be synthesized according
to any of numerous possible synthetic routes.
The reactions for preparing compounds of the invention can be carried out in
suitable solvents which can be readily selected by one of skill in the art of organic
synthesis. Suitable solvents can be substantially non-reactive with the starting
materials (reactants), the intermediates, or products at the temperatures at which the
reactions are carried out, e.g., temperatures which can range from the solvent's
freezing temperature to the solvent's boiling temperature. A given reaction can be
carried out in one solvent or a mixture of more than one solvent. Depending on the
particular reaction step, suitable solvents for a particular reaction step can be selected
by the skilled artisan.
Preparation of compounds of the invention can involve the protection and
deprotection of various chemical groups. The need for protection and deprotection,
and the selection of appropriate protecting groups, can be readily determined by one
skilled in the art. The chemistry of protecting groups can be found, for example, in
Wuts and Greene, Protective Groups in Organic Synthesis, 4th ed., John Wiley &
Sons: New Jersey, (2007), which is incorporated herein by reference in its entirety.
Reactions can be monitored according to any suitable method known in the
art. For example, product formation can be monitored by spectroscopic means, such
as nuclear magnetic resonance spectroscopy (e.g., Ή or , C), infrared spectroscopy,
spectrophotometry (e.g., UV-visible), mass spectrometry, or by chromatographic
methods such as high performance liquid chromatography (HPLC) or thin layer
chromatography (TLC).
Useful intermediates 3-4 can be made according to the methods outlined in
Scheme I. The heterocycloalkyl ring compound 3-1 (such as Cert-butyl 4- hydroxypiperidine-l-carboxylate) can be reacted with phenol 3-2 under Mitsunobu
coupling reaction condition to afford ether 3-3. [See, Mitsunobu, O. (1981). "The Use
of Diethyl Azodicarboxylate and Triphenylphosphine in Synthesis and
Transformation of Natural Products ". Synthesis 1982 (1): 1-28.] The amino
Compound of Formula I can be made by the methods shown in Scheme II. Accordingly formula 4-2 can be formed by reaction of the cyclobutanone of formula 4- 1 with a Horner- Wadsworth-Emmons reagent. A protected pyrazol-4-yl- pyrrolo[2,3-d]pyrimidine or pyrrolo[2,3-b]pyridine of formula 4-3 is reacted with a protected alkene of formula 4-2 in a Michael addition in the presence of a coupling agent to give the compound of formula 4-4. Removal of ether protecting group of formula 4-4 gives an alcohol derivative of formula 4-5, which can be oxidized to give the compound of formula 4-6. The compound of formula 4-6 can be converted to compound of formula 4-7 and 4-8 via reductive animation, which can be deprotected to remove P| to give compounds of the invention.
Scheme II
Specific compounds of Formula 111 can by made by the processes in Schemes III-X. For example, in Scheme III, a 4,6-dichloropyrimidine derivative can be treated with tert-butyl 4-aminopiperidine-l-carboxylate in a nucleophilic aromatic substitution reaction to provide the adduct. The resulting 6-chloropyrimidine is then used in a Stille coupling to afford the enol ether intermediate which can undergo oxidative cleavage to afford the aldehyde. The aldehyde can be reduced to the alcohol using sodium borohydride, and the resulting compound is then Boc-deprotected to provide piperidine for the reductive animation. Reductive animation between the piperidine and the cyclobutanone, employing a mixture of sodium cyanoborohydride
and zinc dichloride in methanol, affords a mixture of cis and trans isomers which are separable by HPLC. Direct deprotection affords the hydroxymethyl pyrimidine (Scheme III). Alternatively, as shown in Scheme IV, the SEM-protected hydroxymethyl intermediate could be converted to the mesylate and the mesylate could be displaced with amines in a mixture of THF/MeOH at temperatures between ambient and 40 °C. The aminomethyl compounds are deprotected the same way.
III
Scheme IV
(trifluoiOmethyl)isonicotinate is produced by metalation of a 2-chloropyridine followed by reaction with di-tert-butyl dicarbonate. Heating this chloropyridine with tert-butyl 4-aminopiperidine-l-carboxylate in DMSO affords the adduct. After hydrolysis of the ester, reduction to the alcohol is effected via reacting the mixed anhydride with sodium borohydride. Boc-deprotection of the piperidine with
HCI/dioxane is followed by reductive animation with the cyclobutanone under the same conditions as in Scheme III. HPLC separation of the isomers allowed for deprotection of the trans isomer, or conversion to the mesylate and formation of amines by displacement (Scheme VI). SEM-deprotection can be carried out after the displacement to form the amines. Alternatively, as shown in Scheme VII, the SEM- protected hydroxymethylpyridme adduct can be used to form the ether (via the same mesylate intermediate) by reacting with methanol at 85 °C.
Scheme V
5
Scheme VII
4-iodopyridine can be reacted via a lithium-halogen exchange, followed by reaction with 1,3,2-dioxathiolane. The sulfate is then hydrolyzed to the alcohol. The chlorine of the resulting 2-chloropyridine can be displaced again by heating with tert-butyl 4- aminopiperidine-l-carboxylate. The resulting adduct is Boc-deprotected using
HCl/dioxane and subjected to the same reductive animation conditions with the cyclobutanone as found in the preceding Schemes. The resulting cis and trans isomers can be separated by HPLC. The isomers were deprotected separately under the usual condions of TFA/DCM followed by ethylenediamine in methanol.
(methylamino)piperidine-l-carboxylate is formed by reductive animation between the piperidinone and methylamine. Displacement of the chloro group is followed by hydrolysis and reduction as previously described. Boc deprotection can be carried out with HCl/dioxane, and reductive animation can then be performed between the deprotected piperidine and cyclobutanone to afford cis and trans isomers, which were separable by HPLC. As in the previous examples, the hydroxymethyl compound can
be directly deprotected, or converted to its mesylate at the SEM-protected stage and reacted with amines before deprotection as shown in Scheme X.
IX
Scheme X
Methods
Compounds of the invention are JAK inhibitors, and the majority of the compounds of the invention are JAKl selective inhibitors. A JAKl selective inhibitor is a compound that inhibits JAKl activity preferentially over other Janus kinases. For example, the compounds of the invention preferentially inhibit JAKl over one or more of JAK2, JAK3, and TYK2. Jn some embodiments, the compounds inhibit JAKl preferentially over JAK2 (e.g., have a JAK1/JAK2 IC5o ratio >1).
JAKl plays a central role in a number of cytokine and growth factor signaling pathways that, when dysregulated, can result in or contribute to disease states. For example, IL-6 levels are elevated in rheumatoid arthritis, a disease in which it has been suggested to have detrimental effects (Fonesca, J.E. et al., Autoimmunity Reviews, 8:538-42, 2009). Because IL-6 signals, at least in part, through JAK l, antagonizing IL-6 directly or indirectly through JAKl inhibition is expected to provide clinical benefit (Guschin, D., N., et al Embo J 14: 1421, 1995; Smolen, J. S., et al. Lancet 371 :987, 2008). Moreover, in some cancers JAKl is mutated resulting in constitutive undesirable tumor cell growth and survival (Mullighan CG, Proc Natl Acad Sci U S A.106:9414-8, 2009; Flex E., et al.J Exp Med. 205:751-8, 2008). In other autoimmune diseases and cancers elevated systemic levels of inflammatory cytokines that activate JAKl may also contribute to the disease and/or associated symptoms. Therefore, patients with such diseases may benefit from JAKl inhibition.
Selective inhibitors of JAK1 may be efficacious while avoiding unnecessary and potentially undesirable effects of inhibiting other JAK kinases.
Selective inhibitors of JAK1, relative to other JAK kinases, may have multiple therapeutic advantages over less selective inhibitors. With respect to selectivity against JAK2, a number of important cytokines and growth factors signal through JAK2 including, for example, erythropoietin (Epo) and thrombopoietin (Tpo) (Parganas E, et al. Cell. 93:385-95, 1998). Epo is a key growth factor for red blood cells production; hence a paucity of Epo-dependent signaling can result in reduced numbers of red blood cells and anemia (Kaushansky K, NEJM 354:2034-45, 2006). Tpo, another example of a JAK2-dependent growth factor, plays a central role in controlling the proliferation and maturation of megakaryocytes - the cells from which platelets are produced (Kaushansky K, NEJM 354:2034-45, 2006). As such, reduced Tpo signaling would decrease megakaryocyte numbers (megakaryocytopenia) and lower circulating platelet counts (thrombocytopenia). This can result in undesirable and/or uncontrollable bleeding. Reduced inhibition of other JAKs, such as JAK3 and Tyk2, may also be desirable as humans lacking functional version of these kinases have been shown to suffer from numerous maladies such as severe-combined immunodeficiency or hyperimmunoglobulin E syndrome (Minegishi, Y, et al. Immunity 25 :745-55, 2006; Macchi P, et al. Nature. 377:65-8, 1995). Therefore a JAK1 inhibitor with reduced affinity for other JAKs would have significant advantages over a less-selective inhibitor with respect to reduced side effects involving immune suppression, anemia and thrombocytopenia.
Another aspect of the present invention pertains to methods of treating a JAK- associated disease or disorder in an individual (e.g., patient) by administering to the individual in need of such treatment a therapeutically effective amount or dose of a compound of the present invention or a pharmaceutical composition thereof. A JAK- associated disease can include any disease, disorder or condition that is directly or indirectly linked to expression or activity of the JAK, including overexpression and/or abnormal activity levels. A JAK-associated disease can also include any disease, disorder or condition that can be prevented, ameliorated, or cured by modulating JAK activity. In some embodiments, the JAK-associated disease is a JAK 1 -associated disease.
Examples of JA -associated diseases include diseases involving the immune system including, for example, organ transplant rejection (e.g., allograft rejection and graft versus host disease).
Further examples of JAK-associated diseases include autoimmune diseases such as multiple sclerosis, rheumatoid arthritis, juvenile arthritis, psoriatic arthritis, type I diabetes, lupus, psoriasis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, myasthenia gravis, immunoglobulin nephropathies, myocarditis, autoimmune thyroid disorders, and the like. In some embodiments, the autoimmune disease is an autoimmune bullous skin disorder such as pemphigus vulgaris (PV) or bullous pemphigoid (BP).
Further examples of JAK-associated diseases include allergic conditions such as asthma, food allergies, atopie dermatitis and rhinitis. Further examples of JAK- associated diseases include viral diseases such as Epstein Barr Virus (EBV), Hepatitis B, Hepatitis C, HIV, HTLV 1, Varicella-Zoster Virus (VZV) and Human Papilloma Virus (HPV).
Further examples of JAK-associated disease include diseases associated with cartilage turnover, for example, gouty arthritis, septic or infectious arthritis, reactive arthritis, reflex sympathetic dystrophy, algodystrophy, Tietze syndrome, costal athropathy, osteoarthritis deformans endemica, Mseleni disease, Handigodu disease, degeneration resulting from fibromyalgia, systemic lupus erythematosus, scleroderma, or ankylosing spondylitis.
Further examples of JAK-associated disease include congenital cartilage malformations, including hereditary chrondrolysis, chrondrodysplasias, and pseudochrondrodysplasias (e.g., microtia, enotia, and metaphyseal
chondrodysplasia).
Further examples of JAK-associated diseases or conditions include skin disorders such as psoriasis (for example, psoriasis vulgaris), atopic dermatitis, skin rash, skin irritation, skin sensitization (e.g., contact dermatitis or allergic contact dermatitis). For example, certain substances including some pharmaceuticals when topically applied can cause skin sensitization. In some embodiments, coadministration or sequential administration of at least one JAK inhibitor of the invention together with the agent causing unwanted sensitization can be helpful in
treating such unwanted sensitization or dermatitis. In some embodiments, the skin disorder is treated by topical administration of at least one JAK inhibitor of the invention.
In further embodiments, the JAK-associated disease is cancer including those characterized by solid tumors (e.g., prostate cancer, renal cancer, hepatic cancer, pancreatic cancer, gastric cancer, breast cancer, lung cancer, cancers of the head and neck, thyroid cancer, glioblastoma, Kaposi's sarcoma, Castleman's disease, melanoma etc.), hematological cancers (e.g., lymphoma, leukemia such as acute lymphoblastic leukemia, acute myelogenous leukemia (AML) or multiple myeloma), and skin cancer such as cutaneous T-cell lymphoma (CTCL) and cutaneous B-cell lymphoma. Example CTCLs include Sezary syndrome and mycosis fungoides.
In some embodiments, the JAK inhibitors described herein, or in combination with other JAK inhibitors, such as those reported in U.S. Ser. No. 1 1/637,545, which is incorporated herein by reference in its entirety, can be used to treat inflammation- associated cancers. In some embodiments, the cancer is associated with inflammatory bowel disease. In some embodiments, the inflammatory bowel disease is ulcerative colitis. In some embodiments, the inflammatory bowel disease is Crohn's disease. In some embodiments, the inflammation-associated cancer is colitis-associated cancer. In some embodiments, the inflammation-associated cancer is colon cancer or colorectal cancer. In some embodiments, the cancer is gastric cancer, gastrointestinal carcinoid tumor, gastrointestinal stromal tumor (GIST), adenocarcinoma, small intestine cancer, or rectal cancer.
JAK-associated diseases can further include those characterized by expression of: JAK2 mutants such as those having at least one mutation in the pseudo-kinase domain (e.g. , JAK2 V617F); JAK2 mutants having at least one mutation outside of the pseudo-kinase domain; JAK1 mutants; JAK3 mutants; erythropoietin receptor (EPOR) mutants; or deregulated expression of CRLF2.
JAK-associated diseases can further include myeloproliferative disorders (MPDs) such as polycythemia vera (PV), essential thrombocythemia (ET), myelofibrosis with myeloid metaplasia (MMM), primary myelofibrosis (PMF), chronic myelogenous leukemia (CML), chronic myelomonocytic leukemia (CMML), hypereosinophilic syndrome (HES), systemic mast cell disease (SMCD), and the like.
In some embodiments, the myeloproliferative disorder is myelofibrosis (e.g., primary myelofibrosis (PMF) or post polycythemia vera/essential thrombocythemia myelofibrosis (Post-PV/ET F)).
The present invention further provides methods of treating psoriasis or other skin disorders by administration of a topical formulation containing a compound of the invention.
In some embodiments, JAK inhibitors described herein can be used to treat pulmonary arterial hypertension.
The present invention further provides a method of treating dermatological side effects of other pharmaceuticals by administration of the compound of the invention. For example, numerous pharmaceutical agents result in unwanted allergic reactions which can manifest as acneiform rash or related dermatitis. Example pharmaceutical agents that have such undesirable side effects include anti-cancer drugs such as gefitinib, cetuximab, erlotinib, and the like. The compounds of the invention can be administered systemically or topically (e.g., localized to the vicinity of the dermatitis) in combination with (e.g., simultaneously or sequentially) the pharmaceutical agent having the undesirable dermatological side effect. In some embodiments, the compound of the invention can be administered topically together with one or more other pharmaceuticals, where the other pharmaceuticals when topically applied in the absence of a compound of the invention cause contact dermatitis, allergic contact sensitization, or similar skin disorder. Accordingly, compositions of the invention include topical formulations containing the compound of the invention and a further pharmaceutical agent which can cause dermatitis, skin disorders, or related side effects.
Further JAK-associated diseases include inflammation and inflammatory diseases. Example mflammatory diseases include sarcoidosis, inflammatory diseases of the eye (e.g., iritis, uveitis, scleritis, conjunctivitis, or related disease), inflammatory diseases of the respiratory tract (e.g., the upper respiratory tract including the nose and sinuses such as rhinitis or sinusitis or the lower respiratory tract including bronchitis, chronic obstructive pulmonary disease, and the like), inflammatory myopathy such as myocarditis, and other inflammatory diseases.
The JAK inhibitors described herein can further be used to treat ischemia reperfusion injuries or a disease or condition related to an inflammatory ischemic event such as stroke or cardiac arrest. The JAK inhibitors described herein can further be used to treat anorexia, cachexia, or fatigue such as that resulting from or 5 associated with cancer. The JAK inhibitors described herein can further be used to treat restenosis, sclerodermitis, or fibrosis. The JAK inhibitors described herein can further be used to treat conditions associated with hypoxia or astrogliosis such as, for example, diabetic retinopathy, cancer, or neurodegeneration. See, e.g., Dudley, A.C. et al. Biochem. J. 2005, 390(Pt 2):427-36 and Sriram, K, et al. J. Biol. Chem. 2004, 10 279(19): 19936-47. Epub 2004 Mar 2, both of which are incorporated herein by reference in their entirety. The JAK inhibitors described herein can be used to treat Alzheimer's disease.
The JAK inhibitors described herein can further be used to treat other inflammatory diseases such as systemic inflammatory response syndrome (SIRS) and 15 septic shock.
The JAK inhibitors described herein can further be used to treat gout and increased prostate size due to, e.g., benign prostatic hypertrophy or benign prostatic hyperplasia.
Further JAK-associated diseases include bone resorption diseases such as0 osteoporosis, osteoarthritis. Bone resorption can also be associated with other conditions such as hormonal imbalance and/or hormonal therapy, autoimmune disease (e.g. osseous sarcoidosis), or cancer (e.g. myeloma). The reduction of the bone resorption due to the JAK inhibitors can be about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, or about 90%.
5 In some embodiments, JAK inhibitors described herein can further be used to treat a dry eye disorder. As used herein, "dry eye disorder" is intended to encompass the disease states summarized in a recent official report of the Dry Eye Workshop (DEWS), which defined dry eye as "a multifactorial disease of the tears and ocular surface that results in symptoms of discomfort, visual disturbance, and tear film0 instability with potential damage to the ocular surface. It is accompanied by increased osmolarity of the tear film and inflammation of the ocular surface." Lemp, "The Definition and Classification of Dry Eye Disease: Report of the Definition and
Classification Subcommittee of the International Dry Eye Workshop", The Ocular Surface, 5(2), 75-92 April 2007, which is incorporated herein by reference in its entirety. In some embodiments, the dry eye disorder is selected from aqueous tear- deficient dry eye (ADDE) or evaporative dry eye disorder, or appropriate combinations thereof. In some embodiments, the dry eye disorder is Sjogren syndrome dry eye (SSDE), In some embodiments, the dry eye disorder is non- Sjogren syndrome dry eye (NSSDE).
In a further aspect, the present invention provides a method of treating conjunctivitis, uveitis (including chronic uveitis), chorioditis, retinitis, cyclitis, sclieritis, episcleritis, or iritis; treating inflammation or pain related to corneal transplant, LASIK (laser assisted in situ keratomileusis), photorefractive keratectomy, or LASEK (laser assisted sub-epithelial keratomileusis); inhibiting loss of visual acuity related to corneal transplant, LASIK, photorefractive keratectomy, or LASEK; or inhibiting transplant rejection in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of the compound of the invention, or a pharmaceutically acceptable salt thereof.
Additionally, the compounds of the invention, or in combination with other JAK inhibitors, such as those reported in U.S. Ser. No. 1 1/637,545, which is incorporated herein by reference in its entirety, can be used to treat respiratory dysfunction or failure associated with viral infection, such as influenza and SARS.
In some embodiments, the present invention provides a compound of Formula I, pharmaceutically acceptable salt thereof, as described in any of the embodiments herein, for use in a method of treating any of the diseases or disorders described herein. In some embodiments, the present invention provides the use of a compound of Formula I as described in any of the embodiments herein, for the preparation of a medicament for use in a method of treating any of the diseases or disorders described herein.
In some embodiments, the present invention provides a compound of Formula I as described herein, or a pharmaceutically acceptable salt thereof, for use in a method of modulating a JAK 1. In some embodiments, the present invention also provides use of a compound of Formula I as described herein, or a pharmaceutically
acceptable salt thereof, for the preparation of a medicament for use in a method of modulating a JAK 1.
As used herein, the term "contacting" refers to the bringing together of indicated moieties in an in vitro system or an in vivo system. For example, "contacting" a JAK with a compound of the invention includes the administration of a compound of the present invention to an individual or patient, such as a human, having a JAK, as well as, for example, introducing a compound of the invention into a sample containing a cellular or purified preparation containing the JAK.
As used herein, the term "individual" or "patient," used interchangeably, refers to any animal, including mammals, preferably mice, rats, other rodents, rabbits, dogs, cats, swine, cattle, sheep, horses, or primates, and most preferably humans.
As used herein, the phrase "therapeutically effective amount" refers to the amount of active compound or pharmaceutical agent that elicits the biological or medicinal response that is being sought in a tissue, system, animal, individual or human by a researcher, veterinarian, medical doctor or other clinician.
As used herein, the term "treating" or "treatment" refers to one or more of (1) preventing the disease; for example, preventing a disease, condition or disorder in an individual who may be predisposed to the disease, condition or disorder but does not yet experience or display the pathology or symptomatology of the disease; (2) inhibiting the disease; for example, inhibiting a disease, condition or disorder in an individual who is experiencing or displaying the pathology or symptomatology of the disease, condition or disorder (i.e., arresting further development of the pathology and/or symptomatology); and (3) ameliorating the disease; for example, ameliorating a disease, condition or disorder in an individual who is experiencing or displaying the pathology or symptomatology of the disease, condition or disorder (i.e., reversing the pathology and/or symptomatology) such as decreasing the severity of disease.
Combination Therapies
One or more additional pharmaceutical agents such as, for example, chemotherapeutics, anti-inflammatory agents, steroids, immunosuppressants, as well as Bcr-Abl, Flt-3, RAF and FAK kinase inhibitors such as, for example, those described in WO 2006/056399, which is incorporated herein by reference in its
entirety, or other agents can be used in combination with the compounds described herein for treatment of JAK-associated diseases, disorders or conditions. The one or more additional pharmaceutical agents can be administered to a patient simultaneously or sequentially.
Example chemotherapeutic include proteosome inhibitors (e.g., bortezomib), thalidomide, revlimid, and DNA-damaging agents such as melphalan, doxorubicin, cyclophosphamide, vincristine, etoposide, carmustine, and the like,
Example steroids include coriticosteroids such as dexamethasone or prednisone.
Example Bcr-Abl inhibitors include the compounds, and pharmaceutically acceptable salts thereof, of the genera and species disclosed in U.S. Pat. No.
5,521, 184, WO 04/005281 , and U.S. Ser. No. 60/578,491, all of which are incorporated herein by reference in their entirety.
Example suitable Flt-3 inhibitors include compounds, and their pharmaceutically acceptable salts, as disclosed in WO 03/037347, WO 03/099771, and WO 04/046120, all of which are incorporated herein by reference in their entirety.
Example suitable RAF inhibitors include compounds, and their pharmaceutically acceptable salts, as disclosed in WO 00/09495 and WO 05/028444, both of which are incorporated herein by reference in their entirety.
Example suitable FAK inhibitors include compounds, and their pharmaceutically acceptable salts, as disclosed in WO 04/080980, WO 04/056786, WO 03/024967, WO 01/064655, WO 00/053595, and WO 01/014402, all of which are incorporated herein by reference in their entirety.
In some embodiments, one or more of the compounds of the invention can be used in combination with one or more other kinase inhibitors including imatinib, particularly for treating patients resistant to imatinib or other kinase inhibitors.
In some embodiments, one or more JAK inhibitors of the invention can be used in combination with a chemotherapeutic in the treatment of cancer, such as multiple myeloma, and may improve the treatment response as compared to the response to the chemotherapeutic agent alone, without exacerbation of its toxic effects. Examples of additional pharmaceutical agents used in the treatment of multiple myeloma, for example, can include, without limitation, melphalan,
melphalan plus prednisone [MP], doxorubicin, dexamethasone, and Velcade (bortezomib). Further additional agents used in the treatment of multiple myeloma include Bcr-Abl, Flt-3, RAF and FAK kinase inhibitors. Additive or synergistic effects are desirable outcomes of combining a JAK inhibitor of the present invention with an additional agent. Furthermore, resistance of multiple myeloma cells to agents such as dexamethasone may be reversible upon treatment with a JAK inhibitor of the present invention. The agents can be combined with the present compounds in a single or continuous dosage form, or the agents can be administered simultaneously or sequentially as separate dosage forms.
In some embodiments, a corticosteroid such as dexamethasone is administered to a patient in combination with at least one JAK bihibitor where the dexamethasone is administered intermittently as opposed to continuously.
In some further embodiments, combinations of one or more JAK inhibitors of the invention with other therapeutic agents can be administered to a patient prior to, during, and/or after a bone marrow transplant or stem cell transplant.
In some embodiments, the additional therapeutic agent is fluocinolone acetonide (Retisert®), or rimexolone (AL-2178, Vexol, Alcoii).
In some embodiments, the additional therapeutic agent is cyclosporine (Restasis®).
In some embodiments, the additional therapeutic agent is a corticosteroid. In some embodiments, the corticosteroid is triamcinolone, dexamethasone, fluocinolone, cortisone, prednisolone, or flumetholone.
In some embodiments, the additional therapeutic agent is selected from Dehydrex™ (Holies Labs), Civamide (Opko), sodium hyaluronate (Vismed, Lantibio/TRB Chemedia), cyclosporine (ST-603, Sirion Therapeutics), ARG101(T) (testosterone, Argentis), AGR1012(P) (Argentis), ecabet sodium (Senju-Ista), gefarnate (Santen), 15-(s)-hydroxyeicosatetraenoic acid (15(S)-H£TE), cevilemine, doxycycline (ALTY-0501, Alacrity), minocycline, iDestrin™ (NP50301, Nascent Pharmaceuticals), cyclosporine A (Nova22007, Novagali), oxytetracycline (Duramycin, MOLI1901 , Lantibio), CF101 (2S,3S,4R,5R)-3,4-dihydroxy-5-[6-[(3- iodophenyl)methylamino]purin-9-yI]-N-methyl-oxolane-2-carbamyl, Can-Fite Biopharma), voclosporin (LX212 or LX214, Lux Biosciences), ARG103 (Agentis),
RX-10045 (synthetic resolvin analog, Resolvyx), DY 15 (Dyanmis Therapeutics), rivoglitazone (DE011, Daiichi Sanko), TB4 (RegeneRx), OPH-01 (Ophtalmis Monaco), PCS101 (Pericor Science), REV1-31 (Evolutec), Lacritin (Senju), rebamipide (Otsuka-Novartis), OT-551 (Othera), PAI-2 (University of Pennsylvania and Temple University), pilocarpine, tacrolimus, pimecrolimus (AMS981, Novartis), loteprednol etabonate, rituximab, diquafosol tetrasodium (INS365, Inspire), KLS- 061 1 (Kissei Pharmaceuticals), dehydroepiandrosterone, anakinra, efalizumab, mycophenolate sodium, etanercept (Embrel®), hydroxychloroquine, NGX267 (TorreyPines Therapeutics), or thalidomide.
In some embodiments, the additional therapeutic agent is an anti-angiogenic agent, cholinergic agonist, TRP-1 receptor modulator, a calcium channel blocker, a mucin secretagogue, MUC1 stimulant, a calcineurin inhibitor, a corticosteroid, a P2Y2 receptor agonist, a muscarinic receptor agonist, another JAK inhibitor, Bcr-Abl kinase inhibitor, Flt-3 kinase inhibitor, RAF kinase inhibitor, and FAK kinase inhibitor such as, for example, those described in WO 2006/056399, which is incorporated herein by reference in its entirety. In some embodiments, the additional therapeutic agent is a tetracycline derivative (e.g., minocycline or doxycline).
In some embodiments, the additional therapeutic agent(s) are demulcent eye drops (also known as "artificial tears"), which include, but are not limited to, compositions containing polyvinylalcohol, hydroxypropyl methylcellulose, glycerin, polyethylene glycol (e.g. PEG400), or carboxymethyl cellulose. Artificial tears can help in the treatment of dry eye by compensating for reduced moistening and lubricating capacity of the tear film. In some embodiments, the additional therapeutic agent is a mucolytic drug, such as N-acetyl-cysteine, which can interact with the mucoproteins and, therefore, to decrease the viscosity of the tear film.
In some embodiments, the additional therapeutic agent includes an antibiotic, antiviral, antifungal, anesthetic, anti-inflammatory agents including steroidal and nonsteroidal anti-inflammatories, and anti-allergic agents. Examples of suitable medicaments include aminoglycosides such as amikacin, gentamycin, tobramycin, streptomycin, netilmycin, and kanamycin; fluoroquinolones such as ciprofloxacin, norfloxacin, ofloxacin, trovafloxacin, lomefloxacin, levofloxacin, and enoxacin; naphthyridine; sulfonamides; polymyxin; chloramphenicol; neomycin; paromomycin;
colistimethate; bacitracin; vancomycin; tetracyclines; rifampin and its derivatives ("rifampins"); cycloserine; beta-lactams; cephalosporins; amphotericins; fluconazole; flucytosine; natamycin; miconazole; ketoconazole; corticosteroids; diclofenac; flurbiprofen; ketorolac; suprofen; cromolyn; lodoxamide; levocabastin; naphazoline; antazoline; pheniramine; or azalide antibiotic.
Pharmaceutical Formulations and Dosage Forms
When employed as pharmaceuticals, the compounds of the invention can be administered in the form of pharmaceutical compositions. These compositions can be prepared in a manner well known in the pharmaceutical art, and can be administered by a variety of routes, depending upon whether local or systemic treatment is desired and upon the area to be treated. Administration may be topical (including transdermal, epidermal, ophthalmic and to mucous membranes including intranasal, vaginal and rectal delivery), pulmonary (e.g., by inhalation or insufflation of powders or aerosols, including by nebulizer; intratracheal or intranasal), oral or parenteral. Parenteral administration includes intravenous, intraarterial, subcutaneous, intraperitoneal intramuscular or injection or infusion; or intracranial, e.g., intrathecal or intraventricular, administration. Parenteral administration can be in the form of a single bolus dose, or may be, for example, by a continuous perfusion pump.
Pharmaceutical compositions and formulations for topical administration may include transdermal patches, ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and powders. Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the like may be necessary or desirable.
This invention also includes pharmaceutical compositions which contain, as the active ingredient, the compound of the invention or a pharmaceutically acceptable salt thereof, in combination with one or more pharmaceutically acceptable carriers (excipients). In some embodiments, the composition is suitable for topical administration. In making the compositions of the invention, the active ingredient is typically mixed with an excipient, diluted by an excipient or enclosed within such a carrier in the form of, for example, a capsule, sachet, paper, or other container. When the excipient serves as a diluent, it can be a solid, semi-solid, or liquid material, which acts as a vehicle, carrier or medium for the active ingredient. Thus, the compositions
can be in the form of tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols (as a solid or in a liquid medium), ointments containing, for example, up to 10% by weight of the active compound, soft and hard gelatin capsules, suppositories, sterile injectable solutions, and sterile packaged powders.
In preparing a formulation, the active compound can be milled to provide the appropriate particle size prior to combining with the other ingredients. If the active compound is substantially msoluble, it can be milled to a particle size of less than 200 mesh. If the active compound is substantially water soluble, the particle size can be adjusted by milling to provide a substantially uniform distribution in the formulation, e.g. about 40 mesh.
The compounds of the invention may be milled using known milling procedures such as wet milling to obtain a particle size appropriate for tablet formation and for other formulation types. Finely divided (nanoparticulate) preparations of the compounds of the invention can be prepared by processes known in the art, e.g., see International App. No. WO 2002/000196.
Some examples of suitable excipients include lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, and methyl cellulose. The formulations can additionally include: lubricating agents such as talc, magnesium stearate, and mineral oil; wetting agents; emulsifying and suspending agents; preserving agents such as methyl- and propylhydroxy-benzoates; sweetening agents; and flavoring agents. The compositions of the invention can be formulated so as to provide quick, sustained or delayed release of the active ingredient after administration to the patient by employing procedures known in the art.
The compositions can be formulated in a unit dosage form, each dosage containing from about 5 to about 1 ,000 mg (1 g), more usually about 100 mg to about 500 mg, of the active ingredient. The term "unit dosage forms" refers to physically discrete units suitable as unitary dosages for human subjects and other mammals, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, in association with a suitable pharmaceutical excipient.
In some embodiments, the compositions of the invention contain from about 5 mg to about 50 mg of the active ingredient. One having ordinary skill in the art will appreciate that this embodies compounds or compositions containing about 5 mg to about 10 mg, about 10 mg to about 15 mg, about 15 mg to about 20 mg, about 20 mg 5 to about 25 mg, about 25 mg to about 30 mg, about 30 mg to about 35 mg, about 35 mg to about 40 mg, about 40 mg to about 45 mg, or about 45 mg to about 50 mg of the active ingredient.
In some embodiments, the compositions of the invention contain from about 50 mg to about 500 mg of the active ingredient. One having ordinary skill in the art
10 will appreciate that this embodies compounds or compositions containing about 50 mg to about 100 mg, about 100 mg to about 150 mg, about 150 mg to about 200 mg, about 200 mg to about 250 mg, about 250 mg to about 300 mg, about 350 mg to about 400 mg, or about 450 mg to about 500 mg of the active ingredient.
In some embodiments, the compositions of the invention contain from about
15 500 mg to about 1,000 mg of the active ingredient. One having ordinary skill in the art will appreciate that this embodies compounds or compositions containing about 500 mg to about 550 mg, about 550 mg to about 600 mg, about 600 mg to about 650 mg, about 650 mg to about 700 mg, about 700 mg to about 750 mg, about 750 mg to about 800 mg, about 800 mg to about 850 mg, about 850 mg to about 900 mg, about
20 900 mg to about 950 mg, or about 950 mg to about 1,000 mg of the active ingredient.
The active compound may be effective over a wide dosage range and is generally administered in a pharmaceutically effective amount. It will be understood, however, that the amount of the compound actually administered will usually be determined by a physician, according to the relevant circumstances, including the
25 condition to be treated, the chosen route of administration, the actual compound administered, the age, weight, and response of the individual patient, the severity of the patient's symptoms, and the like.
For preparing solid compositions such as tablets, the principal active ingredient is mixed with a pharmaceutical exeipient to form a solid preformulation
30 composition containing a homogeneous mixture of a compound of the present invention. When referring to these preformulation compositions as homogeneous, the active ingredient is typically dispersed evenly throughout the composition so that the
composition can be readily subdivided into equally effective unit dosage forms such as tablets, pills and capsules. This solid preformulation is then subdivided into unit dosage forms of the type described above containing from, for example, about 0.1 to about 1000 mg of the active ingredient of the present invention.
The tablets or pills of the present invention can be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action. For example, the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former. The two components can be separated by an enteric layer which serves to resist disintegration in the stomach and permit the inner component to pass intact into the duodenum or to be delayed in release. A variety of materials can be used for such enteric layers or coatings, such materials including a number of polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol, and cellulose acetate.
The liquid forms in which the compounds and compositions of the present invention can be incorporated for administration orally or by injection include aqueous solutions, suitably flavored syrups, aqueous or oil suspensions, and flavored emulsions with edible oils such as cottonseed oil, sesame oil, coconut oil, or peanut oil, as well as elixirs and similar pharmaceutical vehicles.
Compositions for inhalation or insufflation include solutions and suspensions in pharmaceutically acceptable, aqueous or organic solvents, or mixtures thereof, and powders. The liquid or solid compositions may contain suitable pharmaceutically acceptable excipients as described supra. In some embodiments, the compositions are administered by the oral or nasal respiratory route for local or systemic effect. Compositions in can be nebulized by use of inert gases. Nebulized solutions may be breathed directly from the nebulizing device or the nebulizing device can be attached to a face masks tent, or intermittent positive pressure breathing machine. Solution, suspension, or powder compositions can be administered orally or nasally from devices which deliver the formulation in an appropriate manner.
Topical formulations can contain one or more conventional carriers. In some embodiments, ointments can contain water and one or more hydrophobic carriers selected from, for example, liquid paraffin, polyoxyethylene alkyl ether, propylene glycol, white vaseline, and the like. Carrier compositions of creams can be based on
water in combination with glycerol and one or more other components, e.g.
glycerinemonostearate, PEG-glycerinemonostearate and cetylstearyl alcohol. Gels can be formulated using isopropyl alcohol and water, suitably in combination with other components such as, for example, glycerol, hydroxyethyl cellulose, and the like. In some embodiments, topical formulations contain at least about 0.1, at least about 0.25, at least about 0.5, at least about 1, at least about 2, or at least about 5 wt % of the compound of the invention. The topical formulations can be suitably packaged in tubes of, for example, 100 g which are optionally associated with instructions for the treatment of the select indication, e.g., psoriasis or other skin condition.
The amount of compound or composition administered to a patient will vary depending upon what is being administered, the purpose of the administration, such as prophylaxis or therapy, the state of the patient, the manner of administration, and the like. In therapeutic applications, compositions can be administered to a patient already suffering from a disease in an amount sufficient to cure or at least partially arrest the symptoms of the disease and its complications. Effective doses will depend on the disease condition being treated as well as by the judgment of the attending clinician depending upon factors such as the severity of the disease, the age, weight and general condition of the patient, and the like.
The compositions administered to a patient can be in the form of pharmaceutical compositions described above. These compositions can be sterilized by conventional sterilization techniques, or may be sterile filtered. Aqueous solutions can be packaged for use as is, or lyophilized, the lyophilized preparation being combined with a sterile aqueous carrier prior to administration. The pH of the compound preparations typically will be between 3 and 1 1, more preferably from 5 to 9 and most preferably from 7 to 8. It will be understood that use of certain of the foregoing excipients, carriers, or stabilizers will result in the formation of pharmaceutical salts.
The therapeutic dosage of a compound of the present invention can vary according to, for example, the particular use for which the treatment is made, the manner of administration of the compound, the health and condition of the patient, and the judgment of the prescribing physician. The proportion or concentration of a compound of the invention in a pharmaceutical composition can vary depending upon
a number of factors including dosage, chemical characteristics (e.g., hydrophobicity), and the route of administration. For example, the compounds of the invention can be provided in an aqueous physiological buffer solution containing about 0.1 to about 10% w/v of the compound for parenteral administration. Some typical dose ranges are from about 1 μΒ kg to about 1 g/kg of body weight per day. In some embodiments, the dose range is from about 0.01 mg/kg to about 100 mg/kg of body weight per day. The dosage is likely to depend on such variables as the type and extent of progression of the disease or disorder, the overall health status of the particular patient, the relative biological efficacy of the compound selected, formulation of the excipient, and its route of administration. Effective doses can be extrapolated from dose-response curves derived from in vitro or animal model test systems.
The compositions of the invention can further include one or more additional pharmaceutical agents such as a chemotherapeutic, steroid, anti-inflammatory compound, or immunosuppressant, examples of which are listed hereinabove.
In some embodiments, the compound, or pharmaceutically acceptable salt thereof, is administered as an ophthalmic composition. Accordingly, in some embodiments, the methods comprise administration of the compound, or pharmaceutically acceptable salt thereof, and an ophthalmically acceptable carrier. In some embodiments, the ophthalmic composition is a liquid composition, semi-solid composition, insert, film, microparticles or nanoparticles.
In some embodiments, the ophthalmic composition is a liquid composition. In some embodiments, the ophthalmic composition is a semi-solid composition. In some embodiments, the ophthalmic composition is an topical composition. The topical compositions include, but are not limited to liquid and semi-solid compositions. In some embodiments, the ophthalmic composition is a topical composition, In some embodiments, the topical composition comprises aqueous solution, an aqueous suspension, an ointment or a gel. In some embodiments, the ophthalmic composition is topically applied to the front of the eye, under the upper eyelid, on the lower eyelid and in the cul-de-sac. In some embodiments, the ophthalmic composition is sterilized. The sterilization can be accomplished by known techniques like sterilizing filtration of the solution or by heating of the solution in the ampoule ready for use. The ophthalmic compositions of the invention can further contain pharmaceutical
excipients suitable for the preparation of ophthalmic formulations. Examples of such excipients are preserving agents, buffering agents, chelating agents, antioxidant agents and salts for regulating the osmotic pressure.
As used herein, the term "ophthalmically acceptable carrier" refers to any 5 material that can contain and release the compound, or pharmaceutically acceptable salt thereof, and that is compatible with the eye. In some embodiments, the ophthalmically acceptable carrier is water or an aqueous solution or suspension, but also includes oils such as those used to make ointments and polymer matrices such as used in ocular inserts. In some embodiments, the composition may be an aqueous
10 suspension comprising the compound, or pharmaceutically acceptable salt thereof.
Liquid ophthalmic compositions, including both ointments and suspensions, may have a viscosity that is suited for the selected route of administration. In some embodiments, the ophthalmic composition has a viscosity in the range of from about 1,000 to about 30,000 centipoise.
15 In some embodiments, the ophthalmic compositions may further comprise one or more of surfactants, adjuvants, buffers, antioxidants, tonicity adjusters, preservatives (e.g., EDTA, BAK (benzalkonium chloride), sodium chlorite, sodium perborate, polyquaterium-1), thickeners or viscosity modifiers (e.g., carboxymethyl cellulose, hydroxymethyl cellulose, polyvinyl alcohol, polyethylene glycol, glycol
20 400, propylene glycol hydroxymethyl cellulose, hydroxpropyl-guar, hyaluronic acid, and hydroxypropyl cellulose) and the like. Additives in the formulation may include, but are not limited to, sodium chloride, sodium bicarbonate, sorbic acid, methyl paraben, propyl paraben, chlorhexidine, castor oil, and sodium perborate.
Aqueous ophthalmic compositions (solutions or suspensions) generally do not
25 contain physiologically or ophthalmically harmful constituents. In some
embodiments, purified or deionized water is used in the composition. The pH may be adjusted by adding any physiologically and ophthalmically acceptable pH adjusting acids, bases or buffers to within the range of about 5.0 to 8.5. Ophthalmically acceptable examples of acids include acetic, boric, citric, lactic, phosphoric,
30 hydrochloric, and the like, and examples of bases include sodium hydroxide, sodium phosphate, sodium borate, sodium citrate, sodium acetate, sodium lactate, tromethamine, trishydroxymethylamino-methane, and the like. Salts and buffers
include citrate/dextrose, sodium bicarbonate, ammonium chloride and mixtures of the aforementioned acids and bases.
In some embodiments, the methods involve forming or supplying a depot of the therapeutic agent in contact with the external surface of the eye. A depot refers to a source of therapeutic agent that is not rapidly removed by tears or other eye clearance mechanisms. This allows for continued, sustained high concentrations of therapeutic agent to be present in the fluid on the external surface of the eye by a single application. Without wishing to be bound by any theory, it is believed that absorption and penetration may be dependent on both the dissolved drug concentration and the contact duration of the external tissue with the drug containing fluid. As the drug is removed by clearance of the ocular fluid and/or absorption into the eye tissue, more drug is provided, e.g. dissolved, into the replenished ocular fluid from the depot. Accordingly, the use of a depot may more easily facilitate loading of the ocular tissue for more insoluble therapeutic agents. In some embodiments, the depot can remain for up to eight hours or more. In some embodiments, the ophthalmic depot forms includes, but is not limited to, aqueous polymeric suspensions, ointments, and solid inserts.
In some embodiments, the ophthalmic composition is an ointment or gel. In some embodiment, the ophthalmic composition is an oil-based delivery vehicle. In some embodiments, the composition comprises a petroleum or lanolin base to which is added the active ingredient, usually as 0.1 to 2%, and excipients, Common bases may include, but are not limited to, mineral oil, petrolatum and combinations thereof. In some embodiments, the ointment is applied as a ribbon onto the lower eyelid.
In some embodiment, the ophthalmic composition is an ophthalmic insert. In some embodiments, the ophthalmic insert is biologically inert, soft, bio-erodible, viscoelastie, stable to sterilization after exposure to therapeutic agents, resistant to infections from air borne bacteria, bio- erodible, biocompatible, and/or viscoelastie. In some embodiments, the insert comprises an ophthalmically acceptable matrix, e.g., a polymer matrix. The matrix is typically a polymer and the therapeutic agent is generally dispersed therein or bonded to the polymer matrix. In some embodiments, the therapeutic agent may be slowly released from the matrix through dissolution or hydrolysis of the covalent bond. In some embodiments, the polymer is bioerodible
(soluble) and the dissolution rate thereof can control the release rate of the therapeutic agent dispersed therein. In another form, the polymer matrix is a biodegradable polymer that breaks down such as by hydrolysis to thereby release the therapeutic agent bonded thereto or dispersed therein. In further embodiments, the matrix and therapeutic agent can be surrounded with an additional polymeric coating to further control release. In some embodiments, the insert comprises a biodegradable polymer such as polycaprolactone (PCL), an ethylene/vinyl acetate copolymer (EVA), polyalkyl cyanoacrylate, polyurethane, a nylon, or poly (dl-lactide-co-glycolide) (PLGA), or a copolymer of any of these. In some embodiments, the therapeutic agent is dispersed into the matrix material or dispersed amongst the monomer composition used to make the matrix material prior to polymerization. In some embodiments, the amount of therapeutic agent is from about 0.1 to about 50%, or from about 2 to about 20%. In further embodiments, the biodegradable or bioerodible polymer matrix is used so that the spent insert does not have to be removed. As the biodegradable or bioerodible polymer is degraded or dissolved, the therapeutic agent is released.
In further embodiments, the ophthalmic insert comprises a polymer, including, but are not limited to, those described in Wagh, et al., "Polymers used in ocular dosage form and drug delivery systems", Asian J. Pharm., pages 12-17 (Jan. 2008), which is incorporated herein by reference in its entirety. In some embodiments, the insert comprises a polymer selected from polyvinylpyrrolidone (PVP), an acrylate or methacrylate polymer or copolymer (e.g., Eudragit® family of polymers from Rohm or Degussa), hydroxymethyl cellulose, polyacrylic acid, poly(amidoamine) dendrimers, poly(dimethyl siloxane), polyethylene oxide, poly(lactide-co-glycolide), poly(2-hydroxyethylmethacrylate), polyvinyl alcohol), or poly(propylene fumarate). In some embodiments, the insert comprises Gelfoam® R. In some embodiments, the insert is a polyacrylic acid of 450 kDa-cysteine conjugate.
In some embodiments, the ophthalmic composition is a ophthalmic film. Polymers suitable for such films include, but are not limited to, those described in Wagh, et al. (ibid), In some embodiments, the film is a soft-contact lens, such as ones made from copolymers of Ν,Ν-diethylacrylamide and methacrylic acid crosslinked with ethyleneglycol dimethacrylate.
In some embodiments, the ophthalmic compositon comprises microspheres or nanoparticles. In some embodiment, the microspheres comprise gelatin. In some embodiments, the microspheres are injected to the posterior segment of the eye, in the chroroidal space, in the sclera, intravitreally or sub-retinally. In some embodiments, the microspheres or nanoparticles comprises a polymer including, but not limited to, those described in Wagh, et al. (ibid), which is incorporated herein by reference in its entirety. In some embodiments, the polymer is chitosan, a polycarboxylic acid such as polyacrylic acid, albumin particles, hyaluronic acid esters, polyitaconic acid, poly(butyl)cyanoacrylate, polycaprolactone, poly(isobutyl)caprolactone, poly(lactic acid-co-glycolic acid), or poly(lactic acid). In some embodiments, the microspheres or nanoparticles comprise solid lipid particles.
In some embodiments, the ophthalmic composition comprises an ion- exchange resin. In some embodiments, the ion-exchange resin is an inorganic zeolite or synthetic organic resin. In some embodiments, the ion-exchange resin includes, but is not limited to, those described in Wagh, et al. (ibid), which is incorporated herein by reference in its entirety. In some embodiments, the ion-exhange resin is a partially neutralized polyacrylic acid.
In some embodiments, the ophthalmic composition is an aqueous polymeric suspension. In some embodiments, the therapeutic agent or a polymeric suspending agent is suspended in an aqueous medium. In some embodiments, the aqueous polymeric suspensions may be formulated so that they retain the same or substantially the same viscosity in the eye that they had prior to administration to the eye. In some embodiments, they may be formulated so that there is increased gelation upon contact with tear fluid.
Labeled Compounds and Assay Methods
Another aspect of the present invention relates to labeled compounds of the invention (radio-labeled, fluorescent-labeled, etc.) that would be useful not only in imaging techniques but also in assays, both in vitro and in vivo, for localizing and quantitating JAK in tissue samples, including human, and for identifying JAK ligands by inhibition binding of a labeled compound. Accordingly, the present invention includes JAK assays that contain such labeled compounds.
The present invention further includes isotopically-labeled compounds of the invention. An "isotopically" or "radio-labeled" compound is a compound of the invention where one or more atoms are replaced or substituted by an atom having an atomic mass or mass number different from the atomic mass or mass number typically found in nature (i.e., naturally occurring). Suitable radionuclides that may be incorporated in compounds of the present invention include but are not limited to 3H (also written as T for tritium), ' 'C, l 3C, l 4C, ,3N, 15N, 130, l 70, l sO, , BF, 3SS, 36C1, S2Br, 75Br, 76Br, 77Br, 123I, l241, 125I and 131I. The radionuclide that is incorporated in the instant radio-labeled compounds will depend on the specific application of that radio- labeled compound. For example, for in vitro JAK labeling and competition assays, compounds that incorporate 3H, 14C, 82Br, l25I , l 3 ,l, 35S or will generally be most useful. For radio-imaging applications "C, 1SF, , 25I, l23I, l 24I, l311, 75Br, 76Br or 77Br will generally be most useful.
It is to be understood that a "radio-labeled " or "labeled compound" is a compound that has incorporated at least one radionuclide. In some embodiments the radionuclide is selected from the group consisting of 3H, l 4C, , 251 , 35S and 82Br. In some embodiments, the compound incorporates 1, 2, or 3 deuterium atoms.
The present invention can further include synthetic methods for incorporating radio-isotopes into compounds of the invention. Synthetic methods for incorporating radio-isotopes into organic compounds are well known in the art, and an ordinary skill in the art will readily recognize the methods applicable for the compounds of invention.
A labeled compound of the invention can be used in a screening assay to identify/evaluate compounds. For example, a newly synthesized or identified compound (i.e., test compound) which is labeled can be evaluated for its ability to bind a JAK by monitoring its concentration variation when contacting with the JAK, through tracking of the labeling. For example, a test compound (labeled) can be evaluated for its ability to reduce binding of another compound which is known to bind to a JAK (i.e., standard compound). Accordingly, the ability of a test compound to compete with the standard compound for binding to the JAK directly correlates to its binding affinity. Conversely, in some other screening assays, the standard compound is labeled and test compounds are unlabeled. Accordingly, the
concentration of the labeled standard compound is monitored in order to evaluate the competition between the standard compound and the test compound, and the relative binding affinity of the test compound is thus ascertained.
5 Kits
The present invention also includes pharmaceutical kits useful, for example, in the treatment or prevention of JAK-associated diseases or disorders, such as cancer, which include one or more containers containing a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention. Such o kits can further include, if desired, one or more of various conventional
pharmaceutical kit components, such as, for example, containers with one or more pharmaceutically acceptable carriers, additional containers, etc., as will be readily apparent to those skilled in the art. Instructions, either as inserts or as labels, indicating quantities of the components to be administered, guidelines for
5 administration, and/or guidelines for mixing the components, can also be included in the kit.
EXAMPLES
The invention will be described in greater detail by way of specific examples.0 The following examples are offered for illustrative purposes, and are not intended to limit the invention in any manner. Those of skill in the art will readily recognize a variety of non-critical parameters which can be changed or modified to yield essentially the same results. The compounds of the Examples have been found to be JAK inhibitors according to at least one assay described herein. At points throughout the Examples, the stereochemistry of the cyclobutyl ring has been indicated, as currently understood.
Intermediate Example Al. {3-oxo-l-[4-(7-{[2-(trimethylsilyl)ethoxy]methyl}-7H- pyrrolo[2,3-d]pyrimidin-4-yI)-lH-pyrazol-l-yl]cyclobutyl}acetonitrile
Step 1. [2-bromo-l-(bromomethyl)ethoxy](tert-butyl)diphenylsilane
To a solution of l ,3-dibiOmo-2-propanol (20.00 g, 91.79 mmol) in methylene chloride (DCM) (100 mL) cooled to 0 °C was added lH-imidazole (6.56 g, 96.4 mmol) followed by tert-butylchlorodiphenylsilane (25.1 mL, 96.4 mmol) and 4- dimethylaminopyridine (1.12 g, 9.18 mmol). The reaction was stirred with warming to room temperature overnight. The reaction mixture was diluted with diethyl ether, washed with water, and the aqueous layer was again extracted once with ether. The combined organic extracts were washed with water, followed by brine, dried over sodium sulfate, decanted and concentrated. Flash chromatography (eluting with a gradient from 0-15% ethyl acetate/hexanes) afforded desired product (42 g, 100%). Ή NMR (300 MHz, CDC13): δ 7.72-7.66 (m, 4H), 7.51 -7.37 (m, 6H), 4.00-3.91 (m, 1H), 3.49-3.45 (m, 4H), 1.09 (s, 9H).
Step 2. tert-bittyl{[3-(methyh lfinyl)-3-(methylthio)cychbutyl]oxy}diphenylsilarie
To a solution of (methylsulfmyl)(methylthio)methane (27.70 g, 223.0 mmol) in tetrahydrofuran (90 mL) at -10 °C was added dropwise, a solution of 2.5 M n- butyllithium in hexane (89.2 mL, 223 mmol). The mixture was stirred at -1 0 °C for 2 hours. It was then cooled to -78 °C and transferred by cannula in a slow manner to a solution of [2-bromo-l -(bromomethyl)ethoxy](tert-butyl)diphenylsilane (42 g, 93 mmol, from Step 1) in tetrahydrofuran (70 mL, 900 mmol) held at -78 °C. The mixture was stirred with warming to room temperature over 2 nights. Water was added, and then the product was extracted with three portions of DCM. The combined extracts were dried over sodium sulfate, filtered and concentrated. Flash chromatography (eluting with a gradient from 0-100% ethyl acetate/hexanes) afforded desired product as a mixture of diastereomers (34.1 g, 88%). Ή NMR (300 MHz, CDCb), diastereomers: 8 7.74-7.58 (m, 8H), 7.48-7.31 (m, 10H), 4.52 (tt, 1H), 4.42
(tt, IH), 3.05-1.99 (m, 8H), 2.47 (s, 3H), 2.42 (s, 3H), 2.13 (s, 3H), 2.00 (s, 3H), 1.05 (s, 9H), 1.02 (s, 9H).
A solution of tert-butyl{[3-(methylsulfinyl)-3- (methylthio)cyclobutyl]oxy}diphenylsilane (17.05 g, 40.7 mmol, from Step 2) in ether (350 mL) cooled to 0 °C was treated with a solution of 6 M perchloric acid in water (10 mL) that was pre-diluted with water (7 mL). The bath was removed and stirred overnight. The mixture was poured into pH 7 buffer, and the product was extracted with diethyl ether. The combined extracts were dried over sodium sulfate, decanted and concentrated. The reaction was performed again on the same scale and the two batches were combined for purification. Flash chromatography, eluting with a gradient from 0-5% ethyl acetate/hexanes afforded desired product (15.7 g, 59%). Ή NMR (300 MHz, CDCI3): δ 7.75-7.62 (ra, 4Η), 7.49-7.33 (m, 6H), 4.59 (tt, I H), 3.22- 3.03 (m, 4H), 1.07 (s, 9H). Step 4, (3-{[tert-bvty!(diphenyl)silyl]oxy}cyclobutyliderie)acetonitrile
To a solution of 1.0 M potassium ferf-butoxide in tetrahydrofuran (46.0 mL, 46.0 mmol) at 0 °C was added diethyl cyanomethylphosphonate (7.8 mL, 48 mmol). The bath was removed and the reaction mixture was allowed to warm to room temperature over 1 hour. The reacation was re-cooled to 0 °C, and a solution of 3- {[tert-butyI(diphenyl)silyl]oxy}cyclobutanone (15.7 g, 48.4 mmol, from Step 3) in tetrahydrofuran (80 mL) was added. During the course of the addition, additional tetrahydrofuran (50 mL) was added into the receiving flask to facilitate stirring. Upon complete addition of the ketone, the bath was removed and the reaction allowed to reach room temperature and stirred overnight. The reaction mixture was partitioned between water and ethyl acetate and the aqueous was extracted with ethyl acetate a
total of three times. The combined extracts were washed with brine, dried over sodium sulfate, decanted and concentrated. Flash chromatography, eluting with a gradient of 0-10% ethyl acetate in hexanes afforded product (16.1 g, 96%). Ή NMR (300 MHz, CDC¾): δ 7.74-7.58 (m, 4H), 7.49-7.34 (m, 6H), 5.13 (dddd, IH), 4.34 (tt, IH), 3.16-2.90 (m, 4H), 1.05 (s, 9H).
Step 5. cis and trans {3-{[tert-butyl(diphenyl)silyl]oxy}-l-[4-(7-{[2- (trimethylsUyl)ethoxy]methyl}-7H-pyrrolo[2,3 l]pyrimidin-4-yl)-lH-pyrazol-l- yl]cyclobiityl}acetonitrile
To a solution of (3- {[tert- butyl(diphenyl)silyl]oxy}cyclobutylidene)acetonitrile (16.1 g, 35.2 mmol, from Step
4) and 4-(lH-pyrazol-4-yl)-7-{[2-(trimethylsiIyl)ethoxy]methyl}-7H-pyrrolo[2,3- d]pyrimidine (11.1 g, 35.2 mmol) (prepared as in WO2007/070514 Example 65, Step 2) in acetonitrile (100 mL) was added l,8-diazabicyolo[5.4.0]undec-7-ene (5.3 mL, 35 mmol). The reaction was stirred over three nights. The acetonitrile was removed in vacuo. Flash chromatography, eluting with 25% ethyl acetate in hexanes until product began to elute, then 40 to 66% ethyl acetate in hexanes was used to elute desired product as a mixture of diastereomers (17.4 g, 75%). Ή NMR (300 MHz, CDCI3), diastereomers (M=major, min=minor): δ 8.86 (s, IH M), 8.81 (s, IH mi ), 8.37 (s IH, M), 8.30 (s, 1H M), 8.26 (s, IH min), 8.25 (s, lH min), 7.67-7.35 (m, 11 H M & 1 1H min), 6.81 (d, IH M), 6.73 (d, IH min), 5.68 (s, 2H M), 5.66 (s, 2H min), 4.45 (tt, IH min), 4.33 (tt, 1H M), 3.59-3.50 (m, 2H M & 2H min), 3.23 (s, 2H min), 3.11-3.00 (m, 2H min), 2.90 (s, 2H M), 2.88-2.80 (m, 4H M), 2.64-2.54 (m, 2H min), 1.08 (s, 9H min), 1.03 (s, 9H M), 0.97-0.88 (m, 2H M & 2H min), -0.06 (s, 9H M), -0.07 (s, 9H min); LCMS (M+H)+: 663.3.
Step 6. cis and trans {3-hydroxy-l-[4-(7~{[2-(trimethylsilyl)ethoxy]methyl}-7H- pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]cyclobutyl}acetonitrile
To {3-{[tert-butyl(diphenyl)silyl]oxy}-l -[4-(7-{[2- (trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-l H-pyrazol-1 - yl]cyclobutyl}acetonitrile (8.7 g, 13.1 mmol, as a mixture of diastereomers from Step
5) in ethanol (355 mL) was added 5.0 M sodium hydroxide in water (90 mL, 450
mmol). The reaction was stirred for 5 hours. Additional water was added and then the ethanol was removed using rotary evaporation. The mixture was then partitioned between ethyl acetate and water. The aqueous portion was extracted with ethyl acetate a total of three times. The combined organic extracts were washed with water, then brine, dried over sodium sulfate, decanted and concentrated. The residue was azeotroped with benzene. This reaction was performed again on the same scale and the crude product of both runs was combined for purification. Flash chromatography, eluting with a gradient from 0-10% MeOH in DCM afforded product as an off-white foam (9.3 g, 83%). 'H NMR (300 MHz, CD<¾), diastereomers (M=major, min=minor): δ 8.84 (s, 1H M & 1H min), 8.41 (s, 1H min), 8.39 (s, 1H M), 8.31 (s, lH min), 8.30 (s, 1H M), 7.40 (d, 1H M & lH min), 6.80 (d, IH M & l H min), 5.67 (s, 2H M & 2H min), 4.60-4.44 (m, 1H M & 1H min), 3.59-3.46 (m, 2H M & 2H min), 3.25 (s, 2H min), 3.25-3.16 (m, 2H min), 3.08 (s, 2H M), 3.10-3.00 (m, 2H M), 2.84-2.73 (m, 2H M), 2.64-2.51 (m, 2H min), 0.97-0.87 (m, 2H M & 2H min), -0.06 (s, 9H M & 9H min); LCMS (M+H)+: 425.0.
Step 7. {3-oxo-l-[4-(7-{[2-(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2, 3- d]pyrimidin-4-yl)-lH-pyrazol-l-yl]cyclobvtyl}acetonitrile
To a solution of {3-hydroxy-l-[4-(7-{[2-(trimethylsilyl)ethoxy]methyl}-7H- pyrrolo[2,3-d]pyrimidin-4-yl)-l H-pyrazol-l -yl]cyclobutyl}acetonitrile (9.3 g, 22 mmol, as a mixture of diastereomers from Step 6) in methylene chloride (300 mL) at 0 °C was added Dess-Martin periodinane (10.0 g, 24 mmol). After a reaction time of 2 hours, the mixture was poured into IN NaOH and extracted with three portions of DCM. The combined extracts were washed with further IN NaOH, dried over sodium sulfate, decanted and the solvent removed in vacuo. Flash chromatography, eluting with a gradient from 0-10% MeOH in DCM afforded product as a yellow foam. Theoretical yield assumed for use in Step 8. Ή NMR (300 MHz, CDC13): δ 8.85 (s, 1H), 8.50 (s, 1H), 8.35 (s, 1H), 7.42 (d, 1H), 6.80 (d, 1H), 5.68 (s, 2H), 4.11-4.00 (m, 2H), 3.74-3.61 (m, 2H), 3.59-3.50 (m, 2H), 3.31 (s, 2H), 0.96-0.88 (m, 2H), -0.06 (s, 9H); LCMS (M+H)+: 423.0.
Intermediate Example A2. {cis-3-(4-{[4-(hydroxymethyl)-6- (trifluoromethyl)pyridin-2-yl]oxy}piperidin-l-yl)-l-[4-(7-{[2- (trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazoI-l- yl]cyclobutyl}acetonitrile and {trans-3-(4-{[4-(hydroxymethyl)-6- (trifluoromethyl)pyridin-2-yl]oxy}piperidin-l-yl)-l-[4-(7-{[2-
(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l- y I] cyclobuty l}acetonitrile
Step A. [2-Chloro-6-(trifluoromethyl)pyridin-4-yl]methanol
Sodium tetrahydroborate (74 mg, 2.0 mmol) was added to a solution of ethyl
2-chloro-6-(trifluoromethyl)isonicotinate (0.50 g, 2.0 mmol, Anichem) in ethanol (17 mL) at 0 °C. The mixture was stirred at 0 °C for one hour, then was allowed to warm to room temperature and stir for 2 hours. The mixture was recooled in an ice bath and was quenched by the dropwise addition of 4.0 mL IN HCl. The pH was then adjusted to 7 by the addition of saturated sodium bicarbonate solution. The reaction was further diluted with water, and then was extracted with EtOAc. The extract was washed with brine, dried over sodium sulfate, filtered and concentrated. Flash chromatography on silica gel, eluting with a gradient from 0-40% EtOAc in Hexanes afforded product as an oil (0.33 g, 79%). 'H NMR (300 MHZ, CDCl3) δ 7.61 (s, 1H), 7.56 (s, 1H), 4.84 (d, J= 5.2 Hz, 2H), 2.20 (t, J= 5.6 Hz, 1H); LCMS (M+H)+: 212.1.
Step B. 4-({[ tert-Butyl(diphenyl)silyl]oxy}methyl)-2-chloro-6- (trifluoromethyl)pyridine
To a solution of [2-chIoro-6-(trifluoromethyl)pyridin-4-yl]methanol (142 mg, 0.671 mmol) in methylene chloride (1.0 mL) at 0 °C was added IH-imidazole (55 mg, 0.80 mmol) followed by tert-butylchlorodiphenylsilane (190 μί, 0.74 mmol) and 4- dimethylaminopyridine (4 mg, 0.03 mmol). The reaction was stirred with warming to room temperature for 64 hours. The reaction mixture was diluted with diethyl ether and was washed with water followed by brine, dried over sodium sulfate, decanted and concentrated. Flash chromatography on silica gel, eluting with a gradient from 0- 4% EtOAc in hexanes afforded product as a white solid (0.20 g, 66%). Ή NMR (300 MHz, CDCI3) δ 7.70 - 7,58 (m, 4H), 7.55 - 7.34 (m, 8H), 4.77 (s, 2H), 1.12 (s, 9H);
19F NMR (282 MHz, CDC13) δ -68.49 (s); LCMS (M+H)+: 450.1.
Step C. tert-Butyl 4-{[4-({[tert-bittyl(diphenyl)silyl]oxy}methyl)-6- (trifluoromethyl)pyridin-2-yl]oxyjpiperidine-l-carboxylate
To sodium hydride (36 mg, 0.89 mmol, 60% in mineral oil) in tetrahydrofuran
(1.0 mL) was added tert-butyl 4-hydroxypiperidine-l -carboxylate (0.18 g, 0.89 mmol, Aldrich). After stirring for 45 minutes, 4-({[tert-butyl(diphenyl)silyl]oxy}methyl)-2- chloro-6-(trifluoromethyl)pyridine (0.20 g, 0.44 mmol, from Step B) in tetrahydrofuran (0.60 mL) was added and the mixture was stirred overnight. The reaction was quenched and diluted with water and extracted with ether. The extract was washed with water, brine, dried over sodium sulfate, filtered and concentrated. Flash chromatography on silica gel, eluting with a gradient from 0-5% EtOAc in hexanes afforded product as an oil (0.19 g, 52%). LCMS (M-tBu+H)+: 559.2 Step D. 4-({[tert-Butyl(diphenyl)silyl]oxy}methyl)-2-(piperidin-4-yloxy)-6- (trifluoromethyl)pyridine
To a solution of tert-butyl 4-{[4-({[tert-butyl(diphenyl)silyl]oxy}methyl)-6- (trifluoromethyl)pyridin-2-yl]oxy}piperidine-l-oarboxylate (0.19 g, 0.23 mmol, from Step C) in 1,4-dioxane (2.0 mL) was added 4.0 M hydrogen chloride in dioxane (0.50 mL, 2.0 mmol). The reaction mixture was stirred for one hour. Additional 4.0 M hydrogen chloride in dioxane (0.50 mL, 2.0 mmol) was added and stirring was continued for two hours. The mixture was diluted with water, saturated sodium bicarbonate was used to adjust the pH to between 7 and 8, and then the product was extracted with two portions of DCM. The combined extracts were washed with brine, dried over sodium sulfate, filtered and concentrated. Flash chromatography on silica gel, eluting with a gradient from 0-15% MeOH in DCM afforded product as an oil (62 mg, 52%). Ή NMR (400 MHz, CDCI3) δ 7.69 - 7.62 (m, 4H), 7.48 - 7.34 (m, 6H), 7.14 - 7.11 (m, 1H), 6.91 (s, 1H), 5.17 (tt, J= 8.7, 4.0 Hz, 1H), 4.71 (s, 2H), 3.13 (dt, J= 12.7, 4.5 Hz, 2H), 2.78 (ddd, 7= 12.7, 9.7, 3.0 Hz, 2H), 2.07 (dq, /= 12.2, 4.1 Hz, 2H), 1.67 (dtd, J= 13.0, 9.4, 3.9 Hz, 2H), 1.11 (s, 9H); LCMS (M+H)+: 515.2.
Step E. {3-(4-{[4-({[tert-Butyl(diphenyl)silyl]oxy}methyl)-6-(trifluoromethyl)pyridi>i-
2-yl]oxy}piperidin-l-yl)-l-[4-(7-{[2-(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3- d]pyrimidin-4-yl)-lH-pyrazol-l-yl]cyclobiityl}acetonitrile (a mixture of cis- and trans- isomers)
Sodium cyanoborohydride (8.8 mg, 0.14 mmol) and zinc dichloride (9.5 mg, 0.070 mmol) were combined in methanol (0,56 mL, 14 mmol) and stirred for 2 hours to generate the reducing solution referenced in JOC 1 85, 50, 1927-1 32.
Subsequently, {3-oxo-l -[4-(7- { [2-(trimethylsilyl)ethoxy]methyl} -7H-pyrrolo[2,3- d]pyrimidin-4-yl)-lH-pyrazol-l-yl]cyclobutyl}acetonitrile (66 mg, 0.14 mmol, from Step 7 of Example A l ) and 4-({[tert-butyl(diphenyl)silyl]oxy}methyl)-2-(piperidin-4- yloxy)-6-(trifluoromethyl)pyridine (60. mg, 0.12 mmol, from Step D) were combined in methanol (2.0 mL) to dissolve, then the above generated reducing mixture was added. The reaction was stirred overnight. An additional 0.3 eq of the prestirred NaCNB¾/ZnCl2 mixture was added. After stirring for 3 hours, the mixture was diluted with EtOAc and was washed with saturated sodium bicarbonate solution, followed by brine, dried over sodium sulfate, filtered and concentrated. Flash chromatography on silica gel, eluting with a gradient from 0-80% EtOAc in hexanes afforded product as a mixture of cis- and trans- isomers (43 mg, 40%). LCMS (M+2H)2+: 461.4. Step F. {cis-3-(4-{[4-(hydroxymethyl)-6-(trifliioromethyl)pyridin-2-yi]oxy}piperidiri- i-yl)-l-[4-(7-{[2-(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2, 3-d]pyrimidin-4-yl)- lH-pyrazol-l-yl]cyclobutyl}acetonitrile and {trans-3-(4-{[4-(hydroxymethyl)-6- (trifluoromethyl)pyridin-2-yl]oxy}piperidin-l-y!)-l-[4-(7-{[2- (trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l- yljcyclobittyljaceto trile (each diastereomer isolated)
To {3-(4-{[4-({[tert-butyl(diphenyl)silyl]oxy}methyl)-6- (trifluoromethy l)pyridin-2-yl]oxy } piperidin- l-yl)-l-[4-(7-{[2- (trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-l H-pyrazol-l - yl]cyelobutyl}acetonitrile (0.35 g, 0.38 mmol, a mixture of cis- and trans- isomers from Step E) in ethanol (10. mL, 180 mmol) was added 5.0 M sodium hydroxide in water (1.5 mL, 7.6 mmol). After stirring for 3 hours, the reaction mixture was partitioned between DCM and brine. The aqueous layer was extracted with an
additional portion of DCM. The combined extracts were dried over sodium sulfate, filtered and concentrated. Flash chromatography on silica gel, eluting with a gradient from 0-10% MeOH in DCM afforded a mixture of isomers (0.22 g, 76%). The isomers were separated by chiral HPLC (Phenomenex Lux-Cellulose 2 column, eluting with 45% EtOH in hexanes at 18mL/min, ~44mg/injection). Peak 1 retention time: 6.0 min, Peak 2 retention time: 10.2 min.
Peak 1, trans isomer, 83 mg: Ή NMR (500 MHz, CDC13) δ 8.84 (s, IH), 8.47 (s, IH), 8.33 (s, IH), 7.40 (d, J= 3.7 Hz, IH), 7.21 (s, IH), 6.89 (s, IH), 6.81 (d, J= 3.7 Hz, IH), 5.68 (s, 2H), 5.15 (br m, IH), 4.73 (s, 2H), 3.61 - 3.45 (m, 2H), 3.22 (s, 2H), 3.08 - 2.97 (m, 2H), 2.97 - 2.84 (m, IH), 2.67 (br m, 2H), 2.48 (br m, 2H), 2.25 (br m, 2H), 2.07 (br m, 2H), l .84 (br m, 2H), 0.98 - 0.84 (m, 2H), -0.05 (s, 9H); LCMS (M+H)+: 683.4.
Peak 2, cis isomer, 78 mg: Ή NMR (500 MHz, CDCl3) δ 8.83 (s, IH), 8.39 (s, IH), 8.29 (s, IH), 7.39 (d, J= 3.7 Hz, IH), 7.21 (s, IH), 6.90 (s, IH), 6.80 (d, J= 3.7 Hz, IH), 5.67 (s, 2H), 5.20 - 5.06 (m, IH), 4.73 (s, 2H), 3.64 - 3.46 (m, 2H), 3.14 (s, 2H), 2.90 (tt, J= 7.4, 7.8 Hz, IH), 2.84 - 2.76 (m, 2H), 2.75 - 2.52 (m, 4H), 2.28 (br in, 2H), 2.04 (br m, 2H), 1.81 (br m, 2H), 1.69 (s, 2H), 1.01 - 0.81 (m, 2H), -0.06 (s, 9H); LCMS (M+H)+: 683.3. Intermediate Example A3. {3-oxo-l-[4-(l-{[2-(trimethylsUyl)ethoxy]methyl}-lH- pyrrolo[2,3-b]pyridin-4-yl)-lH-pyrazol-l-yl]cyclobutyl}acetonitrile
Step A. {3-{[tert-Butyl(diphenyl)silyl]oxy}-l-[4-(l-{[2- (trimethylsilyl)ethoxy]methyl}-JH-pyrrolo[2,3-b]pyridin-4-yl)-lH-pyrazo!-l- yljcyclobittyljacetonitrile (a mixture of diastereomers)
To a solution of (3-{[tert- butyl(diphenyl)silyl]oxy}cyclobutylidene)aoetonitrile (4.0 g, 8.7 mmol, from Step 4 of Interemdiate Example Al) and 4-(lH-pyrazol-4-yl)-l-{[2- (trimethylsilyl)ethoxy]methyl}-lH-pyrrolo[2,3-b]pyridine (1.50 g, 4.77 mmol, US 20090181959) in aeetonitrile (10 mL, 200 mmol) was added 1 ,8- diazabicycIo[5.4.0]undec-7-ene (0.68 mL, 4.6 mmol). The reaction was stirred overnight. A further portion of l,8-diazabicyclo[5.4.0]undec-7-ene (0.7 mL, 5 mmol) was added and the reaction was allowed to continue for an additional 72 hours. Aeetonitrile was removed in vacuo. Flash chromatography on silica gel, eluting with 0% - 30% EtOAc/Hexanes, was used to purify product, which was obtained as a mixture of diastereomers (2 g, 60%). Ή NMR (300 MHz, CDCI3) δ 8.33 (d, J= 5.0 Hz, 1H major), 8.29 (d, J= 5.0 Hz, 1H minor), 8.06 (s, 1H major), 8.03 (s, 1H major), 8.00 (s, 1H minor), 7.93 (s, 1H minor), 7.70 - 7.31 (m, 10H major and 10H minor), 7.19 (d, J= 5.0 Hz, 1H major), 7.1 1 (d, J= 5.0 Hz, 1H minor), 6.74 (d, J= 3.6 Hz, 1H major), 6.63 (d, J= 3.7 Hz, 1H minor), 5.71 (s, 2H major), 5.69 (s, 2H minor), 4.49- 4.39 (m, 1H minor), 4.33 (tt, J= 7.0, 7.0 Hz, 1 H major), 3.67 - 3.45 (m, 2H major and 2H minor), 3.22 (s, 2H minor), 3.1 1 - 2.95 (m, 2H minor), 2.92 - 2.77 (m, 6H major), 2.65 - 2.50 (m, 2H minor), 1.08 (s, 9H minor), 1.03 (s, 9H major), 0.98 - 0.80 (m, 2H major and 2H minor), -0.06 (s, 9H major), -0.08 (s, 9H minor); LCMS (M+H)+: 662.1. Step B. {3-hydroxy-l-[4-(l-{[2-(trimethylsilyl)ethoxy]methyl}-lH-pyrrolo[2,3- b]pyridin-4-yl)-lH-pyrazol-l-yl]cyclobutyl}acetonitrile(a mixture of diastereomers)
HO
To {3-{[tert-butyl(diphenyl)silyl]oxy}-l-[4-(l -{[2- (trimethylsilyI)ethoxy]metIiyl}-lH-pyrrolo[2,3-b]pyridiri-4-yl)-lH-pyrazol-l- yl]cyclobutyl}acetonitrile (2.0 g, 3.0 mmol, a mixture of diastereomers from Step A) ethanol (82 mL) was added 5.0 sodium hydroxide in water (9 mL, 50 mmol). The reaction was stirred overnight. The reaction mixture was diluted with water and ethanol was removed in vacuo. The aqueous mixture was extracted with ethyl acetate (3x). The combined organic extracts were washed with water, then brine, dried over sodium sulfate, decanted and concentrated. The product, as a mixture of diastereomers, was used without further purification in Step C. LCMS (M+H)+: 424.2.
Step C. {3-oxo-l-[4-(l-{[2-(trimethylsilyl)ethoxy]methyl}-lH-pyrrolo[2, i-b]pyridin- 4-yl)-lH-pyrazol-l-yl]cyclobutyI}acetonitrile
To a solution of {3-hydroxy-l-[4-(l-{[2-(trimethylsilyl)ethoxy]methyl}-l H- pyrrolo[2,3-b]pyridin-4-yl)-lH-pyrazol-l-yl]cyclobutyl}acetonitrile (1 .3 g, 3.1 mmol, a mixture of diastereomers from Step B) in methylene chloride (40 mL) was added Dess-Martin periodinane (1.63 g, 3.84 mmol). After stirring for 1 hour and 15 minutes, the reaction mixture was poured into IN NaOH and extracted with three portions of DCM. The combined extracts were washed with IN NaOH, then brine, dried over sodium sulfate, decanted and solvent was removed in vacuo. Flash chromatography on silica gel, eluting with an initial gradient from 0-30%
EtOAc Hexanes, then a rapid gradient up to 100% EtOAc afforded product (1.1 g, 85%). Ή NMR (300 MHz, CDC¾) δ 8.34 (d, J= 5.0 Hz, 1H), 8.14 (s, 1H), 8.11 (s, 1H), 7.42 (d, J= 3.7 Hz, 1H), 7.18 (d, = 5.0 Hz, 1H), 6.71 (d, J= 3.7 Hz, 1H), 5.71 (s, 2H), 4.10 - 3.97 (m, 2H), 3.74 - 3.61 (m, 2H), 3.61 - 3.47 (m, 2H), 3.28 (s, 2H), 0.98 - 0.86 (m, 2H), -0.07 (s, 9H); LCMS (M+H)+: 422.2.
Example 1. {trans-3-(4-{[4-({[(lS)-2-hydroxy-l-methylethyl]amino}methyl)-6- (trifluoromethyl)pyridin-2-yI]oxy}piperidin-l-yl)-l-[4-(7H-pyrrolo[2,3- d]pyrimidin-4-yI)-lH-pyrazol-l-yl]cycIobutyl}acetoiiitriIe
N,N-Diisopropylethylamine (9.4 uL, 0.054 mmol) and methanesulphonic anhydride (7.9 mg, 0.045 mmol) were added to a solution of {trans-3-(4-{[4- (hydroxymethyl)-6-(trifluoromethyl)pyi'idin-2-yl]oxy}piperidin-l-yl)-l-[4-(7-{[2- (trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l- yl]cyclobutyl}acetonitrile (10.0 mg, 0.018 mmol, Peak 1 from Intermediate Example A2, Step F) in methylene chloride (0.30 mL) , and the mesylate formation was stirred for 30 minutes. The solvent was removed in vacuo and the residue was redissolved in a mixture of tetrahydrofuran (0.30 mL) and methanol (0.10 mL) and (2S)-2- aminopropan- l-ol (20. μί, 0.27 mmol, Acros) was added. The reaction mixture was stirred at 40 °C overnight. Solvent was removed in vacuo and the crude product was deprotecfed by stirring with 1 : 1 TFA:DCM for one hour, then concentrated and stirred with ethylenediamine (0.10 mL) in methanol (1.0 mL) until the deprotection was complete as determined by LCMS. The product was purified using preparative HPLC- MS (C18 eluting with a gradient of MeCN/H20 containing 0.15% NH4OH). The eluent was frozen and lyophilized to afford the product as the free base (6.0 mg, 54%). 'H NMR (400 MHz, CD3OD) δ 8.74 (s, 1H), 8.67 (s, 1H), 8.40 (s, 1H), 7.51 (d, J= 3.6 Hz, 1 H), 7.37 (s, 1H), 7.00 - 6.97 (m, 2H), 5.23 - 5.00 (m, 1H), 3.90 (d, J = 14.8 Hz, 1H), 3.81 (d, 7= 14.8 Hz, 1H), 3.50 (dd, J= 10.9, 4.9 Hz, 1H), 3.41 (dd, J = 10.9, 6.9 Hz, 1H), 3.31 (s, 2H), 3.16 - 3.05 (m, 2H), 2.95 (p, 7= 7.5 Hz, 1H), 2.83 - 2.63 (m, 3H), 2.56 - 2.42 (m, 2H), 2.39 - 2.23 (m, 2H), 2.19 - 2.04 (m, 2H), 1.93 -
1.75 (m, 2H), 1.05 (d, J= 6.4 Hz, 3H). 19F NMR (376 MHz, CD3OD) δ -70.30 (s). LCMS (M+H)+: 610.3
Example 2. {trans-3-(4-{[4-({[(lR)-2-hydroxy-l-methylethyl]amino}methyI)-6- (trifluoromethyl)pyridin-2-yl]oxy}piperidin-l-yl)-l-[4-(7H-pyrrolo[2,3- d]pyrimidin-4-yI)-lH-pyrazol-l-yl]cyclobutyl}acetonitrile
Prepared by the method of Example 1 using (R)-(-)-2-Amino-l -propanol (21 yL, 0.27 mmol, Aldrich) and heating to 60 °C for 30 additional minutes during the displacement step (3.4 mg, 31%). Ή NMR (400 MHz, CD3OD) δ 8.74 (s, 1H), 8.67 (s, 1H), 8.40 (s, 1H), 7.51 (d, J 3.6 Hz, 1H), 7.37 (s, 1H), 7.06 - 6.82 (m, 2H), 5.23 - 5.06 (m, 1H), 3.90 (d, = 14.8 Hz, 1 H), 3.82 (d, = 14.8 Hz, 1H), 3.50 (dd, /= 10.9, 4.9 Hz, 1H), 3.41 (dd, J= 10.9, 6.8 Hz, 1H), 3.31 (s, 2H), 3.19 - 3.03 (m, 2H), 2.96 (p, J= 7.7 Hz, 1H), 2.80 - 2.62 (m, 3H), 2.55 - 2.43 (m, 2H), 2.39 - 2.22 (m, 2H), 2.20 - 2.01 (m, 2H), 1.98 - 1.74 (m, 2H), 1.05 (d, .7= 6.5 Hz, 3H). I9F NMR (376 MHz, CDjOD) δ -70.31 (s). LCMS (M+H)+: 610.3
Example 3. {trans-3-(4-{[4-{[(2-methoxyethyl)amino]methyl}-6- (trifluoromethyl)pyridin-2-yl]oxy}piperidin-l-yl)-l-[4-(7H-pyriOlo[2,3- d]pyrimidin-4-yl)-lH-pyrazol-l-yl]cyclobutyl}acetonitrile
Prepared by the method of Example 1 using {trans-3-(4-{[4-(hydroxymethyl)- 6-(trifluoromethyl)pyridin-2-yl]oxy}piperidin-] -yl)-l-[4-(7-{[2- (trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l - yl]cyolobutyl}acetonitrile (15 mg, 0.022 mmol, Peak 1 from Intermediate Example A2, Step F), N,N-diisopropylethylamine (1 1 μΕ, 0.066 mmol) and methanesulphonic anhydride (9.6 mg, 0.055 mmol, Aldrich) and using 2-methoxyethylamine (19.1 |iL, 0.220 mmol, Aldrich) at room temperature overnight for the displacement step. The product was purified in the manner of Example 1 to afford product as the free base (8.0 mg, 60%). 'H MR (400 MHz, d6-DMSO) δ 12.14 (br s, 1H), 8.83 (s, 1H), 8.69 (s, 1H), 8.42 (s, 1H), 7.60 (d, J= 3.6 Hz, 1H), 7.42 (s, 1H), 7.08 (d, J= 3.6 Hz, 1H), 7.02 (s, 1H), 5.16 - 4.81 (m, 1H), 3.76 (s, 2H), 3.42 (s, 2H), 3.37 (t, J= 5.7 Hz, 2H), 3,22 (s, 3H), 3.07 - 2.97 (m, 2H), 2.81 (p, J= 7.4 Hz, 1H), 2.73 - 2.56 (m, 4H), 2.47 - 2.26 (m, 3H), 2.26 - 2.07 (m, 2H), 2.07 - 1.92 (m, 2H), 1.83 - 1.46 (m, 2H). , 9F NMR (376 MHz, d6-DMSO) δ -68.11 (s). LCMS (M+H)+: 610.3.
Example 4. l-{[2-[(l-{trans-3-(cyanomethyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4- yl)-lH-pyrazol-l-yl]cycIobutyl}piperidin-4-yl)oxy]-6-(trifluoromethyl)pyridin-4- yl]methyl}azetidine-3-carbonitrile
Prepared according to the method of Example 1 using azetidine-3-carbonitrile hydrochloride (13 mg, 0.1 1 mmol, Oakwood) and N,N-diisopropylethy!amine (23 ί, 0.13 mmol) in the displacement step which was carried out at room temperature overnight, and the product was afforded as the free base (7.5 mg, 55%).
'H NMR (400 MHZ, d6-DMSO) δ 12.1 1 (br s, 1 H), 8.83 (s, 1H), 8.69 (s, 1H), 8.42 (s, 1H), 7.60 (d, = 3.6 Hz, 1H), 7.31 (s, 1H), 7.08 (d, J= 3.6 Hz, 1H), 6.96 (s, 1H), 5.28 - 4.71 (m, 1 H), 3.66 (s, 2H), 3.56 - 3.46 (m, 3H), 3.42 (s, 2H), 3.38 - 3.24 (m, 2H), 3.09 - 2.95 (m, 2H), 2.81 (p, 7= 7.4 Hz, 1H), 2.73 - 2.56 (m, 2H), 2.40 - 2.27 (m, 2H), 2.23 - 2.08 (m, 2H), 2.08 - 1.93 (m, 2H), 1.76 - 1.59 (m, 2H). 19F NMR (376 MHz, de-DMSO) δ -67.38 (s). LCMS (M+H)+: 617.3.
Example 5. [trans-l-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]-3-(4- {[4-[(tetrahydro-2H-pyran-4-ylamino)methyl]-6-(trifluoromethyl)pyridin-2- yl]oxy}piperidin-l-yl)cyclobutyl]acetonitrile
The procedure of Example 1 was followed, using tetrahydro-2H-pyran-4-amine (1 1 mg, 0.1 1 mmol, Combi-Blocks) in the displacement step at 40 °C overnight (7.9 mg, 56%).
Ή NMR (400 MHz, d6-DMSO) 8 12.08 (br s, IH), 8.83 (s, IH), 8.69 (s, IH), 8.42 (s, IH), 7.60 (d, .7= 3.6 Hz, IH), 7.44 (s, IH), 7.08 (d, J= 3.6 Hz, I H), 7.06 (s, IH), 5.07 - 4.90 (m, IH), 3.86 - 3.74 (m, 4H), 3.42 (s, 2H), 3.24 (td, J= 1 1.4, 2.1 Hz, 2H), 3.10 - 2.95 (m, 2H), 2.81 (p, .7= 7.5 Hz, IH), 2.72 - 2.59 (m, 2H), 2.59 - 2.51 (m, IH), 2.41 - 2.27 (m, 2H), 2.25 - 2.07 (m, 2H), 2.08 - 1.92 (m, 2H), 1.86 - 1.61 (m, 4H), 1.24 (dtd, J= 13.1 , 11.2, 4.3 Hz, 2H). I9F NMR (376 MHz, d6-DMSO) δ -67.26 (s). LCMS (M+H)+: 636.3.
Example 6. {trans-3-(4-{[4-(2-oxa-6-azaspiro[3.3]hept-6-ylmethyl)-6- (trifluoromethyI)pyridin-2-yl]oxy}piperidin-l-yl)-l-[4-(7H-pyrrolo[2,3- d]pyrimidin-4-yl)-lH-py razol-l-yl]cyclobutyl}acetonitrile
Prepared by the method of Example 1, using 2-oxa-6-azaspiro[3.3]heptane (11 mg, 0.1 1 mmol, J&W Pharmlab) in tetrahydrofuran (0.50 mL) and methanol (0.50 mL) at room temperature for 5.5 hours in the displacement step (7.4 mg , 53%). Ή NMR (400 MHz, d6-DMSO) δ 12.13 (br s, 1H), 8.83 (s, 1 H), 8.69 (s, 1H), 8.42 (s, 1H), 7.60 (d, J = 3.6 Hz, 1H), 7.28 (s, 1H), 7.08 (d, J= 3.6 Hz, 1H), 6.92 (s, 1H), 5.28 - 4.71 (m, 1H), 4.60 (s, 4H), 3.57 (s, 2H), 3.42 (s, 2H), 3.33 (s, 4H), 3.09 - 2.95 (ra, 2H), 2.81 (p, J= 7.6 Hz, 1H), 2,72 - 2.57 (m, 2H), 2.40 - 2.29 (m, 2H), 2.22 - 2.08 (m, 2H), 2.08 - 1.96 (m, 2H), 1.77 - 1.61 (m, 2H). I 9F NMR (376 MHz, d6-DMSO) δ -67.36 (s). LCMS (M+H)+: 634.3.
Example 7. [trans-l-[4-(7H-p rrolo[2,3-d] pyrimidin-4-yl)-lH-pyrazol-l-yl]-3-(4-
{[4-{[(3S)-tetrahydrofuran-3-ylamino]methyl}-6-(trifluoromethyl)pyridin-2- yl]oxy}piperidin-l-yl)cyclobntyl]acetonitrile
Prepared by the method of Example 1 using {trans-3-(4-{[4-(hydroxymethyl)- 6-(trifluoromethy l)pyridin-2-yl]ox } piperidin- 1 -y 1)- 1 -[4-(7- { [2- (trimethylsilyl)ethoxy]methyl}-7H-pyrroIo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l- y]]cyclobutyl}acetonitrile (15 mg, 0.022 mmol, Peak 1 from Intermediate Example A2, Step F) and using (3S)-tetrahydrofuran-3-amine hydrochloride (14 mg, 0.1 1 mmol, Advanced ChemBlocks, Inc.) and N,N-diisopropylethylamine (23 μΙ , 0.13 mmol) in the displacement step. 0.2 mL of ethylenediamine was used in the deprotection. The product was obtained as the free base (4.5 mg, 33%). Ή NMR (400 MHz, d6-DMSO) δ 12.13 (s, lH), 8.83 (s, 1H), 8.69 (s, 1H), 8.42 (s, 1H), 7.60 (dd, = 3.5, 2.4 Hz, 1H), 7.43 (s, 1H), 7.08 (dd, J= 3.6, 1.7 Hz, I H), 7.05 (s, 1 H), 5.23 - 4.71 (m, 1H), 3.82 - 3.70 (m, 3H), 3.72 - 3.57 (m, 2H), 3.48 - 3.37 (m, 3H), 3.27 - 3.17 (m, 1H), 3.09 - 2.95 (m, 2H), 2.81 (p, J= 7.0 Hz, 1H), 2.63 (br m, 2H), 2.43 - 2.28 (m, 2H), 2.16 (br m, 2H), 2.00 (br m, 2H), 1.91 (dq, ./ = 12.6, 7.2 Hz, 1H), 1.78 - 1.61 (m, 3H). 19F NMR (376 MHz, d6-DMSO) δ -67.28 (s). LCMS (M+H)+: 622.3.
Example 8. [trans-l-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]-3-(4-
{[4-}[(3R)-tetrahydrofuran-3-ylamino]methyl}-6-(trifluoromethyl)pyridin-2- yl]oxy}piperidin-l-yl)cyclobutyl]acetonitrile
Prepared by the method of Example 7 using (3R)-tetrahydrofuran-3-amine hydrochloride (14 mg, 0.1 1 mmol, Advanced Chem Blocks) to afford product as the free base (7.8 mg, 57%). Ή NMR (400 MHz, d6-DMSO) δ 12.13 (s, 1H), 8.83 (s, 1H), 8.69 (s, 1H), 8.42 (s, 1H), 7.60 (dd, J= 3.5, 2.4 Hz, 1H), 7.43 (s, 1H), 7.08 (dd, J = 3.6, 1.6 Hz, 1H), 7.05 (s, 1 H), 5.14 - 4.59 (m, 1H), 3.79 - 3.58 (m, 5H), 3.46 - 3.39 (m, 3H), 3.27 - 3.19 (m, 1H), 3.09 - 2.96 (m, 2H), 2.81 (p, .7= 7.3 Hz, 1H), 2.74 - 2.55 (m, 2H), 2.42 - 2.28 (m, 2H), 2.26 - 2.09 (m, 2H), 2.07 - 1.96 (m, 2H), 1.91 (dq, J= 12.4, 7.2 Hz, 1H), 1.79 - 1.53 (m, 3H). 19F NMR (376 MHz, d6-DMSO) δ -67.28 (s). LCMS (M+H)+: 622.3.
Example 9. {trans-3-(4-{[4-{[(3-methyloxetan-3-yI)amino]methyl}-6-
(trifluoromethyl)pyridin-2-yl]oxy}piperidiii-l-yl)-l-[4-(7H-pyrrolo[2,3- d]pyrimidin-4-yl)-lH-pyrazol-l-yl]cyclobutyl}acetonitrile
The procedure of Example 1 was followed, using {trans-3-(4-{[4- (hydroxymethyl)-6-(ti'ifluoromethyl)pyridin-2-yl]oxy}piperidin-l-yl)-l-[4-(7-{[2- (trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l- yl]cyclobutyl}acetonitrile (21 mg, 0,031 mmol, Peak 1 from Intermediate Example A2, Step F), N,N-dusopropylethylamine (1 1 iL, 0.062 mmol) and methanesulphonic anhydride (7.5 mg, 0.043 mmol, Aldrich) in methylene chloride (0.42 niL). However, the substitution step was carried out using 3-methyloxetan-3-amine (40. ί, 0.46 mmol, Synthonix) in tetrahydrofuran (0.42 mL) and methanol (0.20 mL) at 55 °C for 4 hours followed by 50 °C overnight. Deprotection and purification carried out similarly to afford product as the free base (1 1 mg, 58%). Ή NMR (400 MHz, d6- DMSO) δ 12.13 (s, 1H), 8.83 (s, 1H), 8.69 (s, 1H), 8.42 (s, 1H), 7.60 (d, J= 3.6 Hz, 1H), 7.46 (s, 1H), 7.15 - 7.02 (m, 2H), 5.11 - 4.89 (m, 1H), 4.45 (d, = 5.8 Hz, 2H), 4.18 (d, ./= 6.0 Hz, 2H), 3.77 (d, J= 7.4 Hz, 2H), 3.42 (s, 2H), 3.1 1 - 2.95 (m, 3H), 2.81 (p, ,7= 7.4 Hz, 1H), 2.73 - 2.55 (m, 2H), 2.44 - 2.27 (m, 2H), 2.25 - 2.08 (m, 2H), 2.08 - 1.92 (m, 2H), 1.80 - 1.54 (m, 2H), 1.37 (s, 3H). 19F NMR (376 MHz, d6- DMSO) δ -67.29 (s). LCMS (M+H)+: 622.2.
Example 10. {trans-3-(4-{[4-{[(l-methyIcyclopropyl)ammo]methyl}-6- (trifluororaethyl)pyridin-2-yl]oxy}piperidin-l-yl)-l-[4-(7H-pyrrolo[2,3- d]pyrimidin-4-yl)-lH-pyrazol-l-yl]cyclobutyl}acetonitrile
The procedure of Example 9 was followed, using 1-methylcyclopropariamine hydrochloride (33 mg, 0.31 mmol, ChemBridge Corp.) and N,N- diisopropylethylamine (64 μL, 0.37 mmol) in the substitution step, which was carried out at 55°C for 2.5 hours. The product was obtained as the free base (6.2 mg, 33%). 'H MR (400 MHz, d6-DMSO) 8 12.13 (s, IH), 8.83 (s, IH), 8.69 (s, IH), 8.42 (s, IH), 7.60 (d, J= 3.6 Hz, IH), 7.39 (s, IH), 7.08 (d, J= 3.6 Hz, IH), 7.01 (s, IH), 4.99 (tt, J= 8.4, 4.6 Hz, IH), 3.77 (d, J = 6.4 Hz, 2H), 3.42 (s, 2H), 3.10 - 2.94 (m, 2H), 2.81 (p, = 7.3 Hz, IH), 2.71 - 2.54 (m, 3H), 2.41 - 2.30 (m, 2H), 2.25 - 2.09 (m, 2H), 2.07 - 1.91 (m, 2H), 1.78 - 1.57 (m, 2H), 1.20 (s, 3H), 0.48 (dd, J= 5.7, 4.2 Hz, 2H), 0.30 (dd, J= 5.8, 3.8 Hz, 2H). ,9F NMR (376 MHz, d6-DMSO) δ -67.28 (s). LCMS (M+H)+: 606.2.
Example 11. {trans-3-(4-{[4-[(oxetan-3-yIamino)metliyt]-6- (trifluoromethyl)pyridin-2-yl]oxy}piperidin-l-yl)-l-[4-(7H-pyrrolo[2,3- d]pyrimidin-4-yl)-lH-pyrazol-l-yl]cyclobutyl}acetonitrile
The procedure of Example 9 was followed, using oxetan-3-amine (34 mg, 0.46 mmol, Synthonix) in the substitution step, carried out at 55 °C for 1.5 hours. The desired product was obtained as the free base (9.7 mg, 52%). ¾ NMR (400 MHz, d6- DMSO) δ 12.13 (s, 1H), 8.83 (s, 1H), 8.69 (s, 1 H), 8.42 (s, 1H), 7.60 (s, 1H), 7.42 (s, 1H), 7.08 (s, 1H), 7.03 (s, 1H), 5.10 - 4.88 (m, 1 H), 4.56 (t, J= 6.6 Hz, 2H), 4.30 (t, J = 6.2 Hz, 2H), 3.94 - 3.77 (m, 1H), 3.68 (s, 2H), 3.42 (s, 2H), 3.28 - 3.09 (m, 1 H), 3.09 - 2.91 (m, 2H), 2.91 - 2.73 (m, 1H), 2.74 - 2.54 (m, 2H), 2.42 - 2.26 (m, 2H), 2.25 - 2.07 (m, 2H), 2.07 - 1.89 (m, 2H), 1.83 - 1.60 (m, 2H). 19F NMR (376 MHz, d6-DMSO) δ -67.33 (s). LCMS (M+H)+: 608.3
Example 12. {trans-3-(4-{[4-{[(trans-3-hydroxycyclobutyl)amino]methyl}-6-
(trilluoromethyl)pyridin-2-yl]oxy}piperidin-l-yl)-l-[4-(7H-pyrrolo[2,3- d]pyrimidin-4-yl)-lH-pyrazol-l-yl]cyclobutyl}acetonitrile
The procedure of Example 9 was followed, using trans-3-aminocyclobutanol hydrochloride (38 mg, 0.31 mmol, Advanced Chem Blocks) and N,N- diisopropylethylamine (64 μί, 0.37 mmol) in the displacement step, carried out at 55 °C for 1.5 hours (yield 9.8 mg). Ή NMR (400 MHz, d6-DMSO) δ 12.1 1 (s, 1H), 8.83 (s, 1H), 8.69 (s, 1H), 8.42 (s, 1H), 7.60 (d, = 3.6 Hz, 1H), 7.41 (s, 1H), 7.08 (d, = 3.6 Hz, lH), 7.02 (s, 1H), 5.06 - 4.94 (m, 1H), 4.86 (d, J= 5.4 Hz, 1H), 4.23 (h, J = 5.9 Hz, 1H), 3.63 (s, 2H), 3.42 (s, 2H), 3.25 - 3.12 (m, 1H), 3.09 - 2.96 (m, 2H), 2.81 (p, J= 7.4 Hz, 1H), 2.75 - 2.51 (m, 3H), 2.43 - 2.29 (m, 2H), 2.25 - 2.10 (m, 2H), 2.10 - 1.82 (m, 6H), 1.80 - 1.50 (m, 2H). I 9F NMR (376 MHz, d6-DMSO) δ -67.81 (s). LCMS (M+H)+: 622.2.
Example 13. {trans-3-(4-{[4-[(3,3-dimethylazetidin-l-yl)methyl]-6- (trifluoromethyl)pyridin-2-yl]oxy}piperidin-l-yl)-l-[4-(7H-pyrrolo[2,3- d]pyrimidin-4-yl)-lH-pyrazol-l-yl]cyclobutyl}acetonitrile
The procedure of Example 9 was followed, using 3,3-dimethylazetidine hydrochloride (22 mg, 0.18 mmol, Princeton Bio) and N,N-diisopropylethylamine (54 ΐ^, 0.31 mmol) in the displacement step, which was carried out at room temperature overnight. (10 mg, 52%). Ή NMR (300 MHz, d6-DMSO) δ 12.12 (s, 1H), 8.83 (s, 1H), 8.69 (s, 1H), 8.42 (s, 1H), 7.60 (d, J= 3.5 Hz, 1H), 7.30 (s, 1H), 7.08 (d, J= 3.6 Hz, 1H), 6.93 (s, 1H), 5.20 - 4.76 (m, 1 H), 3.62 (s, 2H), 3.42 (s, 2H), 3.10 - 2.96 (m, 2H), 2.92 (s, 4H), 2.81 (p, J= 7.2 Hz, 1H), 2.74 - 2.54 (m, 2H), 2.42 - 2.29 (m, 2H), 2.24 - 2.07 (m, 2H), 2.07 - 1.91 (m, 2H), 1.79 - 1.60 (m, 2H), 1.18 (s, 6H). 19F NMR (282 MHz, d6-DMSO) δ -67.35 (s). LCMS (M+H)+: 620.3
Example 14. {trans-3-(4-{[4-({[(2R)-2-hydroxypropyI]amino}metliyI)-6- (trifluoromethyl)pyridin-2-yl]oxy}piperidin-l-yl)-l-[4-(7H-pyrrolo[2,3- d]pyrimidin-4-yl)-lH-pyrazol-l-yI]cyclobutyl}acetonitrile
The procedure of Example 9 was followed, using (2R)- l-aminopropan-2-ol (12 iL, 0.15 mmol, Aldrich) in the displacement step, which was carried out at 50 °C for 2 hours. The product was obtained as the free base (8.7 mg, 46%). Ή NMR (400 MHz, ds-DMSO) δ 12.13 (s, 1H), 8.83 (s, 1H), 8.69 (s, 1H), 8.42 (s, 1H), 7.60 (d, J = 3.6 Hz, 1H), 7.42 (s, 1H), 7.08 (d, J= 3.6 Hz, 1H), 7.04 (s, 1H), 5.1 1 - 4.90 (m, 1H), 4.49 (d, = 4.4 Hz, 1H), 3.76 (s, 2H), 3.67 (tt, J= 10.3, 5.6 Hz, 1H), 3.42 (s, 2H), 3.11 - 2.96 (m, 2H), 2.81 (p, J= 7.5 Hz, 1H), 2.74 - 2.56 (m, 2H), 2.46 - 2.25 (m, 4H), 2.24 - 2.09 (m, 2H), 2.09 - 1.90 (m, 2H), 1.81 - 1.51 (m, 2H), 1 .03 (d, J = 6.2 Hz, 3H). I 9F NMR (376 MHz, d6-DMSO) δ -67.29 (s). LCMS (M+H)+: 610.3.
Example 15. {trans-3-(4-([4-({[(2S)-2-hydroxypropyl]amino}methyl)-6- (trifluoromethyl)pyridin-2-yl]oxy}piperidin-l-yl)-l-[4-(7H-pyrroIo[2,3- d]pyrimidin-4-yl)-lH-pyrazol-l-yl]cyclobutyl}acetonitrile
41601
The procedure of Example 9 was followed, using (2S)-l-aminopropan-2-ol
(12 μί, 0.15 mmol, Aldrich) in the displacement step, which was carried out at 50 °C
for 2 hours (7.9 mg, 42%). Ή NMR (400 MHz, d6-DMSO) 8 12.13 (s, 1H), 8.83 (s,
1H), 8.69 (s, 1H), 8.42 (s, 1 H), 7.60 (d, = 3.6 Hz, 1H), 7.42 (s, 1H), 7.08 (d, J= 3.6
Hz, 1H), 7.04 (s, 1H), 5.27 - 4.71 (m, 1 H), 4.49 (d, .7= 4.4 Hz, 1H), 3.76 (s, 2H), 3.72
- 3.62 (m, 1H), 3.42 (s, 2H), 3.09 - 2.96 (m, 2H), 2.81 (p, J = 7.4 Hz, 1H), 2.72 - 2.55 (m, 2H), 2.43 - 2.25 (m, 4H), 2.25 - 2.08 (m, 2H), 2.08 - 1.96 (m, 2H), 1.78 - 1.57 (m, 2H), 1.03 (d, J= 6.2 Hz, 3H). , 9F NMR (376 MHz, d6-DMSO) δ -67.29 (s).
LCMS (M+H)+: 610.3.
Example 16. {trans-3-(4-{[4-{[bis(2-hydroxyethyl)amino]methyl}-6-
(trifluoromethyI)pyridin-2-yI]oxy}piperidin-l-yl)-l-[4-(7H-pyrrolo[2,3- d]pyrimidin-4-yI)-lH-pyrazol-l-yi]cyclobutyl}acetonitriIe
The procedure of Example 9 was followed, using diethanolamine (15 μί, 0.15 mmol, Aldrich) in the displacement step, which was carried out at 40 °C overnight (7.4 mg, 38%). Ή NMR (400 MHz, d6-DMSO) δ 12.13 (s, 1H), 8.83 (s, 1H), 8.69 (s, 1H), 8.42 (s, 1H), 7.60 (d, J= 3.6 Hz, 1H), 7.45 (s, 1H), 7.10 (s, 1H), 7.08 (d, = 3.6 Hz, 1H), 5.29 - 4.79 (m, 1H), 4.46 (t, J= 5.2 Hz, 2H), 3.73 (s, 2H), 3.51 - 3.38 (m, 6H), 3.09 - 2.96 (m, 2H), 2.81 (p, J= 7.4 Hz, 1H), 2.73 - 2.58 (m, 2H), 2.53 (t, J= 6.1 Hz, 4H), 2.40 - 2.31 (m, 2H), 2.21 - 2.09 (m, 2H), 2.08 - 1.96 (m, 2H), 1.75 - 1.61 (m, 2H). 19F NMR (376 MHz, d6-DMSO) δ -67.22 (s). LCMS (M+H)+: 640.1.
Example 17. {trans-3-(4-{[4-{[(2-hydroxyethyI)(raethyl)amino]methyl}-6-
(trifluoromethyl)pyridin-2-yl]oxy}piperidin-l-yl)-l-[4-(7H-pyrrolo[2,3- d]pyrimidin-4-yl)-lH-pyrazol-l-yl]cyclobutyl}acetonitrile
The procedure of Example 9 was followed, using 2-(methylamino)ethanol (12 μί, 0.15 mmol, Aldrich) in the displacement step, which was carried out at 40 °C overnight (8.5 mg, 45%). 'H NMR (400 MHz, d6-DMSO) δ 12.12 (s, 1H), 8.83 (s, 1H), 8.69 (s, 1H), 8.42 (s, 1H), 7.60 (d, J= 3.6 Hz, 1H), 7.40 (s, 1H), 7.08 (d, J= 3.6 Hz, 1H), 7.04 (s, 1H), 4.99 (tt, J= 7.6, 3.5 Hz, 1H), 4.49 (t, = 5.4 Hz, 1H), 3.58 (s, 2H), 3.50 (q, J= 5.9 Hz, 2H), 3.42 (s, 2H), 3.10 - 2.95 (m, 2H), 2.81 (p, J= 7.4 Hz, 1H), 2.73 - 2.55 (m, 2H), 2.43 (t, J = 6.1 Hz, 2H), 2.40 - 2.30 (m, 2H), 2.24 - 2.08 (m, 5H), 2.09 - 1.91 (m, 2H), 1.78 - 1.63 (m, 2H). "F R (376 MHz, d6-DMSO) 8 -67.28 (s). LCMS (M+H)+: 610.2.
Example 18. {trans-3-(4-{[4-{[(cis-3-hydroxycyclobutyl)amino]methyl}-6- (trifluoromethyl)pyridin-2-yl]oxy}piperidin-l-yl)-l-[4-(7H-pyrrolo[2,3- d]pyrimidin-4-yl)-lH-pyrazol-l-yl]cyclobufyl}acetonitrile 3.6 x trifluoroacetate salt
{trans-3-(4-{[4-(Hydi'oxymethyl)-6-(trifluororaethyl)pyridin-2- yl]oxy}piperidin-l-yl)-] -[4-(7-{[2-(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3- d]pyrimidin-4-yl)-lH-pyrazol-l -y[]cyclobutyl}acetonitrile (71 mg, 0.010 mmol, Peak 1 from Intermediate Example A2, Step F) was dissolved in methylene chloride (2 mL) and Ν,Ν-diisopropylethylamine (54 (iL, 0.31 mmol) followed by methanesulfonic anhydride (45 mg, 0.26 mmol, Aldrich) were added. The mixture was stirred for 30 minutes and the solvent was removed in vacuo. The residue was redissolved in a mixture of tetrahydrofuran (1.5 mL) and methanol (0.50 mL). Cis-3- aminocyclobutanol hydrochloride (0.064 mL, 0.52 mmol, Synthonix) and N,N- diisopropylethylamine (0.11 mL, 0.62 mmol) were added. The mixture was heated to 40 °C overnight, then at 50 °C for 3 hours. The mixture was concentrated. The residue was dissolved in 2: 1 TFA:DCM and was stirred for 1.5 hours. After concentrating again, the residue was dissolved in methanol (4 mL) and ethylenediamine was added (0.7 mL). When the deprotection was complete as determined by LCMS, the product was purified via two successive preparative HPLC-MS runs (first C 18 eluting with a gradient of MeCN/¾0 containing 0.1% TFA; then after evaporation, C18 eluting with a gradient of MeCN ¾0 containing 0.1 % NH4OH). The fractions containing product were evaporated to rid excess ammonia. The residue was redissolved in MeCN and H20 containing 0.1% TFA, frozen and lyophilized to afford the product as the 3.6 x TFA salt (45 mg, 42%). Ή NMR (500 MHz, CD3OD) δ 8.94 (s, 1H), 8.81
(s, 1H), 8.51 (s, 1H), 7.70 (d, J= 3.7 Hz, 1H), 7.54 (s, 1H), 7.19 (s, 1H), 7.17 (d, J = 3.7 Hz, 1H), 5.42 (br m, 1H), 4.22 (s, 2H), 4.10 (p, J= 7.2 Hz, 1H), 4.06 - 3.94 (m, 1H), 3.83 - 3.09 (m, 9H), 3.1 1 - 2.94 (m, 2H), 2.73 (dddd, = 12.0, 9.2, 6.2, 2.6 Hz, 2H), 2.57 - 2.13 (m, 4H), 2.13 - 2.04 (m, 2H). I 9F NMR (282 MHz, CD3OD) δ -70.42 (s, 3F), -77.54 (s, 10.8F). LCMS (M+H)+: 622.0
Intermediate Example A4. {cis-3-(4-{[4-(2-hydroxyethyl)-6- (trifluoromethyl)pyridin-2-yl]oxy}piperidin-l-yl)-l-[4-(7-{[2- (trimethylsiIyl)ethoxy]methyl}-7H-pyrrolo[2,3-d]pyrimidin-4-yI)-lH-pyrazol-l- yl]cyclobutyl}acetonitrile and {trans-3-(4-{[4-(2-hydroxyethyl)-6- (trifluorom ethy l)py ridin-2-y 1] oxy } piperidin- 1 -y - [4-(7- { [2- (trimethylsilyI)ethoxy]methyl}-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazoI-l- y 1] cy elobuty 1} acetonitrile
Step 1. tert-biilyl 4-{[6-(trifluoromethyl)pyridin-2-yl]oxy}piperidme-l-carboxyl te To a mixture of sodium hydride (0.88 g, 60% in mineral oil, 22 mmol) in tetrahydrofuran (50. mL) at 0 °C was added tert-butyl 4-hydroxypiperidine-l - carboxylate (4.4 g, 22 mmol, Aldrich), The mixture was stirred at room temperature for one hour. A solution of 2-chloro-6-(trifluoromethyl)pyridine (2.0 g, 1 1 mmol, Oakwood) in tetrahydrofuran (10 mL) was added. The mixture was stirred at room
temperature for 2 days. The mixture was quenched by the addition of water, and the product was extracted with EtOAc. The extract was washed with water, followed by brine, was dried over sodium sulfate, filtered and concentrated. Flash chromatography on a 120 g silica gel cartridge, eluting with a gradient from 0-15% EtOAc in hexanes afforded product as a colorless oil (3.8 g, 100%). Ή MR (400 MHz, CDC13) δ 7.75 - 7.64 (m, 1H), 7.23 (d, J= 7.3 Hz, 1H), 6.88 (d, J= 8.4 Hz, 1H), 5.27 (tt, J= 7.7, 3.7 Hz, 1H), 3.83 - 3.66 (m, 2H), 3.31 (ddd, J= 13.4, 8.5, 3.7 Hz, 2H), 1.99 (ddt, J = 13.3, 6.9, 3.7 Hz, 2H), 1.73 (dtd, J= 12.3, 8.1, 3.9 Hz, 2H), 1.47 (s, 9H), , 9F NMR (376 MHz, CDCb) δ -68.94 (s). LCMS (M-tBu+H)+: 291.0.
Step 2. 2-[2-(piperidin-4-yhxy)-6-(Mfluoro ethyl)pyridin-4-yl]ethanol
2.5 M n-Butyllithium in hexanes (1.2 mL, 2.9 mmol) was added dropwise to a solution of tert-butyl 4-{[6-(trifluoromethyl)pyridin-2-yl]oxy}piperidine-l- carboxylate (0.50 g, 1.4 mmol, from Step 1) in tetrahydrofuran (8.0 mL) at -78 °C. The reaction was stirred at this temperature for 1.5 hours, and 1,3,2-dioxathiolane 2,2- dioxide (0.36 g, 2.9 mmol, Aldrich) in Tetrahydrofuran (2.0 mL) was added. The mixture was allowed to warm to room temperature and stir overnight. 12 N Hydrogen chloride in water (0.72 mL, 8.7 mmol) was added to the mixture. The mixture was stirred at room temperature for 4 hours. The mixture was then treated with saturated sodium bicarbonate to pH between 7 and 8, and brine was added. The mixture was then extracted with DCM four times. The combined extracts were dried over sodium sulfate, filtered and concentrated. Preparative HPLC-MS (CI 8 eluting with a gradient of MeCN/¾0 containing 0.15% NH40H) was used to purify the product. It was the second peak to elute having the desired mass.
Ή NMR (300 MHz, CD3OD) δ 7.24 (s, 1H), 6.86 (s, 1 H), 5.16 (tt, J= 8.4, 3.9 Hz, 1H), 3.80 (t, J= 6.3 Hz, 2H), 3.06 (dt, J= 12.6, 4.6 Hz, 2H), 2.85 (t, = 6.3 Hz, 2H), 2.73 (ddd, J= 12.7, 9.5, 3.2 Hz, 2H), 2.13 - 1.93 (m, 2H), 1.68 (dtd, J= 13.0, 9.1 , 3.9 Hz, 2H). I 9F NMR (282 MHz, CD3OD) 8 -70.29 (s). LCMS (M+H)+: 291.1 Step 3. fcis-3-(4-{[4-(2-hydroxyethyl)-6-(trifluoromethyl)pyridiri-2-yl]oxy}piperidin- l-yl)-l-[4-(7-{[2-(trimethylsilyl)ethoxy] et yl}-7H-pyrrolo[2,3-d]pyrimidiri-4-yl)- lH-pyrazol-l-yl]cyclobutyl}acetomtrile and {trans-3-(4-{[4-(2-hydroxyethyl)-6-
(trifliioromethyl)pyridin-2-yl]oxy}piperidm-l-yl)-l-[4-(7-{[2-
(trimethylsilyl)e^oxy]methyl}-7H-pyrrolo[2,3- ]pyrimidin-4-yl)-lH-pyrazol-l- yljcyclobiityljacetomtrile
Sodium cyanoborohydride (8.2 mg, 0.13 mmol) and zinc dichloride (8.9 mg, 0.065 mmol) were combined in methanol (0.48 niL) and stirred for 2 hours. 2-[2- (piperidin-4-yloxy)-6-(trifluoromethyl)pyridin-4-yl]ethanol (27 mg, 0.093 mmol, from Step 2) and {3-oxo-l-[4-(7-{[2-(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3- d]pyrimidin-4-yl)-lH-pyrazol-l-yl]cyclobutyl}acetonitrile (47 mg, 0.11 mmol, from Intermediate Example Al, Step 7) were mixed in methanol (1 .3 mL) and stirred briefly to dissolve, then the prestirred solution of and zinc dichloride in methanol was added. The reaction was stirred for 2.5 hours, then the products were purified via preparative HPLC-MS (C18 eluting with a gradient of MeCN/H20 containing 0.15% NH4OH) (waters 2525, XBridge C18, 30x100mm, 5μηι particle size, gradient 45.1- 63.1% ACN from 1.0 min to 13.0 min, peak 1 : 9.6-10.3 min, peak 2: 10.5- 1 1 .2 min). Peak 1 was the cis isomer, peak 2 was the trans isomer. Peak 1, Cis-: 'H NM (400 MHz, CD3OD) δ 8.73 (s, 1H), 8.69 (s, 1H), 8.37 (s, 1H), 7.63 (d, J = 3.7 Hz, 1H), 7.24 (s, 1H), 7.07 (d, /= 3.7 Hz, 1H), 6.86 (s, 1H), 5.68 (s, 2H), 5.17 - 5.07 (m, 1H), 3.80 (t, 7= 6.3 Hz, 2H), 3.64 - 3.53 (m, 2H), 3.35 (s, 2H), 2.99 (p, J= 7.9 Hz, 1H), 2.88 - 2.59 (m, 8H), 2.43 - 2.25 (m, 2H), 2.15 - 2.03 (m, 2H), 1.88 - 1.73 (m, 2H), 0.97 - 0.79 (m, 2H), -0.09 (s, 9H). , 9F NMR (376 MHz, CD3OD) δ -70.27 (s). LCMS (M+H)+; 697.2. Peak 2, Trans: Ή NMR (400 MHz, CD3OD) δ 8.75 (s, 1H), 8.73 (s, 1H), 8.40 (s, 1H), 7.62 (d, = 3.6 Hz, 1H), 7.23 (s, 1H), 7.05 (d, J= 3.6 Hz, 1H), 6.85 (s, 1H), 5.68 (s, 2H), 5.12 (br m, 1H), 3.79 (t, J= 6.3 Hz, 2H), 3.58 (t, J= 8.0 Hz, 2H), 3.34 (s, 2H), 3.17 - 3.06 (m, 2H), 2.95 (p, J= 7.4 Hz, 1H), 2.84 (t, J= 6.2 Hz, 2H), 2.79 - 2.67 (m, 2H), 2.53 - 2.37 (m, 2H), 2.38 - 2.22 (m, 2H), 2.17 - 2.04 (m, 2H), 1.91 - 1.74 (m, 2H), 0.88 (t, J= 8.0 Hz, 2H), -0.09 (s, 9H). 19F NMR (376 MHz, CD3OD) δ -70.26 (s). LCMS (M+H)+: 697.2.
Example 20. {trans-3-(4-{[4-(2-hydroxyethyl)-6-(trifluoromethyI)pyridin-2- yl]oxy}piperidin-l-yl)-l-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l- yl]cyclobutyl}acetonitrile
{trans-3-(4-{[4-(2-hydroxyethyl)-6-(trifluoromethyl)pyridin-2- yl]oxy}piperidin-l-yI)-l-[4-(7-{[2-(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3- d]pyrimidin-4-yl)-lH-pyrazol-l-yl]cyclobutyl}acetonitrile (9.0 mg, 0.013 mmol, Peak 2 from Intermediate Example A4, Step 3) was deprotected and purified by stirred in a mixture of methylene chloride (0.50 mL) and trifluoroacetic acid (0.50 mL) for one hour. The solvents were removed in vacuo and the residue was stirred in methanol (0.1 mL) containing ethylenediamine (0.1 mL). Purification via preparative HPLC- MS (C 18 eluting with a gradient of MeCN H20 containing 0. 15% NH4OH) afforded product as the free base (5.8 mg, 79%). Ή NMR (300 MHz, d6-DMSO) δ 12.12 (s, 1H), 8.83 (s, 1H), 8.69 (s, 1H), 8.42 (s, 1H), 7.60 (d, J= 3.6 Hz, 1H), 7.34 (s, 1H), 7.08 (d, = 3.6 Hz, 1 H), 6.95 (s, 1H), 4.99 (tt, J= 8.2, 4.1 Hz, 1H), 4.73 (t, 7= 4.9 Hz, 1H), 3.66 (q, 7= 5.9 Hz, 2H), 3.42 (s, 2H), 3.1 1 - 2.95 (m, 2H), 2.90 - 2.71 (m, 3H), 2.71 - 2.56 (m, 2H), 2.44 - 2.30 (m, 2H), 2.15 (t, 7 = 9.2 Hz, 2H), 2.09 - 1.82 (m, 2H), 1.83 - 1.58 (m, 2H). I 9F NMR (282 MHz, d6-DMSO) δ -67.26 (s). LCMS (M+H)+: 567.2.
Example 21. {trans-3-(4-{[4-{[(2-hydroxyethyl)amino]methyl}-6-
(trifluoromethyl)pyridin-2-yl]oxy}piperidin-l-yl)-l-[4-(lH-pyrrolo[2,3- b]pyridin-4-yl)-lH-pyrazol-l-yl]cyclobu<yl}acetonitrile
Step I. terl-bulyl 2-chloro-6-(trifl oromethyl)isonicolinate
2-Chloro-6-(trifluoromethyl)pyridine (20.0 g, 0.11 mol, Oakwood) was dissolved in tetrahydrofuran (397 mL) and then 1 ,0 M lithium chloride - chloro(2,2,6,6-tetramethylpiperidin-l-yl)magnesium (1 : 1) in THF (132.2 mL, 132.2 mmol, Aldrich) was added. The reaction was stirred at ambient temperature for 1 hour and was then cooled to -78 °C, and then a solution of di-tert-Butyldicarbonate (48.1 g, 0.22 mol, Aldrich) in tetrahydrofuran (100 mL) was added. The reaction was stirred at -78 °C for 1 hour and then allowed to warm to room temperature overnight. The reaction was quenched with water, then ammonium chloride was added. The layers were separated and the aqueous was extracted with two portions of ethyl acetate, The combined organic extracts were washed with water, then sat'd NaCl solution, dried over NajS04, filtered and concentrated. The crude product, which was a mixture of two regioisomers, was purified by flash chromatography, eluting with 2% EtOAc in hexanes, in 3 batches, each on a 330 g silica gel cartridge. The first product to elute was the desired regioisomer, which also contained some unreacted starting material, The product rystallized on standing and the oil, which contained some unreacted starting material, was decanted away, leaving a more pure crystalline product (9.58 g,
30%). 'H NMR (300 MHz, CDC13) δ 8.07 (d, J= 1.1 Hz, 1H), 8.02 - 7.99 (m, 1H), 1.62 (s, 9H). ,9F NMR (282 MHz, CDC13) δ -68.43 (s). LCMS (M-tBu+H)+:
225.9/227.9. Step 2. 2-([l-(teii-butoxycarbonyl)piperidm-4-y!]oxy}-6-(trifliwromethyl)isomcotmic acid
To sodium hydride (60% in mineral oil, 0.36 g, 8.9 mmol) in tetrahydrofuran (15 mL) at 0 °C was added tert-butyl 4-hydroxypiperidine-l-carboxylate (1.8 g, 8.9 mmol, Aldrich). The reaction mixture was allowed to reach room temperature and stir for 1 hour. A solution of tert-butyl 2-chloro-6-(trifluoromethyl)isonicotinate (1.0 g, 3.6 mmol, from Step 1) in tetrahydrofuran (4.9 mL, 60. mmol) was introduced and the mixture was stirred at room temperature over five nights. The mixture was quenched by the careful addition of IN NaOH ( 15 mL) and allowed to stir overnight. The reaction was diluted with additional water and the aqueous layer was washed with Et20. The aqueous layer was then acidified by the addition of c.HCI to achieve pH~3. The product was extracted with three portions of ethyl acetate. The combined EtOAc extracts were dried over sodium sulfate, filtered and concentrated. The product was used without farther purification. LCMS (M-tBu+H)+; 335.1. Step 3. tert-butyl 4-{[4-(hydroxymethyl)-6-(trifluoromethyl)pyridin-2- yl]oxy}piperidine-l-carboxylate
To a solution of 2-{[l-(tert-butoxycarbonyl)piperidin-4-yl]oxy)-6- (trifluoromethyl)isonicotinic acid (1.4 g, 3.6 mmol, prepared by the method of Step 2) in methanol (70. mL) at 0 °C was added 2.0 M trimethylsilyldiazomethane in ether (18 mL, 36 mmol) dropwise until TLC indicated complete reaction. Excess reagent was discharged by dropwise addition of acetic acid to the mixture cooled in an ice bath. Solvent was removed by rotary evaporation. The residue was dissolved in ethanol (28 mL) , cooled to 0 °C, and sodium tetrahydroborate (0.26 g, 7.0 mmol) was added. The cooling was discontinued and the reaction was allowed to stir at room temperature for 30 minutes. It was re-cooled in an ice bath and an additional portion of Sodium tetrahydroborate (0.27 g, 7.2 mmol) was added. The reaction mixure was allowed to reach room temperature and stir until the reaction was complete as
determined by analytical LCMS and TLC. The reaction was quenched by the addition of saturated ammonium chloride, diluted with water, and extracted with EtOAc (2x). The combined organic extracts were washed with brine, dried over sodium sulfate, filtered and concentrated. Flash chromatography, using a 120 g silica gel cartridge and 5 eluting with a gradient from 0-30% EtOAc in hexanes afforded product as a colorless oil (0.90 g, 67%). 'H NMR (400 MHz, CDC13) δ 7.22 (s, 1H), 6.90 (s, 1H), 5.27 (tt, J = 7.7, 3.7 Hz, 1H), 4.74 (d, = 2.5 Hz, 2H), 3.81 - 3.63 (m, 2H), 3.31 (ddd, J= 13.4, 8.4, 3.7 Hz, 2H), 1.98 (ddt, J= 13.5, 7.0, 3.8 Hz, 2H), 1.72 (dtd, J= 12.5, 8.2, 4.0 Hz, 2H), 1.47 (s, 9H). I9F NMR (376 MHz, CDC13) δ -69.21 (s). LCMS (M-tBu+H)+: 10 321.1.
Step 4. [2-(piperidin-4-yloxy)-6-(trifluoromethyl)pyridin-4-yl]methanol
4.0 M Hydrogen chloride in dioxane (12 mL, 47 mmol) was added to a solution of tert-butyl 4-{[4-(hydroxymethyl)-6-(trifluoromethyl)pyridin-2-
15 yl]oxy}piperidine-l -carboxylate (0.89 g, 2.4 mmol, from Step 3) in 1,4-dioxane (12 mL) and the reaction was stirred for 3 hours. The reaction was made basic by the addition of IN NaOH to achieve a pH between 12 and 13. The product was extracted with DCM (6x) and the combined extracts were dried over sodium sulfate, filtered and concentrated to afford product as a light yellow solid (0.50 g, 75%). Ή NMR
20 (300 MHz, CDC13) δ 7.22 (s, 1H), 6.91 (s, 1H), 5.23 (tt, J= 7.9, 3.8 Hz, 1H), 4.74 (s, 2H), 3.26 - 3.06 (m, 2H), 2.88 (ddd, J= 12.3, 8.6, 3.4 Hz, 2H), 2.1 1 (ddt, J= 12.9, 6.7, 3.2 Hz, 2H), 1.92 - 1.56 (m, 2H). 19F NMR (282 MHz, CDCI3) 5 -68.89 (s). LCMS (M+H)+: 277.0. 5 Step 5. {cis-3-(4-{[4-(hydroxymethyl)-6-(triflitoro ethyl)pyridiri-2-yl]oxy}piperidir)- l-yl)-l-[4-(l-{[2-(trimethylsilyl)ethoxy]methyl}-lH-pyrrolo[2, 3-b]pyridin-4-yl)-lH- pyrazol-l-yl]cyclobutyl}acetomtrile and {tram-3-(4-{[4-(hydroxymethyl)-6- (triflaoromethyl)pyridin-2-yl]oxy}piperidin-i-yl)-I-[4-(l-{[2- (trimethylsilyl)ethoxy]methyl}-lH-pyrrolo[2,3-b]pyridin-4-yl)-lH-pyrazol-l-0 yl]cyclobutyl}acetonitri
Sodium cyanoborohydride (83 mg, 1.3 mmol) and zinc dichloride (90. rag, 0.66 mmol) were pre-combined in methanol (5.0 mL) and stirred for one hour. {3-
oxo-l-[4-(l-{[2-(trimethylsilyl)ethoxy]methyl}-lH-pyrrolo[2,3-b]pyridin-4-yl)-lH- pyrazol-l-yl]cyclobutyl}acetonitrile (0.40 g, 0.95 mmol, Intermediate Example A3, Step C) and [2-(piperidin-4-yloxy)-6-(trifluoiOmethyl)pyridin-4-yl]methanol (0.26 g, 0.95 mmol, from Step 4) were stirred briefly in methanol (13 mL) to dissolve, then the pre-stirred mixture of Sodium cyanoborohydride and zinc dichloride in methanol was added and the reaction was stirred for 16 hours. The mixture was diluted with DCM and washed with saturated sodium bicarbonate solution. The aqueous layer was extracted with a further two portions of DCM, and the combined extracts were dried over sodium sulfate, filtered and concentrated. Flash chromatography on a 120 g silica gel cartridge, eluting with a slow gradient from 0-100% EtOAc in hexanes afforded separation of the two isomers: Peak 1, cis- isomer: 0.25 g, 39%; Peak 2, trans- isomer: 0.2g, 30%).
Step 6. {trans-3-(4-{[4-{[(2-hydroxyethyl)amino]methyl}-6-(trifluoromethyl)pyridin- 2-yl]oxy}piperidin-l-yl)-l-[4-(lH-pyrrolo[2 -b]pyridin-4-yl)-lH-pyrazol-l- yl]cyclobuty!}acetonitrile
Methanesulphonic anhydride (43 mg, 0.25 mmol, Aldrich) was added to a solution of {trans-3-(4-{[4-(hydroxymethyl)-6-(trifluoromethyl)pyridin-2- yl]oxy}piperidin-l -yl)-l -[4-(l-{[2-(trimethylsilyl)ethoxy]methyl}-lH-pyrrolo[2,3- b]pyridin-4-yl)-l H-pyrazol-l-yl]cyclobutyl}acetonitrile (85 mg, 0.10 mmol, Peak 2 from Step 5) and N,N-diisopropylethylamine (52 uL, 0.30 mmol) in Methylene chloride (2.0 mL) . The mixture was stirred for 30 minutes. Solvent was removed in vacuo and the residue was re-dissolved in a mixture of Tetrahydrofuran (1.0 mL) and methanol (1.0 mL). Ethanolamine (60.2 \\L, 0.997 mmol, Aldrich) was added and the mixture was stirred for 5 hours and concentrated. The crude product was deprotected by stirring in a 2: 1 mixture of TFA/DCM for 1 ,5 hours, followed by rotovapping and stirring of the residue in methanol (5 mL) containing ethylenediamine (0.4 mL) until deprotection was determined to be complete by LCMS analysis. Purification via preparative HPLC-MS (C18 eluting with a gradient of MeCN H20 containing 0.15% NH4OH) afforded the desired compound as the free base (32 mg , 54%). Ή NMR (400 MHz, d6-DMSO) δ 1 1.69 (s, 1H), 8.71 (s, lH), 8.27 (s, 1H), 8.19 (d, J= 5.0 Hz, 1H), 7.57 - 7.49 (m, 1H), 7.42 (s, 1H), 7.33 (d, J= 5.0 Hz, 1H), 7.04 (s, 1 H), 6.93 -
6.80 (m, 1H), 5.29 - 4.73 (m, 1H), 4.50 (t, J= 5.4 Hz, 1H), 3.76 (s, 2H), 3.45 (q, =
5.7 Hz, 2H), 3.39 (s, 2H), 3.31 (s, lH), 3.05 - 2.92 (m, 2H), 2.81 (p, J= 7.0 Hz, 1H), 2.73 - 2.56 (m, 2H), 2.56 - 2.50 (m, 2H), 2.40 - 2.29 (ra, 2H), 2.27 - 2.07 (m, 2H),
2.08 - 1.93 (m, 2H), 1.78 - 1.60 (m, 2H).
5 "F NMR (376 MHz, d6-DMSO) δ -67.28 (s). LCMS (M+H)+: 595.3.
Example 22. {trans-3-(4-{[4-(lH-imidazol-l-ylmethyl)-6-
(trifluoromethyl)pyridin-2-yl]oxy}piperidin-l-yl)-l-[4-(7H-pyrrolo[2,3- d]pyrimidin-4-yl)-lH-pyrazoI-l-y cetonitriIe
N,N-Diisopropylethylamine (1 1 pL, 0.062 mmol) and methanesulphonic anhydride (7.5 mg, 0.043 mmol) were added to a solution of {trans-3-(4-{[4- (hydroxymethyl)-6-(trifiiioi methyl)pyridin-2-yl]oxy}piperidin-l -yl)-l -[4-(7-{[2- (trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-
15 yl]cyclobutyl}acetonitrile (21 mg, 0.031 mmol, Peak 1 from Intermediate Example A2, Step F), in methylene chloride (0.42 mL) . The reaction was stirred for 30 minutes and the solvent was removed in vacuo. The residue was dissolved in N,N- dimethylformamide (0.40 mL, 5.2 mmol) and lH-imidazole (10. mg, 0.15 mmol, Aldrich) and potassium carbonate (13 mg, 0.092 mmol) were added. After stirring for
20 30 minutes at room temperature, the reaction mixture was heated to 40 °C for 2 hours.
The mixture was then diluted with water and extracted with EtOAc. The organic layer was washed twice with water, once with brine, dried over sodium sulfate and concentrated. The crude product was deprotected by stirring in a 1 : 1 mixture of
TFA DCM for one hour, removing solvents, then stirring in methanol (1 mL), containing ethylenediamine (0.1 mL) until complete as determined by analytical LCMS. Purification via preparative HPLC-MS (C18 eluting with a gradient of MeCN/H20 containing 0.15% N¾OH) afforded the desired compound as the free base (6.4 mg, 34%). 'H NMR (400 MHz, d6-DMSO) δ 12.12 (s, 1H), 8.82 (s, 1H), 8.69 (s, 1H), 8.42 (s, 1H), 7.80 (s, 1 H), 7.60 (d, J= 3.6 Hz, 1H), 7.30 (s, 1H), 7.27 (s, 1H), 7.08 (d, J= 3.6 Hz, 1H), 6.96 (s, 1H), 6.72 (s, 1H), 5.31 (s, 2H), 4.98 (tt, J= 7.6, 3.4 Hz, 1H), 3.41 (s, 2H), 3.07 - 2.91 (m, 2H), 2.80 (p, J= 7.1 Hz, 1H), 2.71 - 2.54 (m, 2H), 2.39 - 2.28 (m, 2H), 2.26 - 2.06 (m, 2H), 2.06 - 1.89 (m, 2H), 1 .76 - 1.57 (m, 2H). "F NMR (376 MHz, d6-DMSO) δ -67.51 (s). LCMS (M+H)+: 603.2.
Example 23. [trans-l-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]-3-
(4-{[4-(lH-l,2,4-triazol-l-ylmethyl)-6-(trifluoromethyl)pyridin-2- yI]oxy}piperidin-l-yl)cycIobutyl]a
The procedure of Example 22 was followed, using lH-l,2,4-triazole (1 1 mg,
0.15 mmol, Aldrich) instead of IH-imidazole, with heating first to 40 °C for 2 hours, then to 50 °C overnight in the displacement step. Purification via preparative HPLC- MS (CI 8 eluting with a gradient of MeCN/H20 containing 0.15% NH4OH) afforded separation of the major (peak 2, compound of this Example) and minor isomer (peak
1, see Example 24). Yield: (6.2 mg, 33%). Ή NMR (400 MHz, CD3OD) δ 8.73 (s, 1 H), 8.67 (s, 1H), 8.63 (s, 1H), 8.40 (s, 1H), 8.06 (s, 1H), 7.51 (d, J= 3.6 Hz, 1H),
7.21 (s, IH), 6.99 (d, J= 3.7 Hz, IH), 6.76 (s, IH), 5.52 (s, 2H), 5.14 (tt, J= 7.8, 4.0 Hz, IH), 3.31 (s, 2H), 3.16 - 3.05 (m, 2H), 2.95 (p, J= 7.6 Hz, IH), 2.82 - 2.63 (m, 2H), 2.55 - 2.42 (m, 2H), 2.40 -2.21 (m, 2H), 2.17 - 2.02 (m, 2H), 1.92 - 1.76 (m, 2H). I9F NMR (376 MHz, CD3OD) δ -70.50 (s). LCMS (M+H)+: 604.2.
Example 24. [trans-l-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]-3-
(4-{[4-(4H-l,2,4-triazoI-4-ylmethyl)-6-(trifluororaetliyI)pyridin-2- yl]oxy}piperidin-l-yl)cyclobutyl]a
Isolated as the minor product (Peak 1) from the procedure of Example 23 (2.4 mg, 13%). Ή NMR (400 MHz, CD3OD) δ 8.73 (s, IH), 8.67 (s, IH), 8.65 (s, 2H), 8.40 (s, IH), 7.51 (d, J= 3.6 Hz, IH), 7.24 (s, IH), 6.99 (d, J= 3.6 Hz, IH), 6.75 (s, IH), 5.43 (s, 2H), 5.20 - 5,04 (m, IH), 3.31 (s, 2H), 3.17 - 3.02 (m, 2H), 2.95 (p, J = 7.6 Hz, IH), 2.82 - 2.63 (m, 2H), 2.55 - 2.42 (m, 2H), 2.41 -2.22 (m, 2H), 2.20 - 2.01 (m, 2H), 1.95 - 1.73 (ra, 2H). I9F NMR (376 MHz, CD3OD) S -70. 1 (s). LCMS (M+H)+: 604.2.
Example 25. {trans-3-(4-{[4-(lH-pyrazol-l-ylmethyl)-6-(trifluoromethyl)pyridin-
2-yl]oxy}piperidin-l-yl)-l-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l- yl]cyclobutyl}acetonitrile
Using lH-pyrazole (10. mg, 0.15 mmol, Aldrich) as the heterocyole in the displacement step, the procedure of Example 24 was followed to afford the product as the free base (6.6 mg, 36%). Ή NMR (400 MHz, d6-DMSO) δ 12.13 (s, 1H), 8.82 (s, 1H), 8.69 (s, 1H), 8.42 (s, 1H), 7.91 (d, J = 2.2 Hz, 1H), 7.60 (d, J= 3.6 Hz, 1H), 7.54 (d, J= 1.4 Hz, 1H), 7.20 (s, 1H), 7.07 (d, J= 3.6 Hz, 1H), 6.65 (s, 1H), 6.34 (t, J= 2.1 Hz, 1H), 5.46 (s, 2H), 4.98 (tt, J= 8.9, 4.1 Hz, 1H), 3.41 (s, 2H), 3.07 - 2.94 (m, 2H), 2.80 (p, J= 7.5 Hz, 1H), 2.69 - 2.54 (m, 2H), 2.41 - 2.29 (m, 2H), 2.22 - 2.04 (m, 2H), 2.05 - 1.87 (m, 2H), 1.76 - 1.54 (m, 2H). , 9F NMR (376 MHz, d6-DMSO) S - 67.55 (s). LCMS (M+H)+: 603.3.
Example 26. {trans-3-(4-{[4-[(3,3-dimethylazetidin-l-yl)carbonyl]-6-
(trifluoromethyl)pyridin-2-yl]oxy}piperidin-l-yl)-l-[4-(7H-pyrrolo[2,3- d]pyrimidin-4-yl)-lH-pyrazol-l-yl]cyclobutyl}acetonitrile
Step 1. tert-bitty! 4-{[4-[(3,3-dimelhylazetidin-l-yl)carbonyl]-6- (trifluoromethyl)pyridin-2-yl]oxy}piperidine-l-carboxylate
To a solution of 2-{[l-(tert-butoxycarbonyl)piperidin-4-yl]oxy}-6- (trifluororaethyl)isonicotinic acid (0.100 g, 0.256 mmol, from Example 21, Step 2)
and 3,3-dimethylazetidine hydrochloride (0.037 g, 0.30 tnmol, Princeton Bio) and
triethylamine (90 μί, 0.6 mmol) in methylene chloride (1 mL) was added
benzotriazol-l-yloxytris(dimethylamino)phosphonium hexafluorophosphate (0, 12 g,
0.28 mmol, Advanced Chem Tech) . The reaction was stirred overnight. Solvent was
removed in vacuo and the product was purified by flash chromatography, eluting with
a gradient from 0-3% MeOH in DCM. LCMS (M+Na)+: 480.1.
Step 2. 4-[(3,3-dimethylazetidin-l-yl)carbonyl]-2-(piperidin-4-yloxy)-6- (triflitoromethyljpyridine
tert-Butyl 4-{[4-[(3,3-dimethylazetidin- l-yl)carbonyI]-6- (trifluoromethyl)pyridin-2-yl]oxy}piperidine-l-carboxylate (0.029 g, 0.063 mmol,
from Step 2) was dissolved in 1,4-dioxane (1 mL) and 4.0 M hydrogen chloride in
dioxane (1 mL, 4 mmol) was added. After stirring for 4 hours, the reaction mixture
was poured into saturated sodium bicarbonate and the product was extracted with
three portions of ethyl acetate. The combined extracts were dried over sodium sulfate,
filtered and concentrated to afford the deprotected piperidine. Theoretical yield was
assumed and the product used without further purification in Step 4. LCMS (M+H)+:
358.2.
Step 3. {trans-3-(4-{[4-[(3,3-dimethylazetidin-l-yl)carbonyl]-6- (trifluoromethyl)pyridm-2-ylJoxy}p^eridm-l-y!)-]-[4-(7H^yrrolo[2,3-d]pyiimidiri- 4-yl)-lH-pyrazol - 1 -yljcyclob tyljacetonitrile
Sodium cyanoborohydride (0.013 g, 0.21 mmol) and zinc dichloride (0.0142
g, 0.104 mmol) were stirred in methanol (0.400 mL, 9.89 mmol) for 2 hours. The
piperidine from Step 3 and {3-oxo-l-[4-(7-{[2-(trimethylsilyl)ethoxy]methyl}-7H- pyrrolo[2,3-d]pyrimrdin-4-yl)- lH-pyrazol-l-yl]cyclobutyl}acetonitrile (0.027 g, 0.063
mmol, from Intermediate Example Al, Step 7) were stirred in methanol (0.5 mL, 10
mmol) for a few minutes to dissolve. One-third of the NaCNBUj/ZnCk solution was
added. The reaction was stirred overnight and in the morning, an additional one-third of the reducing mixture was added and the reaction was continued for 5 hours. The resulting cis- and trans- isomers at the SEM protected stage were well separated under the following conditions: Waters mass directed fractionation system as described in (K. Blom, B. Glass, R. Sparks, A. Combs, J.Combi. Chem., 6, 874-883 (2004); Waters XBridge C18 column, 5 urn particle size, 30x100 mm,
Aq(0.1 %NH4OH)/AcN; flow rate 60 mL/min, 49, 1-67.1 B in 12 min. Retention time for peak 1 (cis-): 10.85 min, for peak 2 (trans-): 11.90 min. Each isomer was separately subjected to rotary evaportation, then stirred with 1 : 1 TFA:DCM for 1 hour, evaporated, and stirred with 0.2 mL ethylenediamine in methanol until deprotection was complete. The final products were purified via preparative HPLC- MS (C 18, eluting with a gradient of MeCN/¾0 containing 0.15% NH4OH) to afford product as the free base. Ή NMR (300 MHz, CDC13) δ 9.29 (s, 1H), 8.82 (s, 1H), 8.47 (s, 1H), 8.32 (s, 1H), 7.41 (d, J= 1.0 Hz, 1H), 7.36 (dd, J= 3.6, 2.2 Hz, 1H), 7.01 (s, 1H), 6.80 (dd, J= 3.6, 1.7 Hz, 1H), 5.30 - 4.96 (m, 1H), 3.95 (s, 2H), 3.87 (s, 2H), 3.20 (s, 2H), 3.09 - 2.97 (m, 2H), 2.97 - 2.83 (m, 1H), 2.72 - 2.53 (m, 2H), 2.52 - 2.41 (m, 2H), 2.30 - 2.13 (m, 2H), 2.13 - 1.97 (m, 2H), 1.95 - 1.74 (m, 2H), 1.30 (s, 6H). , 9F NMR (282 MHz, CDC13) δ -68.98 (s). LCMS (M+H)+: 634.3.
Example 27. {trans-3-(4-{[6-(hydroxymethyl)-2-(trifluoromethyl)pyrimidin-4- yl]aniino}piperidin-l-yl)-l-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l- yI]cyclobutyl}acetonitrile
T U 2013/041601
Step 1. tert-butyl 4-{[6-chloro-2-(trifluoromethyl)pyrimidm-4-yl]amino}piperidine-l- carboxylate
tert-But l 4-aminopiperidine-l-carboxylate (1.4 g, 7.1 mraol, Aldrich) was
dissolved in methylene chloride (10. mL) and to this solution was added N,N- diisopropylethylamine (2.5 mL, 14 mmol) and 4,6-dichloro-2- (trifluoromethyl)pyrimidine (1.7 g, 7.8 mmol, Synchem). The reaction was stirred
overnight. The mixture was diluted with water and the product was extracted with
EtOAc. The organic layer was washed twice with water, once with brine, dried over
sodium sulfate, filtered and concentrated to afford product which was used without
further purification in Step 2. LCMS ( +H)+: 381.1.
Step 2. tert-butyl 4-{ [6-[(Z)-2-ethoxyvinyl] -2-(trifliioromethyl)pyrimidin-4- yl] amino}piperidine-l -carboxylate
A mixture of tert-butyl 4-{[6-chloro-2-(trifluoromethyl)pyrimidin-4- yl]amino}piperidine-l-carboxylate (1.0 g, 2.6 mmol, from Step 1), tributyl[(Z)-2- ethoxyvinyl]stannane (0.96 mL, 2.9 mmol, Synthonix Corp.) and
tetrakis(triphenylphosphine)palladium(0) (0.15 g, 0.13 mmol, Strem) in toluene (3.0
mL) was degassed and then heated to 1 10 °C for 3 hours, then lowered to 90 °C
overnight. The mixture was concentrated and flash chromatographed on a 120 g silica
gel cartridge, eluting with a gradient from 0-20% EtOAc in hexanes to afford product
as a white solid (0.8 g, 73%). Ή N R (400 MHz, CDCI3) δ 7.08 (s, 1H), 6.58 (d, J
= 7.1 Hz, 1H), 5.40 (d, 7= 7.1 Hz, 1H), 4.98 (br s, 1H), 4, 18 - 4.00 (m, 4H), 3.82 (br
s, 1 H), 2.94 (t, J= 1 1.7 Hz, 2H), 2.12 - 1.95 (m, 2H), 1.52 - 1.31 (m, 14H). '*F NM (376 MHz, CDCI3) δ -71.77 (s). LCMS (M+H)+: 417.2.
Step 3. tert-but l 4-{[6-formyl-2-(trifluoromethyl)pyrimidin-4-yl]ammo}piperidim-l- carboxylate
tert-Butyl 4-{[6-[(Z)-2-ethoxyviiiyl]-2-(trifluoromethyl)pyrimidin-4- yl]amino}piperidine-l-carboxylate (0.80 g, 1.9 mmol, from Step 2) was dissolved in 1,4-dioxane (56 mL) and water (14 mL), then sodium periodate (1,2 g, 5.8 mmol) was added followed by osmium tetraoxide (4 wt% in water, 0.424 mL, 0.0666 mmol). After stirring for 24 hours, the reaction mixture was partitioned between water and EtOAc, the phases were separated and the aqueous phase was extracted with additional EtOAc. The combined organic extracts were washed with water, then sat'd NaCl, dried over Na2S04, filtered and solvent removed in vacuo. The crude product was used in the next reaction without purification. LCMS (M+H)+: 375.0;
(M+¾0+H)+: 393.0.
Step 4. tert-butyl 4-{[6-(hydroxymethyl)-2-(trifluoromethyl)pyrimidin-4- yl]amino}piperidwe- 1 -carboxylate
Sodium tetrahydroborate (73 mg, 1.9 mmol) was added to a solution of tert- butyl 4-{[6-formyl-2-(trifluoromethyl)pyrimidin-4-yl]amino}piperidine- l -carboxylate (0.90 g, 1.9 mmol, from Step 3) in Isopropyl alcohol (15 mL) at 0 °C. After stirring at this temperature for 1.5 hours, the reaction was quenched by the addition of saturated ammonium chloride. The mixture was further diluted with water and extracted with EtOAc. The organic extract was washed with water and brine, dried over sodium sulfate, filtered and concentrated. Flash chromatography on a 40g silica gel cartridge, eluting with a gradient from 0-100% EtOAc in hexanes afforded product as a white solid (0.58 g, 80% over the two steps). ¾ NMR (400 MHz, CDCI3) S 6.50 (s, 1H), 4.66 (d, J= 5.1 Hz, 2H), 4.30 - 3.89 (m, 2H), 2.95 (t, J= 12.0 Hz, 2H), 2.73 (t, J = 5.2 Hz, 1H), 2.22 - 1.88 (m, 2H), 1.53 - 1.33 (m, ΠΗ). 19F NMR (376 MHz, CDCb) δ -71.74 (s). LCMS (M+H)+: 377.1.
Step 5. [6-(piperidin-4-ylamirio)-2-(trifluoromethyl)pyrimidm-4-yl]methanol
4,0 M Hydrogen chloride in dioxane (8.0 mL, 32 mmol) was added to a solution of tert-buty) 4-{[6-(hydroxymethyl)-2-(trifluoromethyl)pyrimidin-4- yl]amino}piperidine-l-carboxylate (0.58 g, 1.5 mmol, from Step 4) in 1,4-dioxane (3.9 mL) and the mixture was stirred until deprotection was complete as determined by LCMS. The mixture was then quenched by the addition of IN NaOH to pH 12-13 (pH needs to be high enough for better extraction), and was saturated with solid NaCl. The product was extracted with 6 portions of chloroform , and the combined extracts were dried over sodium sulfate, filtered and concentrated to afford product as a white solid (0.43 g, 91%). Ή NMR (400 MHz, CDCk) δ 6.48 (s, 1H), 4.65 (s, 2H), 3.13 (dt, J= 1 1.9, 2.9 Hz, 2H), 2.81 - 2.66 (m, 2H), 2.04 (d, J= 10.3 Hz, 2H), 1.51 - 1.31 (m, 2H). 19F NMR (376 MHz, CDC13) δ -71.75 (s). LCMS (M+H)+: 277.1.
Step 6. {cis-3-(4-{[6-(hydroxymethyl)-2-(trifluoro ethyl)pyri idin-4- yl]annno}piperidm-l-yl)-l-[4-(7-{[2-(trimet ylsilyl)ethoxy]methylj-7H-pyrrolo[2,3- d]pyrimidin-4-yl)-lH-pyrazol-l-yJ]cyclobiityl}acetomtrile and {trans-3-(4-{[6- (hydroxymethyl)-2-(lriflwromethyl)pyrimidm-4-yl]amino}piperidiri-l-yl)
(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2 -d]pyrimidiri-4-yl)-lH-pyrazol-l- yl]cyclobutyl}acetonitrile
Sodium cyanoborohydride (64 mg, 1.0 mmol) and zinc dichloride (69 mg, 0.51 mmol) were dissolved in methanol (3.6 mL) and stirred for 2 hours. At this time, [6-(piperidin-4-ylamino)-2-(trifluoromethyl)pyrimidin-4-yl]methanol (0.20 g, 0,72 mmol, from Step 5) and {3-oxo-l-[4-(7-{[2-(trimethylsilyl)ethoxy]methyl}-7H- pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]cyclobutyl}acetonitrile (0.30 g, 0.72 mmol, Intermediate Example Al, Step 7) were combined in methanol (9.1 mL) and stirred for a few minutes to dissolve. The reducing mixture prepared from combining the sodium cyanoborohydride and zinc dichloride was then added and stirred overnight. Purification via preparative HPLC-MS (CI 8 eluting with a gradient of MeCN/¾0 containing 0.15% NH OH) to give the two isomers: Peak 1, eis- isomer: (64 mg, 13%), LCMS (M+H)+: 683.3; Peak2, trans-isomer: (62 mg, 12%), LCMS (M+H)+: 683.3.
Step 7. {trans-3-(4-{[6-(hydroxymethyl)-2-(trifluoromethyl)pyrimidin-4-
13 041601
yl]amino}piperidin-l-yl)-l-[4-(7H-py}rolo[2 -d]pyrimidin-4-yl)-lH-pyrazol-l- yl]cyclobutyl}acetonitrile
{trans-3-(4-{[6-(Hydroxymethyl)-2-(trifluoromethyl)pyi'imidin-4- yl]amino}piperidin-l-yl)-l-[4-(7-{[2-(triiTiethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3- d]pyrimidin-4-yl)-lH-pyrazol-l-y]]cyclobutyl}acetonitrile (11 mg, 0.016 mmol, Peak
2 from Step 7) was stirred for 1 hour in a 1 : 1 mixture of TFA/DCM and solvents were
removed in vacuo. The residue was stirred with ethylenediamine (0.1 mL) in
methanol (1.0 mL) until deprotection was complete. Purification via preparative
HPLC-MS (C18 eluting with a gradient of MeCN/H20 containing 0.15% NH4OH)
afforded the desired product as the free base (5.9 mg, 66%). Ή NMR (400 MHz, d6- DMSO, rotamers) δ 12.13 (s, 1H), 8.83 (s, 1H), 8.69 (s, 1H), 8.42 (s, 1H), 8.1 1 - 8.00
(m, 0.2H), 7.94 (d, J= 7.3 Hz, 0.8H), 7.60 (d, J= 3.6 Hz, 1H), 7.08 (d, J= 3.6 Hz,
1H), 6.75 (s, 0.8H), 6.69 (s, 0.2H), 5.55 (s, 1H), 4.45 - 4.28 (m, 2H), 3.82 (s, 1H),
3.41 (s, 2H), 3.12 - 2.92 (m, 2H), 2.92 - 2.68 (m, 3H), 2.40 - 2.19 (m, 2H), 2.04 - 1.77 (m, 4H), 1.66 - 1.32 (m, 2H). I9F NMR (376 MHz, d6-DMSO) δ -70.05 (s), - 70.23 (s). LCMS (M+H)+: 553.2.
Example 28. {trans-3-(4-{[6-[(ethylamino)methyl]-2-(trifluoromethyl)pyrimidin- 4-yl]araino}piperidin-l-yl)-l-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l- yl]cyclobutyl}acetonitrile
N,N-Diisopropylethylamine (14 L, 0.082 mmol) and methanesulphonic
anhydride (12 mg, 0.070 mmol, Aldrich) were added to a solution of {trans-3-(4-{[6-
2013/041601
(hydroxymethyl)-2-(ti fluoromethyl)pyrimidin -yl]amino}piperidin-l-yl)-l-[4-(7- {[2-(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazoI-l- yl]cyclobutyl}acetonitrile (16 mg, 0.023 mmol) (Peak 2 from Example 27, Step 6) in
methylene chloride (0.32 mL) . After stirring for 30 minutes, solvent was removed in
vauco and replaced by Tetrahydrofuran (0.32 mL). Ethylamine (6.6 μί, 0.12 mmol,
Aldrich) and methanol (0.13 mL) were added and the misture was stirred for 2 hours
at room temperature. Solvent was removed in vacuo and the crude product was
deprotected first by stirring in a 1 : 1 mixture of TFA/DCM for 1 hour, followed by
removal of solvents, then stirring with ethylenediamine (0.15 mL) in methanol (1.0
mL) until deprotection was complete as determined by LCMS. Purification via
preparative HPLC-MS (C18 eluting with a gradient of MeCN/H20 containing 0.15%
NH4OH) afforded product as the free base (4.6 mg, 34%). Ή NMR (400 MHz, d6- DMSO, retainers) δ 12.13 (s, 1H), 8.83 (s, 1H), 8.69 (s, 1H), 8.42 (s, 1H), 8.04 - 7.94
(m, 0.2H), 7.89 (d, J= 7.4 Hz, 0.8H), 7.60 (d, J= 3.6 Hz, 1H), 7.08 (d, J= 3.6 Hz,
1H), 6.73 (s, IH), 3.90 - 3.73 (m, 1H), 3.59 (s, 2H), 3.41 (s, 2H), 3.13 - 2.92 (m, 2H),
2.92 - 2.65 (m, 3H), 2.55 (q, J= 7.1 Hz, 2H), 2.40 - 2.27 (m, 2H), 2.21 (br s, J = 22.0
Hz, 1H), 2.02 - 1.76 (m, 4H), 1.60 - 1.34 (m, 2H), 1.03 (t, J= 7.1 Hz, 3H). 19F NMR
(376 MHz, d6-DMSO) δ -70.01 (s), -70.18 (s). LCMS (M+H)+: 580.3. Example 29. {trans-3-(4-{[6-{[(2-hydroxyethyI)amino]raethyl}-2-
(trifluoromethyI)pyrimidin-4-yl]amino}piperidin-l-yI)-l-[4-(7H-pyrrolo[2,3- d]pyrimidin-4-yl)-lH-pyrazol-l-yl]cydobutyl}acetonitrile
Prepared according to the procedure of Example 28, using ethanolamine (7.1 μΐ^, 0.12 mmol, Aldrich) in the displacement step, which was carried out at 40 °C for 2 hours. Yield: (5.9 mg, 42%). Ή N R (400 MHz, d6-DMSO, rotamers) δ 12.13 (s, 1H), 8.83 (s, 1H), 8.69 (s, 1H), 8.42 (s, 1H), 7.99 (d, J= 7.6 Hz, 0.2H), 7.90 (d, J = 7.2 Hz, 0.8H), 7.60 (d, J= 3.6 Hz, 1H), 7.08 (d, J= 3.6 Hz, 1H), 6.77 (s, 0.2H), 6.72 (s, 0.8H), 4.53 (t, = 5.3 Hz, 1H), 3.81 (s, OH), 3.62 (s, 2H), 3.47 (q, J= 5.5 Hz, 2H), 3.41 (s, 2H), 3.1 1 - 2.92 (m, 2H), 2.90 - 2.70 (m, 3H), 2.59 (t, J= 5.7 Hz, 2H), 2.40 - 2.12 (m, 2H), 2.03 - 1.76 (m, 4H), 1.63 - 1.34 (m, 2H). ,9F NMR (376 MHz, d6- DMSO) δ -70.00 (s), -70.18 (s). LCMS (M+H)+: 596.3.
Example 30. {trans-3-(4-{[6-{[(trans-3-hydroxycyclobutyl)amino]methyl}-2- (trifluoromethyI)pyrimidin-4-yl]amino}piperidiii-l-yI)-l-[4-(7H-pyrrolo[2,3- d]pyrimidin-4-yl)-lH-pyrazol-l-yI]cyclobutyl}acetonitrile
Prepared according to the procedure of Example 28, using trans-3- aminocyclobutanol hydrochloride (14 mg, 0.12 mmol, Advanced Chem Blocks) and diisopropylethylamine (0.020 mL, 0.12 mmol) in the displacement step, which was carried out at 40 °C for 2 hours. Yield: (4.2 mg, 29%). Ή NMR (400 MHz, d6-
DMSO, rotamers) δ 12.13 (s, IH), 8.83 (s, IH), 8.69 (s, IH), 8.42 (s, IH), 7.98 (d, = 8.0 Hz, 0.2H), 7.90 (d, J= 7.3 Hz, 0.8H), 7.60 (d, J= 3.6 Hz, IH), 7.08 (d, J= 3.6 Hz, IH), 6.73 (s, IH), 4.88 (d, J= 5.7 Hz, IH), 4.37 - 4.16 (m, IH), 3.81 (s, IH), 3.49 (s, 2H), 3.41 (s, 2H), 3.32 - 3.14 (m, IH), 3.09 - 2.93 (m, 2H), 2.93 - 2.69 (m, 3H), 2.49 - 2.26 (m, 3H), 2.04 - 1.77 (m, 8H), 1.62 - 1.36 (m, 2H). 19F NMR (376 MHz, d6- DMSO) S -70.00 (s), -70.17 (s). LCMS (M+H)+: 622.3.
Example 31. {trans-3-(4-{[4-(hydroxymethyI)-6-(trifluoromethyl)pyridin-2- yl]amino}piperidin-l-yl)-l-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l- yl]cyclobutyl}acetonitrile
Sep /. tert-butyl 2-{[l-(tert-bittoxycarbonyl)p\peridin-4-yl]amm' o}-6- (trifluoromethyl)isonicotinate
A solution of tert-butyl 2-chloro-6-(trifluoromethyl)isonicotinate (3.0 g, 1 1 mmol, Example 21, Step 1), tert-butyl 4-aminopiperidine-l-carboxylate (4.3 g, 21 mmol, Aldrich) and N,N-diisopropylethylamine (3,7 mL, 21 mmol) in dimethyl sulfoxide (9.2 mL) was heated to 100 °C for 20 hours. The mixture was cooled to room temperature and diluted with EtOAc. The combined organic extracts were washed with water (3 times) and brine, dried over sodium sulfate, filtered and concentrated. Flash chromatography using a 120 g silica gel cartridge and eluting with a gradient from 0-15% EtOAc in hexanes afforded product as a white solid (3.4 g, 72%). LCMS (M+Na)+: 468.2.
Step 2. 2-{[l-(tert-butoxycarbonyl)piperidin-4-yl]amino}-6- (trifluoromethyl)isonicotinic acid
tert-Butyl 2-{[l-(tert-butoxycarbonyl)piperidin-4-yl]amino}-6- (trifluoromethyl)isonicotinate (3.4 g, 7.6 mmol, from Step 1) was treated with potassium hydroxide (3.4 g, 61 mmol) in tetrahydrofuran (50. mL) . After 2 hours, the mixture was acidified to pH 2-3 by the addition of 1.0 N HCl. Brine (50 mL) was also added and the product was extracted with three 50 mL portions of chloroform. The extracts were dried over sodium sulfate, filtered and concentrated to afford product as a light yellow powder (2.8 g, 94%). LCMS (M+Na)+: 412.0.
Step 3. tert-butyl 4-{[4-(hydroxymethyl)-6-(trifluoromethyl)pyridin-2-
41601
yl]amino}piperidine-l-carboxylate
Isobutyl chloroform ate (1.1 mL, 8.6 mmol) was added to a solution of 2-{[l - (tert-butoxycarbonyl)piperidin-4-yl]amino}-6-(trifluoromethyl)isonicotinic acid (2,8
g, 7.2 mmol, from Step 2) and triethylamine (2.0 mL, 14 mmol) in tetrahydrofuran
(30. mL) at 0 °C. After stirring for 30 minutes, the reaction mixture was filtered
through a short pad of celite into a flask containing a mixture of sodium
tetrahydroborate (0.95 g, 25 mmol) in water (15 mL) at 0 °C. The celite pad was
rinsed with three portions of THF (3 x 30 mL) into the reaction flask. The reaction
was allowed to warm to room temperature and stir for 1 hour. The reaction mixture
was recooled in an ice bath and was quenched by the addition of saturated ammonium
chloride solution. The product was extracted with a 150 mL portion of ethyl acetate.
The organic layer was washed with water and brine, was dried over sodium sulfate,
filtered and concentrated. Flash chromatography, using a 120 g silica gel cartridge and
eluting with a gradient from 0-80% EtOAc in hexanes afforded product as a white
solid (2.7 g, 100%). Ή NM (400 MHz, CDC13) δ 6.87 (s, 1H), 6.56 (s, 1H), 5.02 - 4.36 (m, 2H), 4.09 - 3.94 (m, 2H), 3.81 (dtt, J = 14.2, 8.0, 3.9 Hz, 1H), 3.03 - 2.85
(m, 2H), 2.07 - 1.97 (m, 2H), 1.46 (s, 9H), 1.37 (qd, J= 12.2, 3.8 Hz, 2H). 19F NMR
(376 MHz, CDCb) δ -69.21 (s). LCMS (M+Na)+: 398.0. Step 4. [2-(piperidin-4-yl mmo)-6-(trifl}ioromelhyl)pyridin-4-yl]methariol
4.0 M Hydrogen chloride in dioxane (36 mL, 140 mmol) was added to a
solution of tert-butyl 4-{[4-(hydroxymethyl)-6-(trifluoromethyl)pyridin-2- yl]amino}piperidine-l-carboxylate (2.7 g, 7.2 mmol, from Step 3) in 1,4-dioxane (18
mL). After stirring for 30 minutes, the mixture was then basified to pH 12-13 by the
addition of 1.0 N NaOH. The product was extracted with DCM (6 x). The combined
organic extracts were dried over sodium sulfate, filtered and concentrated to afford
the product as a white powder (1.64 g, 83%). Ή NMR (400 MHz, d6-DMSO) 6 6.94
(d, J= 7.6 Hz, 1H), 6.77 (s, 1H), 6.67 (s, 1H), 5.39 (t, J= 5.8 Hz, 1H), 4.42 (d, J= 5.5
Hz, 2H), 3.76 - 3.60 (m, 1H), 2.92 (dt, = 12.4, 3.3 Hz, 2H), 2.57 - 2.43 (m, 2H),
1.87 - 1.77 (m, 2H), 1.25 (qd, J = 1 1.8, 3.8 Hz, 2H). 19F NMR (376 MHz, d6-DMSO)
δ -67.68 (s).
LCMS (M+H)+: 276.1.
I l l
Step 5. {cis-3-(4-{[4-(hydroxymethyl)-6-(trifliioromethyl)pyridin-2- yl]amino}piperidin-l-yl)-l-[4-(7-{[2-(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3- d]pyrimidin-4-yl)-l H-pyrazol-1 ' -yljcyclobuty!jacetonitrile and {trans-3-(4-{[4- (hydroxymet yl)-6-(trifltioromethyl)pyridin-2-yl]amirio}piperidin-l-yl)-l-[4-(7-{[2- (trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-d]pyrimidm-4-yl)-lH-pyrazol-l- yl]cyclohutyl} cetonitrile
A reducing mixture was generated by combining sodium cyanoborohydride (0.27 g, 4.4 mmol) and zinc dichloride (0.30 g, 2.2 mmol) in methanol (25 mL) and stirring for 2 hours). {3-oxo-l-[4-(7-{[2-(trrniethylsilyl)ethoxy]methyl}-7H- pyrrolo[2,3-d]pyrimidin-4-yl)-l H-pyrazol-l -yl]cyclobutyl)acetonitrile (1.5 g, 3.5 mmol, Intermediate Example Al, Step 7) and [2-(piperidin-4-ylamino)-6- (trifluoromethyl)pyridin-4-yl]methanol (1 ,0 g, 2.9 mmol, from Step 4) were combined in methanol (52 mL) and stirred for a few minutes just to dissolve. The reducing mixture was then added and the reaction was continued for 1 hour. Additional {3-oxo- l-[4-(7-{[2-(trimethyIsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH- pyrazol-l-yl]cyclobutyl}acetonitrile (0,24 g, 0.58 mmol) was then added and the reaction continued for 3 additional hours. Saturated sodium bicarbonate was added to the mixture and then the mixture was diluted with additional water. The product was then extracted with a mixture of EtOAc/DCM. The combined organic extracts were washed twice with water, once with brine, dried over sodium sulfate, filtered and concentrated. Flash chromatography using a 120 g silica gel cartridge and elutmg with a slow gradient from 0-10% MeOH in EtOAc afforded separation of the diastereomers (Peak 1, cis- : 0.59 g 30%; Peak 2 trans- 0.54 g, 27%). Peak 1, Cis- isomer: LCMS (M+H)+: 682.1. Peak 2, Trans-isomer: LCMS (M+H)+: 682.2. Alternatively, the isomers could be separated using preparative HPLC-MS (CI 8 eluting with a gradient of MeCN and ¾0 containing 0.15% NH4OH) to afford Peakl, cis- isomer and Peak 2, trans- isomer. Step 6. {tratis-3-(4-{[4-(hydroxymethyl)-6-(triflvoromethyl)pyridm-2- yl]amino}piperidin-l-yl)-l-[4-(7H^yrrolo[2,3-d]pyrimidm-4-yl)-lH-pyrazol-l- yljcyclobiity!jacetonitrile
Each isomer from Step 5 was deprotected separately by stirring in a solution of 1 : 1 TFA DCM for one hour, evaporation of solvents, and stirring with ethylenediamine (0.1 mL) in MeOH (1.0 mL) until the deprotection was complete. Purification of the final deprotected products using preparative HPLC-MS (CI 8 eluting with a gradient of MeCN and ¾0 containing 0.15% Ν¾ΟΗ) afforded the desired products as the free base.
Cis: Ή NMR (400 MHz, d6-DMSO) δ 12.1 1 (br s, 1H), 8.68 (s, 1H), 8.67 (s, 1H), 8.38 (s, 1H), 7.59 (d, ,7= 3.5 Hz, 1H), 7.05 (d, J= 3.5 Hz, 1H), 6.96 (d, J = 7.4 Hz, 1H), 6.77 (s, 1 H), 6.66 (s, 1H), 5.38 (br, 1H), 4.41 (s, 2H), 3.64 (br, 1H), 3.45 (s, 2H), 2.87 (p, J= 7.6 Hz, 1H), 2.82 - 2.68 (m, 2H), 2.62 - 2.52 (m, 4H), 2.02 - 1.71 (m, 4H), 1.46 - 1.29 (m, 2H). , 9F MR (376 MHz, d6-DMSO) δ -67.67 (s). LCMS (M+H)+: 552.2.
Trans: 'H NMR (400 MHz, d6-DMSO) δ 12.11 (br s, 1H), 8.83 (s, 1H), 8.69 (s, 1H), 8.42 (s, 1H), 7.60 (d, .7= 3.6 Hz, 1H), 7.08 (d, .7= 3.6 Hz, 1H), 6.98 (d, .7 = 7.5 Hz, 1H), 6.79 (s, 1 H), 6.68 (s, 1H), 5.40 (br s, 1H), 4.43 (s, 2H), 3.65 (br s, 1H), 3.41 (s, 2H), 3.05 - 2.96 (m, 2H), 2.89 - 2.70 (m, 3H), 2.41 - 2.27 (m, 2H), 1.98 - 1.82 (m, 4H), 1.51 - 1.35 (m, 2H). I F NMR (376 MHz, d6-DMSO) δ -67.68 (s). LCMS (M+H)+: 552.2. Example 32. {trans-3-(4-{[4-[(ethylamino)methyl]-6-(trifluoromethyl)pyridin-2- yl]amino}piperidin-l-yl)-l-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l- yl]cyclobutyl}acetonitrile
Methanesulphonic anhydride (12 mg, 0.070 mmol, Aldrich) and N,N- diisopropylethylamine (14 \)L, 0.082 mmol) were added to a solution of {trans-3-(4- {[4-(hydroxymethyl)-6-(trifluoromethyl)pyridin-2-yl]amino}piperidin-l-yl)- l -[4-(7- {[2-(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l - yl]cyclobutyl}acetonitrile (16 mg, 0.023 mmol, Peak 2 from Example 31, Step 5) in methylene chloride (0.32 mL) . After stirring for 30 minutes, solvent was removed in vacuo and replaced with tetrahydrofuran (0.32 mL) and methanol (0.13 mL) and ethylamine (6.6 μί, 0.12 mmol, Aldrich) was added. The mixture was stirred at room temperature for 1,5 hours. Solvent was again removed in vacuo and the crude product was deprotected by stirring in a I r I mixture of TFA/DCM for one hour, followed by evaporation and stirring with ethylenediamine (0.2 mL) in methanol (1.0 mL) until deprotection was complete as determined by analytical LCMS. Purification via preparative HPLC-MS (CI 8 eluting with a gradient of MeCN and H20 containing 0.15% NH4OH) afforded the product as the free base (8.4 mg, 62%). Ή NMR (300 MHz, d6-DMSO) S 12.1 1 (br s, 1H), 8.83 (s, 1 H), 8.69 (s, 1H), 8.42 (s, 1H), 7.60 (d, J = 3.5 Hz, 1H), 7.08 (d, J= 3.6 Hz, 1H), 6.93 (d, J= 7.5 Hz, 1H), 6.85 (s, 1H), 6.67 (s, 1H), 3.76 - 3.52 (m, 3H), 3.41 (s, 2H), 3.09 - 2.91 (m, 2H), 2.90 - 2.67 (m, 3H), 2.46 (q, J= 7.1 Hz, 2H), 2.41 - 2.22 (m, 2H), 2.01 - 1.75 (m, 4H), 1.54 - 1.27 (m, 2H), 1.01 (t, = 7.1 Hz, 3H). 19F NMR (282 MHz, d6-DMSO) δ -67.58 (s). LCMS (M+H)+: 579.3.
Example 33. {trans-3-(4-{[4-{[(2-hydrox ethyl)amino]methyl}-6-
(trifluoromethyl)pyridiii-2-yl]amino}piperidin-l-yl)-l-[4-(7H- d]pyrimidin-4-yl)-lH-pyrazol-l-yl]cycIobutyl}acetonitrile
Prepared according to the procedure of Example 32 using ethanolamine (7.1 μΐ,, 0.12 mmol, Aldrich) in the displacement step, which was carried out at 40 °C for 1.5 hours. Yield: (6.7 mg, 48%). Ή NMR (300 MHz, d6-DMSO) δ 12.07 (br s, 1H), 8.83 (s, 1H), 8.69 (s, 1 H), 8.42 (s, 1H), 7.60 (d, J= 3.6 Hz, 1H), 7.08 (d, J = 3.6 Hz, 1 H), 6.93 (d, J= 7.4 Hz, 1H), 6.85 (s, 1H), 6.68 (s, 1H), 4.49 (t, J= 5.3 Hz, 1H), 3.63 (s, 2H), 3.45 (q, J = 5.6 Hz, 2H), 3.41 (s, 2H), 3.1 1 - 2.91 (m, 2H), 2.90 - 2.63 (m, 3H), 2.52 (q, J= 5.9 Hz, 2H), 2.41 - 2.26 (m, 2H), 2.02 - 1.77 (m, 4H), 1.43 (q, J= 10.3 Hz, 2H). 1 F NMR (282 MHz, d6-DMSO) δ -67.58 (s). LCMS (M+H)+: 595.3.
Example 34. {trans-3-(4-{[4-{[(trans-3-hydroxycyclobutyI)amino]methyl}-6- (trifluoromethyl)pyridin-2-yl]amino}piperidin-l-yl)-l-[4-(7H-pyrrolo[2,3- d]pyrimidin-4-yl)-lH-pyrazol-l-yl]cyclobutyl}acetonitrile
Prepared according to the procedure of Example 32 using trans-3- aminocyclobutanol hydrochloride (28 mg, 0.24 mmol, Advanced Chem Blocks) and diisopropylethylamine (0.04 mL, 0.24 mmol) in the displacement step, which was carried out at 40 °C overnight. Yield: (4.2 mg, 29%). Ή NMR (300 MHz, d6-DMSO) 5 8.83 (s, 1H), 8.69 (s, 1H), 8.42 (s, 1H), 7.60 (d, J= 3.6 Hz, 1H), 7.08 (d, J = 3.6 Hz, 1H), 6.93 (d, J= 7.5 Hz, 1H), 6.83 (s, 1H), 6.66 (s, 1H), 4.85 (d, = 5.1 Hz, 1H), 4.24 (h, J= 6.3, 5.8 Hz, 1H), 3.76 - 3.55 (m, 1H), 3.49 (s, 2H), 3.41 (s, 2H), 3.20 (tt, J = 7.7, 4.3 Hz, 1H), 3.07 - 2.91 (m, 2H), 2.91 - 2.69 (m, 3H), 2.40 - 2.27 (m, 2H), 2.08 - 1.81 (m, 8H), 1.43 (q, J= 10.4, 10.0 Hz, 2H). I9F NMR (282 MHz, d6-DMSO) δ - 67.57 (s). LCMS (M+H)+: 621.3.
Example 35. {trans-3-(4-{[4-[(3,3-dimethylazetidin-l-yI)methyl]-6- (tr!fluoromethyl)pyridin-2-yl]amino}piperidiii-l-yl)-l-[4-(7H-pyrrolo[2,3- d]pyrimidin-4-yl)-lH-pyrazol-l-yl]cyclobutyl}acetonitrile
Ν,Ν-diisopropyIethylamine (15 μL·, 0.088 mmol) and methanesulphonic anhydride (13 mg, 0.073 mmol, Aldrich) were added to a solution of {trans-3-(4-{[4- (hydroxymethyl)-6-(trifluoromethyl)pyridin-2-yl]amino}piperidin-l-yl)-l -[4-(7-{[2- (trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l- yl]eyclobutyl}acetonitrile (20. mg, 0.029 mmol, Peak 2 from Example 31, Step 5) in methylene chloride (0.40 mL) . After stirring for 30 minutes, solvent was removed in vacuo and replaced with tetrahydrofuran (0.19 mL) and methanol (0.19 mL). N,N- diisopropylethylamine (51 (iL, 0.29 mmol) and 3,3-dimethylazetidine hydrochloride ( 18 mg, 0.15 mmol, Princeton Bio) were added and the reaction was heated to 40 °C for 1 hour. The mixture was then concentrated on the rotovap. The crude product was deprotected by stirring in 1 : 1 TFA/DCM for one hour, concentrating and then stirring in methanol (2.0 mL) with ethylenediamine (0.40 mL). Purification via preparative HPLC-MS (C18 eluting with a gradient of MeCN and H20 containing 0. 15% NH4OH) afforded the product as the free base (7.3 mg, 40%). Ή NM (400 MHz, d6-DMSO) δ 12.13 (br s, 1H), 8.83 (s, 1 H), 8.69 (s, 1H), 8.42 (s, 1H), 7.60 (d, J= 3.6 Hz, 1H), 7.08 (d, J = 3.6 Hz, 1H), 6.98 (d, J = 7.3 Hz, 1H), 6.72 (s, 1H), 6.62 (s, 1H), 3.71 - 3.57 (m, 1H), 3.48 (s, 2H), 3.41 (s, 2H), 3.07 - 2.95 (m, 2H), 2.90 (s, 4H), 2.85 - 2.70 (m, 3H), 2.40 - 2.26 (m, 2H), 2.01 - 1.80 (m, 4H), 1.42 (q, J = 103 Hz, 2H), 1.18 (s, 6H). , 9F NMR (376 MHz, d6-DMSO) δ -67.67 (s). LCMS (M+H)+: 619.4.
Example 36. {trans-3-(4-{[4-[(3,3-difluoropyrrolidin-l-yl)methyl]-6-
(trifluoromethyl)pyridiii-2-yl]amino}piperidin-l-yI)-l-[4-(7H-pyrrolo[2,3- d]pyrimidin-4-yl)-lH-pyrazol-l-yI]cyclobutyl}acetoiiitrile
Prepared by the method of Example 35, using 3,3-difluoropyrrolidine hydrochloride (21 mg, 0,15 mmol, Matrix) and N,N-diisopropylethylamine (51 |iL, 0.29 mmol) in the displacement step. Yield: (8.8 mg, 47%). Ή NMR (400 MHz, d6- DMSO) δ 12.10 (b s, 1H), 8.83 (s, 1H), 8.69 (s, 1H), 8.42 (s, 1H), 7.60 (d, J= 3.6 Hz, 1H), 7.08 (d, J= 3.6 Hz, 1H), 7.04 (d, J= 7.3 Hz, 1H), 6.79 (s, 1H), 6.67 (s, 1H), 3.66 (br s, 1H), 3.56 (s, 2H), 3.41 (s, 2H), 3.10 - 2.95 (m, 2H), 2.89 (t, J= 13.3 Hz, 2H), 2.84 - 2.74 (m, 3H), 2.71 (t, J= 7.0 Hz, 2H), 2.38 - 2.19 (m, 4H), 2.05 - 1 .62 (m, 4H), 1.43 (q, J= 10.4 Hz, 2H). 19F NMR (376 MHz, d6-DMSO) δ -67.69 (s), - 91.33 (p, J= 15.2, 14.7 Hz). LCMS (M+H)+: 641.3.
Example 37. {trans-3-(4-{[4-{[cyclopropyl(methyl)amino]methyl}-6- (trifluoromethyl)pyridin-2-yl]amino}piperidin-l-yl)-l-[4-(7H-pyrrolo[2,3- d]pyrimidin-4-yl)-lH-pyrazol-l-yl]cyclobutyl}acetonitrile
Prepared by the method of Example 35, using N-methylcyclopropanamine hydrochloride (16 mg, 0.15 mmol, Acoela ChemBio) and N,N-diisopropylethylamine (51 nL, 0.29 mmol) in the displacement step. Yield: (7.8 mg, yield 44%). Ή NMR (400 MHz, d6-DMSO) δ 12.10 (br s, 1H), 8.83 (s, 1H), 8,69 (s, 1H), 8.42 (s, 1H), 7.60 (d, = 3.6 Hz, 1H), 7.08 (d, J = 3.6 Hz, 1H), 6.98 (d, J = 7.4 Hz, 1H), 6.73 (s, 1H), 6.61 (s, 1H), 3.72 - 3.59 (m, 1H), 3.54 (s, 2H), 3.41 (s, 2H), 3.09 - 2.92 (m, 2H), 2.86 - 2.70 (m, 3H), 2.3 - 2.27 (m, 2H), 2.16 (s, 3H), 2.01 - 1.81 (m, 4H), 1.76 (tt, J= 6.6, 3.6 Hz, 1H), 1.42 (q, /= 10.6 Hz, 2H), 0.50 - 0.42 (m, 2H), 0.37 - 0.31 (m, 2H).
10 19F NMR (376 MHz, d6-DMSO) δ -67.62 (s). LCMS (M+H)+: 605.3.
Example 38. {cis-3-(4-{[4-(2-hydroxyethyl)-6-(trifluoromethyl)pyridin-2- yl]amino}piperidin-l-yl)-l-[4-(7H-pyrroIo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l- yl]cyclobutyl}acetonitrile and {trans-3-(4-{[4-(2-hydroxyethyl)-6- 15 (trifluoromethyl)pyridin-2-yllamino}piperidin-l-yl)-l-[4-(7H-pyrrolo[2,3- d]pyrimidiii-4-yl)-lH-pyrazol-l-yl]cyclobutyl}acetonitrile
Step 1. 2-[2-chloro-6-(trifluoromethyl)pyridin-4-yl]ethanol
2-Chloro-4-iodo-6-(trifluoromethyl)pyridine (0.50 g, 1.6 mmol, European Journal of Organic Chemistry, (18), 3793-3798, 2004) was dissolved in tetrahydrofuran (9.0 mL) and cooled to -78 °C. 2.5 M n-Butyllithium in hexanes (0.98 mL, 2.4 mmol) was added dropwise. The reaction was stirred at -78 °C for 45 minutes, at which time 1,3,2-dioxathiolane 2,2-dioxide (0.24 g, 2.0 mmol, Aldrich) in Tetrahydrofuran (2.2 mL) was added. The mixture was then allowed to warm to ambient temperature and stir over 1.5 hours. 12.0 M hydrogen chloride in water (0.81 mL, 9.8 mmol) was added to the mixture and the reaction was stirred overnight IN NaOH was then added to achieve a pH between 8 and 9, and brine was also added. The product was extracted with EtOAc, and the organic layer was dried over sodium sulfate, filtered and concentrated. Flash chromatography using a 40 g silica gel cartridge, eluting with a gradient from 0-40% EtOAc in hexanes afforded product as a mixture of isomers, which contained about 50% of the desired isomer (0.09 g, 24%). LCMS (M+H)+: 226.0/228.1.
Step 2. 2-[2-(piperidin-4-ylamino)-6-(triflitoroviethyl)pyridin-4-yl]ethanol
A mixture of 2-[2-chloro-6-(trifluoromethyl)pyridin-4-yl]ethanol (0.085 g,
0.38 mmol, from Step 1), tert-butyl 4-aminopiperidine-l-carboxylate (0.30 g, 1.5 mmol) and N,N-diisopropylethylamine (0.16 mL, 0.94 mmol) in dimethyl sulfoxide (0.86 mL) was heated in the microwave to 100 °C for one hour, then to 140 °C for 140
minutes. The reaction mixture was concentrated. The residue was dissolved in 1,4- dioxane (2.8 mL) and was treated with 4.0 M hydrogen chloride in dioxane (2.8 mL, 1 1 mmol). After stirring overnight, solvent was removed in vacuo. Purification via preparative HPLC-MS (C 18 eluting with a gradient of MeCN and ¾0 containing 0.15% NH OH) afforded two major fractions, the desired product was the first eluting of the peaks having the desired mass (16 mg, 15%). LCMS (M+H)+: 290.1.
Step 3. {cis-3-(4-{[4-(2-hydroxyethyI)-6-(trifluoromethyl)pyridin-2- yl]amino}piperidin-l-yl)-l-[4-(7H-pyrrolo[2,3-d]pyrimidm-4-yl)-lH-pyrazol-l- yljcyclobutylj cetonitrile
and {trans-3-(4-{[4-(2-hydroxyethyi)-6-(trifluoromethyl)pyridin-2- yl]amino}piperidin-l-yl)-l-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l- yl]cyclobutyl}acetomtrile
Sodium cyanoborohydride (7.3 mg, 0.12 mmol) and zinc dichloride (8.1 mg, 0.060 mmol) were combined in methanol (0.45 mL) and stirred for 2 hours to generate the reducing solution. {3-oxo-l-[4-(7-{[2-(trimethylsilyl)ethoxy]methyl}- 7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]cyclobutyl}acetonitrile (36 mg, 0.086 mmol, Intermediate Example Al , Step 7) and 2-[2-(piperidin-4-ylamino)-6- (ti'ifluoromethyl)pyridin-4-yl]ethanol (15 mg, 0.052 mmol, from Step 2) were dissolved in methanol (0.93 mL) and the reducing solution generated above was added. After a reaction time of 80 minutes, preparative HPLC-MS (CI 8 eluting with a gradient of MeCN and H20 containing 0.15% NH4OH) was used to separate and purify the cis- and trans- isomers. The two isomers were then deprotected separately according to the following procedure: first the compound was stirred with 1 : 1 TFA DCM for one hour, then solvents were removed in vacuo and the residue was stirred with ethylenediamine (0.10 mL) in methanol (1 mL) until the deprotection was complete. Preparative HPLC-MS (C I 8 eluting with a gradient of MeCN and ¾0 containing 0.15% NH4OH) was used to purify the final compounds, which were obtained as the free base. (Peak 1 yield: 2.3 mg, 8%. Peak 2 yield: 2.1 mg, 7%). Peak 1 : LCMS (M+H)+: 566.0.
Peak 2: LCMS (M+H)+: 566.1.
Example 39. {trans-3-(4-{[4-(azetidin-l-ylmethyl)-6-(trifluoromethyI)pyridin-2- yl]amino}piperidin-l-yl)-l-[4-(7H-pyrroIo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l- yl]cyclobutyl}acetonitrile
Methanesulphonic anhydride (9.6 mg, 0.055 mmol, Aldrich) was added to a solution of {trans-3-(4-{[4-(hydroxymethyl)-6-(trifluoromethyl)pyridin-2- yl]amino}piperidin-l-yl) -[4-(7-{[2-(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3- d]pyrimidin-4-yl)-lH-pyrazol-l-yl]cyolobutyl}acetonitrile (15 mg, 0.022 mmol, Peak 2 of Example 31, Step 5) and Ν,Ν-diisopropylethylamine (1 1 ί, 0.066 mmol) in methylene chloride (0.30 mL) . After 30 minutes, solvent was removed in vacuo and replaced with tetrahydrofuran (0.30 mL). Azetidine (0.008 mL, 0.1 mmol, Aldrich) and methanol (0.12 mL, 3.0 mmol) were added and the reaction was stirred overnight. Solvent was again removed and the crude product was deprotected by stirring with 1 :1 TFA/DCM for 1 hour, evaporating, and stirring with ethylenediamine (0.15 mL) in methanol (1.0 mL). Purification via preparative HPLC-MS (CI 8 eluting with a gradient of MeCN and H20 containing 0.15% H4OH) afforded product as the free base. Purification on pHIO prep-LCMS gave the desired products. Yield: (3.3 mg, 25%).
'H NMR (400 MHz, d6-DMSO) δ 12.13 (br s, 1H), 8.83 (s, 1H), 8.69 (s, 1H), 8.42 (s, 1H), 7.60 (d, 7 = 3.6 Hz, 1H), 7.08 (d, J= 3.6 Hz, 1H), 6.97 (d, 7= 7.5 Hz, 1H), 6.73 (s, 1H), 6.62 (s, 1H), 3.73 - 3.53 (m, 1H), 3.45 (s, 2H), 3.41 (s, 2H), 3.14 (t, J= 7.0 Hz, 4H), 3.07 - 2.92 (m, 2H), 2.85 - 2.69 (m, 3H), 2.41 - 2.25 (m, 2H), 1.99 (p, J =
6.9 Hz, 2H), 1.94 - 1.81 (m, 4H), 1.53 - 1.29 (m, 2H). 19F NMR (376 MHz, d6- DMSO) δ -67.68 (s). LCMS (M+H)+: 591.2.
Example 40. {trans-3-(4-{[4-(morpholin-4-ylmethyl)-6-(trifluoromethyl)pyridin- 2-yl]aniino}piperidin-l-yl)-l-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l- yljcyclobutyljacetonitrile
Prepared according to the method of Example 39, using morpholine (0.010 mL, 0.1 mmol, Aldrich) in the displacement step, which was carried out at 40 °C overnight. Yield: (5.1 mg, 37%). Ή NMR (400 MHz, d6-DMSO) δ 12.12 (br s, 1H), 8.83 (s, 1H), 8.69 (s, 1H), 8.42 (s, 1H), 7.60 (d, /= 3.6 Hz, 1H), 7.08 (d, J = 3.6 Hz, 1H), 7.01 (d, J= 7.4 Hz, 1H), 6.81 (s, 1H), 6.68 (s, 1H), 3.76 - 3.61 (m, 1H), 3.61 - 3.50 (m, 4H), 3.41 (s, 2H), 3.39 (s, 2H), 3.07 - 2.94 (m, 2H), 2.86 - 2.70 (m, 3H), 2.43 - 2.25 (m, 6H), 2.01 - 1,81 (m, 4H), 1.43 (q, J= 10.1 Hz, 2H). 19F NMR (376 MHz, d6-DMSO) δ -67.65 (s). LCMS (M+H)+: 621.1.
Example 41. {trans-3-(4-{[4-[(3-hydroxyazetidin-l-yl)methyl]-6-
(trifluoromethyl)pyridin-2-yl]amino}piperidin-l-j'l)-l-[4-(7H-pyrrolo[2,3- d]pyrimidin-4-yl)-lH-pyrazol-l-yl]cyclobutyl}acetonitrile
Prepared according to the method of Example 39, using azetidin-3-ol hydrochloride (12 mg, 0.1 1 mmol, Oakwood) and N,N-diisopropylethylamine (0.019 mL, 0.1 1 mmol) in the displacement step. Yield: (4.7 mg, 35%). Ή NMR (400 MHz, d6- DMSO) δ 12.12 (br s, 1H), 8.83 (s, 1H), 8.69 (s, 1H), 8.42 (s, 1H), 7.60 (d, J= 3.6 Hz, 1H), 7.08 (d, J= 3.6 Hz, 1H), 6.97 (d, J = 7.4 Hz, 1H), 6.73 (s, 1H), 6.61 (s, 1H), 5.34 (d, 7 = 6.4 Hz, 1H), 4.20 (h, .7= 6.0 Hz, 1 H), 3.72 - 3.56 (m, 1H), 3.52 (td, J = 6.1, 1.9 Hz, 2H), 3.48 (s, 2H), 3.41 (s, 2H), 3.06 - 2.95 (m, 2H), 2.87 - 2.69 (m, 5H), 2.41 - 2.21 (m, 2H), 2.01 - 1.79 (m, 4H), 1.42 (q, = 10.9 Hz, 2H). , 9F NMR (376 MHz, d6-DMSO) δ -67.67 (s). LCMS (M+H)+: 607.2.
Example 42, {trans-3-(4-{[4-{[(2-hydroxyethyl)(methyl)amino]methyl}-6-
(trifluoromethyl)pyridin-2-yl]amino}piperidin-l-yl)-l-[4-(7H-pyrrolo[2,3- d)pyrimidin-4-yl)-lH-pyrazol-l-yl]cyclobutyl}acetonitrile
Prepared according to the method of Example 39, using 2- (methylamino)ethanol (0.009 mL, 0.1 mmol, Aldrich) in the displacement step, which was carried out at 40°C overnight. Yield: (5.4 mg, 40%). Ή NMR (400 MHz, d6- DMSO) δ 12.12 (br s, 1H), 8.83 (s, 1H), 8.69 (s, 1H), 8.42 (s, 1H), 7.60 (d, J= 3.6 Hz, 1 H), 7.08 (d, J = 3.6 Hz, 1H), 6.97 (d, = 7.4 Hz, 1H), 6.83 (s, 1 H), 6.67 (s, 1H), 4.45 (t, J= 5.4 Hz, 1H), 3.73 - 3.57 (m, 1H), 3.50 (q, J= 6.2 Hz, 2H), 3.43 (s, 2H), 3.41 (s, 2H), 3.01 (ddd, J = 10.0, 7.2, 1.9 Hz, 2H), 2.86 - 2.72 (m, 3H), 2.42 ( , J = 6.3 Hz, 2H), 2.39 - 2.28 (m, 2H), 2.16 (s, 3H), 2.00 - 1.81 (m, 4H), 1.43 (q, 7= 10.4 Hz, 2H). I9F NMR (376 MHz, d6-DMSO) δ -67.60 (s). LCMS (M+H)+: 609.3.
Example 43. {trans-3-(4-{[4-{[(3S)-3-hydroxypyrrolidin-l-yl]methyl}-6-
(trifluoromethyl)pyridin-2-yl]amino}piperidin-l-yl)-l-[4-(7H-pyrrolo[2,3- d]pyrimidin-4-yl)-lH-pyrazol-l-yl]cyclobutyl}acetonitrile
Prepared according to the method of Example 39, using (3S)-pyrrolidin-3-ol (0.009 mL, 0.1 mmol, Acros) in the displacement step. Yield: (5.3 mg, 39%). Ή NMR (400 MHz, d6-DMSO) δ 3.65 (s, OH), 3.56 - 3.43 (m, 7H), 3.41 (s, 6H), 3.01 (ddd, J= 10.1, 7.2, 1.9 Hz, 10H), 2.78 (t, J= 7.4 Hz, 15H), 2.67 (dd, J= 9.6, 6.2 Hz, 4H), 2.57 (q, J= 7.8 Hz, 5H), 2.41 (td, J= 8.1, 5.7 Hz, 5H), 2,37 - 2.23 (m, 11H), 2.07 - 1.77 (m, 1 1H), 1.62 - 1.50 (m, 5H), 1.43 (q, /= 10.4, 9.8 Hz, 5H). I 9F NMR (376 MHz, d6-DMSO) δ -67.62 (s). LCMS (M+H)+: 621.3. Example 44. {trans-3-(4-{[4-{[(3R)-3-hydroxypyrrolidin-l-yl]me(hyl}-6- (trifluoromethyl)pyridin-2-yl]amino}piperidin-l-yl)-l-[4-(7H-pyrrolo[2,3- d]pyrimidin-4-yl)-lH-pyrazol-l-yl]cyclobutyl}acetonitrile
Prepared according to the method of Example 39, using (3R)-pyrrolidin-3-ol (0.009 mL, 0.1 mmol, Acros) in the displacement step. Yield: (6.4 mg, 47%). Ή NMR (400 MHz, d6-DMSO) δ 12.14 (br s, 1H), 8.83 (s, 1H), 8.70 (s, 1H), 8.43 (s, 1H), 7.61 (d, J= 3.6 Hz, 1H), 7.09 (d, = 3.6 Hz, 1H), 6.98 (d, J= 7 A Hz, 1H), 6.80 (s, 1H), 6.67 (s, 1H), 4.73 (d, /= 4.3 Hz, 1H), 4.20 (tt, J= 7.7, 3.8 Hz, 1H), 3.79 - 3.59 (m, 1H), 3.56 - 3.44 (m, 2H), 3.42 (s, 2H), 3.09 - 2.93 (m, 2H), 2.87 - 2.72 (m, 3H), 2.68 (dd, J= 9.6, 6.2 Hz, 1H), 2.58 (q, J= 7.8 Hz, 1H), 2.42 (td, J= 8.1 , 5.6 Hz, 1H), 2.38 - 2.26 (m, 3H), 2.08 - 1.79 (m, 5H), 1.55 (dddd, J= 13.1, 8.0, 5.5, 3.5 Hz, 1H), 1.43 (q, J= 10.9, 10.4 Hz, 2H). 19F NMR (376 MHz, d6-DMSO) δ -67.62 (s). LCMS (M+H)+: 621.2.
Example 45. {trans-3-(4-{[4-(methoxymethyl)-6-(trifluoromethyl)pyridin-2- yl]amino}piperidin-l-yl)-l-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l- yl]cyclobutyl}acetonitrile
Methanesulphonic anhydride (13 mg, 0.073 mmol, Aldrioh) was added to a solution of {trans-3-(4-{[4-(hydiOxymethyl)-6-(trifluoromethyl)pyi'idin-2- yl]amino}piperidin-l-yl)-l-[4-(7-{[2-(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3- d]pyrimidin-4-yl)-lH-pyrazol-l-yl]cyclobutyl}acetoniti'ile (20. mg, 0.029 mmol, Peak 2 of Example 31, Step 5) and N,N-diisopropylethylamine (15 uL, 0.088 mmol) in methylene chloride (1.0 mL). After stirring for 30 minutes, solvent was removed in vacuo and replaced with methanol (1.0 mL). The mixture was heated in a sealed vial to 80 °C for 30 minutes, then to 85 °C for 3.5 hours. The methanol was removed in vacuo and the crude product was deprotected by stirring with 1 : 1 mixture of TFA/DCM for one hour, followed by evaporation of solvents and stirring with ethylenediamine (0.1 mL) in methanol (1.0 mL) for 10 minutes. Purification via preparative HPLC-MS (C18 eluting with a gradient of MeCN and H20 containing 0.15% ΝΗ,ΟΗ) afforded product as the free base (8.0 mg, 48%). Ή NM (400 MHz, d6-DMSO) δ 12.13 (br s, 1H), 8.83 (s, 1H), 8.69 (s, 1H), 8.42 (s, 1H), 7.60 (d, J = 3.6 Hz, 1H), 7.08 (d, J= 3.6 Hz, 1H), 7.04 (d, J= 7.5 Hz, 1H), 6.77 (s, 1H), 6.66 (s, 1H), 4.37 (s, 2H), 3.72 - 3.58 (m, 1H), 3.41 (s, 2H), 3.32 (s, 3H), 3.07 - 2.94 (m, 2H), 2.86 - 2.69 (m, 3H), 2.41 - 2.26 (m, 2H), 2.01 - 1.76 (m, 4H), 1.43 (q, J= 10.6 Hz, 2H). I F NMR (376 MHz, d6-DMSO) S -67.76 (s). LCMS (M+H)+: 566.0.
Example 46. {trans-3-(4-{[4-(2-oxa-6-azaspiro[3.3]hept-6-ylmethyl)-6-
(trifluoromethyl)pyridin-2-yl]amiao}piperidin-l-yl)-l-[4-(7H-pyrrolo[2,3- d]pyrimidm-4-yl)-lH-pyrazol-l-yl]cyeIobutyl}acetonitrile
Prepared according to the method of Example 39, using 2-oxa-6- azaspiro[3.3]heptane (11 mg, 0.1 1 mmol, J&W Pharmlab) in a mixture of THF (0.5 mL) and methanol (0.5 mL) in the displacement step, which was carried out at room temperature for 2 hours. Yield: (6.4 mg, 46%). Ή NMR (400 MHz, CD3OD) δ 8.74 (s, 1H), 8.67 (s, 1H), 8.41 (s, 1H), 7.51 (d, J= 3.6 Hz, 1H), 7.00 (d, J= 3.7 Hz, 1H), 6.76 (s, 1H), 6.53 (s, 1H), 4.73 (s, 4H), 3.92 - 3.72 (m, 1 H), 3.50 (s, 2H), 3.45 (s, 4H), 3.18 - 3.04 (m, 2H), 3.02 - 2.80 (m, 3H), 2.55 - 2.41 (m, 2H), 2.27 - 1.95 (m, 4H), 1.70 - 1.36 (m, 2H). 19F NMR (376 MHz, CD3OD) δ -70.74 (s). LCMS (M+H)+:
633.3. Example 47. {trans-3-{4-[[4-(hydroxymethyl)-6-(trifluoromethyl)pyridin-2- yl](methyl)amino]piperidin-l-yl}-l-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH- pyrazol-l-yl]cyclobufyl}acetonitrile
Step 1. tert-bntyl 4-(methylamino)piperidine-l-carboxylate
To a solution of tert-butyl 4-oxo-l -piperidinecarboxylate (0.50 g, 2.5 mmol, Aldrich) and 2.0 M methylamine in Tetrahydrofuran (10. mL, 20. mmol, Aldrich) was added sodium triacetoxyborohydride (1.3 g, 6.3 mmol). After stirring of the suspension overnight, the reaction was quenched with water and stirred for 1 hour. Brine was added and the product was extracted with two portions of DCM. The combined organic extracts were dried over sodium sulfate, filtered and concentrated. The product was used without further purification in Step 2. LCMS (M+H)+: 215.2.
Step 2. tert-butyl 2-[[l-(tert-butoxycarbonyl)piperidin-4-yl](methyl)amino]-6- (trifluoromethyl)isomcotmate
A mixture of tert-butyl 2-chloro-6-(trifluoromethyl)isonicotinate (0.47 g, 1.7 mmol, from Example 21, Step 1), tert-butyl 4-(methylamino)piperidine-l -carboxylate (0.54 g, 2.5 mmol, from Step 1) and N,N-diisopropylethylamine (0.58 mL, 3.4 mmol) in dimethyl sulfoxide (1.4 mL) was heated in an oil bath held at 100 °C for 26 hours. The mixture was cooled to room temperature and diluted with EtOAc. The organic solution was washed with three portions of water, one portion of brine, was dried over sodium sulfate, filtered and concentrated. Flash chromatography using a 40 g silica gel cartridge and eluting with a gradient from 0-20% EtOAc in hexanes afforded product as a white solid (0.30 g, 39%).
'H NMR (400 MHZ, CDC13) 5 7.31 (d, .7= 0.8 Hz, 1H), 7.22 (s, 1H), 4.80 - 4.52 (m, 1H), 4.23 (br m, 2H), 2.94 (s, 3H), 2.81 (br m, J= 28.1 Hz, 2H), 1.73 - 1.61 (m, 4H),
1.60 (s, 9H), 1.48 (s, 9H). 19F MR (376 MHz, CDC13) δ -69.15 (s). LCMS (M- tBu+H)+: 404.0.
Step 3. tert-butyl 4-[[4-(hydroxymethyl)-6-(trifluoromethyl)pyridin-2- yl](methyl)amino]piperidine-l-carboxylate
Potassium hydroxide (0.29 g, 5.2 mmol) was added to a solution of tert-butyl 2-[[l-(tert-butoxycarbonyl)piperidin-4-yl](methyl)amino]-6- (trifluoromethyl)isonicotinate (0.30 g, 0.65 mmol, from Step 2) in tetrahydrofuran (4.3 mL). After stirring for 1 hour, the mixture was treated with 1.0 N HCl to achieve a pH between 2 and 3. Brine was added (10 mL) and the product was extracted with three portions of CHCI3 (10 mL each). The combined extracts were dried over sodium sulfate, filtered and concentrated to afford product as a light yellow powder (0.38 g). The carboxylic acid was dissolved in tetrahydrofuran (3.0 mL) and cooled in an ice bath. Triefhylamine (0.18 mL, 1.3 mmol) followed by Isobutyl chloroformate (0.10 mL, 0.78 mmol) were introduced. After stirring for 30 minutes, the reaction was filtered through a short pad of celite into a flask containing ice-cold Sodium tetrahydroborate (86 mg, 2.3 mmol) in Water (1.4 mL). THF (10 mL) was used to rinse through the celite pad, into the reaction flask. The reaction was allowed to warm to room temperature and stir for 1 hour. Saturated ammonium chloride solution was introduced to quench the reaction. The product was extracted into ethyl acetate. The organic solution was washed with brine, dried over sodium sulfate, filtered and concentrated. Flash chromatography, using a 40 g silica gel cartridge and eluting with a gradient fromO-50% EtOAc in hexanes afforded product as a white solid (50 mg, 20%). Ή NMR (400 MHz, CDC13) δ 6.85 (s, 1H), 6.67 (s, 1H), 4.74-4.62 (m, 1H), 4.69 (s, 2H), 4.15 (br m, J = 57.8 Hz, 2H), 2.95-2.73 (br m, 2H), 2.89 (s, 3H), 1.74 - 1.52 (m, 4H), 1.47 (s, 9H). LCMS (M-tBu+H)+: 334.0.
Step 4. {cis-3-{4-[[4-(hydroxymethyl)-6-(trifliioro ethyl)pyridin-2- yl](melhyl)amino]piperidin-l-yl}-l-[4-(7-{[2-(trimethylsilyl)ethoxy]methyl}-7H- pyrrolo[2 -d]pyrimidm-4-yl)-lH-pyrazol-l-yl]cyclob tyl}acetoivtrile and {trans-3- {4-[[4-ftydroxymethyl)-6-(triflimromethyl)pyridiri-2-yl](methyl)ammo]piperidm-l- yl}-l-[4-(7-{[2-(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-
pyrazol-l-yl]cyclobutyl}acetomtrile
A solution of tert-butyl 4-[[4-(hydroxymethyl)-6-(trifluoromethyl)pyridin-2- yl](methyl)amino]piperidine-l-carboxylate (43 mg, 0.11 mmol, from Step 3) in 1,4- dioxane (1.0 mL) was treated with 4.0 M hydrogen chloride in dioxane (0.55 mL, 2.2 mmol) and stirred for 1.5 hours. The mixture was treated with 1.0 N NaOH to achieve pH~12, then was saturated with NaCl and extracted with six portions of chloroform. The combined organic extracts were dried over sodium sulfate, filtered and concentrated. A reducing mixture was prepared by combining sodium cyanoborohydride (16 mg, 0.25 mmol) and zinc dichloride (17 mg, 0.13 mmol) in methanol (0.95 mL) and stirring for 2 hours. After the Boc-deprotection and extraction, the piperidine was mixed with {3-oxo-l-[4-(7-{[2- (trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l- yl]cyclobutyl}acetonitrile (78 mg, 0.18 mmol, Intermediate Example Al, Step 7) in methanol (2.0 mL) and the reducing mixture generated by combining NaCNB¾ and Zn<¾ was added. The reaction was stirred until determined complete by analytical LCMS. Purification via preparative HPLC-MS (C18 eluting with a gradient of MeCN and ¾0 containing 0.15% NH4OH) afforded separated products (Peak 1, cis- isomer: 7.0 mg, 9%, Peak 2, trans- isomer: 10.1 mg, 13%). Cis-isomer: Ή NMR (400 MHz, CDC ) δ 8.85 (s, 1H), 8.39 (s, 1H), 8.30 (s, 1H), 7.40 (d, J= 3.7 Hz, 1 H), 6.84 (s, 1H), 6.80 (d, J= 3.7 Hz, 1H), 6.66 (s, 1H), 5.68 (s, 2H), 4.69 (s, 2H), 4.61 - 4.39 (m, 1H), 3.64 - 3.36 (m, 2H), 3.14 (s, 2H), 3.02 - 2.76 (m, 5H), 2.91 (s, 3H), 2.76 - 2.65 (m, 2H), 2.09 - 1.94 (m, 2H), 1.85 - 1.67 (m, 4H), 1.02 - 0.74 (m, 2H), -0.05 (s, 9H). LCMS (M+H)+: 696.0.
Trans-isomer: Ή NMR (400 MHz, CDCb) δ 8.86 (s, 1H), 8.48 (s, 1H), 8.34 (s, 1H), 7.41 (d, J= 3.7 Hz, 1H), 6.84 (s, 1H), 6.82 (d, J= 3.7 Hz, 1H), 6.67 (s, 1H), 5.68 (s, 2H), 4.69 (s, 2H), 4.57 - 4.45 (m, 1H), 3.61 - 3.47 (m, 2H), 3.22 (s, 2H), 3.09 - 2.98 (m, 4H), 2.97-2.88 (m, 1H), 2.95 (s, 3H), 2.52 - 2.39 (m, 2H), 1.96 (td, J= 11.4, 2.0 Hz, 2H), 1.88 - 1.63 (m, 4H), 0.98 - 0.86 (m, 2H), -0.06 (s, 9H). LCMS (M+H)+: 696.0.
Step 5. {trans-3-{4-[[4-(hydroxymethyS)-6-(trifliioromethyI)pyridin-2- ylJ(methyl)ammoJpiperidin-l-yl}-l-[4-(7H-pyrrolo[2,3-dJpyrimidw-4-yl)-lH- pyrazol-l-yl]cyc biity}}acetonitrile
{trans-3-{4-[[4-(Hydroxymethyl)-6-(trifluoromethyI)pyridin-2- yl](methyl)amino]piperidin-l-yl}-l-[4-(7-{[2-(trimethylsi1yl)ethoxy]methyl}-7H- pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]cyclobutyl}acetonitrile (5.0 mg, 0.0072 minol, Peak 2 from Step 4) was dissolved in a 1 : 1 mixture of TFA DCM and stirred for one hour, then solvents were removed in vacuo. The residue was then stirred in methanol (1.0 mL) containing ethylenediamine (0.1 mL) for 10 minutes. Purification via preparative HPLC-MS (C18 editing with a gradient of MeCN and H20 containing 0.15% NH4OH) afforded product as the free base (2.0 mg, 49%). Ή NMR (400 MHz, CD3OD) δ 8.75 (s, 1H), 8.67 (s, 1H), 8.41 (s, 1H), 7.52 (d, J= 3.6 Hz, 1H), 7.00 (d, J= 3.6 Hz, 1H), 6.89 (s, 1H), 6.81 (s, 1H), 4.60 (s, 2H), 3.32 (s, 2H), 3.18 - 3.05 (m, 4H), 3.03-2.92 (m, 1 H), 2.97 (s, 3H), 2.57 - 2.41 (m, 2H), 2.04 (t, J= 1 1.1 Hz, 2H), 1.89 (qd, J= 12.2, 11.7, 3.5 Hz, 2H), 1.80 - 1.63 (m, 2H). 19F NMR (376 MHz, CD3OD) δ -70.65 (s). LCMS (M+H)+: 566.1.
Example 48. {trans-3-{4-[[4-[(ethylamino)methyl]-6-(trifluoromethyl)pyridin-2- yl](methyl)amino]piperidin-l-yl}-l-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH- pyrazol-l-yl]cyclobiityl}acetonitrile
Methanesulphonic anhydride (3.8 mg, 0.022 mmol, Aldrich) was added to a
solution of {trans-3-{4-[[4-(hydroxymethyl)-6-(trifluoromethyl)pyndin-2- yl](methyl)araino]piperidin-l-yl}-l-[4-(7-{[2-(trimethyIsilyl)ethoxy]methyI}-7H- pyrrolo[2,3 -d]pyrim idin-4-y 1)- 1 H-pyrazol- 1 -y ljcyclobutyl} acetonitri le (5.0 mg, 0.0072 mmol, Peak 2 from Example 47, Step 4) and N,N-diisopropylethylamine (6.2xL, 0.036 mmol) in methylene chloride (0.20 mL) and the reaction was stirred for 30 minutes. Solvent was removed in vacuo and replaced by tetrahydrofuran (0.20 mL). Ethylamine (16 μί, 0.29 mmol, Aldrich) was added, followed by methanol (0.10 mL). The mixture was heated to 40 °C for 30 minutes. The crude product was deprotected by stirring in 1 : 1 TFA/DCM for 1 hour, removal of solvents, then stirring with ethylenediamine (0.1 mL) in methanol (1.0 mL) until deprotection was complete. Purification via preparative HPLC-MS (CI 8 eluting with a gradient of MeCN and H20 containing 0.15% NH4OH) afforded product as the free base (1.7 mg, 40%). Ή NM (400 MHz, CD3OD) δ 8.75 (s, 1H), 8.67 (s, 1H), 8.41 (s, lH), 7.52 (d, J= 3.6 Hz, 1H), 7.00 (d, J= 3.6 Hz, 1H), 6.93 (s, 1H), 6.81 (s, 1H), 4.68 - 4.50 (m, 1H), 3.74 (s, 2H), 3.32 (s, 2H), 3.17 - 3.06 (m, 4H), 3.02-2.90 (m, 1H), 2.97 (s, 3H), 2.64 (q, J = 7.2 Hz, 2H), 2.54 - 2.44 (m, 2H), 2.04 (t, J= 11.1 Hz, 2H), 1.89 (qd, J= 12.4, 3.5 Hz, 2H), 1.79 - 1.68 (m, 2H), 1.15 (t, J = 7.2 Hz, 3H). I 9F NMR (376 MHz, CD3OD) δ - 70.62 (s). LCMS (M+H)+: 593.1. Example 49. {trans-3-(4-{[4-(3-hydroxyoxetaii-3-yl)-6-(trifluoromethyl)pyridin- 2-yl]oxy}piperidin-l-yl)-l-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yI)-lH-pyrazol-l- yl]cyclobutyl}acetonitrile
To a solution of 2-chloiO-4-iodo-6-(trifluoromethyl)pyridine (1 ,00 g, 3.25 mmol, European Journal of Organic Chemistry, (18), 3793-3798, 2004) in tetrahydrofuran (20 mL) at 0 °C was added dropwise 2.0 M isopropylmagnesium chloride in diethyl ether (1.95 mL, 3.90 mmol, Aldrich) . After stirring for 30 minutes at 0 °C, a solution of oxetan-3-one (0.281 g, 3.90 mmol, Synthonix) in
Tetrahydrofuran (5 mL) was added. After stirring for 1 hour, the reaction was quenched by the addition of water and ammonium chloride. The product was extracted with two portions of ethyl acetate. The combined organic extracts were dried over sodium sulfate, filtered and concentrated. Flash chromatography, eluting with a gradient from 0-40% EtOAc in hexanes on a 40 g silica gel cartridge afforded purified product (0.31 g , 38%). LCMS (M+H)+: 254.1.
Step 2. tert-butyl 4-{[4-(3-hydroxyoxetan-3-yl)-6-(trifluoro ethyl)pyridin-2- yl]oxy}piperidine-l -carboxylate
To sodium hydride (60% in mineral oil, 0.20 g, 4.9 mmol) in a dry flask was added tetrahydrofuran (20 mL), followed by tert-butyl 4-hydroxypiperidine-l- carboxylate (0.98 g, 4.9 mmol, Aldrich). After stirring for 1 hour at room temperature, a solution of 3-[2-chloro-6-(trifluoromethyl)pyridin-4-yl]oxetan-3-ol (0.31 g, 1.2 mmol, from Step 1) in tetrahydrofuran (1 1 mL) was introduced. The reaction was stirred at ambient temperature for 2 hours, followed by heating to 65 °C overnight. The reaction was cooled to room temperature and water was added, followed by saturated ammonium chloride to adjust the pH to between 7 and 8. The product was extracted with two portions of DCM. The combined organic extracts were dried over sodium sulfate, decanted and concentrated. The product was purified by flash chromatography, eluting with a gradient from 0-20% EtOAc in hexanes, on a 40 g silica gel column to afford 0.17 g of desired product (yield 30%). Ή NMR (400 MHz, CDC13) δ 7.58 (d, /= 1.3 Hz, 1H), 7.22 - 7.15 (m, 1H), 5.28 (tt, J= 7.6, 3.7 Hz, 1H), 4.91 (d, 7 = 7.6 Hz, 2H), 4.77 (d, J= 6.9 Hz, 2H), 3.72 (ddd, y= 12.5, 6.6, 3.9 Hz, 2H), 3.32 (ddd, y= 13.8, 8.0, 3.7 Hz, 2H), 1.98 (ddt, y= 13.6, 7.1 , 3.6 Hz, 2H), 1.73 (ddt, = 16.5, 8.1, 3.9 Hz, 2H), 1.46 (s, 9H). I9F NMR (376 MHz, CDC¾) δ - 68.78 (s). LCMS (M+Na)+: 441.1.
Step 3. 3-[2-(piperidin-4-yloxy)-6-(triflitoromethyl)pyridin-4-yl]oxetan-3-ol
A solution of tert-butyl 4-{[4-(3-hydroxyoxetan-3-yl)-6- (trifluoromethyl)pyridin-2-yl]oxy}piperidine-l -carboxylate (0.080 g, 0.17 mmol, from Step 2) in 1,4-dioxane (1.0 mL) was treated with a few drops of water and six drops of concentrated H2SO4 and was stirred overnight. The mixture was made basic with 10 mL of saturated sodium bicarbonate solution and the product was extracted with three portions of DCM. The combined extracts were dried over sodium sulfate, filtered and concentrated to afford crude product, which was used directly in the next step (44 mg, 81%). Ή NMR (300 MHz, CDCI3) δ 7.58 (d, J= 1.2 Hz, 1H), 7.18 (s, 1H), 5.22 (tt, J= 8.2, 3.9 Hz, 1H), 4.91 (d, J= 7.4 Hz, 2H), 4.78 (d, J= 7.4 Hz, 2H), 3.10 (dt, J= 1 1.9, 4.3 Hz, 2H), 2.79 (ddd, J= 12.5, 9.1, 3.1 Hz, 2H), 2.16 - 1 .98 (m, 2H), 1.70 (dtd, J= 12.7, 8.8, 3.8 Hz, 2H). I 9F NMR (282 MHz, CDC13) δ -68.76 (s). LCMS (M+H)+: 319.1.
Step 4. {cis-3-(4-{[4-(3-hydroxyoxetan-3-yl)-6-(trifluoromethyl)pyridin-2- yl]oxy}piperidm-l-yl)-l-[4-(7H-pyi olo[2,3-d]pyrimidm-4-yl)-lH-pyrazol-l- yl]cyclobutyl}acetonitrile and {trans-3-(4-{[4-(3-hydroxyoxetan-3-yl)-6- (trifluoro ethyl)pyridin-2-yl]oxy}piperidin-l-yl)-l-[4-(7H-pyrrolo[2,3-d]pyrimidin- 4-yl)-lH-pyrazol-l-yI]cyclobutyl}acetomtrile
A reducing mixture was prepared by combining sodium cyanoborohydride (1 1 mg, 0.17 mmol) and zinc dichloride (12 mg, 0.087 mmol) in methanol (0.65 mL) and stirring for 2 hours. Then, 3-[2-(piperidin-4-yloxy)-6-(trifluoromethyl)pyridin-4- yl]oxetan-3-ol (44 mg, 0.12 mmol, from Step 3) and {3-oxo-l-[4-(7H-pyrrolo[2,3- d]pyrimidin-4-yl)-lH-pyrazol-l-yl]cyclobutyl}acetonitriIe (44 mg, 0.15 mmol) (prepared by stirring the product of Intermediate Example Al , Step 7 in 1 : 1 TFA/DCM for an hour, then evaporating solvent and stirring with ammonium hydroxide/Methanol until deprotection complete, followed by purification via preparative HPLC-MS (C 18, eliiting with a gradient of MeCN/¾0 containing 0.15% NH40H)) were mixed in methanol (1.8 mL) and stirred just enough time to dissolve, then the reducing mixture generated above was added. After stirring overnight, the mixture was purified via preparative HPLC-MS (CI 8, eluting with a gradient of
MeCN H20 containing 0.15% NH4OH) to afford a mixture of two
diastereomers. (15.7 mg. yield 21%). The two diastereomers were separated using a chiral HPLC column (Phenomenex Lux Cellulose-2, eluting with 45% EtOH in Hexanes at 18 ml/min, using a loading of ~6mg/injection). Retention time for Peak 1 : 7.25 min, trans-isomer, 4.2 mg, 5.6% yield. Retention time for Peak2: 9.84 min, cis- isomer, 4.5 mg, 6% yield. Peak 1, Trans-isomer: Ή NMR (400 MHz, d6-DMSO) δ 12.13 (s, 1H), 8.83 (s, 1H), 8.43 (s, 1H), 7.67 - 7.50 (m, 2H), 7.22 (s, 1H), 7.08 (dd, 7 = 3.5, 1.7 Hz, lH), 6.79 (s, 1H), 5.04 (br s, 1H), 4.77 (d, J= 6.9 Hz, 2H), 4.67 (d, J = 6.8 Hz, 2H), 3.42 (s, 2H), 3.09 - 2.94 (m, 2H), 2.94 - 2.74 (m, 1H), 2.74 - 2.57 (m, 2H), 2.43 - 2.28 (m, 2H), 2.28 - 2.1 1 (m, 2H), 2.11 - 1.90 (m, 2H), 1.84 - 1.59 (m, 2H). 19F NMR (376 MHz, d6-DMSO) δ -67.38 (s). LCMS (M+H)+: 595.3. Peak 2, Cis- isomer: Ή NMR (400 MHz, d6-DMSO) δ 12.13 (s, 1H), 8.70 (s, 1H), 8.68 (s, 1H), 8.40 (s, 1H), 7.60 (d, J= 3.9 Hz, 1H), 7.22 (s, 1H), 7.07 (d, J= 3.6 Hz, 1H), 6.80 (s, 1H), 5.04 (tt, J= 8.3, 4.0 Hz, 1H), 4.77 (d, J= 7.1 Hz, 2H), 4.67 (d, J= 7.1 Hz, 2H), 3.47 (s, 2H), 2.94 (p, J= 7.6 Hz, 1H), 2.72 - 2.54 (m, 6H), 2.28 - 2.10 (m, 2H), 2.07 - 1.90 (m, 2H), 1 .76 - 1.62 (m, 2H). I 9F NMR (376 MHz, d6-DMSO) δ -67.38 (s). LCMS (M+H)+: 595.2
Example 50. {trans-3-(4-{[4-(3-aminooxetan-3-yl)-6-(trifluoromethyl)pyridiii-2- yl]oxy}piperidin-l-yl)-l-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l- yl]cyclobutyl}acetoiiitrile
Step I. tert-butyl 4-{[4-{3-[(methylsulfortyl)oxy]oxetan-3-yl}-6-
(trifliioromethyl)pyridin-2-yl]oxy}piperidine-l -carboxylate
Methanesulfonyl chloride (50. .iL, 0.64 mmol) was added to a solution of tert- butyl 4-{ [4-(3-hydroxyoxetan-3-yl)-6-(trifluoromethyl)pyridin-2-yl]oxy}piperidine- l - carboxylate (0.20 g, 0.43 mmol, from Example 49, Step 2) and triethylamine (120 μί, 0.86 mmol) in methylene chloride (5.0 mL) at 0 °C. The mixture was allowed to warm to room temperature and stir for 1 hour, then the reaction was further diluted with DCM and water, and the mixture was neutralized by the addition of saturated sodium bicarbonate. The organic layer was separated and washed with water and brine, was dried over sodium sulfate, filtered and concentrated to afford 0.22 g of a light yellow oil. The oil was dissolved in dimethyl sulfoxide (2.0 mL) and sodium azide (0.17 g, 2.6 mmol) was added. The reaction was stirred at room temperature for 50 minutes and then was heated to 40 °C overnight, followed by 70 °C for 3 hours. The mixture was then cooled to room temperature and was diluted with EtOAc. The organic solution was washed with water (3x), brine (lx), dried over sodium sulfate, filtered and concentrated to afford 0.14 g crude product, yield 66%. 'H NMR (300 MHz, CDCla) S 7.45 (d, J = 1.3 Hz, 1H), 7. 12 - 7.02 (m, 1H), 5.29 (tt, J = 7.9, 3.9 Hz, 1H), 5.06 (d, J = 7.5 Hz, 2H), 4.86 (d, J= 7.5 Hz, 2H), 3.75 (ddd, J= 12.1 , 6.2, 3.7 Hz, 2H), 3.33 (ddd, J = 13.3, 8.3, 3.6 Hz, 2H), 1.99 (ddt, J = 10.3, 7.0, 3.6 Hz, 2H), 1.75 (dtd, J = 1 2.7, 8.3, 4.1 Hz, 2H), 1.47 (s, 9H). , 9F NMR (282 MHz, CDC13) δ -68.86 (s). LCMS (M+Na)+: 466. 1 .
Step 2. tert-butyl 4-{[4-(3-ammooxetan-3-yl)-6-(lrifliiorome1hyl)pyridin-2- yl]oxy}piperidine-l-carboxylate
To a solution of tert-butyl 4-{[4-(3-azidooxetan-3-yl)-6- (trifluoromethyl)pyridin-2-yl]oxy}piperidine-l-carboxylate (0.14 g, 0.28 mmol, from Step 1) in tetrahydrofuran (6.3 mL) and water (2 mL) was added dropwise a solution of 1 .0 M trimethylphosphine in THF (0.34 mL, 0.34 mmol, Aldrich). After 20 minutes, the mixture was partitioned between water and DCM, and the aqueous layer was extracted with one additional portion of DCM. The combined organic extracts were dried over sodium sulfate, filtered and concentrated. Purification using flash chromatography on a 12 g silica gel column, eluting with a gradient of 0-5% MeOH in DCM afforded product as an oil (0.10 g, 86%).
'H NMR (300 MHz, CDC13) 8 7.53 (br s, 2H), 7.34 (d, J = 1.0 Hz, 1 H), 6.99 - 6.85 (m, 1H), 5.36 - 5.19 (m, 1H), 5.12 (d, /= 6.6 Hz, 2H), 4.87 (d, = 6,6 Hz, 2H), 3.82 - 3.66 (m, 2H), 3.32 (ddd, J= 13.2, 8.3, 3.6 Hz, 2H), 1.99 (ddt, J= 13.9, 7.0, 3.6 Hz, 2H), 1.85 - 1.62 (m, 2H), 1.47 (s, 9H). 19F NMR (282 MHz, CDCI3) δ -68.80 (s). LCMS (M+Na)+: 440.1.
Step 3. {cis-3-(4-{[4-(3-aminooxetan-3-yl)-6-(trifliioromethyl)pyridin-2- ylJoxy}piperidm-l-yl)-l-[4-(7H-pyrro [2,3-d]pyrimidin-4-yl)-lH-pyi-azol-l- yljcyclobiityljacetonitrile and {trans-3-(4-{[4-(3-aminooxetan-3-yl)-6- (trifluowmethyl)pyridin-2~yl]oxy}piperidin-l-yl)^-[4-(7H^yrrolo[2,3-d]pyrm d ^ 4-yl)-lH-pyrazol-l-yl]cyclobutyl}acetonitrile
tert-Butyl 4-{[4-(3-aminooxetan-3-yl)-6-(trifIuoromethyl)pyridin-2- yI]oxy}piperidine-l-carboxylate (95 mg, 0.23 mmol, from Step 2) was Boc- deprotected by stirring in 1,4-dioxane (1.3 mL) containing a few drops of water and a few drops of .H2SO4 overnight. The mixture was basified by the addition of 15 mL saturated sodium bicarbonate solution and the product was extracted with chloroform (4x). The combined organic extracts were dried over sodium sulfate, filtered and concentrated to afford the crude product, LCMS (M+H)+: 318.1. This product was dissolved along with {3-oxo-l-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l- yl]cyclobutyl}acetonitrile (66 mg, 0.23 mmol, prepared as described in Example 49, Step 4) in methanol (5.0 mL) . Then a pre-generated solution of sodium cyanoborohydride (20. mg, 0.32 mmol) and Zinc dichloride (22 mg, 0.16 mmol) in methanol (1.0 mL) (which had been stirred for 2 hours) was added. The reductive amination step was carried on for 4 hours. Purification via preparative HPLC-MS (C18 eluting with a gradient of MeCN/H20 containing 0.15% NH4OH) afforded the product as a mixture of cis- and trans- diastereomers (33 mg, 24%). The isomers were separated by chiral HPLC: Phenomenex Lux Cellulose-1, 21.2x250mm, 5μιη, 2.5 mg/inj, eluting with 20% ethanol in hexanes at 18ml/min. Retention time of Peakl, cis-isomer: 12.22 min, (yield: 1 1 mg, 8%). Retention time of Peak2, trans-isomer: 16.25 min, (yield: 12 mg, 9%). Peak 1, Cis-isomer: Ή NMR (400 MHz, d6-DMSO) δ 12.13 (s, 1H), 8.70 (s, 1 H), 8.69 (s, 1H), 8.40 (s, 1H), 7.65 (s, 1H), 7.60 (dd, .7= 3.3, 2.4 Hz, 1H), 7.24 (s, 1H), 7.07 (dd, 7= 3.4, 1.6 Hz, 1H), 5.09 - 4.98 (m, 1H), 4.64 (s,
4H), 3.47 (s, 2H), 3.06 - 2.54 (m, 7H), 2.29 - 2.13 (m, 2H), 2.07 - 1.88 (m, 2H), 1.76 - 1.61 (m, 2H). "F NMR (376 MHz, d6-DMSO) δ -67.27 (s). LCMS (M+H)+: 594.2. Peak 2, Trans-isomer: Ή NMR (400 MHz, d6-DMSO) δ 12.13 (s, 1H), 8.83 (s, 1H), 8.69 (s, 1H), 8.42 (s, 1H), 7.64 (d, J= 0.9 Hz, 1H), 7.61 (d, J= 2.5 Hz, 1H), 7.23 (s, 1H), 7.08 (d, J= 3.4 Hz, 1H), 5.04 (tt, J= 8.7, 4.1 Hz, 1H), 4.63 (s, 4H), 3.42 (s, 2H), 3.11 - 2.94 (m, 2H), 2.92 - 2.56 (m, 5H), 2.41 - 2.27 (m, 2H), 2.27 - 2.09 (m, 2H), 2.02 (s, 2H), 1.78 - 1.64 (m, 2H). 19F NMR (376 MHz, d6-DMSO) 8 -67.27 (s). LCMS (M+H)+: 594.2. Example A: In vitro JA Kinase Assay
Compounds herein were tested for inhibitory activity of JAK targets according to the following in vitro assay described in Park et a!., Analytical Biochemistry 1999, 269, 94-104. The catalytic domains of human JAKl (a.a. 837-1 142) and JAK2 (a.a. 828-1 132) with an N-terminal His tag were expressed using baculovirus in insect cells and purified. The catalytic activity of JAKl and JAI 2 was assayed by measuring the phosphorylation of a biotinylated peptide. The phosphorylated peptide was detected by homogenous time resolved fluorescence (HTRF). ICsos of compounds were measured for each kinase in the 40 microL reactions that contain the enzyme, ATP and 500 nM peptide in 50 mM Tris (pH 7.8) buffer with 100 mM NaCl, 5 mM DTT, and 0.1 mg/mL (0.01%) BSA. For the 1 mM ICso measurements, ATP concentration in the reactions was 1 mM. Reactions were carried out at room temperature for 1 hour and then stopped with 20 μΐ, 45 mM EDTA, 300 nM SA-APC, 6 nM Eu-Py20 in assay buffer (Perkin Elmer, Boston, MA). Binding to the Europium labeled antibody took place for 40 minutes and HTRF signal was measured on a Fusion plate reader (Perkin Elmer, Boston, MA). See Table A for data related to compounds of the
Examples (at 1 mM). Data is indicated as ranges: <20 nM (+), 20 to <150 nM (++), 150 to 500 nM (+++).
Table A
Example JAKl IC50 (nM) JAK2 IC50 (nM) JAK2/JAK1 at I mM ATP at 1 mMATP
1 + ++ >10
2 + ++ >10
Example JA l IC50 (nM) JAK2 IC50 (nM) JAK2/JAK1 at 1 mM ATP at l mM ATP
3 + ++ >10
4 + ++ >10
5 + ++ >10
6 + ++ >10
7 + ++ >10
8 + ++ >10
9 + ++ >10
10 + ++ >10
11 + ++ >10
12 + ++ >10
13 + ++ >10
14 + ++ >10
15 + ++ >10
16 + ++ >10
17 + ++ >10
18 + ++ >10
20 + ++ >10
21 + +++ >10
22 + ++ >10
23 + ++ >10
24 + ++ >10
25 + +-H- >10
26 + +++ >10
27 + ++ >10
28 + ++ >10
29 + ++ >10
30 + ++ >10
31 + ++ >10
32 + ++ >10
33 + ++ >10
Example JAK1 IC50 (nM) JAK2 IC50 (nM) JAK2/JAK1 at 1 mMATP at 1 mM ATP
34 + ++ >10
35 + ++ >10
36 + +++ >10
37 + +++ >10
38 + ++ >10
39 + ++ >10
40 + ++ > 10
41 + ++ >10
42 + ++ >10
43 + ++ >10
44 + ++ >10
45 + ++ >10
46 + ++ >10
47 + +++ >10
48 + ++ >10
49 + ++ >10
50 + ++ >10
Example B: Cellular Assays
Cancer cell lines dependent on cytokines and hence JA /STAT signal transduction, for growth, can be plated at 6000 cells per well (96 well plate format) in
RPMI 1640, 10% FBS, and 1 nG/mL of appropriate cytokine. Compounds can be added to the cells in DMSO/media (final concentration 0.2% DMSO) and mcubated for 72 hours at 37 °C, 5% CO2. The effect of compound on cell viability is assessed using the CellTiter-Glo Luminescent Cell Viability Assay (Promega) followed by TopCount (Perkin Elmer, Boston, MA) quantitation. Potential off-target effects of compounds are measured in parallel using a non-JAK driven cell line with the same assay readout. All experiments are typically performed in duplicate.
The above cell lines can also be used to examine the effects of compounds on phosphorylation of JAK kinases or potential downstream substrates such as STAT
proteins, Akt, Shp2, or Erk. These experiments can be performed following an overnight cytokine starvation, followed by a brief preincubation with compound (2 hours or less) and cytokine stimulation of approximately 1 hour or less. Proteins are then extracted from cells and analyzed by techniques familiar to those schooled in the art including Western blotting or ELISAs using antibodies that can differentiate between phosphorylated and total protein. These experiments can utilize normal or cancer cells to investigate the activity of compounds on tumor cell survival biology or on mediators of inflammatory disease. For example, with regards to the latter, cytokines such as IL-6, IL-12, IL-23, or IFN can be used to stimulate JAK activation resulting in phosphorylation of STAT protein(s) and potentially in transcriptional profiles (assessed by array or qPCR technology) or production and/or secretion of proteins, such as IL-17. The ability of compounds to inhibit these cytokine mediated effects can be measured using techniques common to those schooled in the art.
Compounds herein can also be tested in cellular models designed to evaluate their potency and activity against mutant JAKs, for example, the JA 2V617F mutation found in myeloid proliferative disorders. These experiments often utilize cytokine dependent cells of hematological lineage (e.g. BaF/3) into which the wild- type or mutant JAK kinases are ectopically expressed (James, C, et al. Nature 434: 1 144-1 148; Staerk, J., et al. JBC 280:41893-41899). Endpoints include the effects of compounds on cell survival, proliferation, and phosphorylated JAK, STAT, Akt, or Erk proteins.
Certain compounds herein can be evaluated for their activity inhibiting T-cell proliferation. Such as assay can be considered a second cytokine {i.e. JAK) driven proliferation assay and also a simplistic assay of immune suppression or inhibition of immune activation. The following is a brief outline of how such experiments can be performed. Peripheral blood mononuclear cells (PBMCs) are prepared from human whole blood samples using Ficoll Hypaque separation method and T-cells (fraction 2000) can be obtained from PBMCs by eliitriation. Freshly isolated human T-cells can be maintained in culture medium (RPMI 1640 supplemented with 10% fetal bovine serum, 100 U/ml penicillin, 100 μg/ml streptomycin) at a density of 2 x 106 cells/ml at 37 °C for up to 2 days. For IL-2 stimulated cell proliferation analysis, T-cells are first treated with Phytohemagglutinin (PHA) at a final concentration of 10 μg/mL for 72h.
After washing once with PBS, 6000 cells/well are plated in 96-well plates and treated with compounds at different concentrations in the culture medium in the presence of 100 U/mL human IL-2 (ProSpec-Tany TechnoGene; ehovot, Israel). The plates are incubated at 37 °C for 72h and the proliferation index is assessed using CellTiter-Glo Luminescent reagents following the manufactory suggested protocol (Promega; Madison, WI).
Example C: In vivo anti-tumor efficacy
Compounds herein can be evaluated in human tumor xenograft models in immune compromised mice. For example, a tumorigenic variant of the ΓΝΑ-6 plasmacytoma cell line can be used to inoculate SCID mice subcutaneously (Burger, R., el al. Hematol J. 2:42-53, 2001). Tumor bearing animals can then be randomized into drug or vehicle treatment groups and different doses of compounds can be administered by any number of the usual routes including oral, i.p., or continuous infusion using implantable pumps. Tumor growth is followed over time using calipers. Further, tumor samples can be harvested at any time after the initiation of treatment for analysis as described above (Example B) to evaluate compound effects on JAK activity and downstream signaling pathways. In addition, selectivity of the compound(s) can be assessed using xenograft tumor models that are driven by other know kinases (e.g. Bcr-Abl) such as the 562 tumor model.
Example D: Murine Skin Contact Delayed Hypersensitivity Response
Test
Compounds herein can also be tested for their efficacies (of inhibiting JAK targets) in the T-cell driven murine delayed hypersensitivity test model. The murine skin contact delayed-type hypersensitivity (DTH) response is considered to be a valid model of clinical contact dermatitis, and other T-lymphocyte mediated immune disorders of the skin, such as psoriasis (Immunol Today. 1998 Jan;19(l):37-44). Murine DTH shares multiple characteristics with psoriasis, including the immune infiltrate, the accompanying increase in inflammatory cytokines, and keratinocyte hyperproliferation. Furthermore, many classes of agents that are efficacious in
treating psoriasis in the clinic are also effective inhibitors of the DTH response in mice (Agents Actions. 1993 Jan;38(l-2):116-21).
On Day 0 and 1, Balb/c mice are sensitized with a topical application, to their shaved abdomen with the antigen 2,4,dinitro-fluorobenzene (DNFB). On day 5, ears are measured for thickness using an engineer's micrometer. This measurement is recorded and used as a baseline. Both of the animals' ears are then challenged by a topical application of DNFB in a total of 20 μΐ, (10 on the internal pinna and 10 ]i on the external pinna) at a concentration of 0.2%. Twenty-four to seventy-two hours after the challenge, ears are measured again. Treatment with the test compounds is given throughout the sensitization and challenge phases (day -1 to day 7) or prior to and throughout the challenge phase (usually afternoon of day 4 to day 7). Treatment of the test compounds (in different concentration) is administered either systemically or topically (topical application of the treatment to the ears). Efficacies of the test compounds are indicated by a reduction in ear swelling comparing to the situation without the treatment. Compounds causing a reduction of 20% or more were considered efficacious. In some experiments, the mice are challenged but not sensitized (negative control).
The inhibitive effect (inhibiting activation of the JAK-STAT pathways) of the test compounds can be confirmed by immiinohistochemical analysis. Activation of the JAK-STAT pathway(s) results in the formation and translocation of functional transcription factors. Further, the influx of immune cells and the increased proliferation of keratinocytes should also provide unique expression profile changes in the ear that can be investigated and quantified. Formalin fixed and paraffin embedded ear sections (harvested after the challenge phase in the DTH model) are subjected to immunohistochemical analysis using an antibody that specifically interacts with phosphorylated STAT3 (clone 58E12, Cell Signaling Technologies). The mouse ears are treated with test compounds, vehicle, or dexamethasone (a clinically efficacious treatment for psoriasis), or without any treatment, in the DTH model for comparisons. Test compounds and the dexamethasone can produce similar transcriptional changes both qualitatively and quantitatively, and both the test compounds and dexamethasone can reduce the number of infiltrating cells. Both systemically and topical administration of the test compounds can produce inhibitive
effects, i.e., reduction in the number of infiltrating cells and inhibition of the transcriptional changes.
Example E: In vivo anti-inflammatory activity
Compounds herein can be evaluated in rodent or non-rodent models designed to replicate a single or complex inflammation response. For instance, rodent models of arthritis can be used to evaluate the therapeutic potential of compounds dosed preventatively or therapeutically. These models include but are not limited to mouse or rat collagen-induced arthritis, rat adjuvant-induced arthritis, and collagen antibody- induced arthritis. Autoimmune diseases including, but not limited to, multiple sclerosis, type I-diabetes mellitus, uveoretinitis, thyroditis, myasthenia gravis, immunoglobulin nephropathies, myocarditis, airway sensitization (asthma), lupus, or colitis may also be used to evaluate the therapeutic potential of compounds herein. These models are well established in the research community and are familiar to those schooled in the art (Current Protocols in Immunology, Vol 3., Coligan, J.E. et al, Wiley Press.; Methods in Molecular Biology: Vol. 225, Inflammation Protocols., Winyard, P.G. and Willoughby, D.A., Humana Press, 2003.).
Example F: Animal Models for the Treatment of Dry Eye, Uveitis, and Conjunctivitis
Agents may be evaluated in one or more preclinical models of dry eye known to those schooled in the art including, but not limited to, the rabbit concanavalin A (ConA) lacrimal gland model, the scopolamine mouse model (subcutaneous or transdermal), the Botulinumn mouse lacrimal gland model, or any of a number of spontaneous rodent auto-immune models that result in ocular gland dysfunction (e.g. NOD-SCID, MRL/lpr, or NZB NZW) (Barabino et al., Experimental Eye Research 2004, 79, 613-621 and Schrader et al., Developmental Opthalmology, arger 2008, 41, 298-312, each of which is incorporated herein by reference in its entirety). Endpoints in these models may include histopathology of the ocular glands and eye (cornea, etc.) and possibly the classic Schirmer test or modified versions thereof
(Barabino et al.) which measure tear production. Activity may be assessed by dosing
via multiple routes of administration (e.g. systemic or topical) which may begin prior to or after measurable disease exists.
Agents may be evaluated in one or more preclinical models of uveitis known to those schooled in the art. These include, but are not limited to, models of experimental autoimmune uveitis (EAU) and endotoxin induced uveitis (EIU). EAU experiements may be performed in the rabbit, rat, or mouse and may involve passive or activate immunization. For instance, any of a number or retinal antigens may be used to sensitize animals to a relevant immunogen after which animals may be challenged ocuarly with the same antigen. The EIU model is more acute and involves local or systemic administration of lipopolysaccaride at sublethal doses. Endpoints for both the EIU and EAU models may include fundoscopic exam, histopathology amongst others. These models are reviewed by Smith et al. (Immunology and Cell Biology 1998, 76, 497-512, which is incorporated herein by reference in its entirety). Activity is assessed by dosing via multiple routes of administration (e.g. systemic or topical) which may begin prior to or after measurable disease exists. Some models listed above may also develop scleritis/episcleritis, chorioditis, cyclitis, or iritis and are therefore useful in investigating the potential activity of compounds for the therapeutic treatment of these diseases.
Agents may also be evaluated in one or more preclinical models of conjunctivitis known those schooled in the art. These include, but are not limited to, rodent models utilizing guinea-pig, rat, or mouse. The guinea-pig models include those utilizing active or passive immunization and/or immune challenge protocols with antigens such as ovalbumin or ragweed (reviewed in Groneberg, D.A., et al., Allergy 2003, 58, 1101-11 13, which is incorporated herein by reference in its entirety). Rat and mouse models are similar in general design to those in the guinea- pig (also reviewed by Groneberg). Activity may be assessed by dosing via multiple routes of administration (e.g. systemic or topical) which may begin prior to or after measurable disease exists. Endpoints for such studies may include, for example, histological, immunological, biochemical, or molecular analysis of ocular tissues such as the conjunctiva.
Example G: In vivo protection of bone
Compounds may be evaluated in various preclinical models of osteopenia, osteoporosis, or bone resorption known to those schooled in the art. For example, ovariectomized rodents may be used to evaluate the ability of compounds to affect 5 signs and markers of bone remodeling and/or density (W.S.S. Jee and . Yao, J Musculoskel. Nueron. interact, 2001, 1(3), 193-207, which is incorporated herein by reference in its entirety). Alternatively, bone density and architecture may be evaluated in control or compound treated rodents in models of therapy (e.g.
glucocorticoid) induced osteopenia (Yao, et al. Arthritis and Rheumatism, 2008,
10 58(6), 3485-3497; and id. 58(1 1), 1674-1686, both of which are incorporated herein by reference in its entirety). In addition, the effects of compounds on bone resorption and density may be evaluable in the rodent models of arthritis discussed above (Example E). Endpoints for all these models may vary but often include histological and radiological assessments as well as immunohisotology and appropriate
15 biochemical markers of bone remodeling.
Various modifications of the invention, in addition to those described herein, will be apparent to those skilled in the art from the foregoing description. Such modifications are also intended to fall within the scope of the appended claims. Each reference, including all patent, patent applications, and publications, cited in the0 present application is incorporated herein by reference in its entirety.
Claims
1. A compound of claim 1, 2, 8, or 9 having Formula Ila,
Ila
ir a pharmaceutically acceptable salt thereof, wherein:
R3 is cyclopropyl, cyclobutyl, tetrahydro-2H-pyran ring, tetrahydrofuran ring, ir oxetane ring, wherein said cyclopropyl, cyclobutyl, tetrahydro-2H-pyran ring, etrahydrofuran ring, and oxetane ring are each optionally substituted with 1 or 2 ;roups independently selected from CH3, CN, OH, and OCH3; and
R4 is H.
2. A compound of claim 1, 2, 8, or 9 having Formula Ila,
lla
r a pharmaceutically acceptable salt thereof, wherein:
R3 and R4, taken together with the nitrogen atom to which they are attached, arm an azetidinyl group, which is optionally substituted with 1 or 2 independently elected R3a groups;
each R3a is independently CH3, CN, OH, OCH3, or -CH2-OH;
or alternatively, two R3a groups, taken together with the carbon atom to which iey are both attached, form a oxetane ring; and
3. A compound of claim 1, 2, 8, or 9 having Formula lla,
Ha
r a pharmaceutically acceptable salt thereof, wherein:
R3 and R4, taken together with the nitrogen atom to which they are attached, orm a IH-pyrazolyl, a IH-iniidazolyl, a lH-l,3,4-triazolyl, or a lH-l ,2,4-triazolyl roup.
A compound of claim 1, having Formula III:
III
>r a pharmaceutically acceptable salt thereof.
eterocycloalkyl, C,.7 heteroaryl, -ORal, -SRal, -S(=0)Rbl, -S(=0)2Rbl,
S(=0)2NRe lRfl, -C(=0)Rbl, -C(=0)ORa], -C(=0)NRe lRfl, -OC(=0)R l,
0C(=O)NRelR l, -NRe,Rfl, -NRclC(=0)Rdl, -NRclC(=0)ORd l, -NRclC(=0)NRdl , NRcl S(=0)2Rdl, or -NRcl S(=0)2NRelRfl .
7. A compound of any one of claims 14 to 15, wherein Rg is C2.7
eterocycloalkyl, C,-7 heteroaryl, -ORal, or -NRe1Rfl .
8. A compound of any one of claims 14 to 17, wherein:
each Ral, Rcl, Rdl, Rel, and Rfl is independently selected from H, C,.6 alkyl, ^i_6 haloalkyl, cycloalkyl, C3-7 cycloalkyl-Ci.3-alkyl, C2.7 heterocycloalkyl, C2_7 ieterocycloalkyl-Ci.3-alkyl, phenyl, phenyl-Ci.3-alkyl, Ci -7 heteroaryl, and C|.7 ieteroaryl-Ci.3-alkyl; wherein said Ci-6 alkyl, C2.6 alkenyl, C2.6 alkynyl, C3.7 ycloalkyl, C3-7 cycloalkyl-Ci.3-alkyl, C2-7 heterocycloalkyl, C2.7 heterocycloalkyl-Ci. -alkyl, phenyl, phenyl-Ci.3-alkyl, Ci.7 heteroaryl, and Ci-7 heteroaryl-Ci-3-alky] are ach optionally substituted by 1 or 2 Rh groups independently selected from cyano, lalo, hydroxyl, Q^ alkoxy, C^ haloalkoxy, amino, Ci_4 alkylatnino, and di-Ci-4- lkylamino;
each Rbl is independently selected from Ci.6 alkyl, Ci_6 haloalkyl, C3.7 ycloalkyl, C3-7 cycloalkyl-Ci^-alkyl, C2.7 heterocycloalkyl, C2-7 heterocycloalkyl-Ci- -alkyl, phenyl, phenyl-Ci .3-alkyl, C\.7 heteroaryl, and Ci.7 heteiOaryl-C|_3-alkyl; vherein said C\.6 alkyl, C3.7 cycloalkyl, C3.7 cycloalkyl-C|-3-alkyl, C2.7
leterocycloalkyl, C2.7 heterocycloalkyl-Ci_3-alkyl, phenyl, phenyl-Ci.3-alkyl, Ci-7 leteroa yl, and C i-7 heteroaryl-Ci_3-alkyl are each optionally substituted by 1 or 2 Rh ;roups independently selected from cyano, halo, hydroxyl, Ci^ alkoxy, C1.4 laloalkoxy, amino, Ci_4 alkylamino, and di-Ci_4-alkylamino.
/herein R1 is Ci-3 alkyl substituted by C2-7 heterocycloalkyl, -ORal, or -NRelRfl .
1. A compound of claim 14, or a pharmaceutically acceptable salt thereof, therein:
R1 is Ci-3 alkyl substituted by -ORal, -NRelRfl, or C2.7 heterocycloalkyl;
Ra' is H or Cu alkyl;
Rel is H or Ci-4 alkyl; wherein C1.4 alkyl is substituted by 1 or 2 independently elected Rh groups;
Rn is H, Ci .4 alkyl, cyclopropyl, cyclobutyl, or cyclohexyl; wherein C]-4 alkyl, yclopropyl, cyclobutyl, or cyclohexyl are each substituted by 1 or 2 independently elected Rh groups; and
each Rh is independently selected from hydroxy, halo, cyano, C alkyl, and |_4 alkoxy.
2. A compound of any one of claims 14 to 21, or a pharmaceutically acceptable alt thereof, wherein R2 is CF3.
3. A compound of any one of claims 14 to 22, or a pharmaceutically acceptable alt thereof, wherein Y is N.
4. A compound of any one of claims 14 to 22, or a pharmaceutically acceptable alt thereof, wherein Y is CH.
5. A compound of any one of claims 14 to 24, or a pharmaceutically acceptable alt thereof, wherein X is N.
X is N or CH;
L is NR2a;
Y is CH or N;
R1 is Ci-3 alkyl substituted by -ORal, -NRelRfl, or C2-7 heterocycloalkyl;
R2 is CF3;
R2a is H or CH3;
Ral is H or C 1 -4 alkyl;
Re l is H or Ci-4 alkyl; wherein C 1.4 alkyl is substituted by 1 or 2 independently elected Rh groups;
Rfl is H, C 1 -4 alkyl, cyclopropyl, cyclobutyl, or cyclohexyl; wherein C|-4 alkyl, yclopropyl, cyclobutyl, or cyclohexyl are each substituted by 1 or 2 independently elected Rh groups; and
each Rh is independently selected from hydroxy, halo, cyano, Ci-4 alkyl, and "i-4 alkoxy.
8. The compound of claim 1, selected from:
{trans-3-(4-{[4-({[(l S)-2-hydroxy-l -methylethyl]amino}methyl)-6- trifluoromethyl)pyridin-2-yl]oxy}piperidin- l -yl)-l-[4-(7H-pyrrolo[2,3-d]pyrirnidin- -y 1)- 1 H-pyrazol- 1 -yl]cyclobutyl } acetonitri le;
{trans-3-(4-{[4-({[(l R)-2-hydroxy- l -methylethyl]amino} methyl)-6- irifluoromethyl)pyridin-2-yl]oxy}piperidin-l -yl)-l-[4-(7H-pyrrolo[2,3-d]pyrimidin- -yl)-lH-pyrazol-l -yl]cyclobutyl} acetonitrile;
{trans-3-(4- { [4- { [(2-methoxyethyl)amino]methyl} -6-(trifluoromethyl)pyridin- -yl]oxy}piperidin-l-yl)-l-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-l H-pyrazol-l- l]cyclobutyl}acetonitrile;
l]oxy}piperidin-l-yl)cyclobutyl]acetonitrile;
{trans-3-(4-{[4-(2-oxa-6-azaspiro[3.3]hept-6-ylmethyl)-6- trifluoromethyl)pyridin-2-yl]oxy}piperidin- l -yl)-l-[4-(7H-pyrrolo[2,3-d]pyrimidin- -yl)- 1 H-pyrazol- 1 -yljcyclobutyl} acetonitrile;
[trans-l -[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazoI-l -yl]-3-(4-{[4- [(3S)-tetrahydi furan-3-ylamino]methyl}-6-(trifluoromethyl)pyridin-2- l]oxy}piperidin-l-yl)cyclobutyl]acetonitrile;
[trans-l-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol- l-yl]-3-(4-{[4- [(3R)-tetrahydrofuran-3-ylamino]methyl}-6-(trifluoromethyl)pyridin-2- l]oxy}piperidin- l -yl)cyclobutyl]acetonitrile;
{ trans-3-(4- { [4- { [(3 -methy loxetan-3 -y l)amino]methy 1 } -6- trifluoromethyl)pyridin-2-yl]oxy} piperidin- l -yl)-l -[4-(7H-pyrrolo[2,3-d]pyrimidin- -yl)- 1 H-pyrazol- 1 -y l]cyclobutyl} acetonitri le;
{trans-3 -(4- { [4- { [( 1 -methylcyclopropyl)amino]methyl } -6- trifluoromethyl)pyridin-2-yl]oxy}piperidin-l-yl)- l-[4-(7H-pyrrolo[2,3-d]pyrimidin- -yl)- 1 H-pyrazol- 1 -yljcyclobutyl} acetonitrile;
{trans-3-(4-{[4-[(oxetan-3-ylamino)ir)ethyl]-6-(trifluoromethyl)pyridin-2- l]oxy}piperidin-l-yl)- l-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)- l H-pyrazol- 1- l]cyclobutyl} acetonitrile;
{trans-3-(4-{[4-{[(trans-3-hydroxycyclobutyl)amino]methyl}-6- trifluoromethyl)pyridin-2-yl]oxy}piperidin-l -yl)-l-[4-(7H-pyrrolo[2,3-d]pyrimidin- -yl)-lH-pyrazol-l -yljcyclobutyl} acetonitrile;
{trans-3-(4-{ [4-[(3,3-dimethylazetidin-l-yl)methyl]-6- trifluoromethyl)pyridin-2-yl]oxy}piperidin-l -yl)-l-[4-(7H-pyrrolo[2,3-d]pyrimidin- -y 1)- 1 H-pyrazol- 1 -yI]cyclobuty 1 } acetonitrile;
-yl)- lH-pyrazol-l-yl]cyclobutyl}acetonitrile;
{trans-3-(4- { [4- { [bis(2-hydroxyethyl)amino]methy 1} -6- trifluoromethyl)pyridin-2-yl]oxy}piperidin- l-yl)- l -[4-(7H-pyrrolo[2,3-d]pyrimidin- -y 1)- 1 H-pyrazol- 1 -yljcyclobutyl} acetonitrile;
{trans-3-(4- { [4- { [(2-hydroxyethyl)(methyl)amino]methy 1} -6- trifluoromethyl)pyridin-2-yl]oxy}piperidin-l-yl)-l-[4-(7H-pyrrolo[2,3-d]pyrimidin- -y 1)- lH-pyrazol- 1 -y l]cyclobuty 1 } acetonitrile;
{trans-3-(4- { [4- { [(cis-3-hydroxycyclobutyl)amino]methy 1 } -6- trifluoromethyl)pyridin-2-yl]oxy}piperidin-l-yl)-l-[4-(7H-pyrrolo[2,3-d]pyrimidin- -y 1)-1 H-pyrazol- l -yl]cyclobutyl} acetonitrile;
{trans-3-(4-{[4-(2-hydi xyethyl)-6-(trifluoromethyl)pyridin-2- l]oxy}piperidin-l -yl)-l-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-l H-pyrazol- 1 - l]cyclobutyl}acetonitrile;
{trans-3-(4-{[4-{[(2-hydroxyethyl)amino]methyl}-6-(trifluoromethyl)pyridin- -yl]oxy} piperidin- 1 -yl)- 1 -[4-(l H-pyrrolo[2,3-b]pyridin-4-yl)- 1 H-pyrazol- 1 - l]cyclobutyl}acetonitrile;
{trans-3-(4-{[4-(lH-imidazol-l-ylmethyl)-6-(trifluoromethyl)pyridin-2- l]oxy}piperidin-l-yl)-l-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l- l]cyclobutyl} acetonitrile;
[trans-l-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)- lH-pyrazol- l -yl]-3-(4-{[4-( l H- ,2,4-triazol- 1 -ylmethyl)-6-(trifliioromethyl)pyridin-2-y l]oxy } piperidin- 1 - l)cyclobutyl]acetonitrile;
[trans- 1 -[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)- 1 H-pyrazol- 1 -yl]-3 -(4- { [4- 4H-l,2,4-triazol-4-yhnethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy}piperidin-l - l)cyclobutyl]acetonitrile;
-yl)- 1 H-pyrazol- 1 -yl]cyclobutyl} acetonitrile;
{trans-3-(4-{[6-(hydroxymethyl)-2-(trifluoiOmethyl)pyrimidin-4- 4]amino}piperidin-l -yl)-l-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l- 'l]cyclobutyl} acetonitrile;
{trans-3-(4-{[6-[(ethylamino)methyl]-2-(trifluoromethyl)pyrimidin-4- 4]amino}piperidin-] -yl)-l-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l- 'ljcyclobutyl} acetonitrile;
{trans-3-(4-{[6-{[(2-hydroxyethyl)amino]methyl}-2- trifluoromethyl)pyrimidin-4-yl]amino} piperidin- 1 -yl)- 1 -[4-(7H-pyrrolo[2,3- l]pyrimidin-4-yl)-l H-pyrazol- l-yl]cyclobutyl} acetonitrile;
{trans-3 -(4- { [6- { [(trans-3 -hydroxycyclobutyl)amino]methyl} -2- trifluoromethyl)pyrimidin-4-yl]amino}piperidin- l-yl)-l -[4-(7H-pyrrolo[2,3- l]pyrimidin-4-yl)-l H-pyrazol- l -yl]cyclobutyl} acetonitrile;
{trans-3-(4-{[4-(hydroxymethyl)-6-(trifluoromethyI)pyridin-2- 'l]amino}piperidin-l -yl)-l-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l - 'l]cyclobutyl}acetonitrile;
{trans-3-(4-{[4-[(ethylamino)methyl]-6-(trifluoromethyl)pyridin-2- 'ljamino} piperidin- 1 -yl)- 1 -[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)- 1 H-pyrazol- 1 - rl]cyclobutyl} acetonitrile;
{trans-3-(4-{ [4-{[(2-hydroxyethyl)amino]methyl}-6-(trifluoromethyl)pyridin- :-yl]amino}piperidin-l -yl)-l-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l - rl]cyclobutyl} acetonitrile;
{trans-3-(4-{[4-{[(trans-3-hydroxycyclobutyl)amino]methyl}-6- trifluoromethyl)pyridin-2-yl]amino}piperidin-l-yl)-l -[4-(7H-pyrrolo[2,3- IJpyrim idin-4-y 1) - 1 H-pyrazol- 1 -yl]cyclobutyl} acetonitrile;
]pyrimidin-4-yl)-lH-pyrazol-l -yl]cyclobutyl}acetonitrile;
{trans-3 -(4- { [4- { [cyclopropyl(methyl)amino]methyl} -6- trifluoromethyl)pyridin-2-yl]amino}piperidin-l-yl)-l-[4-(7H-pyrrolo[2,3- ]pyrimidin-4-yl)-lH-pyrazol-l-yl]cyclobutyl}acetonitrile;
{cis-3-(4-{[4-(2-hydroxyethyl)-6-(trifluoromethyl)pyridin-2- l]amino}piperidin-l-yl)- l -[4-(7H-pyi olo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l- ljcyclobutyl } acetonitrile
and {trans-3-(4-{[4-(2-hydroxyethyl)-6-(trifluoromethyl)pyridin-2- l]amino} piperidin- 1 -yl)- 1 -[4-(7H-pyrrolo[2, 3-d]pyrimidin-4-yl)- 1 H-pyrazol- 1 - ljcyclobutyl} acetonitrile;
{trans-3-(4-{[4-(azetidin-l -ylmethyl)-6-(trifluoromethyl)pyridin-2- l]amino}piperidin- 1 -yl)- 1 -[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)- 1 H-pyrazol-1 - l]cyclobutyl} acetonitrile;
{trans-3-(4-{[4-(morpholin-4-ylmethyl)-6-(trifluoiOmethyl)pyridin-2- ljamino} piperidin- 1 -yl)- 1 -[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-l H-pyrazol-1 - ljcyclobutyl} acetonitrile;
{trans-3-(4-{[4-[(3-hydroxyazetidin-l -yl)methyl]-6-(tnfluoromethyl)pyridin- -yl]amino}piperidin-l -yl)- l-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-l H-pyrazol- 1 - l]cyclobutyl}acetonitrile;
{trans-3-(4-{[4-{[(2-hydroxyethyl)(methyl)amino]methyl}-6- :rifluoromethyl)pyridin-2-yI]amino}piperidin- l-yl)- l -[4-(7H-pyrrolo[2,3- ]pyrimidin-4-yl)-l H-pyrazol- l -yl]cyclobutyl}acetonitrile;
{trans-3-(4-{ [4-{[(3S)-3-hydroxypyrrolidin-l-yl]methyl}-6- :rifliioromethyl)pyridin-2-yl]ainino}piperidin-l -yl)-l -[4-(7H-pyrrolo[2,3- ]pyrimidin-4-yl)-lH-pyrazol- l-yl]cyclobutyl}acetonitrile;
1] eye lobuty 1 } aceton itr i le ;
{trans-3-(4-{ [4-(2-oxa-6-azaspiro[3.3]hept-6-ylmethyl)-6- trifluoromethyl)pyridin-2-yl]amino}piperidin-l-yl)-l -[4-(7H-pyrrolo[2,3- ]pyrimidin-4-yl)-lH-pyrazol-l-yl]cyclobutyl}acetonitrile;
{trans-3-{4-[[4-(hydroxymethyl)-6-(trifluoromethyl)pyridin-2- l](methyl)amino]piperidin- 1 -yl } - 1 -[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)- 1 H- yrazol- 1 -yljcyclobuty 1 } acetonitrile;
{trans-3-{4-[[4-[(ethylamino)methyl]-6-(trifluoromethyl)pyridin-2- l](methyl)amino]piperidin^ -yl}-l -[4-(7H-pyn lo[2,3-d]pyrimidin-4-yl)- l H- yrazol- 1 -yljcyclobuty 1 } acetonitrile;
{trans-3-(4-{[4-(3-hydroxyoxetan-3-yl)-6-(trifluoromethyl)pyridin-2- l]oxy}piperidin-l-yl)-l-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-l H-pyrazol- l- ljcyclobutyl} acetonitrile; and
{trans-3-(4-{[4-(3-aminooxetan-3-yl)-6-(trifluoromethyl)pyridin-2- l]oxy}piperidin-l-yl)-1 4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol- l - l]cyclobutyl} acetonitrile;
or a pharmaceutically acceptable salt of any of the aforementioned.
9. The compound according to any one of claims 1 to 27, or a pharmaceutically cceptable salt thereof, wherein the cyclobutyl ring in Formula I is the cis form.
0. The compound according to any one of claims 1 to 27, or a pharmaceutically cceptable salt thereof, wherein the cyclobutyl ring in Formula I is the trans form.
1. A composition comprising a compound according to any one of claims 1 to 0, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically cceptable carrier.
cceptabie salt tnereor, is selective ror JARI over JA .
4. A method of treating an autoimmune disease, a cancer, a myeloproliferative isorder, an inflammatory disease, a bone resorption disease, or organ transplant sjection in a patient in need thereof, comprising administering to said patient a lerapeutically effective amount of a compound of any one of claims 1 to 30, or a harmaceutically acceptable salt thereof.
5. A method according to claim 34, wherein said autoimmune disease is a skin isorder, multiple sclerosis, rheumatoid arthritis, psoriatic arthritis, juvenile arthritis, pe I diabetes, lupus, inflammatory bowel disease, Crohn's disease, myasthenia ravis, immunoglobulin nephropathies, myocarditis, or autoimmune thyroid disorder.
6. A method according to claim 34, wherein said autoimmune disease is iieumatoid arthritis.
7. A method according to claim 34, wherein said autoimmune disease is a skin isorder.
8. A method according to claim 37, wherein said skin disorder is atopic ermatitis, psoriasis, skin sensitization, skin irritation, skin rash, contact dermatitis or llergic contact sensitization.
9. A method according to claim 34, wherein said cancer is a solid tumor.
0. A method according to claim 34, wherein said cancer is prostate cancer, renal ancer, hepatic cancer, breast cancer, lung cancer, thyroid cancer, Kaposi's sarcoma, !astleman's disease or pancreatic cancer.
tietapiasia witn myeioriDrosis (MMM;, primary myeionorosis (rivir j, cnronic riyelogenous leukemia (CML), chronic myelomonocytic leukemia (CMML), lypereosinophilic syndrome (HES), idiopathic myelofibrosis (IMF), or systemic mast ell disease (SMCD).
3. A method according to claim 34, wherein said myeloproliferative disorder is myelofibrosis.
4. A method according to claim 34 wherein said myeloproliferative disorder is rimary myelofibrosis (PMF).
5. A method according to claim 34, wherein said bone resorption disease is steoporosis, osteoarthritis, bone resorption associated with hormonal imbalance, one resorption associated with hormonal therapy, bone resorption associated with utoimmune disease, or bone resorption associated with cancer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261648869P | 2012-05-18 | 2012-05-18 | |
US61/648,869 | 2012-05-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2013173720A1 true WO2013173720A1 (en) | 2013-11-21 |
Family
ID=48790572
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2013/041601 WO2013173720A1 (en) | 2012-05-18 | 2013-05-17 | Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors |
Country Status (4)
Country | Link |
---|---|
US (1) | US9193733B2 (en) |
AR (1) | AR091079A1 (en) |
TW (1) | TW201406761A (en) |
WO (1) | WO2013173720A1 (en) |
Cited By (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9079912B2 (en) | 2005-12-13 | 2015-07-14 | Incyte Corporation | Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as Janus kinase inhibitors |
US9216984B2 (en) | 2009-05-22 | 2015-12-22 | Incyte Corporation | 3-[4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl]octane—or heptane-nitrile as JAK inhibitors |
US9221845B2 (en) | 2013-03-06 | 2015-12-29 | Incyte Holdings Corporation | Processes and intermediates for making a JAK inhibitor |
US9249145B2 (en) | 2009-09-01 | 2016-02-02 | Incyte Holdings Corporation | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
US9334274B2 (en) | 2009-05-22 | 2016-05-10 | Incyte Holdings Corporation | N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
US9359358B2 (en) | 2011-08-18 | 2016-06-07 | Incyte Holdings Corporation | Cyclohexyl azetidine derivatives as JAK inhibitors |
US9464088B2 (en) | 2010-03-10 | 2016-10-11 | Incyte Holdings Corporation | Piperidin-4-yl azetidine derivatives as JAK1 inhibitors |
US9487521B2 (en) | 2011-09-07 | 2016-11-08 | Incyte Holdings Corporation | Processes and intermediates for making a JAK inhibitor |
US9498467B2 (en) | 2014-05-30 | 2016-11-22 | Incyte Corporation | Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1 |
WO2016196244A1 (en) | 2015-05-29 | 2016-12-08 | Incyte Corporation | Pyridineamine compounds useful as pim kinase inhibitors |
US9550765B2 (en) | 2013-01-15 | 2017-01-24 | Incyte Holdings Corporation | Thiazolecarboxamides and pyridinecarboxamide compounds useful as Pim kinase inhibitors |
WO2017044730A1 (en) | 2015-09-09 | 2017-03-16 | Incyte Corporation | Salts of a pim kinase inhibitor |
US9611269B2 (en) | 2011-06-20 | 2017-04-04 | Incyte Corporation | Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors |
WO2017059251A1 (en) | 2015-10-02 | 2017-04-06 | Incyte Corporation | Heterocyclic compounds useful as pim kinase inhibitors |
US9655854B2 (en) | 2013-08-07 | 2017-05-23 | Incyte Corporation | Sustained release dosage forms for a JAK1 inhibitor |
US9676750B2 (en) | 2013-01-14 | 2017-06-13 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors |
US9822124B2 (en) | 2014-07-14 | 2017-11-21 | Incyte Corporation | Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors |
US9890162B2 (en) | 2014-07-14 | 2018-02-13 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors |
US10000507B2 (en) | 2013-08-23 | 2018-06-19 | Incyte Corporation | Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors |
US10166191B2 (en) | 2012-11-15 | 2019-01-01 | Incyte Corporation | Sustained-release dosage forms of ruxolitinib |
US10596161B2 (en) | 2017-12-08 | 2020-03-24 | Incyte Corporation | Low dose combination therapy for treatment of myeloproliferative neoplasms |
US10640506B2 (en) | 2010-11-19 | 2020-05-05 | Incyte Holdings Corporation | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidines derivatives as JAK inhibitors |
US10758543B2 (en) | 2010-05-21 | 2020-09-01 | Incyte Corporation | Topical formulation for a JAK inhibitor |
CN112105608A (en) * | 2018-01-30 | 2020-12-18 | 因赛特公司 | Process for preparing (1- (3-fluoro-2- (trifluoromethyl) isonicotinanyl) piperidin-4-one) |
US11213528B2 (en) | 2007-06-13 | 2022-01-04 | Incyte Holdings Corporation | Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
US11304949B2 (en) | 2018-03-30 | 2022-04-19 | Incyte Corporation | Treatment of hidradenitis suppurativa using JAK inhibitors |
US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2845856A1 (en) | 2009-06-29 | 2015-03-11 | Incyte Corporation | Pyrimidinones as PI3K inhibitors |
EP3660016A1 (en) | 2010-12-20 | 2020-06-03 | Incyte Holdings Corporation | N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors |
SG11201400232WA (en) | 2011-09-02 | 2014-03-28 | Incyte Corp | Heterocyclylamines as pi3k inhibitors |
AR090548A1 (en) | 2012-04-02 | 2014-11-19 | Incyte Corp | BICYCLIC AZAHETEROCICLOBENCILAMINS AS PI3K INHIBITORS |
EP2917221A1 (en) | 2012-11-01 | 2015-09-16 | Incyte Corporation | Tricyclic fused thiophene derivatives as jak inhibitors |
HUE043573T2 (en) * | 2013-05-17 | 2019-08-28 | Incyte Corp | Bipyrazole salt as jak inhibitor |
CN105555313A (en) | 2013-08-20 | 2016-05-04 | 因赛特公司 | Survival benefit in patients with solid tumors with elevated c-reactive protein levels |
PL3110409T3 (en) | 2014-02-28 | 2018-12-31 | Incyte Corporation | Jak1 inhibitors for the treatment of myelodysplastic syndromes |
PT3129021T (en) | 2014-04-08 | 2020-11-16 | Incyte Corp | Treatment of b-cell malignancies by a combination jak and pi3k inhibitor |
CN106687462A (en) | 2014-04-30 | 2017-05-17 | 因赛特公司 | Processes of preparing a jak1 inhibitor and new forms thereto |
WO2015191677A1 (en) | 2014-06-11 | 2015-12-17 | Incyte Corporation | Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors |
US9586949B2 (en) | 2015-02-09 | 2017-03-07 | Incyte Corporation | Aza-heteroaryl compounds as PI3K-gamma inhibitors |
EP3262046B1 (en) | 2015-02-27 | 2020-11-04 | Incyte Corporation | Salts of pi3k inhibitor and processes for their preparation |
US9732097B2 (en) | 2015-05-11 | 2017-08-15 | Incyte Corporation | Process for the synthesis of a phosphoinositide 3-kinase inhibitor |
US9988401B2 (en) | 2015-05-11 | 2018-06-05 | Incyte Corporation | Crystalline forms of a PI3K inhibitor |
WO2016183071A1 (en) | 2015-05-11 | 2016-11-17 | Incyte Corporation | Hetero-tricyclic compounds and their use for the treatment of cancer |
WO2017027717A1 (en) | 2015-08-12 | 2017-02-16 | Incyte Corporation | Bicyclic fused pyrimidine compounds as tam inhibitors |
WO2017035366A1 (en) | 2015-08-26 | 2017-03-02 | Incyte Corporation | Pyrrolopyrimidine derivatives as tam inhibitors |
EP4086259A1 (en) | 2015-11-06 | 2022-11-09 | Incyte Corporation | Heterocyclic compounds as pi3k-gamma inhibitors |
EP3400221B1 (en) | 2016-01-05 | 2020-08-26 | Incyte Corporation | Pyrazol / imidazol substituted pyridines as pi3k-gamma inhibitors |
CN114456175B (en) | 2016-03-28 | 2024-09-03 | 因赛特公司 | Pyrrolotriazine compounds as TAM inhibitors |
TW201803871A (en) | 2016-06-24 | 2018-02-01 | 英塞特公司 | Heterocyclic compounds as PI3K-[gamma] inhibitors |
WO2019067594A1 (en) | 2017-09-27 | 2019-04-04 | Incyte Corporation | Salts of pyrrolotriazine derivatives useful as tam inhibitors |
BR112020007593A2 (en) | 2017-10-18 | 2020-09-24 | Incyte Corporation | condensed imidazole derivatives replaced by tertiary hydroxy groups as pi3k-gamma inhibitors |
CN118557580A (en) | 2018-02-16 | 2024-08-30 | 因赛特公司 | JAK1 pathway inhibitors for the treatment of cytokine-related disorders |
WO2019191679A1 (en) | 2018-03-30 | 2019-10-03 | Incyte Corporation | Biomarkers for inflammatory skin disease |
KR20210018218A (en) | 2018-04-13 | 2021-02-17 | 인사이트 코포레이션 | Biomarker for graft versus host disease |
CA3101323A1 (en) | 2018-06-01 | 2019-12-05 | Incyte Corporation | Dosing regimen for the treatment of pi3k related disorders |
MX2021000127A (en) | 2018-06-29 | 2021-03-29 | Incyte Corp | Formulations of an axl/mer inhibitor. |
IL309869A (en) | 2018-09-05 | 2024-02-01 | Incyte Corp | Crystalline forms of a phosphoinositide 3-kinase (pi3k) inhibitor |
MX2021004946A (en) | 2018-10-31 | 2021-07-15 | Incyte Corp | Combination therapy for treatment of hematological diseases. |
EP3897627A1 (en) | 2018-12-19 | 2021-10-27 | Incyte Corporation | Jak1 pathway inhibitors for the treatment of gastrointestinal disease |
CN114007621A (en) | 2019-03-05 | 2022-02-01 | 因赛特公司 | JAK1 pathway inhibitors for the treatment of chronic lung allograft dysfunction |
EP3941474A2 (en) | 2019-03-19 | 2022-01-26 | Incyte Corporation | Biomarkers for vitiligo |
US20210123931A1 (en) | 2019-10-10 | 2021-04-29 | Incyte Corporation | Biomarkers for graft-versus-host disease |
EP4041204A1 (en) | 2019-10-10 | 2022-08-17 | Incyte Corporation | Biomarkers for graft-versus-host disease |
US11992490B2 (en) | 2019-10-16 | 2024-05-28 | Incyte Corporation | Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Lichen planus (LP) |
JP7518900B2 (en) | 2019-10-16 | 2024-07-18 | インサイト・コーポレイション | Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and lichen planus (LP) - Patent Application 20070233334 |
MX2022006176A (en) | 2019-11-22 | 2022-08-17 | Incyte Corp | Combination therapy comprising an alk2 inhibitor and a jak2 inhibitor. |
AR122505A1 (en) | 2020-06-02 | 2022-09-14 | Incyte Corp | PROCESSES TO PREPARE A JAK1 INHIBITOR |
JP2023539126A (en) | 2020-08-18 | 2023-09-13 | インサイト・コーポレイション | Methods and intermediates for preparing JAK inhibitors |
IL300557A (en) | 2020-08-18 | 2023-04-01 | Incyte Corp | Process and intermediates for preparing a jak1 inhibitor |
WO2022120131A1 (en) | 2020-12-04 | 2022-06-09 | Incyte Corporation | Jak inhibitor with a vitamin d analog for treatment of skin diseases |
KR20230118118A (en) | 2020-12-08 | 2023-08-10 | 인사이트 코포레이션 | JAK1 pathway inhibitors for the treatment of vitiligo |
CA3207859A1 (en) | 2021-01-11 | 2022-07-14 | Incyte Corporation | Combination therapy comprising jak pathway inhibitor and rock inhibitor |
WO2022235613A1 (en) | 2021-05-03 | 2022-11-10 | Incyte Corporation | Jak1 pathway inhibitors for the treatment of prurigo nodularis |
WO2023288197A1 (en) | 2021-07-12 | 2023-01-19 | Incyte Corporation | Process and intermediates for preparing baricitinib |
WO2024030600A1 (en) | 2022-08-05 | 2024-02-08 | Incyte Corporation | Treatment of urticaria using jak inhibitors |
Citations (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5521184A (en) | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
WO2000009495A1 (en) | 1998-08-11 | 2000-02-24 | Novartis Ag | Isoquinoline derivatives with angiogenesis inhibiting activity |
WO2000053595A1 (en) | 1999-03-06 | 2000-09-14 | Astrazeneca Ab | Pyrimidine compounds |
WO2001014402A1 (en) | 1999-08-19 | 2001-03-01 | Isis Pharmaceuticals, Inc. | Antisense modulation of focal adhesion kinase expression |
WO2001064655A1 (en) | 2000-03-01 | 2001-09-07 | Astrazeneca Ab | 2, 4-di(hetero-)arylamino (-oxy)-5-substituted pyrimidines as antineoplastic agents |
WO2002000196A2 (en) | 2000-06-28 | 2002-01-03 | Smithkline Beecham P.L.C. | Wet milling process |
WO2003024967A2 (en) | 2001-09-19 | 2003-03-27 | Aventis Pharma S.A. | Indolizines as kinase protein inhibitors |
WO2003037347A1 (en) | 2001-10-30 | 2003-05-08 | Novartis Ag | Staurosporine derivatives as inhibitors of flt3 receptor tyrosine kinase activity |
WO2003099771A2 (en) | 2002-05-29 | 2003-12-04 | Novartis Ag | Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases |
WO2004005281A1 (en) | 2002-07-05 | 2004-01-15 | Novartis Ag | Inhibitors of tyrosine kinases |
WO2004046120A2 (en) | 2002-11-15 | 2004-06-03 | Vertex Pharmaceuticals Incorporated | Diaminotriazoles useful as inhibitors of protein kinases |
WO2004056786A2 (en) | 2002-12-20 | 2004-07-08 | Pfizer Products Inc. | Pyrimidine derivates for the treatment of abnormal cell growth |
WO2004080980A1 (en) | 2003-03-14 | 2004-09-23 | Novartis Ag | 2, 4- di (phenylamino) pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders |
WO2005028444A1 (en) | 2003-09-24 | 2005-03-31 | Novartis Ag | 1,4-disubstituted isoquinilone derivatives as raf-kinase inhibitors useful for the treatment of proliferative diseases |
WO2006056399A2 (en) | 2004-11-24 | 2006-06-01 | Novartis Ag | Combinations of jak inhibitors and at least one of bcr-abl, flt-3, fak or raf kinase inhibitors |
WO2007070514A1 (en) | 2005-12-13 | 2007-06-21 | Incyte Corporation | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors |
WO2011112662A1 (en) * | 2010-03-10 | 2011-09-15 | Incyte Corporation | Piperidin-4-yl azetidine derivatives as jak1 inhibitors |
WO2012068450A1 (en) * | 2010-11-19 | 2012-05-24 | Incyte Corporation | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors |
Family Cites Families (238)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2985589A (en) | 1957-05-22 | 1961-05-23 | Universal Oil Prod Co | Continuous sorption process employing fixed bed of sorbent and moving inlets and outlets |
US3832460A (en) | 1971-03-19 | 1974-08-27 | C Kosti | Anesthetic-vasoconstrictor-antihistamine composition for the treatment of hypertrophied oral tissue |
DE3036390A1 (en) | 1980-09-26 | 1982-05-13 | Troponwerke GmbH & Co KG, 5000 Köln | Antiinflammatory intermediate 7H-pyrrolo-(2,3-D)-pyrimidine derivs. - prepd. by dealkylation of 7-phenyl:ethyl derivs. by reaction with hydrochloric, phosphoric or poly:phosphoric acid |
DE3220113A1 (en) | 1982-05-28 | 1983-12-01 | Basf Ag, 6700 Ludwigshafen | DIFLUORMETHOXIPHENYLTHIOPHOSPHORSAEUREESTER |
US4402832A (en) | 1982-08-12 | 1983-09-06 | Uop Inc. | High efficiency continuous separation process |
US4548990A (en) | 1983-08-15 | 1985-10-22 | Ciba-Geigy Corporation | Crosslinked, porous polymers for controlled drug delivery |
US4498991A (en) | 1984-06-18 | 1985-02-12 | Uop Inc. | Serial flow continuous separation process |
NL8403224A (en) | 1984-10-24 | 1986-05-16 | Oce Andeno Bv | DIOXAPHOSPHORINANS, THEIR PREPARATION AND THE USE FOR SPLITTING OF OPTICALLY ACTIVE COMPOUNDS. |
CA1306260C (en) | 1985-10-18 | 1992-08-11 | Shionogi & Co., Ltd. | Condensed imidazopyridine derivatives |
JPH0710876Y2 (en) | 1989-08-31 | 1995-03-15 | 石垣機工株式会社 | Cleaning device for dehydration cylinder in screw press |
US5378700A (en) | 1989-10-11 | 1995-01-03 | Teijin Limited | Fused pyrimidine derivative, process for preparation of same and pharmaceutical preparation comprising same as active ingredient |
IT1258781B (en) | 1992-01-16 | 1996-02-29 | Zambon Spa | OPHTHALMIC PHARMACEUTICAL COMPOSITION CONTAINING N-ACETYLCISTEIN AND POLYVINYL ALCOHOL |
FR2695126B1 (en) | 1992-08-27 | 1994-11-10 | Sanofi Elf | Thienyl or pyrrolyl carboxylic acid derivatives, their preparation and medicaments containing them. |
EP0727217A3 (en) | 1995-02-10 | 1997-01-15 | Suntory Ltd | Pharmaceutical composition containing god-type ellagitannin as active ingredient |
US5856326A (en) | 1995-03-29 | 1999-01-05 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
IL117580A0 (en) | 1995-03-29 | 1996-07-23 | Merck & Co Inc | Inhibitors of farnesyl-protein transferase and pharmaceutical compositions containing them |
ES2167586T3 (en) | 1995-07-05 | 2002-05-16 | Du Pont | FUNGICIDE PYRIMIDINONES. |
PT836605E (en) | 1995-07-06 | 2002-07-31 | Novartis Ag | PYRROLOPYRIMIDINES AND PROCESSES FOR THEIR PREPARATION |
US5630943A (en) | 1995-11-30 | 1997-05-20 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Discontinuous countercurrent chromatographic process and apparatus |
GB9604361D0 (en) | 1996-02-29 | 1996-05-01 | Pharmacia Spa | 4-Substituted pyrrolopyrimidine compounds as tyrosine kinase inhibitors |
EP0906099A4 (en) | 1996-04-03 | 2001-02-07 | Merck & Co Inc | A method of treating cancer |
AU2802297A (en) | 1996-04-18 | 1997-11-07 | Merck & Co., Inc. | A method of treating cancer |
US5795909A (en) | 1996-05-22 | 1998-08-18 | Neuromedica, Inc. | DHA-pharmaceutical agent conjugates of taxanes |
JP2000508335A (en) | 1996-05-30 | 2000-07-04 | メルク エンド カンパニー インコーポレーテッド | How to treat cancer |
US6624138B1 (en) | 2001-09-27 | 2003-09-23 | Gp Medical | Drug-loaded biological material chemically treated with genipin |
EP0973396A4 (en) | 1997-04-07 | 2001-02-07 | Merck & Co Inc | A method of treating cancer |
US6063284A (en) | 1997-05-15 | 2000-05-16 | Em Industries, Inc. | Single column closed-loop recycling with periodic intra-profile injection |
US6060038A (en) | 1997-05-15 | 2000-05-09 | Merck & Co., Inc. | Radiolabeled farnesyl-protein transferase inhibitors |
US5908841A (en) | 1997-08-11 | 1999-06-01 | Boehringer Ingelheim Pharmaceuticals, Inc. | 5,11-dihydro-6H-dipyrido 3,2-b:2',3'-e!azepine-6-ones and their use in the prevention of treatment of HIV infection |
US6075056A (en) | 1997-10-03 | 2000-06-13 | Penederm, Inc. | Antifungal/steroid topical compositions |
US6232320B1 (en) | 1998-06-04 | 2001-05-15 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory compounds |
KR20010052570A (en) | 1998-06-04 | 2001-06-25 | 스티븐 에프. 웨인스톡 | Cell adhesion-inhibiting antiinflammatory compounds |
PA8474101A1 (en) | 1998-06-19 | 2000-09-29 | Pfizer Prod Inc | PYROLEUM [2,3-D] PIRIMIDINE COMPOUNDS |
PL198640B1 (en) | 1998-06-19 | 2008-07-31 | Pfizer Prod Inc | PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS |
JP2000119271A (en) | 1998-08-12 | 2000-04-25 | Hokuriku Seiyaku Co Ltd | 1h-imidazopyridine derivative |
CA2343148C (en) | 1998-09-10 | 2005-11-15 | Nycomed Danmark A/S | Quick release pharmaceutical compositions of drug substances |
US6375839B1 (en) | 1998-10-29 | 2002-04-23 | Institut Francais Du Petrole | Process and device for separation with variable-length chromatographic zones |
FR2785196B1 (en) | 1998-10-29 | 2000-12-15 | Inst Francais Du Petrole | METHOD AND DEVICE FOR SEPARATION WITH VARIABLE LENGTH CHROMATOGRAPHIC AREAS |
US6413419B1 (en) | 1998-10-29 | 2002-07-02 | Institut Francais Du Petrole | Process and device for separation with variable-length chromatographic |
JP2002538121A (en) | 1999-03-03 | 2002-11-12 | メルク エンド カムパニー インコーポレーテッド | Inhibitors of prenyl protein transferase |
US6217895B1 (en) | 1999-03-22 | 2001-04-17 | Control Delivery Systems | Method for treating and/or preventing retinal diseases with sustained release corticosteroids |
US6239113B1 (en) | 1999-03-31 | 2001-05-29 | Insite Vision, Incorporated | Topical treatment or prevention of ocular infections |
AU3565999A (en) | 1999-04-16 | 2000-11-02 | Coelacanth Chemical Corporation | Synthesis of azetidine derivatives |
US6921763B2 (en) | 1999-09-17 | 2005-07-26 | Abbott Laboratories | Pyrazolopyrimidines as therapeutic agents |
AU766233B2 (en) | 1999-10-13 | 2003-10-09 | Banyu Pharmaceutical Co., Ltd. | Substituted imidazolidinone derivatives |
ATE380031T1 (en) | 1999-12-10 | 2007-12-15 | Pfizer Prod Inc | COMPOSITIONS CONTAINING PYRROLO 2,3-D PYRIMIDINE DERIVATIVES |
KR100755622B1 (en) | 1999-12-24 | 2007-09-04 | 아벤티스 파마 리미티드 | Azaindoles |
US7235551B2 (en) | 2000-03-02 | 2007-06-26 | Smithkline Beecham Corporation | 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases |
DK1142566T3 (en) | 2000-04-07 | 2004-02-09 | Medidom Lab | Ophthalmological formulations based on cyclosporine, hyaluronic acid and polysorbate |
AU4878601A (en) | 2000-04-20 | 2001-11-07 | Mitsubishi Corporation | Aromatic amide compounds |
WO2001098344A2 (en) | 2000-06-16 | 2001-12-27 | Curis, Inc. | Angiogenesis-modulating compositions and uses |
US7498304B2 (en) | 2000-06-16 | 2009-03-03 | Curis, Inc. | Angiogenesis-modulating compositions and uses |
US6335342B1 (en) | 2000-06-19 | 2002-01-01 | Pharmacia & Upjohn S.P.A. | Azaindole derivatives, process for their preparation, and their use as antitumor agents |
WO2001097849A1 (en) | 2000-06-23 | 2001-12-27 | Mitsubishi Pharma Corporation | Antitumor effect potentiators |
HUP0301114A3 (en) | 2000-06-26 | 2004-11-29 | Pfizer Prod Inc | Pyrrolo[2,3-d]pyrimidine compounds as immunosuppressive agents and pharmaceutical compositions containing them |
WO2002016370A1 (en) | 2000-08-22 | 2002-02-28 | Hokuriku Seiyaku Co., Ltd. | 1h-imidazopyridine derivatives |
AU2002228783A1 (en) | 2000-12-05 | 2002-06-18 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases |
US20040077654A1 (en) | 2001-01-15 | 2004-04-22 | Bouillot Anne Marie Jeanne | Aryl piperidine and piperazine derivatives as inducers of ldl-receptor expression |
WO2002060492A1 (en) | 2001-01-30 | 2002-08-08 | Cytopia Pty Ltd | Methods of inhibiting kinases |
CA2446864C (en) | 2001-05-16 | 2011-02-15 | Vertex Pharmaceuticals Incorporated | Inhibitors of src and other protein kinases |
US7301023B2 (en) | 2001-05-31 | 2007-11-27 | Pfizer Inc. | Chiral salt resolution |
GB0115393D0 (en) | 2001-06-23 | 2001-08-15 | Aventis Pharma Ltd | Chemical compounds |
DE60216115T2 (en) | 2001-08-01 | 2007-05-31 | Merck & Co., Inc. | BENZIMIDAZO 4,5-föISOCHINOLINONE DERIVATIVES |
US6429231B1 (en) | 2001-09-24 | 2002-08-06 | Bradley Pharmaceuticals, Inc. | Compositions containing antimicrobials and urea for the treatment of dermatological disorders and methods for their use |
JP2003155285A (en) | 2001-11-19 | 2003-05-27 | Toray Ind Inc | Cyclic nitrogen-containing derivative |
WO2003048111A1 (en) | 2001-11-30 | 2003-06-12 | Teijin Limited | Process for producing 5-(3-cyanophenyl)-3-formylbenzoic acid compound |
GT200200234A (en) | 2001-12-06 | 2003-06-27 | NEW CRYSTAL COMPOUNDS | |
US6995144B2 (en) | 2002-03-14 | 2006-02-07 | Eisai Co., Ltd. | Nitrogen containing heterocyclic compounds and medicines containing the same |
TW200403058A (en) | 2002-04-19 | 2004-03-01 | Bristol Myers Squibb Co | Heterocyclo inhibitors of potassium channel function |
WO2003091246A1 (en) | 2002-04-26 | 2003-11-06 | Vertex Pharmaceuticals Incorporated | Pyrrole derivatives as inhibitors of erk2 and uses thereof |
US7125888B2 (en) | 2002-05-02 | 2006-10-24 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
BR0309844A (en) | 2002-05-07 | 2005-02-15 | Control Delivery Sys Inc | Processes for forming a drug delivery device |
ATE377004T1 (en) | 2002-05-23 | 2007-11-15 | Cytopia Pty Ltd | PROTEIN KINASE INHIBITORS |
EP1535934A4 (en) | 2002-06-26 | 2005-11-02 | Idemitsu Kosan Co | Hydrogenated copolymer, process for producing the same, and hot-melt adhesive composition containing the same |
GB0215844D0 (en) | 2002-07-09 | 2002-08-14 | Novartis Ag | Organic compounds |
EP1541563A4 (en) | 2002-07-10 | 2007-11-07 | Ono Pharmaceutical Co | Ccr4 antagonist and medicinal use thereof |
AU2003278727A1 (en) | 2002-09-20 | 2004-04-08 | Alcon, Inc. | Use of cytokine synthesis inhibitors for the treatment of dry eye disorders |
US20040204404A1 (en) | 2002-09-30 | 2004-10-14 | Robert Zelle | Human N-type calcium channel blockers |
US7259161B2 (en) | 2002-11-04 | 2007-08-21 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of JAK and other protein kinases |
PL378246A1 (en) | 2002-11-26 | 2006-03-20 | Pfizer Products Inc. | Method of treatment of transplant rejection |
TWI335819B (en) | 2002-12-24 | 2011-01-11 | Alcon Inc | Use of oculosurface selective glucocorticoid in the treatment of dry eye |
TW200418806A (en) | 2003-01-13 | 2004-10-01 | Fujisawa Pharmaceutical Co | HDAC inhibitor |
US7444183B2 (en) | 2003-02-03 | 2008-10-28 | Enteromedics, Inc. | Intraluminal electrode apparatus and method |
EP1611125A1 (en) | 2003-02-07 | 2006-01-04 | Vertex Pharmaceuticals Incorporated | Heteroaryl substituted pyrolls useful as inhibitors of protein kinases |
AU2004230841A1 (en) | 2003-04-03 | 2004-10-28 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of protein kinases |
SE0301373D0 (en) | 2003-05-09 | 2003-05-09 | Astrazeneca Ab | Novel compounds |
SE0301372D0 (en) | 2003-05-09 | 2003-05-09 | Astrazeneca Ab | Novel compounds |
FR2857454B1 (en) | 2003-07-08 | 2006-08-11 | Aventis Pasteur | DOSAGE OF TECHIC ACIDS OF BACTERIA GRAM + |
US20050043346A1 (en) | 2003-08-08 | 2005-02-24 | Pharmacia Italia S.P.A. | Pyridylpyrrole derivatives active as kinase inhibitors |
AU2004268621C1 (en) | 2003-08-29 | 2011-08-18 | Exelixis, Inc. | c-Kit modulators and methods of use |
WO2005026129A1 (en) | 2003-09-15 | 2005-03-24 | Gpc Biotech Ag | Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases |
TWI343256B (en) | 2003-10-24 | 2011-06-11 | Santen Pharmaceutical Co Ltd | Cornea-conjunctiva disorder treating agent |
MY141220A (en) | 2003-11-17 | 2010-03-31 | Astrazeneca Ab | Pyrazole derivatives as inhibitors of receptor tyrosine kinases |
BRPI0416909A (en) | 2003-11-25 | 2007-01-16 | Pfizer Prod Inc | atherosclerosis treatment method |
AU2004305317A1 (en) | 2003-12-17 | 2005-07-07 | Pfizer Products Inc. | Pyrrolo [2,3-D] pyrimidine compounds for treating transplant rejection |
DE602004016211D1 (en) | 2003-12-19 | 2008-10-09 | Schering Corp | Thiadiazole als cxc- und cc-chemokinrezeptorliganden |
AU2004308299B2 (en) | 2003-12-19 | 2011-11-24 | Plexxikon, Inc. | Compounds and methods for development of Ret modulators |
AU2004303602C1 (en) | 2003-12-23 | 2009-05-28 | Astex Therapeutics Limited | Pyrazole derivatives as protein kinase modulators |
US20050165029A1 (en) | 2004-01-13 | 2005-07-28 | Ambit Biosciences Corporation | Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases |
US20050277629A1 (en) | 2004-03-18 | 2005-12-15 | The Brigham And Women's Hospital, Inc. | Methods for the treatment of synucleinopathies (Lansbury) |
NZ584499A (en) | 2004-03-30 | 2011-08-26 | Vertex Pharma | Azaindoles Useful as Inhibitors of Jak and Other Protein Kinases |
US8076338B2 (en) | 2004-04-23 | 2011-12-13 | Exelixis, Inc. | Kinase modulators and methods of use |
WO2005105814A1 (en) | 2004-04-28 | 2005-11-10 | Incyte Corporation | Tetracyclic inhibitors of janus kinases |
US7558717B2 (en) | 2004-04-28 | 2009-07-07 | Vertex Pharmaceuticals Incorporated | Crystal structure of human JAK3 kinase domain complex and binding pockets thereof |
CA2563569A1 (en) | 2004-05-03 | 2005-11-10 | Novartis Ag | Combinations comprising a s1p receptor agonist and a jak3 kinase inhibitor |
WO2005110410A2 (en) | 2004-05-14 | 2005-11-24 | Abbott Laboratories | Kinase inhibitors as therapeutic agents |
PE20060426A1 (en) | 2004-06-02 | 2006-06-28 | Schering Corp | TARTARIC ACID DERIVATIVES AS INHIBITORS OF MMPs, ADAMs, TACE AND TNF-alpha |
AR049511A1 (en) | 2004-06-10 | 2006-08-09 | Irm Llc | COMPOUNDS AND COMPOSITIONS AS PROTEIN QUINASE INHIBITORS |
WO2006001463A1 (en) | 2004-06-23 | 2006-01-05 | Ono Pharmaceutical Co., Ltd. | Compound having s1p receptor binding potency and use thereof |
AU2005260689B2 (en) | 2004-06-30 | 2012-05-10 | Vertex Pharmaceuticals Incorporated | Azaindoles useful as inhibitors of protein kinases |
US7138423B2 (en) | 2004-07-20 | 2006-11-21 | Bristol-Myers Squibb Company | Arylpyrrolidine derivatives as NK-1 /SSRI antagonists |
FR2873691B1 (en) | 2004-07-29 | 2006-10-06 | Sanofi Synthelabo | AMINO-PIPERIDINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION |
WO2006013114A1 (en) | 2004-08-06 | 2006-02-09 | Develogen Aktiengesellschaft | Use of a timp-2 secreted protein product for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome |
CN101006186A (en) | 2004-08-23 | 2007-07-25 | 财团法人牧岩生命工学研究所 | Primer and probe for detection of sars coronavirus, kit comprising the primer and/or the probe, and detection method thereof |
US20070054916A1 (en) | 2004-10-01 | 2007-03-08 | Amgen Inc. | Aryl nitrogen-containing bicyclic compounds and methods of use |
EP1802625B1 (en) | 2004-10-13 | 2008-06-18 | F. Hoffmann-Roche AG | Disubstituted pyrazolobenzodiazepines useful as inhibitors for cdk2 and angiogesis, and for the treatment of breast, colon, lung and prostate cancer |
UY29177A1 (en) | 2004-10-25 | 2006-05-31 | Astex Therapeutics Ltd | SUBSTITUTED DERIVATIVES OF PURINA, PURINONA AND DEAZAPURINA, COMPOSITIONS THAT CONTAIN METHODS FOR THEIR PREPARATION AND ITS USES |
MY179032A (en) | 2004-10-25 | 2020-10-26 | Cancer Research Tech Ltd | Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors |
EP1812440B1 (en) | 2004-11-04 | 2010-09-22 | Vertex Pharmaceuticals, Inc. | Pyrazolo[1,5-a]pyrimidines useful as inhibitors of protein kinases |
US7517870B2 (en) | 2004-12-03 | 2009-04-14 | Fondazione Telethon | Use of compounds that interfere with the hedgehog signaling pathway for the manufacture of a medicament for preventing, inhibiting, and/or reversing ocular diseases related with ocular neovascularization |
US20060128803A1 (en) | 2004-12-14 | 2006-06-15 | Alcon, Inc. | Method of treating dry eye disorders using 13(S)-HODE and its analogs |
AR054416A1 (en) | 2004-12-22 | 2007-06-27 | Incyte Corp | PIRROLO [2,3-B] PIRIDIN-4-IL-AMINAS AND PIRROLO [2,3-B] PIRIMIDIN-4-IL-AMINAS AS INHIBITORS OF THE JANUS KINASES. PHARMACEUTICAL COMPOSITIONS. |
TW200635899A (en) | 2004-12-22 | 2006-10-16 | Astrazeneca Ab | Chemical compounds |
EP1844037A1 (en) | 2005-01-20 | 2007-10-17 | Pfizer Limited | Chemical compounds |
KR20070104641A (en) | 2005-02-03 | 2007-10-26 | 버텍스 파마슈티칼스 인코포레이티드 | Pyrrolopyrimidines useful as inhibitors of protein kinase |
US7683171B2 (en) | 2005-02-04 | 2010-03-23 | Bristol-Myers Squibb Company | 1H-imidazo[4,5-d]thieno[3,2-b]pyridine based tricyclic compounds and pharmaceutical compositions comprising same |
CA2600144A1 (en) | 2005-03-15 | 2006-09-28 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
RU2007140903A (en) | 2005-04-05 | 2009-05-20 | Фармакопия, Инк. (Us) | PURINE AND IMIDAZOPYRIDINE DERIVATIVES FOR IMMUNOSUPRESSION |
GB0510139D0 (en) | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds B1 |
GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
CA2609126A1 (en) | 2005-05-20 | 2006-11-30 | Vertex Pharmaceuticals Incorporated | Pyrrolopyridines useful as inhibitors of protein kinase |
MX286273B (en) | 2005-06-08 | 2011-05-04 | Rigel Pharmaceuticals Inc | Compositions and methods for inhibition of the jak pathway. |
WO2006136823A1 (en) | 2005-06-21 | 2006-12-28 | Astex Therapeutics Limited | Heterocyclic containing amines as kinase b inhibitors |
HUE027370T2 (en) | 2005-06-22 | 2016-10-28 | Plexxikon Inc | Pyrrolo [2,3-b]pyridine derivatives as protein kinase inhibitors |
CN102127078A (en) | 2005-07-14 | 2011-07-20 | 安斯泰来制药株式会社 | Heterocyclic janus kinase 3 inhibitors |
DE102005037754A1 (en) | 2005-08-10 | 2007-02-15 | Basf Ag | Improved driving for the production of polyesters |
FR2889662B1 (en) | 2005-08-11 | 2011-01-14 | Galderma Res & Dev | OIL-IN-WATER EMULSION FOR TOPICAL APPLICATION IN DERMATOLOGY |
WO2007025090A2 (en) | 2005-08-25 | 2007-03-01 | Kalypsys, Inc. | Heterobicyclic and - tricyclic inhibitors of mapk/erk kinase |
US20070149506A1 (en) | 2005-09-22 | 2007-06-28 | Arvanitis Argyrios G | Azepine inhibitors of Janus kinases |
SG151327A1 (en) | 2005-09-30 | 2009-04-30 | Vertex Pharmaceuticals Incopor | Deazapurines useful as inhibitors of janus kinases |
WO2007044894A2 (en) | 2005-10-11 | 2007-04-19 | Chembridge Research Laboratories, Inc. | Cell-free protein expression systems and methods of use thereof |
AU2006300182B2 (en) | 2005-10-14 | 2012-01-19 | Sumitomo Chemical Company, Limited | Hydrazide compound and pesticidal use of the same |
AU2006307657B2 (en) | 2005-10-28 | 2010-10-28 | Astrazeneca Ab | 4- (3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer |
NZ567851A (en) | 2005-11-01 | 2011-09-30 | Targegen Inc | Bi-aryl meta-pyrimidine inhibitors of kinases |
WO2007062459A1 (en) | 2005-11-29 | 2007-06-07 | Cytopia Research Pty Ltd | Selective kinase inhibitors based on pyridine scaffold |
US20130137681A1 (en) | 2005-12-13 | 2013-05-30 | Incyte Corporation | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS |
WO2007076423A2 (en) | 2005-12-22 | 2007-07-05 | Smithkline Beecham Corporation | INHIBITORS OF Akt ACTIVITY |
CA2634787C (en) | 2005-12-23 | 2014-10-21 | Smithkline Beecham Corporation | Azaindole inhibitors of aurora kinases |
KR101235103B1 (en) | 2006-01-17 | 2013-02-21 | 버텍스 파마슈티칼스 인코포레이티드 | Azaindoles useful as inhibitors of Janus kinases |
TW200738709A (en) | 2006-01-19 | 2007-10-16 | Osi Pharm Inc | Fused heterobicyclic kinase inhibitors |
US20090018156A1 (en) | 2006-02-01 | 2009-01-15 | Jun Tang | Pyrrolo [2,3,B] Pyridine Derivatives Useful As RAF Kinase Inhibitors |
US7745477B2 (en) | 2006-02-07 | 2010-06-29 | Hoffman-La Roche Inc. | Heteroaryl and benzyl amide compounds |
AU2007225836A1 (en) | 2006-03-10 | 2007-09-20 | Ono Pharmaceutical Co., Ltd. | Nitrogenated heterocyclic derivative, and pharmaceutical agent comprising the derivative as active ingredient |
TWI382984B (en) | 2006-04-03 | 2013-01-21 | Astellas Pharma Inc | Hetero compound |
CA2648250A1 (en) | 2006-04-05 | 2007-10-18 | Vertex Pharmaceuticals Incorporated | Deazapurines useful as inhibitors of janus kinases |
EP2059515A2 (en) | 2006-04-12 | 2009-05-20 | Pfizer Limited | Pyrrolidine derivatives as modulators of chemokine ccr5 receptors |
WO2007129195A2 (en) | 2006-05-04 | 2007-11-15 | Pfizer Products Inc. | 4-pyrimidine-5-amino-pyrazole compounds |
AU2007252994A1 (en) | 2006-05-18 | 2007-11-29 | Bayer Healthcare Ag | Pharmaceutical compositions comprising implitapide and methods of using same |
US7691811B2 (en) | 2006-05-25 | 2010-04-06 | Bodor Nicholas S | Transporter-enhanced corticosteroid activity and methods and compositions for treating dry eye |
TWI398252B (en) | 2006-05-26 | 2013-06-11 | Novartis Ag | Pyrrolopyrimidine compounds and their uses |
EP2044061A2 (en) | 2006-07-20 | 2009-04-08 | Mehmet Kahraman | Benzothiophene inhibitors of rho kinase |
WO2008013622A2 (en) | 2006-07-27 | 2008-01-31 | E. I. Du Pont De Nemours And Company | Fungicidal azocyclic amides |
US8492378B2 (en) | 2006-08-03 | 2013-07-23 | Takeda Pharmaceutical Company Limited | GSK-3β inhibitor |
CA2660560A1 (en) | 2006-08-16 | 2008-02-21 | Boehringer Ingelheim International Gmbh | Pyrazine compounds, their use and methods of preparation |
RU2009112719A (en) | 2006-09-08 | 2010-10-20 | Новартис АГ (CH) | N-BIARIL (HETERO) ARILSULFONAMIDE DERIVATIVES APPLICABLE IN THE TREATMENT OF DISEASES MEDIATED BY THE INTERACTION OF LYMPHOCYTES |
WO2008035376A2 (en) | 2006-09-19 | 2008-03-27 | Council Of Scientific & Industrial Research | A novel bio-erodible insert for ophthalmic applications and a process for the preparation thereof |
WO2008043031A1 (en) | 2006-10-04 | 2008-04-10 | Pharmacopeia, Inc. | 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression |
CL2007002867A1 (en) | 2006-10-04 | 2008-06-27 | Pharmacopeia Inc | COMPOUNDS DERIVED FROM 2- (BENCIMIDAZOLIL) PURINA, INHIBITORS OF JANUS QUINASA 3; PHARMACEUTICAL COMPOSITION THAT CONTAINS THEM; AND ITS USE TO TREAT AUTOIMMUNE, INFLAMMATORY, CARDIOVASCULAR DISEASES, IMPLANT REJECTION, AMONG OTHERS. |
WO2008058126A2 (en) | 2006-11-06 | 2008-05-15 | Supergen, Inc. | Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors |
US20080119496A1 (en) | 2006-11-16 | 2008-05-22 | Pharmacopeia Drug Discovery, Inc. | 7-Substituted Purine Derivatives for Immunosuppression |
US7767675B2 (en) | 2006-11-22 | 2010-08-03 | Incyte Corporation | Imidazotriazines and imidazopyrimidines as kinase inhibitors |
WO2008067119A2 (en) | 2006-11-27 | 2008-06-05 | Smithkline Beecham Corporation | Novel compounds |
US7834039B2 (en) | 2006-12-15 | 2010-11-16 | Abbott Laboratories | Oxadiazole compounds |
WO2008079291A2 (en) | 2006-12-20 | 2008-07-03 | Amgen Inc. | Substituted heterocycles and methods of use |
MX2009006543A (en) | 2006-12-20 | 2009-06-26 | Amgen Inc | Heterocyclic compounds and their use in treating inflammation, angiogenesis and cancer. |
AU2007338210B2 (en) | 2006-12-22 | 2013-01-31 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Gel useful for the delivery of ophthalmic drugs |
CA2673038C (en) | 2006-12-22 | 2015-12-15 | Incyte Corporation | Substituted tricyclic heteroaryl compounds as janus kinase inhibitors |
WO2008082840A1 (en) | 2006-12-29 | 2008-07-10 | Abbott Laboratories | Pim kinase inhibitors as cancer chemotherapeutics |
KR20080062876A (en) | 2006-12-29 | 2008-07-03 | 주식회사 대웅제약 | Novel antifungal triazole derivatives |
WO2008082839A2 (en) | 2006-12-29 | 2008-07-10 | Abbott Laboratories | Pim kinase inhibitors as cancer chemotherapeutics |
JP5330274B2 (en) | 2007-03-01 | 2013-10-30 | ノバルティス アーゲー | PIM kinase inhibitor and method of use thereof |
BRPI0809998B8 (en) | 2007-04-03 | 2021-05-25 | Array Biopharma Inc | imidazo[1,2-a]pyridine compound as receptor tyrosine kinase inhibitors, their uses, their preparation processes and pharmaceutical compositions |
GB0709031D0 (en) | 2007-05-10 | 2007-06-20 | Sareum Ltd | Pharmaceutical compounds |
WO2008145681A2 (en) | 2007-05-31 | 2008-12-04 | Boehringer Ingelheim International Gmbh | Ccr2 receptor antagonists and uses thereof |
GB0710528D0 (en) | 2007-06-01 | 2007-07-11 | Glaxo Group Ltd | Novel compounds |
CL2008001709A1 (en) | 2007-06-13 | 2008-11-03 | Incyte Corp | Compounds derived from pyrrolo [2,3-b] pyrimidine, jak kinase modulators; pharmaceutical composition; and use in the treatment of diseases such as cancer, psoriasis, rheumatoid arthritis, among others. |
ME00960B (en) | 2007-06-13 | 2012-06-20 | Incyte Corp | Salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
BRPI0815042A2 (en) | 2007-08-01 | 2015-02-10 | Pfizer | PIRAZOL COMPOUNDS |
WO2009049028A1 (en) | 2007-10-09 | 2009-04-16 | Targegen Inc. | Pyrrolopyrimidine compounds and their use as janus kinase modulators |
EP2217235A4 (en) | 2007-11-15 | 2011-01-12 | Musc Found For Res Dev | Inhibitors of pim protein kinases, compositions, and methods for treating cancer |
UA104849C2 (en) | 2007-11-16 | 2014-03-25 | Інсайт Корпорейшн | 4-pyrazolyl-n-arylpyrimidin-2-amines and 4-pyrazolyl-n-heteroarylpyrimidin-2-amines as inhibitors of janus kinases |
GB0723815D0 (en) | 2007-12-05 | 2008-01-16 | Glaxo Group Ltd | Compounds |
PL2231689T3 (en) | 2008-01-18 | 2017-01-31 | Inst Of Organic Chemistry And Biochemistry Of The Acad Of Sciences Of The Czech Republic | Novel cytostatic 7-deazapurine nucleosides |
US8273744B2 (en) | 2008-02-04 | 2012-09-25 | Mercury Therapeutics, Inc. | AMPK modulators |
PE20091577A1 (en) | 2008-03-03 | 2009-11-05 | Novartis Ag | PIM KINASE INHIBITORS AND METHODS FOR THEIR USE |
BRPI0909040B8 (en) | 2008-03-11 | 2021-05-25 | Incyte Holdings Corp | azetidine and cyclobutane derivatives, their uses, and composition |
KR101408517B1 (en) | 2008-03-21 | 2014-06-17 | 노파르티스 아게 | Novel heterocyclic compounds and uses therof |
CA2727928A1 (en) | 2008-06-18 | 2009-12-23 | Merck Sharp & Dohme Corp. | Inhibitors of janus kinases |
WO2009158687A1 (en) | 2008-06-26 | 2009-12-30 | Anterios, Inc. | Dermal delivery |
TWI461423B (en) | 2008-07-02 | 2014-11-21 | Astrazeneca Ab | Thiazolidinedione compounds useful in the treatment of pim kinase related conditions and diseases |
FR2933409B1 (en) | 2008-07-03 | 2010-08-27 | Centre Nat Rech Scient | NEW PYRROLO ° 2,3-a! CARBAZOLES AND THEIR USE AS INHIBITORS OF PIM KINASES |
WO2010022081A1 (en) | 2008-08-19 | 2010-02-25 | Array Biopharma Inc. | Triazolopyridine compounds as pim kinase inhibitors |
TWI496779B (en) | 2008-08-19 | 2015-08-21 | Array Biopharma Inc | Triazolopyridine compounds as pim kinase inhibitors |
NZ605292A (en) | 2008-08-20 | 2014-06-27 | Zoetis Services Llc | Pyrrolo[2,3-d]pyrimidine compounds |
DK2344474T3 (en) | 2008-09-02 | 2015-12-14 | Novartis Ag | Picolinamidderivater as kinase inhibitors |
EP2342190A1 (en) | 2008-09-02 | 2011-07-13 | Novartis AG | Bicyclic kinase inhibitors |
MX2011002362A (en) | 2008-09-02 | 2011-04-04 | Novartis Ag | Heterocyclic pim-kinase inhibitors. |
CL2009001884A1 (en) | 2008-10-02 | 2010-05-14 | Incyte Holdings Corp | Use of 3-cyclopentyl-3- [4- (7h-pyrrolo [2,3-d] pyrimidin-4-yl) -1h-pyrazol-1-yl) propanonitrile, janus kinase inhibitor, and use of a composition that understands it for the treatment of dry eye. |
JOP20190230A1 (en) | 2009-01-15 | 2017-06-16 | Incyte Corp | Processes for preparing jak inhibitors and related intermediate compounds |
EP2210890A1 (en) | 2009-01-19 | 2010-07-28 | Almirall, S.A. | Oxadiazole derivatives as S1P1 receptor agonists |
LT2432472T (en) | 2009-05-22 | 2020-02-10 | Incyte Holdings Corporation | 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors |
US8716303B2 (en) | 2009-05-22 | 2014-05-06 | Incyte Corporation | N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
CN102574857B (en) | 2009-07-08 | 2015-06-10 | 利奥制药有限公司 | Heterocyclic compounds as jak receptor and protein tyrosine kinase inhibitors |
WO2011025685A1 (en) | 2009-08-24 | 2011-03-03 | Merck Sharp & Dohme Corp. | Jak inhibition blocks rna interference associated toxicities |
TW201111385A (en) | 2009-08-27 | 2011-04-01 | Biocryst Pharm Inc | Heterocyclic compounds as janus kinase inhibitors |
US9249145B2 (en) | 2009-09-01 | 2016-02-02 | Incyte Holdings Corporation | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
EP2475659B1 (en) | 2009-09-08 | 2015-10-28 | F.Hoffmann-La Roche Ag | 4-substituted pyridin-3-yl-carboxamide compounds and methods of use |
EP2305660A1 (en) | 2009-09-25 | 2011-04-06 | Almirall, S.A. | New thiadiazole derivatives |
MX2012004180A (en) | 2009-10-09 | 2012-07-17 | Incyte Corp | Hydroxyl, keto, and glucuronide derivatives of 3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclo pentylpropanenitrile. |
EP2332917B1 (en) | 2009-11-11 | 2012-08-01 | Sygnis Bioscience GmbH & Co. KG | Compounds for PIM kinase inhibition and for treating malignancy |
US20130129675A1 (en) | 2009-12-04 | 2013-05-23 | Board Of Regents, The University Of Texas System | Interferon therapies in combination with blockade of stat3 activation |
KR20140015162A (en) | 2010-01-12 | 2014-02-06 | 에프. 호프만-라 로슈 아게 | Tricyclic heterocyclic compounds, compositions and methods of use thereof |
EP2536729A1 (en) | 2010-02-18 | 2012-12-26 | Incyte Corporation | Cyclobutane and methylcyclobutane derivatives as janus kinase inhibitors |
MX2012011941A (en) | 2010-04-14 | 2013-08-27 | Array Biopharma Inc | 5, 7-substituted-imidazo [1, 2-c] pyrimidines as inhibitors of jak kinases. |
EP2390252A1 (en) | 2010-05-19 | 2011-11-30 | Almirall, S.A. | New pyrazole derivatives |
BR112012029653B1 (en) | 2010-05-21 | 2021-01-12 | Incyte Holdings Corporation | pharmaceutical formulation for topical application on skin and its use |
US9351943B2 (en) | 2010-07-01 | 2016-05-31 | Matthew T. McLeay | Anti-fibroblastic fluorochemical emulsion therapies |
ES2536415T3 (en) | 2010-11-19 | 2015-05-25 | Incyte Corporation | Pyrrolopyridines and heterocyclic substituted pyrrolopyrimidines as JAK inhibitors |
ES2547916T3 (en) | 2011-02-18 | 2015-10-09 | Novartis Pharma Ag | MTOR / JAK inhibitor combination therapy |
CA2839767A1 (en) | 2011-06-20 | 2012-12-27 | Incyte Corporation | Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors |
WO2013007768A1 (en) | 2011-07-13 | 2013-01-17 | F. Hoffmann-La Roche Ag | Tricyclic heterocyclic compounds, compositions and methods of use thereof as jak inhibitors |
WO2013007765A1 (en) | 2011-07-13 | 2013-01-17 | F. Hoffmann-La Roche Ag | Fused tricyclic compounds for use as inhibitors of janus kinases |
EP2741747A1 (en) | 2011-08-10 | 2014-06-18 | Novartis Pharma AG | JAK P13K/mTOR COMBINATION THERAPY |
TW201313721A (en) | 2011-08-18 | 2013-04-01 | Incyte Corp | Cyclohexyl azetidine derivatives as JAK inhibitors |
UA111854C2 (en) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | METHODS AND INTERMEDIATE COMPOUNDS FOR JAK INHIBITORS |
EP2917221A1 (en) | 2012-11-01 | 2015-09-16 | Incyte Corporation | Tricyclic fused thiophene derivatives as jak inhibitors |
BR112015021458B1 (en) | 2013-03-06 | 2022-06-07 | Incyte Holdings Corporation | "PROCESSES AND INTERMEDIARIES FOR PREPARING {1-{1-[3-FLUORINE2-(TRIFLUORMETHYL)ISONICOTINOYL] PIPERIDIN-4-IL}-3-[4-(7HPIRROLO[2,3-D]PYRIMIDIN-4-IL)- 1H-PYRAZOL-1-IL]AZETIDIN-3-YL}ACETONITRILE, USEFUL IN THE TREATMENT OF DISEASES RELATED TO THE ACTIVITY OF JANUS KINASES |
HUE043573T2 (en) | 2013-05-17 | 2019-08-28 | Incyte Corp | Bipyrazole salt as jak inhibitor |
-
2013
- 2013-05-17 US US13/896,802 patent/US9193733B2/en active Active
- 2013-05-17 AR ARP130101717A patent/AR091079A1/en unknown
- 2013-05-17 TW TW102117596A patent/TW201406761A/en unknown
- 2013-05-17 WO PCT/US2013/041601 patent/WO2013173720A1/en active Application Filing
Patent Citations (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5521184A (en) | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
WO2000009495A1 (en) | 1998-08-11 | 2000-02-24 | Novartis Ag | Isoquinoline derivatives with angiogenesis inhibiting activity |
WO2000053595A1 (en) | 1999-03-06 | 2000-09-14 | Astrazeneca Ab | Pyrimidine compounds |
WO2001014402A1 (en) | 1999-08-19 | 2001-03-01 | Isis Pharmaceuticals, Inc. | Antisense modulation of focal adhesion kinase expression |
WO2001064655A1 (en) | 2000-03-01 | 2001-09-07 | Astrazeneca Ab | 2, 4-di(hetero-)arylamino (-oxy)-5-substituted pyrimidines as antineoplastic agents |
WO2002000196A2 (en) | 2000-06-28 | 2002-01-03 | Smithkline Beecham P.L.C. | Wet milling process |
WO2003024967A2 (en) | 2001-09-19 | 2003-03-27 | Aventis Pharma S.A. | Indolizines as kinase protein inhibitors |
WO2003037347A1 (en) | 2001-10-30 | 2003-05-08 | Novartis Ag | Staurosporine derivatives as inhibitors of flt3 receptor tyrosine kinase activity |
WO2003099771A2 (en) | 2002-05-29 | 2003-12-04 | Novartis Ag | Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases |
WO2004005281A1 (en) | 2002-07-05 | 2004-01-15 | Novartis Ag | Inhibitors of tyrosine kinases |
WO2004046120A2 (en) | 2002-11-15 | 2004-06-03 | Vertex Pharmaceuticals Incorporated | Diaminotriazoles useful as inhibitors of protein kinases |
WO2004056786A2 (en) | 2002-12-20 | 2004-07-08 | Pfizer Products Inc. | Pyrimidine derivates for the treatment of abnormal cell growth |
WO2004080980A1 (en) | 2003-03-14 | 2004-09-23 | Novartis Ag | 2, 4- di (phenylamino) pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders |
WO2005028444A1 (en) | 2003-09-24 | 2005-03-31 | Novartis Ag | 1,4-disubstituted isoquinilone derivatives as raf-kinase inhibitors useful for the treatment of proliferative diseases |
WO2006056399A2 (en) | 2004-11-24 | 2006-06-01 | Novartis Ag | Combinations of jak inhibitors and at least one of bcr-abl, flt-3, fak or raf kinase inhibitors |
WO2007070514A1 (en) | 2005-12-13 | 2007-06-21 | Incyte Corporation | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors |
US20090181959A1 (en) | 2005-12-13 | 2009-07-16 | Incyte Corporation | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS |
WO2011112662A1 (en) * | 2010-03-10 | 2011-09-15 | Incyte Corporation | Piperidin-4-yl azetidine derivatives as jak1 inhibitors |
WO2012068450A1 (en) * | 2010-11-19 | 2012-05-24 | Incyte Corporation | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors |
Non-Patent Citations (38)
Title |
---|
ADV PHARMACOL., vol. 47, 2000, pages 113 - 74 |
AGENTS ACTIONS, vol. 38, no. 1-2, January 1993 (1993-01-01), pages 116 - 21 |
ARTHRITIS AND RHEUMATISM, vol. 58, no. 11, pages 1674 - 1686 |
BARABINO ET AL., EXPERIMENTAL EYE RESEARCH, vol. 79, 2004, pages 613 - 621 |
BOUDNY, V.; KOVARIK, J., NEOPLASM, vol. 49, 2002, pages 349 - 355 |
BOWMAN, T. ET AL., ONCOGENE, vol. 19, 2000, pages 2474 - 2488 |
BURGER, R. ET AL., HEMATOL J., vol. 2, 2001, pages 42 - 53 |
COLIGAN, J.E. ET AL,: "Current Protocols in Immunology", vol. 3, WILEY PRESS. |
DUDLEY, A.C ET AL., BIOCHEM. J, vol. 390, 2005, pages 427 - 36 |
EUROPEAN JOURNAL OF ORGANIC CHEMISTRY, 2004, pages 3793 - 3798 |
FLEX E. ET AL., J EXP MED., vol. 205, 2008, pages 751 - 8 |
FONESCA, J.E. ET AL., AUTOIMMUNITY REVIEWS, vol. 8, 2009, pages 538 - 42 |
GRONEBERG, D.A. ET AL., ALLERGY, vol. 58, 2003, pages 1101 - 1113 |
GUSCHIN, D., N., EMBO J, vol. 14, 1995, pages 1421 |
ININIUNOL TODAY, vol. L9, no. L, January 1998 (1998-01-01), pages 37 - 44 |
JAMES, C. ET AL., NATURE, vol. 434, pages 1144 - 1148 |
JCI, vol. 113, pages 1664 - 1675 |
JOC, vol. 50, 1985, pages 1927 - 1932 |
K. BLOM; B. GLASS; R. SPARKS; A. COMBS, J.COMBI. CHEM., vol. 6, 2004, pages 874 - 883 |
KAUSHANSKY K, NEJM, vol. 354, 2006, pages 2034 - 45 |
LEMP: "The Definition and Classification of Dry Eye Disease: Report of the Definition and Classification Subcommittee of the International Dry Eye Workshop", THE OCULAR SURFACE, vol. 5, no. 2, April 2007 (2007-04-01), pages 75 - 92 |
LEVIN ET AL., CANCER CELL, vol. 7, 2005, pages 387 - 397 |
MACCHI P ET AL., NATURE, vol. 377, 1995, pages 65 - 8 |
MINEGISHI, Y ET AL., IMMUNITY, vol. 25, 2006, pages 745 - 55 |
MULLIGHAN CG, PROC NATL ACAD SCI U S A., vol. 106, 2009, pages 9414 - 8 |
ORTMANN, R. A.; T. CHENG ET AL., ARTHRITIS RES, vol. 2, no. 1, 2000, pages 16 - 32 |
PARGANAS E ET AL., CELL, vol. 93, 1998, pages 385 - 95 |
PARK ET AL., ANALYTICAL BIOCHEMISTRY, vol. 269, 1999, pages 94 - 104 |
RODIG, S. J.; M. A. MERAZ ET AL., CELL, vol. 93, no. 3, 1998, pages 373 - 83 |
SCHRADER ET AL.: "Developmental Opthalmology", vol. 41, 2008, KARGER, pages: 298 - 312 |
SMITH ET AL., IMMUNOLOGY AND CELL BIOLOGY, vol. 76, 1998, pages 497 - 512 |
SMOLEN, J. S. ET AL., LANCET, vol. 371, 2008, pages 987 |
SRIRANI, K. ET AL., J. BIOL. CHEM., vol. 279, no. 19, 2 March 2004 (2004-03-02), pages 19936 - 47 |
STAERK, J. ET AL., JBC, vol. 280, pages 41893 - 41899 |
W.S.S. JEE; W. YAO, J MUSCULOSKEL. NUERON. INTERACT., vol. 1, no. 3, 2001, pages 193 - 207 |
WAGH ET AL.: "Polymers used in ocular dosage form and drug delivery systems", ASIAN J. PHARM., January 2008 (2008-01-01), pages 12 - 17 |
WINYARD, P.G. AND WILLOUGHBY, D.A.: "Inflammation Protocols", vol. 225, 2003, HUMANA PRESS, article "Methods in Molecular Biology" |
YAO ET AL., ARTHRITIS AND RHEUMATISM, vol. 58, no. 6, 2008, pages 3485 - 3497 |
Cited By (72)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11331320B2 (en) | 2005-12-13 | 2022-05-17 | Incyte Holdings Corporation | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors |
US9206187B2 (en) | 2005-12-13 | 2015-12-08 | Incyte Holdings Corporation | Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as Janus kinase |
US9814722B2 (en) | 2005-12-13 | 2017-11-14 | Incyte Holdings Corporation | Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors |
US11744832B2 (en) | 2005-12-13 | 2023-09-05 | Incyte Corporation | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors |
US10398699B2 (en) | 2005-12-13 | 2019-09-03 | Incyte Holdings Corporation | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors |
US9079912B2 (en) | 2005-12-13 | 2015-07-14 | Incyte Corporation | Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as Janus kinase inhibitors |
US9662335B2 (en) | 2005-12-13 | 2017-05-30 | Incyte Holdings Corporation | Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors |
US10639310B2 (en) | 2005-12-13 | 2020-05-05 | Incyte Corporation | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors |
US9974790B2 (en) | 2005-12-13 | 2018-05-22 | Incyte Corporation | Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors |
US11213528B2 (en) | 2007-06-13 | 2022-01-04 | Incyte Holdings Corporation | Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
US9334274B2 (en) | 2009-05-22 | 2016-05-10 | Incyte Holdings Corporation | N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
US9216984B2 (en) | 2009-05-22 | 2015-12-22 | Incyte Corporation | 3-[4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl]octane—or heptane-nitrile as JAK inhibitors |
US9623029B2 (en) | 2009-05-22 | 2017-04-18 | Incyte Holdings Corporation | 3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]octane- or heptane-nitrile as JAK inhibitors |
US9249145B2 (en) | 2009-09-01 | 2016-02-02 | Incyte Holdings Corporation | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
US9999619B2 (en) | 2010-03-10 | 2018-06-19 | Incyte Holdings Corporation | Piperidin-4-yl azetidine derivatives as JAK1 inhibitors |
US11285140B2 (en) | 2010-03-10 | 2022-03-29 | Incyte Corporation | Piperidin-4-yl azetidine derivatives as JAK1 inhibitors |
US10695337B2 (en) | 2010-03-10 | 2020-06-30 | Incyte Holdings Corporation | Piperidin-4-yl azetidine derivatives as JAK1 inhibitors |
US9464088B2 (en) | 2010-03-10 | 2016-10-11 | Incyte Holdings Corporation | Piperidin-4-yl azetidine derivatives as JAK1 inhibitors |
US10869870B2 (en) | 2010-05-21 | 2020-12-22 | Incyte Corporation | Topical formulation for a JAK inhibitor |
US11590136B2 (en) | 2010-05-21 | 2023-02-28 | Incyte Corporation | Topical formulation for a JAK inhibitor |
US10758543B2 (en) | 2010-05-21 | 2020-09-01 | Incyte Corporation | Topical formulation for a JAK inhibitor |
US11571425B2 (en) | 2010-05-21 | 2023-02-07 | Incyte Corporation | Topical formulation for a JAK inhibitor |
US11219624B2 (en) | 2010-05-21 | 2022-01-11 | Incyte Holdings Corporation | Topical formulation for a JAK inhibitor |
US10640506B2 (en) | 2010-11-19 | 2020-05-05 | Incyte Holdings Corporation | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidines derivatives as JAK inhibitors |
US10513522B2 (en) | 2011-06-20 | 2019-12-24 | Incyte Corporation | Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors |
US11214573B2 (en) | 2011-06-20 | 2022-01-04 | Incyte Holdings Corporation | Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors |
US9611269B2 (en) | 2011-06-20 | 2017-04-04 | Incyte Corporation | Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors |
US9359358B2 (en) | 2011-08-18 | 2016-06-07 | Incyte Holdings Corporation | Cyclohexyl azetidine derivatives as JAK inhibitors |
US9487521B2 (en) | 2011-09-07 | 2016-11-08 | Incyte Holdings Corporation | Processes and intermediates for making a JAK inhibitor |
US9718834B2 (en) | 2011-09-07 | 2017-08-01 | Incyte Corporation | Processes and intermediates for making a JAK inhibitor |
US11337927B2 (en) | 2012-11-15 | 2022-05-24 | Incyte Holdings Corporation | Sustained-release dosage forms of ruxolitinib |
US10166191B2 (en) | 2012-11-15 | 2019-01-01 | Incyte Corporation | Sustained-release dosage forms of ruxolitinib |
US11896717B2 (en) | 2012-11-15 | 2024-02-13 | Incyte Holdings Corporation | Sustained-release dosage forms of ruxolitinib |
US11576865B2 (en) | 2012-11-15 | 2023-02-14 | Incyte Corporation | Sustained-release dosage forms of ruxolitinib |
US10874616B2 (en) | 2012-11-15 | 2020-12-29 | Incyte Corporation | Sustained-release dosage forms of ruxolitinib |
US11576864B2 (en) | 2012-11-15 | 2023-02-14 | Incyte Corporation | Sustained-release dosage forms of ruxolitinib |
US9676750B2 (en) | 2013-01-14 | 2017-06-13 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors |
US10828290B2 (en) | 2013-01-15 | 2020-11-10 | Incyte Corporation | Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors |
US10265307B2 (en) | 2013-01-15 | 2019-04-23 | Incyte Corporation | Thiazolecarboxamides and pyridinecarboxamide compounds useful as Pim kinase inhibitors |
US9550765B2 (en) | 2013-01-15 | 2017-01-24 | Incyte Holdings Corporation | Thiazolecarboxamides and pyridinecarboxamide compounds useful as Pim kinase inhibitors |
US11229631B2 (en) | 2013-01-15 | 2022-01-25 | Incyte Corporation | Thiazolecarboxamides and pyridinecarboxamide compounds useful as Pim kinase inhibitors |
US10517858B2 (en) | 2013-01-15 | 2019-12-31 | Incyte Holdings Corporation | Thiazolecarboxamides and pyridinecarboxamide compounds useful as PIM kinase inhibitors |
US9849120B2 (en) | 2013-01-15 | 2017-12-26 | Incyte Holdings Corporation | Thiazolecarboxamides and pyridinecarboxamide compounds useful as Pim kinase inhibitors |
US9221845B2 (en) | 2013-03-06 | 2015-12-29 | Incyte Holdings Corporation | Processes and intermediates for making a JAK inhibitor |
US9714233B2 (en) | 2013-03-06 | 2017-07-25 | Incyte Corporation | Processes and intermediates for making a JAK inhibitor |
US9655854B2 (en) | 2013-08-07 | 2017-05-23 | Incyte Corporation | Sustained release dosage forms for a JAK1 inhibitor |
US10561616B2 (en) | 2013-08-07 | 2020-02-18 | Incyte Corporation | Sustained release dosage forms for a JAK1 inhibitor |
US11045421B2 (en) | 2013-08-07 | 2021-06-29 | Incyte Corporation | Sustained release dosage forms for a JAK1 inhibitor |
US10000507B2 (en) | 2013-08-23 | 2018-06-19 | Incyte Corporation | Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors |
US9498467B2 (en) | 2014-05-30 | 2016-11-22 | Incyte Corporation | Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1 |
US9890162B2 (en) | 2014-07-14 | 2018-02-13 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors |
US9822124B2 (en) | 2014-07-14 | 2017-11-21 | Incyte Corporation | Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors |
US9540347B2 (en) | 2015-05-29 | 2017-01-10 | Incyte Corporation | Pyridineamine compounds useful as Pim kinase inhibitors |
WO2016196244A1 (en) | 2015-05-29 | 2016-12-08 | Incyte Corporation | Pyridineamine compounds useful as pim kinase inhibitors |
US9802918B2 (en) | 2015-05-29 | 2017-10-31 | Incyte Corporation | Pyridineamine compounds useful as Pim kinase inhibitors |
WO2017044730A1 (en) | 2015-09-09 | 2017-03-16 | Incyte Corporation | Salts of a pim kinase inhibitor |
US12043614B2 (en) | 2015-09-09 | 2024-07-23 | Incyte Corporation | Salts of a Pim kinase inhibitor |
US9862705B2 (en) | 2015-09-09 | 2018-01-09 | Incyte Corporation | Salts of a pim kinase inhibitor |
US10336728B2 (en) | 2015-09-09 | 2019-07-02 | Incyte Corporation | Salts of a Pim kinase inhibitor |
US11505540B2 (en) | 2015-09-09 | 2022-11-22 | Incyte Corporation | Salts of a Pim kinase inhibitor |
US11066387B2 (en) | 2015-09-09 | 2021-07-20 | Incyte Corporation | Salts of a Pim kinase inhibitor |
US10450296B2 (en) | 2015-10-02 | 2019-10-22 | Incyte Corporation | Heterocyclic compounds useful as Pim kinase inhibitors |
US11053215B2 (en) | 2015-10-02 | 2021-07-06 | Incyte Corporation | Heterocyclic compounds useful as Pim kinase inhibitors |
US9920032B2 (en) | 2015-10-02 | 2018-03-20 | Incyte Corporation | Heterocyclic compounds useful as pim kinase inhibitors |
WO2017059251A1 (en) | 2015-10-02 | 2017-04-06 | Incyte Corporation | Heterocyclic compounds useful as pim kinase inhibitors |
US10596161B2 (en) | 2017-12-08 | 2020-03-24 | Incyte Corporation | Low dose combination therapy for treatment of myeloproliferative neoplasms |
US11278541B2 (en) | 2017-12-08 | 2022-03-22 | Incyte Corporation | Low dose combination therapy for treatment of myeloproliferative neoplasms |
CN112105608A (en) * | 2018-01-30 | 2020-12-18 | 因赛特公司 | Process for preparing (1- (3-fluoro-2- (trifluoromethyl) isonicotinanyl) piperidin-4-one) |
CN112105608B (en) * | 2018-01-30 | 2023-07-14 | 因赛特公司 | Process for the preparation of (1- (3-fluoro-2- (trifluoromethyl) isonicotinyl) piperidin-4-one |
US10899736B2 (en) | 2018-01-30 | 2021-01-26 | Incyte Corporation | Processes and intermediates for making a JAK inhibitor |
US11304949B2 (en) | 2018-03-30 | 2022-04-19 | Incyte Corporation | Treatment of hidradenitis suppurativa using JAK inhibitors |
US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
Also Published As
Publication number | Publication date |
---|---|
AR091079A1 (en) | 2014-12-30 |
TW201406761A (en) | 2014-02-16 |
US20140005166A1 (en) | 2014-01-02 |
US9193733B2 (en) | 2015-11-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9193733B2 (en) | Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors | |
US10640506B2 (en) | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidines derivatives as JAK inhibitors | |
US10695337B2 (en) | Piperidin-4-yl azetidine derivatives as JAK1 inhibitors | |
EP2640725B1 (en) | Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors | |
US9249145B2 (en) | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors | |
AU2018204090A1 (en) | Tricyclic fused thiophene derivatives as jak inhibitors | |
WO2013026025A1 (en) | Cyclohexyl azetidine derivatives as jak inhibitors | |
EP2721028A1 (en) | Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors | |
AU2017201801B2 (en) | Piperidin-4-yl azetidine derivatives as jak1 inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13737004 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 13737004 Country of ref document: EP Kind code of ref document: A1 |